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Summary 
Standard treatment for patients with locally advanced rectal cancer (LARC) is currently 
preoperative radiotherapy with or without concurrent chemotherapy followed by total 
mesorectal excision. Approximately 10-20% of patients who receive preoperative therapy 
currently achieve a complete pathological or clinical response to therapy (pCR and cCR 
respectively). These patients have been demonstrated to have improved long-term outcomes, 
such as disease-free survival. At present, there are no methods available to reliably predict 
which patients will achieve pCR or cCR before surgical intervention or clinical examination 
respectively. This thesis aims to explore the technical aspects relating to a range of circulating 
biomarkers that might be used to facilitate this understanding for future evaluation in larger 
data sets. 
As part of this thesis, we developed an assay for the extraction and analysis of exosome-
derived microRNA (exoRNA) in patients with LARC. Using this assay, we detected variable 
levels of Mir-31, Mir-99a* and Mir-125b in longitudinal plasma samples. No significant 
associations were observed between microRNA levels and patient clinical outcomes.  
Circulating tumour DNA (ctDNA) detection in longitudinal plasma samples was lower than 
expected. The low rate of detection seen in patients with LARC may have been due to technical 
limitations. Alternatively, this may be indicative of limited ctDNA shedding in this cohort, 
bringing into question the potential utility of this biomarker in these patients as a future 
routine test.  
We also investigated the ability of immune and derived systemic inflammatory ratios to 
predict patient response to therapy in an expanded cohort of 235 patients with LARC. Again, 
few significant findings were observed. Overall, our findings suggest that the use of these 
circulating biomarkers may have limited clinical efficacy in patients with LARC.  
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1 Introduction 
1.1 Incidence 
Colorectal cancer (CRC) is the fourth most common cancer type in the UK, and third for both 
men and women. In 2016, approximately 42,000 new cases were diagnosed in the UK and the 
10-year Overall Survival (OS) for patients with CRC is approximately 57% (CRUK 2016). 
Approximately 30% of CRCs are located in the rectum (Conde-Muino et al. 2015). 
Rectal cancers are clinically defined as tumours which arise within 15cm of the anal margin, 
where more proximal tumours are colon cancers. Rectal tumours can be subcategorised based 
on location: as high (10-15cm from anal margin), middle (5-10cm) or low (<5cm) rectal cancer. 
There is growing evidence that distinct differences exist between colon and rectal cancers 
(Glynne-Jones et al. 2017). Patients with rectal cancer often have a poor prognosis due to high 
risk of the development of distant metastases and their anatomical position result in more 
complex surgical intervention and risks of local recurrence.  
1.2 Differences Between Colon and Rectal Cancer 
Although the two disorders are often combined under a single umbrella (colorectal or bowel 
cancer) numerous differences exist between colon and rectal cancers regarding development, 
commonly observed alterations, clinical management and prognosis.  
Rectal tumours are define anatomically as growing in the rectum of a patient whilst colon 
cancers are located in the caecum, ascending, transverse, descending or sigmoid colon. Colon 
tumours which occur in the proximal to the splenic fixture (i.e. the ascending and transverse 
colons) are referred to as right-sided or proximal tumours, whilst tumours occurring distal to 
the splenic fixture (i.e. the descending and sigmoid colons) are referred to as left-sided or 
distal colon tumours (Li and Lai 2009).  
The differences between colon and rectal tumours are not as superficial as location alone. 
There are also molecular differences between tumours which arise within the different regions 
of the colon as well as with the rectum. Approximately 24% of all proximal colon tumours were 
reported as having microsatellite instability (MSI), whilst only 2% of rectal tumours were MSI 
positive in comparison (Slattery et al. 2009) . Furthermore, studies have also reported that 
rectal tumours generally display greater involvement of TP53, the β-catenin pathway and 
COX2 overexpression, and lower frequencies of KRAS mutations (Dimberg et al. 1999; Kapiteijn 
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et al. 2001a; Li and Lai 2009) . These differences in the molecular pathogenesis of disease 
between the two anatomical locations are likely a result of the fact that proximal colon tissue 
develops embryogenically from the midgut, whilst the distal colon and rectum develop from 
the hindgut (Li and Lai 2009).  
At this time, standard therapy for patients with LARC is neoadjuvant therapy followed by 
surgery (See section 1.3.2 for further details), whereas patients with colon cancer only receive 
adjuvant therapy. Surgery is performed in rectal cancer due to the relative ease of access 
anatomically, allowing a less invasive surgery. Although, treatment is currently similar, 
historically survival and relapse rates have been poorer in patients with rectal cancer (Paschke 
et al. 2018).  
1.3 Current Clinical Management of Patients with Locally Advanced Rectal 
Cancer 
1.3.1 Diagnosis and Staging 
The treatment and clinical management for patients with rectal cancer has some distinct 
differences to that of patients with colon cancer. 
1.3.1.1 Current Methods of Clinical Staging 
Patients with rectal cancer are usually diagnosed with an endoscopy, Digital Rectal 
Examination (DRE), and a tumour biopsy for histopathological confirmation (Glynne-Jones et 
al. 2017). After diagnosis, Computed Tomography (CT) imaging is used to determine the extent 
of disease. The pelvis, abdomen and chest are all scanned to help identify distant disease and 
Magnetic resonance imaging (MRI) of the pelvis is used to provide locoregional assessment 
including T stage, lymph-node involvement and vascular invasion (Trakarnsanga et al. 2012). 
Patient tumours are staged as part of treatment decision-making and risk stratification using 
CT imaging, MRI and histopathology (Glynne-Jones et al. 2017). The current standard for 
tumour staging is based on tumour size, lymph node involvement and the presence of 
metastases (T/N/M). Tumours can be staged clinically by clinical examination and imaging 
methods (cT/cN/cM), or tumour size and lymph node involvement can be determined 
pathologically at the time of surgery (pT/pN). T/N/M staging can be grouped into pathological 
TNM stages (stages I-IV) according to Brierely and colleagues (2016) for determining patient 
treatment. Use of this patient system is currently recommended by the European Society for 
Medical Oncology (ESMO). 
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Within our study, we focus primarily on patients with Locally Advanced Rectal Cancer (LARC). 
LARC is clinically defined as pathological stage II/III or T3b or greater with the presence of 
extramural vascular invasion (EMVI+) (Glynne-Jones et al. 2017).  
1.3.1.2 Future Methods of Clinical Staging  
In recent years, there have been attempts to improve how patients with rectal cancer are 
staged in order to incorporate targeted therapies and molecular biomarkers available for risk 
stratification. The Colorectal Cancer Subtyping Consortium (CRCSC) investigated gene-
expression data from 4151 tumours (Guinney et al. 2015) and have since suggested a novel 
taxonomy for CRC subtyping consisting of four Consensus Molecular Subgroups (CMS1-CMS4). 
In the 2,651 patients with known tumour site (i.e. left colon, right colon or rectum) only 15% 
had rectal cancer and these were integrated combined with patients with colon cancer 
without any adjustments. This was performed because this study had previously seen no clear 
differences between patients with colon and rectal cancer based on downloaded TCGA RNA-
Seq data (Guinney et al. 2015). However, this data was not shown within this report. 
In a similar vein, Bertotti and colleagues (2016) investigated cancer cell intrinsic transcriptional 
traits by performing gene expression profiling analysis on 515 patient derived xenograft (PDX) 
models from 244 patients with CRC; removing stromal content. Unsupervised clustering on the 
resulting profiles identified 5 CRC intrinsic subtypes (CRIS) defined as CRIS-A–E. 
Both systems incorporate biomarkers such as CpG Island Methylator Phenotype (CIMP) and 
Microsatellite instability (MSI) status among other molecular markers. Both taxonomies may 
assist by further dividing chromosomal instability (CIN) patients into smaller subgroups (CMS2-
4; CRIS-C-E); as they represent 85% of the patients and are very heterogeneous (Bertotti et al. 
2016; Isella et al. 2017), each having specific driving mechanisms. However, studies have 
previously demonstrated that MSI-high and dMMR tumours are much rarer in patients with 
rectal cancer than colon cancer (Ostwal et al. 2019). This may limit the usefulness of these 
specific subgroups in patients with rectal cancer which should be considered when moving 
forward. 
Applying uniform taxonomies can assist in defining a consistent framework for subtyping in 
future studies and clinical analyses. It has the potential to help overcome inconsistencies and 
contradictory results between separate reports, facilitating the investigation of the effects of 
treatment and biomarkers in a more standardised fashion.  
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Consistency is valuable in both research and the clinic, playing a pivotal role in predicting 
survival outcomes and stratifying treatment options. Recently, MSI-High/MMR-deficient 
(dMMR) patients with CRC were reported to have an improved response to immune 
checkpoint inhibitors than their MMR-proficient counterparts (Fujiyoshi et al. 2017). As a 
result, the FDA have approved both Pembrolizumab and Nivolumab as third line therapies in 
MSI-High/MMR-deficient CRC patients (Research 2018a,b) highlighting the importance of 
consistent subtyping. 
Although these subtyping systems are applied to CRC, further investigation specifically into 
patients with rectal cancer may facilitate the prediction of patient response to standard 
therapy. 
1.3.2 Patient Treatment 
For patients with LARC, treatment is centred around the completion of surgery with curative 
intent (Glynne-Jones et al. 2017). In order to facilitate curative surgery, pre-operative 
radiotherapy, with or without concurrent chemotherapy, is generally administered. Successful 
therapy aims to downsize and downstage patient tumours to enable curative surgery whilst 
also attempting to allow sphincter-saving procedures to improve patient quality of life (Sauer 
et al. 2004).  
1.3.2.1 Surgery 
The primary aims of surgery are to achieve local disease control (i.e. reduce local recurrence) 
and improve long-term survival (Glynne-Jones et al. 2017). Surgical methods can vary from 
local excision to radical resection, based on patient stage and response to neoadjuvant 
therapy. These different methods can have a variable benefit on survival and quality of life 
through sphincter preservation (Smith and Garcia-Aguilar 2015). Currently, available surgical 
methods include trans anal endoscopic microsurgery (TEM) and total mesorectal excision 
(TME). 
TEMs are a local excision surgery (without lymph node resection) which are appropriate for 
very small and early tumours T1 or less (Glynne-Jones et al. 2017). These are normally 
performed as a single modality treatment, without the need of pre- or post-operative adjuvant 
therapy. 
TME has become the standard surgical technique for treating patients with rectal cancer. 
Patients with LARC are generally excised using this method, rather than TEM, due to the 
increased risk of local recurrence and local lymph-node involvement in these patients. A TME 
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is performed to excise and remove mesorectal fat and lymph-nodes surrounding the primary 
tumour (Slater et al. 2016). 
There are also more complex surgeries, such as the Abdominoperineal Resection (APR) or 
Extra-Levator Abdominoperineal excision (ELAPE) for low rectal tumours which result in a 
permanent stoma and perineal wound with complete removal of the anal sphincter complex  
(Shen et al. 2015). 
1.3.2.2 Neoadjuvant Therapy 
1.3.2.2.1 Radiotherapy 
In the 1990s, clinical trials demonstrated that pre-operative radiotherapy followed by surgery 
provided improved local control and survival in patients with LARC in comparison to patients 
who only received surgery (Cedermark et al. 1997). Similarly, a recent systematic-review has 
demonstrated that overall mortality at 4-12 years was reduced in patients who received pre-
operative radiotherapy compared to those who were treated with  surgery alone (Abraha et al. 
2018). Furthermore, local control was significantly improved with pre-operative radiotherapy. 
However, disease-specific mortality remained fairly consistent between the two treatment 
regimens (Abraha et al. 2018). This study also suggested that patient who received TME did 
not receive a significant benefit in overall survival from preoperative short course radiotherapy 
with immediate surgery (Abraha et al. 2018). Although patients do appear to benefit from 
neoadjuvant treatment, this improvement is likely to be bolstered by recent improvements in 
surgical techniques. 
Radiotherapy can be administered as pre-operative long- or short-course therapy over five 
weeks or one week respectively (Glynne-Jones et al. 2017). Long-course radiotherapy exposes 
patients to low doses (1.8-2Gy per dose/fraction) over a 5-week period whilst short-course 
radiotherapy involves much higher levels (5Gy per dose/fraction) over a shorter period (1 
week). 
Studies have reported that no differences were seen in local control or survival between 
patients who received short vs long course preoperative radiotherapy (Erlandsson et al. 2017; 
Wang et al. 2018), whilst others have found that long-course radiotherapy was associated with 
improved OS and less toxicity in patients with LARC (Margalit et al. 2019). In contrast to this, 
Erlandsson and colleagues (2019) reported that short-course radiotherapy with delayed time 
to surgery was associated with an improved rate of pathological complete response (pCR) in 
comparison to long-course radiotherapy with delay. At present, there are no strict guidelines 
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for whether to use short- or long-course radiotherapy with or without chemotherapy for 
patients with LARC. Treatment regimens may be decided according to factors such as patient 
frailty or co-morbidities. 
Clinical studies have also attempted to improve patient outcomes through the addition of 
chemotherapy or targeted therapies to concurrent radiotherapy. 
1.3.2.2.2 Chemotherapy 
Pre-operative radiotherapy may be administered with concurrent chemotherapy, which 
includes fluorourpyrimidines as standard. 5-FU is a fluorourpyrimidine, which is commonly 
used alongside radiotherapy pre-operatively in patients with LARC due to the radiosensitizing 
nature of 5-FU in tumour cells. 5-FU has been demonstrated to improve tumour response to 
radiotherapy in patients with LARC (Crane et al. 2003) but does not impact tumour growth in 
un-targeted locoregional lymph-nodes or distant metastases. Capecitabine (also known as 
Xeloda) is an orally ingested fluoropyrimidine which is metabolised into 5-FU within the 
tumour tissue and cells by thymidine phosphorylase (Pentheroudakis and Twelves 2002). An 
improvement was initially sought to combat the limitations of 5-FU administration, such as the 
drug’s limited plasma half-life and the difficulties associated with regular intra-venous 
administration (Pentheroudakis and Twelves 2002). These issues were potentially solved using 
an oral pro-drug substitute. 
Both 5-FU and Capecitabine have similar mechanisms for sensitizing tumour cells to 
radiotherapy through inhibiting DNA synthesis. Fluorouracils inhibit thymidine synthase and 
block the production of thymidylate, blocking downstream cellular DNA synthesis. 
Furthermore, alternative metabolites of 5-FU (FUTP) are incorporated into RNA in place of 
UTP. This interferes with RNA synthesis and downstream translation. The activity of thymidine 
phosphorylase, which is a key enzyme in the metabolism of capecitabine metabolites into 5-
FU, was seen to be three times higher in tumour cells than adjacent tissue (Pentheroudakis 
and Twelves 2002). This explains the low levels of toxicity and adverse experience observed in 
patients undergoing capecitabine therapy over intravenous 5-FU treatment. 
Irinotecan has also been used concurrently preoperatively with fluorouracils in patients with 
LARC. Irinotecan produces cytotoxic affects through inhibiting topoisomerase I. Topoisomerase 
I is a key enzyme in DNA replication and repair (Xu and Her 2015) this has been further 
explored in the UK ARISTOTLE trial- with results awaited (ISRCTN09351447). 
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1.3.2.2.2.1 The ARISTOTLE Clinical Trial 
The ARISTOTLE clinical trial is currently investigating the potential benefit of adding Irinotecan 
to standard preoperative chemoradiotherapy in patients with LARC. The clinical trial has two 
separate arms (A and B), in both of which patients are treated with radiotherapy (45Gy in 25 
fractions over five weeks) with concurrent capecitabine treatment (900mg/m2 or 650mg/m2 
orally twice daily in arms A and B respectively). Patients in Arm B also received Irinotecan 
intravenously (60mg/m2) once per week during weeks 1-4 of treatment. The primary outcome 
measured in this trial was 3-year disease-free survival after the completion of therapy. This is 
illustrated below in Figure 1. 
 
Figure 1: Illustration of the overall process and two treatment arms in the ARISTOTLE clinical trial. 
 
There are numerous other cytotoxic agents and families used in the treatment of patients with 
rectal cancer; such as Oxaliplatin and Leucovorin, among others. Oxaliplatin is a platinum-
based agent from the same family as cisplatin. Oxaliplatin binds to guanine and cytosine in 
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DNA, inhibiting DNA synthesis and transcription. Leucovin is derivative of folic acid and 
facilitates the metabolism of 5-FU downstream by stabilising the bond of 5-FUMP to thymidine 
synthetase. Therefore, it has been used to enhance the cytotoxic effects of Fluorouracils. 
Studies have demonstrated that the addition of concurrent chemotherapy to preoperative 
radiotherapy improved pathological response and local control in patients with LARC (Ceelen 
et al. 2009; De Caluwe et al. 2013). However, these studies also demonstrated that adding 
chemotherapy did not improve disease free survival (DFS) or OS in patients with stage II/III 
LARC (Ceelen et al. 2009; De Caluwe et al. 2013). 
In addition to the standard treatment described previously, other targeted therapies can be 
administered or are under current research for future utility. Among these are anti-Epidermal 
Growth Factor Receptor (EGFR) monoclonal antibodies (Cetuximab and Panitumumab) and 
anti-Programmed Cell Death-1 (PD-1) antibodies (Pembrolizumab, Durvalumab etc.).  
1.3.2.3 Anti-EGFR Monoclonal Antibodies 
Anti-EGFR antibodies are only used for treating patients with metastatic CRC. Anti-EGFR 
monoclonal antibodies, including cetuximab and panitumumab, bind to the extracellular 
domain of the EGFR protein. This stops the activation of EGFR by blocking its activating binding 
partners, such as EGF. However, variants in the EGFR gene or in genes downstream of EGFR, 
such as KRAS, NRAS, BRAF or PIK3CA, can circumvent the need for EGFR activation. Therefore, 
these monoclonal antibodies are only used to treat patients with wild-type KRAS, NRAS and 
BRAF.  
1.3.2.4 Immune Checkpoint Inhibitors 
Immune checkpoint inhibitors are still in the very early stages of trials in patients with rectal 
cancer in comparison to more standardised therapies. This family of cytotoxic agents enhances 
the patient’s immune response to tumour cells. They perform this action by blocking the 
binding of immune checkpoints with corresponding receptors on T-cells. Immune checkpoints 
(such as programmed cell death-1; PD-1) are expressed on normal tissue to prevent auto-
immune activity. However, these receptors are co-opted by tumour cells and inhibit or 
‘exhaust’ the activity of T-cells by disrupting the recognition of non-self-cells and blocking the 
immune synapse which stimulate T-cell function (Ramsay 2013). 
Immune checkpoint inhibitors have shown improved therapeutic efficacy in patients with 
dMMR tumours (Cohen et al. 2019), but these changes are very rare in patients with rectal 
cancers (Ostwal et al. 2019). Trials have also commenced in the combination of anti-PD-1 
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therapy with radiotherapy to enhance the immunogenic activity of such immunotherapies 
(Overman et al. 2017).  
In addition to the treatments described there are other targeted therapies available, such as 
anti-angiogenic monoclonal antibodies (bevacizumab or cediranib) and Poly-ADP Ribose 
Polymerase (PARP) inhibitors (veliparib). PARP inhibitors have recently been explored in an 
attempt to enhance tumour response to radiotherapy in patients with rectal cancer (Shelton et 
al. 2013). There are also other approaches such as the ‘watch and wait’ or “active monitoring” 
approach described below. 
1.3.2.5 The ‘Watch and Wait’ or Active Monitoring Approach 
An alternative option to post neoadjuvant surgery which has recently been suggested is the 
‘watch and wait‘ approach. In this case, patients who achieved a complete clinical response 
(cCR) did not initially receive any surgery and are monitored closely instead. cCR is assessed 
both clinically and using medical imaging methods. cCR is defined by ESMO as the absence of 
any palpable tumour during DRE, no visible tumour lesions at rectoscopy and the absence of 
detectable tumour at primary site or in drained lymph nodes using imaging techniques such as 
MRI or endorectal ultrasound (ERUS). 
cCR and pCR have been previously demonstrated to have poor concordance in patients with 
breast cancer (Smith et al. 2012) as pCR is defined by the lack of detectable tumour cells at the 
time of surgery.  
The watch and wait approach has been suggested in order to avoid the adverse effects of 
surgery, such as the risk of perioperative complications (Marijnen 2015) and sexual 
dysfunction (Den Oudsten et al. 2012). Studies have been investigating the effect of surgery vs 
watch and wait on patient outcomes. Renehan and colleagues (2016) have previously reported 
that the watch and wait approach had similar DFS as surgery at 3 years and was, thus, 
oncologically safe. However, there has been wide variability in the local recurrence rate of 
patients treated with the watch and wait approach (5-60%) (Renehan et al. 2016). This wide 
variability may be due to numerous differences between these studies, such as follow-up time, 
and surveillance intensity. 
Therefore, as investigations continue to analyse the oncological safety of this approach, this 
has not yet been widely implemented in the treatment of patients with LARC.  
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Although there are numerous options for the treatment of patients with LARC, the current 
standard remains neoadjuvant chemoradiotherapy followed by surgery. How this will develop 
with the emergence and development of immunotherapies remains to be seen. 
1.3.3 Follow-Up and Surveillance 
To date, there are no current biomarkers which can predict the efficacy of treatment or long-
term clinical outcomes in patients with LARC undergoing preoperative chemoradiotherapy 
(pCRT). For the moment, close surveillance by clinical examinations, colonoscopies and regular 
CT or MRI imaging is applied to detect tumour recurrence in these patients. Biomarkers, 
circulating or otherwise, need to be developed in this group of patients to identify those at 
greater or lesser risk of local recurrence and distant metastases down the line. 
1.3.4 Clinical Outcomes 
1.3.4.1 Response and Survival 
Currently, patient response to therapy can be gauged by MRI and/or at the time of surgery. 
Post-operative levels of carcinoembryonic antigen (CEA) may also be indicative of tumour 
burden or patient response to therapy.  
After neoadjuvant treatment, approximately 10-20% of patients experience pCR where the 
tumour has been eliminated by therapy (Maas et al. 2010). The remaining patients can 
experience variable outcomes, from a good response with large amounts of regression to 
minimal or no response.  
Patients with LARC who achieve a pCR may have a decreased likelihood of experiencing local 
recurrence but are still at risk of distant metastases (Sun et al. 2019). Therefore, patients 
achieving a complete pathological response may not necessarily receive any distinct benefits 
with regards to OS.  
When patients with rectal cancer have localised disease  and surgical resection is curative, 
survival is still relatively poor, with 10-year survival being ~50% (van Gijn et al. 2011). 
Disseminated disease is the most frequent cause of mortality in patients with rectal cancer, 
but local recurrence can also have severe consequences which may be fatal.  
Current treatment in patients with LARC focus on the primary tumour lesion and locoregional 
lymph-nodes, not on distant lymph-nodes or metastases. Therefore, although local control 
may be achieved, the growth of distant micro-metastases can remain undetected and 
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unchecked until clinical symptoms arise or radiological imaging identifies distant metastases 
during patient post-operative follow-up. 
1.4 Predictors of Long-Term Clinical Outcomes in Patients with Locally 
Advanced Rectal Cancer 
There are a limited number of biomarkers which can facilitate treatment decision-making by 
prognosticating or predicting long- or short-term clinical outcomes in patients with LARC. At 
present, only tumour response at time of surgery and post-treatment circulating CEA levels are 
used clinically. Here, we review surgical, tissue-based and circulating biomarkers, expanding 
from what is currently available in the clinic to what is of growing interest in the literature in 
patients with CRC, focussing on rectal cancer where possible. 
1.4.1 Surgical/Pathological Markers 
1.4.1.1 Surgical Outcomes 
After the completion of surgery, the response of the tumour to neoadjuvant therapy is 
quantified, usually applying a tumour regression grade (TRG) system. TRG systems quantify the 
response of neoadjuvant therapy from a pCR to no response or tumour progression. Various 
grading systems are available, including the Dworak’s and Rodel’s TRG systems (Trakarnsanga 
et al. 2012). Although the tumour growth/shrinkage occurs in these patients during 
neoadjuvant therapy, changes can be measured more accurately at the time of surgery. 
The detection of pCR after neoadjuvant therapy can be suggestive of improved local control 
and disease-free survival (Molinari et al. 2015; Bottarelli et al. 2018). Studies have shown an 
improved DFS in patients who achieved pCR compared to those who did not (Rodel et al. 
2005). TRG has been demonstrated to be a prognostic factor for the occurrence of distant 
metastases (Fokas et al. 2014). However, poor response to therapy may be indicative of 
tumour aggressiveness and advanced tumour stage rather than merely indicative of the 
occurrence of distant metastases. 
Patients who achieved a complete response to neoadjuvant therapy could also be identified 
using radiological imaging and clinical examination if surgery is not to be undertaken owing to 
patient wishes or comorbidities/frailty. This is defined as a cCR but is a macroscopic evaluation 
only and is not as accurate without histopathological confirmation, requiring surgical resection 
(Glynne-Jones et al. 2017). 
12 
 
At this time, there are no methods which can accurately predict which patients will achieve 
pCR or a good response/TRG and those who will not before the initiation of therapy. Such a 
predictive biomarker would facilitate treatment-decision making for patients on an almost 
individual basis. The ability to predict which patients will or will not respond to neoadjuvant 
therapy could help improve patient treatment stratification and improve patient quality of life 
by limiting their exposure to toxic agents unnecessarily or preventing the need for surgery. 
1.4.2 Tissue-Based Biomarkers  
1.4.2.1 Tumour Infiltrating Lymphocytes 
In recent years, our understanding of the role of immunity in tumour growth has grown 
significantly. This has progressed research towards the clinical implementation of 
immunotherapies in patients with various cancer-types. Immune-related biomarkers have 
begun to develop for prognostic and response prediction purposes in patients treated with 
immunotherapies. These can be either tissue-based, such as tumour-infiltrating lymphocyte 
(TIL) density levels, or circulating, such as white cell counts (WCCs), lymphocyte sub-classes, 
neutrophil (NLR), monocyte (LMR) or platelet (PLR) to lymphocyte ratios. 
With regards to TILs, studies have primarily focussed on infiltrating T-lymphocytes in patients 
with various solid tumours. T-cells are CD3+ lymphocytes which can be divided into two 
subsets in TIL analysis; these being CD8+ cytotoxic T-lymphocytes (CTLs) and CD4+ regulatory 
T-cells (Ramsay 2013). Each of these two subsets have been shown to perform different roles 
with regards to patient tumour cells. CTLs perform an anti-tumour function by targeting 
tumour cells, via tumour specific antigens, for destruction. In contrast, CD4+ T-cells regulate 
the activity of CTLs and limit their activity to a more pro-tumour function, especially FoxP3+ 
regulatory T-cells. Consequently, recent studies have investigated different T-cell subsets in TIL 
analysis, as opposed to T-cells as a whole. 
Previous reports have demonstrated that high densities of pre-treatment CD8+ T-cells (within 
the tumour micro-environment) were associated with improved response (Yasuda et al. 2011; 
Matsutani et al. 2018) and survival (Shinto et al. 2014; Teng et al. 2015) after neoadjuvant 
therapy in patients with rectal cancer. In agreement with this, a recent meta-analysis reported 
that high densities of CD3+, CD8+ and FoxP3+ were associated with improved OS in patients in 
CRC (Kong et al. 2019). In patients with LARC, high CD8+ TIL density, were predictive of 
improved tumour regression after chemoradiotherapy (Kong et al. 2019) and greater 
sensitivity to neoadjuvant therapy (Matsutani et al. 2018).  
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The influence of CD4+ density is more controversial in patients with rectal cancer. Whilst some 
studies have shown that high density CD4+ TILs are associated with improved response to 
neoadjuvant therapy (Yasuda et al. 2011), other studies have shown contradictory findings 
(Huang et al. 2019). Studies have also reported that general counts of CD8+ or FoxP3+ T-cells 
were not a significant prognostic indicator of outcomes, but changes in the CD8+/FoxP3+ ratio 
as a result of therapy were associated with OS and Progression Free Survival (PFS) (Mirjolet et 
al. 2018). 
It has also been reported that the location of lymphocyte infiltration, either into the malignant 
epithelium or the surrounding stroma, is another important feature to consider in patients 
with LARC. Huang and colleagues (2019) demonstrated that intraepithelial CD45+ and CD8+ 
TILs were associated with an improved response to neoadjuvant therapy in patients with LARC, 
whereas stromal TILs had no significant association. 
Tumours with a high density of pre-treatment lymphocyte infiltration are seen to be more 
immunogenic and attract anti-tumour CD8+ CTLs (Yasuda et al. 2011). Radiotherapy directly 
causes immunogenic cell death to cancer cells which causes a release of Tumour Associated 
Antigens (TAAs) and Damage-Associated-Molecular Patterns (DAMPs). Released TTAs, DAMPs 
and cytokines then stimulate anti-tumour immunity and CTL maturation (Wennerberg et al. 
2017). However, TILs may be inactive or ‘exhausted’ due to the presence of expressed immune 
checkpoints, such as PD-1 or CTLA-4 by tumour cells and/or regulatory T-cells (Ramsay 2013). 
Therefore, the addition of immune checkpoint inhibitors, (such as pembrolizumab of 
nivolumab) may integrate well with pre-operative chemoradiotherapy. 
The reporting of contradictory findings in the literature may be due to the presence and 
activity of CD4+ T-cell subsets. Although several studies used CD4+ as a marker for regulatory 
T-cells, the T-cells can be divided into subgroups with pro- or anti-tumour functional variability. 
FoxP3 is a specific marker for a subgroup of CD3+ T-cells, thus CD4+ and FoxP3+ TIL density are 
not necessarily the same. Furthermore, studies also vary in methodology, as not all studies 
were quantitative or semi-quantitative in the IHC analysis. Hence, direct comparisons may be 
misleading. 
There has been interest in the infiltration of Natural Killer (NK) cells in patients with rectal 
cancer. Lim and colleagues (2014) reported that NK cells were significantly lower in density in 
rectal cancer tissue in comparison to normal tissue. High NK cell TIL density was associated 
with improved progression but not survival (Lim et al. 2014). In agreement with these findings, 
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Alderdice and colleagues (Alderdice et al. 2017) reported that a high expression NK cell 
signature in the gene expression profiling of patients with LARC was indicative of improved 
TRG.  
With regards to T-cells, these findings enabled the development of the immunoscore and the 
initiation of clinical trials testing the efficacy of immunoscores in predicting high risk patients 
with colon cancer (NCT03422601). Immunoscores are acquired from tumour tissue using 
ImmunoHistoChemistry (IHC) to evaluate the density of CD3+ and CD8+ lymphocyte 
populations in the tumour margin and tumour core (Zeitoun et al. 2019). This is not currently 
in place for patients with rectal cancer but is certainly a biomarker of interest to monitor in 
clinical trials for future potential utility. 
1.4.2.2 Protein Expression 
Studies have previously investigated the levels of apoptotic and DNA damage repair proteins in 
rectal cancer tissue as possible predictors of patient response to neoadjuvant therapy. This is 
because chemoradiotherapy induces cell death through large scale double stranded DNA 
damage. The ability of a cell to repair DNA damage and resist apoptosis has previously been 
linked to response to ionising radiation. However, these studies have only achieved limited 
success in identifying proteins which can reliably predict patient response to neoadjuvant 
therapy.  
Studies have previously investigated the p53 protein before or after radiotherapy to identify 
any associations between expression and response to therapy. However, these studies have 
general found no significant association to clinical outcomes in patients with LARC (Kobayashi 
et al. 2007; Terzi et al. 2008). In contrast, the proteins Ki-67 (Jakob et al. 2008) and Survivin (Yu 
et al. 2016), involved in proliferation and inhibiting apoptosis respectively, have both been 
found to significantly associate with response and recurrence rates respectively. Similar 
studies have seen no significant associations between these proteins and response or 
prognosis (Terzi et al. 2008). 
Studies have also reported significant associations between clinical outcomes and proteins 
such as COX-2 (Kobayashi et al. 2007; Peng et al. 2016), APAF-1 (Peng et al. 2016) and β-
catenin (Gomez-Millan et al. 2017) in patients with LARC. These are generally small studies 
(n<100) and will require further validation in larger cohorts. Furthermore, these studies have 
large differences between each of them, creating difficulties in identifying clinically significant 
proteins in patients with LARC. These differences can vary from treatment administered or the 
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stratification of patients as good or poor responders. Furthermore, these studies use IHC for 
the quantification of expression, which is very subjective and difficult to remove bias from. 
These studies do not include genetic analysis; the presence of tumour specific variants in each 
of these genes may impact the importance of protein expression in patients with LARC. A 
missense variant in the DNA-binding domain of TP53 may limit the functional capabilities of 
the p53 protein, but not alter protein expression. 
Although these studies have provided some interesting findings, the quantification of protein 
expression by IHC is still limited. The coupling of this with genetic analysis and/or gene 
expression profiling may be beneficial in future studies. 
1.4.2.3 Genomic Alterations 
At present, the only genomic variants available to predict patient outcome to therapy are the 
presence of variants in KRAS and NRAS in the context of anti-EGFR monoclonal antibody 
therapy (Hsu et al. 2016). In the context of neoadjuvant therapy and surgery, no genomic 
alterations can predict patient response or long-term clinical outcomes. 
As previously alluded to, studies have recently suggested that tumour specific genomic 
variants may influence tumour response to neoadjuvant therapy in patients with LARC. Many 
of these studies have focussed on the predictive or prognostic roles of KRAS and TP53 among 
other frequently mutated genes in rectal cancer. However, these reports have lacked 
consistency. 
In patients with rectal cancer, the presence of variants in KRAS have been previously reported 
to associate with poorer response to neoadjuvant therapy and a decreased likelihood of 
patients achieving pCR (Duldulao et al. 2013). In contrast, numerous studies have shown no 
difference in response to neoadjuvant therapy between patients with KRAS mutant or wild-
type disease (Sclafani et al. 2019). As far as we are aware, no studies reported an association 
between KRAS status and survival in patients with rectal cancer. 
Interestingly, a study which showed no significant differences in response to therapy between 
patients with wild-type and mutant KRAS, reported small differences in response between two 
different variants in KRAS (p.G13D and p.G12V) (Gaedcke et al. 2010). Similarly, other studies 
have reported that patients with a KRAS variant at p.G13 were less likely to experience tumour 
downstaging or pCR after therapy; even though both studies reported that KRAS status was 
not significantly associated with clinical outcome  (Lee et al. 2015; Martellucci et al. 2015). The 
prognostic or predictive differences between different variants in KRAS may be worth 
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consideration in future studies. At present, the influence that mutant KRAS may impose on 
response to neoadjuvant therapy in not clear. 
Variants in TP53 have been reported to correlate with worse response after therapy (Sclafani 
et al. 2019) and decreased rates of pCR (Chen et al. 2012). Sakai and colleagues (Sakai et al. 
2014) have reported that variants in TP53 were enriched in tumour tissue after the completion 
of chemoradiotherapy. Based on this finding, Sakai and colleagues hypothesised that the 
administration of therapy created an evolutionary advantage of mutant TP53 tumour cells to 
grow within. Due to the role of p53 in DNA repair and apoptosis, this hypothesis is feasible and 
in line with reports demonstrating the poor prognostic significance of TP53 variants.  
Interestingly, numerous studies have reported that the presence of variants in both KRAS and 
TP53 are indicative of worse PFS (Sclafani et al. 2019) and decreased likelihood of achieving 
pCR (Chow et al. 2016). Larger scale studies are required to determine whether this predictive 
value is true and significant in a wider cohort of patients with rectal cancer. 
1.4.2.4 Micro Satellite Instability and DNA Mismatch Repair Status 
In patients with CRC, ~15% of patients have dMMR functions within their tumour. 
Consequently, this creates MSI, where intergenic microsatellites are found at highly variable 
and unregulated lengths throughout tumour tissue. Patients with CRC can have MSI- High 
(MSI-H), -Low (MSI-L) or microsatellite stable (MSS) disease. In the clinical context, MSI is 
analysed as a marker of dMMR. In patients with CRC, dMMR is a good prognostic indicator and 
associated with improved OS and DFS after neoadjuvant therapy (Hong et al. 2012).  
In patients with rectal cancer, dMMR status is considerably rarer (~1-2%) and the impact that 
MMR status can have on response to DNA damaging agents is currently not understood 
(Ostwal et al. 2019). Studies have reported that patients with MSI rectal cancer had a reduced 
rate of pCR after pCRT (Hasan et al. 2018) and high levels of MSH6 protein was indicative of 
improved OS and local control (Huh et al. 2016). This would suggest that proficient MMR 
(pMMR) function improved patient outcomes after treatment, which is contrary to reports in 
patients with colon cancer (Hong et al. 2012). However, previous reports have demonstrated 
that patients with MSI rectal cancer had an improved DFS and OS after neoadjuvant therapy, 
which contradicts other studies (Colombino et al. 2002; Du et al. 2013). As previously stated, 
with regards to neoadjuvant therapy, the current effects of MMR status remain unclear. 
In patients with colon cancer, dMMR has been shown to be predictive of patient response to 
immune checkpoint inhibitors. However, if this remains relevant in patients with rectal cancer, 
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it will be difficult to determine due to the rarity of patients with dMMR rectal cancer. It will be 
of interest to investigate the presence of any interactions between MMR/MSI status and 
checkpoint inhibitor efficacy in future clinical studies. 
Like MSI/MMR status, Tumour Mutational Burden (TMB) is the quantitative measurement of 
how frequently variations occur in the genome of cancer tissue. This is generally quantified 
using large gene panels or whole exome/genome sequencing as reports have demonstrated 
that >1Mega base pair (Mbp) of DNA was required for accurate TMB identification (Allgauer et 
al. 2018). TMB is generally higher in patients with dMMR and MSI-H tumours. TMB has also 
been suggested as a predictive biomarker for response to radiotherapy with immune 
checkpoint inhibitors in patients with non-small cell lung carcinoma (NSCLC) (Wilkins et al. 
2019). However, Wilkins and colleagues (2019) found no association between levels of TMB 
and response to immune checkpoint inhibitors. 
1.4.2.5 Tumour Heterogeneity Markers 
Tumour heterogeneity markers have been investigated for their predictive and prognostic 
values in patients treated with neoadjuvant therapies. Tumour heterogeneity scores and 
indexes have been used to quantify levels and changes in intra-tumour heterogeneity in 
tumour tissue. Tumour heterogeneity can be calculated according to the number of variants 
and median variant allelic frequency (VAF) across a tumour sample. This also requires large 
sequencing panel (>400 genes) or whole exome/genome sequencing for accurate 
quantification  
The clonal and subclonal composition of tumour tissue can also provide further information 
regarding patient response to therapy. In patients with CRC, studies have demonstrated that 
whether resistance-associated variants are contained in small tumour subclones or across all 
tumour cells can influence time to relapse after targeted therapies in patients with CRC 
(Normanno et al. 2015). These values can be quantified based on VAF and tumour cellularity in 
patient tissue to generate a tumour heterogeneity score. If variants or signatures are found to 
be associated to radiotherapy resistance, heterogeneity scores could provide valuable 
information as part of treatment-decision making. 
Overall, tumour heterogeneity may provide valuable prognostic or predictive information with 
regards to patient prognosis, response to therapy or long-term clinical outcomes. This field is 
still in its infancy and must undergo more rigorous testing in larger patient cohorts. However, 
with the general trend moving towards tumour profiling with panel-based or whole genome 
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sequencing, large scale metrics such as TMB and heterogeneity scores/indexes may have the 
potential for frequent clinical application. 
Consequently, a larger amount of DNA may be required, and small biopsies may no longer be 
sufficient for such analysis. Furthermore, such analyses may also be limited by their application 
on a tumour biopsy representing a small region of the tumour, rather than the whole tumour.  
1.4.3 Circulating Biomarkers 
As an invasive CRC evolves, cancer cells and stromal products are shed into the circulation of 
an individual. Novel technologies have enabled the identification and tracking of these readily 
accessible tumour “envoys” as potential disease biomarkers.  
Minimally invasive testing with liquid samples (such as whole blood, plasma, urine, cerebral-
spinal fluid, ascites or sputum samples) for disease monitoring has become particularly 
attractive for researchers and clinicians in recent years.  
Circulating biomarkers are of significant interest in the clinical setting due to the potential for 
regular serial sampling taken in ‘real-time’ as a patient undergoes various therapies. Tumour 
biopsies are an invasive procedure and are thus impracticable to perform for sequential 
tumour analysis in patients. Circulating biomarkers provide a minimally invasive alternative 
which can allow frequent sequential sampling and analysis. However, circulating biomarkers 
may be limited by high background levels being secreted or released by non-tumour tissue 
which can hamper the identification of tumour-specific signatures. Previous studies have also 
demonstrated that tumour-derived circulating biomarkers can vary depending on tumour size 
and stage, and therefore have limited potential in early stage pre-metastatic cancer patients 
(Bettegowda et al. 2014). 
1.4.3.1 Clinical Circulating Biomarkers 
There are currently very few established circulating biomarkers commonly used in in the 
clinical setting for patients with rectal cancer. Among these are CEA and Carbohydrate Antigen 
19-9 (CA19-9). 
Most notably, CEA levels can be quantified before the initiation of pCRT as part of treatment 
decision making/risk stratification. Alternatively, CEA can be measured post-operatively during 
follow-up for patients monitoring and surveillance to assess tumour response and detect 
recurrence.  
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CEA is an oncofetal antigen which is secreted by epithelial tumour cells in the digestive tract. It 
is usually analysed in patient serum using immunosorbence assays, such as Enzyme-Linked 
Immunosorbance Assay (ELISA) (Sorensen et al. 2016). Because it is secreted by epithelial 
tissue under normal physiological conditions, CEA is determined to be high or low by using cut-
offs as recommended by guidelines from the ESMO (Glynne-Jones et al. 2017). In research, this 
cut-off value is often variable from 2.5– 10ng/mL (Nicholson et al. 2015; Sorensen et al. 2016). 
In patients with LARC, pre- and post-treatment CEA concentrations and changes there within 
were associated with pathological response to neoadjuvant therapy and disease recurrence 
(Peng et al. 2018; Saito et al. 2018). This is hypothesised to be the case because consistently 
high CEA concentrations after surgery can be indicative of distant undetected micro-
metastases (Saito et al. 2018).  
With regards to clinical utility, the ambition is to reliably predict which patients will and will 
not respond well to neoadjuvant therapy before administering treatment. High CEA levels may 
therefore be used to do so. However, studies have also demonstrated that CEA has significant 
limitations as a biomarker in disease monitoring; including low sensitivity and specificity in CRC 
diagnosis and prognostication (Primrose et al. 2014; Sorensen et al. 2016). CEA is also secreted 
in benign conditions of the colon and is detected more frequently in heavy smokers, which can 
influence the potential efficacy of CEA in risk stratification or prognostication (Nicholson et al. 
2015). 
CA19-9 is another tumour marker which has previously been demonstrated to predict survival 
after therapy in patients with rectal cancer. Recent reports have demonstrated that large 
decreases in CA19-9 concentration were associated with increased rates of pCR (Song et al. 
2018) whilst elevated pre-treatment CA19-9 was predictive of reduced OS (Miki et al. 2018). 
However, as previously stated with CEA, the presence of contradictory findings in the reliability 
of pre-treatment CA19-9 to predict patient response (Buijsen et al. 2014) makes the use of 
CA19-9 a controversial matter. 
Studies have demonstrated that the combined utility of CEA and CA19-9 could identify patients 
with worse survival in the context of both rectal cancer (Zhang et al. 2015) and CRC (Stiksma et 
al. 2014). Furthermore, Buijsen and colleagues (2014) reported that CA19-9 and CEA 
concentrations correlated well together in patients with LARC. Therefore, the combination of 
these two biomarkers in a pre- or post-therapeutic setting may increase sensitivity and 
specificity of response and outcome prediction in patients with rectal cancer. 
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1.4.3.2 Systemic Inflammatory Ratios 
1.4.3.2.1 Neutrophil Lymphocyte Ratio 
With the emergence of immune checkpoint inhibitors among other immunotherapies, there 
has been increasing interest in immune-related biomarkers. The use of NLRs, identified from 
routine differential white cell counts in the peripheral circulation has re-emerged as an area of 
interest; both prognostically and predictively. Neutrophils and lymphocytes were selected for 
their respective roles in inflammation and anti-tumour functions. Inflammation and 
inflammatory markers have been demonstrated to promote tumour growth or protect tumour 
tissue from a host immune response, of which lymphocytes are central.  
At present, outside of MSI status, there are no clinically validated biomarkers to predict patient 
response to immune checkpoint inhibitors (Friedman and Postow 2016) Theoretically, the 
development of an immunological biomarker could be used to predict patient response to 
immunotherapies. In agreement with this, various groups have reported that low NLR (<5) is 
indicative of improved survival in patients undergoing ipilimumab therapy for metastatic 
melanoma (Ferrucci et al. 2015). 
Pine and colleagues (2015) reported that high NLR (≥5) predicted decreased OS and DFS for 
CRC patients undergoing surgery with curative intent and that NLR correlated to tumour stage 
and could predict disease recurrence. This study further reported that a low NLR was 
associated with increased lymphocytic reaction in the invasive margin and a better prognosis. 
NLRs may be relevant to CMS1 and 3 subgroups, which are characterized as enriched for MSI-
High, hyper-mutated genotypes with increased tumour infiltrate (Guinney et al. 2015). 
Similarly, CRIS-A tumours are either MSI or ‘MSI-like’ and CRIS-B tumours presented with an 
inflammatory phenotype with strong Tumour Growth Factor Beta (TGF-β) activity (Isella et al. 
2017); though both presented inflammatory traits. Patient response to immunotherapies 
within these subtypes will require further exploration. As previously stated, high MSI and/or 
dMMR tumours are much rarer in patients with rectal cancer compared to colon cancer. 
Therefore, this brings into question the efficacy of analysing these subtypes in patients with 
rectal cancer and, perhaps, immune-derived systemic markers such as NLRs. This is a factor we 
aim to investigate further in patients with LARC as part of this thesis. 
As these tumour types display increased immune or ‘MSI-like’ profile and immune infiltration, 
these patients are potentially more likely to respond to immunotherapies. The potential utility 
of NLR or derived NLR (dNLR) has been hinted by reports that dNLR levels were generally good 
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indicators of response to chemotherapy across mutations; (Wood et al. 2017) especially so for 
BRAF mutant tumours which are commonly MSI-High (Dienstmann et al. 2017b). 
Unfortunately, this group also reported that NLR was not associated with MMR status, but 
neutrophil counts and c-reactive protein levels may have been (Pine et al. 2015). 
NLR does show promise in that, even with relatively low patient numbers, consistent results 
have been seen with regards to checkpoint inhibitor response. Furthermore, this assay is 
relatively cheap, simple to perform and part of routine practice; a large advantage with 
regards to embedding a biomarker into a clinical setting (Wood et al. 2017). 
1.4.3.2.2 Other Markers 
Similar inflammatory index markers have been investigated in patients with rectal cancer 
undergoing neoadjuvant therapy but apart from NLRs, systemic inflammatory markers have 
not performed consistently. Studies have previously reported that low pre-treatment LMRs 
were associated with worse OS (Deng et al. 2017) and DFS (Yamamoto et al. 2019a). Similarly, 
high PLRs have been demonstrated to predict worse response to therapy (Kim et al. 2018). 
Platelets have previously been associated with promoting tumour growth via increased 
angiogenesis and metastatic spread. Similarly, monocytes have been reported to induce 
tumour growth, migration and invasion from within the tumour microenvironment (Condeelis 
and Pollard 2006). 
A different study demonstrated that there was no significant association between PLR and 
survival and that CEA was superior when predicting DFS and OS than PLR in patients with rectal 
cancer (Portale et al. 2018). These ratios are limited by using inconsistent cut-off values when 
determining high or low levels. Therefore, the assignment of high or low and resulting 
outcome analysis is highly variable between studies. This factor will require standardisation 
before similar inflammatory index markers can become effective in guiding clinical practice. At 
this time, these markers have provided valuable information regarding the role of systemic 
inflammation in tumourigensis and tumour response to neoadjuvant therapy. 
These studies are currently limited by small patient numbers with regards to those comparing 
systemic inflammatory ratios with patient response. Further research also needs to be 
undertaken in order to determine whether such ratios are predictive of therapeutic response 
or general outcome, due to the correlation with tumour staging (Pine et al. 2015). Finally, how 
these ratios compare in predicting outcome to other circulating biomarkers also remains to be 
seen. 
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1.4.3.3 Circulating Tumour DNA 
1.4.3.3.1 Cell Free DNA Secretion 
Circulating tumour DNA (ctDNA) is a tumour derived sub-population of circulating free DNA 
(cfDNA) in patients with various solid tumours, including CRC. There are two hypothesised 
mechanisms of cfDNA release, these are passive release through cell death (Diehl et al. 2008) 
and active release via extracellular vesicles, such as exosomes (Figure 2)  (Wang et al. 2017). 
During passive cfDNA release, apoptotic or necrotic activity causes the fragmentation of DNA 
into ~180-200bp fragments (Thierry et al. 2010). Studies have suggested that these kinds of 
cell death invoke an immune response that release cfDNA through T-cell-mediated cell 
destruction (Thierry et al. 2010). Alternatively, other studies have suggested that oncogenic 
DNA is selectively packaged into exosomes and exocytosed to promote local or distant 
oncogenic activity (Wang et al. 2017). Alternatively, other studies have reported that 
exosomes are used to secrete harmful DNA in response to DNA damage in tumour cells 
(Takahashi et al. 2017). DNA has been demonstrated to migrate through nuclear pores into the 
cytoplasm in response to large amounts of DNA damage. The accumulation of nuclear DNA in 
the cytoplasm can then induce an immune response. Researchers have consequently 
hypothesised that tumour cells can circumvent this process by actively excreting cytoplasmic 
DNA via exosomes (Takahashi et al. 2017). 
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Figure 2: The various mechanisms of cfDNA release into the circulation from tumour and non-tumour tissue in patients with LARC.
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1.4.3.3.2 Clinical Utility of Cell Free DNA as a Circulating Biomarker 
cfDNA can be released into the circulation by either tumour or non-tumour tissue (Thierry et 
al. 2010). Distinguishing the fraction of tumour-derived from non-tumour DNA in plasma has 
been accomplished by detecting tumour specific genetic alterations. This can be achieved 
using a variety of methods, such as next-generation sequencing (NGS), digital PCR or 
pyrosequencing. CtDNA has been demonstrated to predict progression, relapse, monitor levels 
of disease and detect the emergence of treatment-resistant clones (Jia et al. 2017). 
CtDNA levels have been reported to vary depending on clinical factors, such as tumour stage 
and the presence of metastases (Bettegowda et al. 2014) in patients with CRC and a number of 
other solid tumours. In patients with rectal cancer, ctDNA levels were also demonstrated to 
correlate with tumour size (Tie et al. 2015). 
Quantitative changes in ctDNA levels during first line chemotherapy could act as early 
biomarkers of therapeutic response in patients with CRC before current methods allow, 
preventing the futile use of expensive and toxic therapies. Reports suggest that ctDNA was a 
more sensitive method for detecting disease progression than current methods, as ctDNA 
frequency changes occur significantly earlier than changes in CEA or radiological imaging 
(Carpinetti et al. 2015; Tie et al. 2015; Sun et al. 2018). 
Post-operative ctDNA variant allelic frequencies were reported to help predict 3-year response 
free survival (RFS) after neoadjuvant therapy in patients with LARC (Tie et al. 2019). In patients 
with metastatic CRC, significant early decreases in ctDNA were indicative of improved PFS (Tie 
et al. 2015). In comparison, CEA was reported to have no positive predictive value to predict 
patient response to chemotherapy, and was particularly poor in comparison to ctDNA fold-
changes (Tie et al. 2015). Similar reports have suggested that post-surgical ctDNA levels in 
plasma are a significant predictor for later relapse in patients with CRC undergoing adjuvant 
therapy (Reinert et al. 2015). 
Russo and colleagues (2015) reported that they could detect KRAS mutations in patient ctDNA 
which were absent in the primary tumour biopsy of a patients with CRC. These variants were 
later detected within metastatic lesions. This is an agreement with findings from a separate 
study which reported that ctDNA had an improved concordance with metastatic tissue than 
primary tumours (Brannon et al. 2014). This finding indicates the potential use of a ctDNA to 
detect the presence or emergence of sub-clones/metastatic lesions before the initiation of 
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treatment and facilitate risk stratification and treatment decision making, both of which are 
being explored in prospective clinical trials.  
Developing CRC subtyping systems will likely influence how ctDNA is utilised in the future. 
Though ctDNA currently looks likely to monitor and detect KRAS/NRAS mutations, the 
emergence of these novel systems may lead to alternative mutations being analysed as part of 
subtype allocation/validation. One possibility could be that monitoring of CRIS-D patients may 
include levels of IGF2 copy number variations, or mutations within other genes vital to WNT 
signalling (Isella et al. 2017). Similarly, CMS1 may include tracking ATM or PTEN mutations 
throughout therapy (Dienstmann et al. 2017b). The numbers of genes of interest for tracking 
will likely expand as our knowledge of genetic alterations associated with each subtype 
increases. 
There remain several limitations associated with ctDNA, such as the generally low cfDNA 
concentrations extracted from plasma which can hinder analysis. Furthermore, ctDNA is often 
found fragmented into short lengths of DNA, limiting the molecular alterations which can be 
reliably detected; though evolving techniques are swiftly overcoming this issue. Other features 
have also been suggested to cause an increase in cfDNA/ctDNA levels, including inflammation 
and trauma (Thierry et al. 2010). These are factors which must be considered when 
investigating patients being treated with cytotoxic agents and surgery. 
Furthermore, a significant proportion of cfDNA can originate from non-tumour cells. This can 
cause a high background level of non-tumour cfDNA and hinder tumour DNA detection 
(Bettegowda et al. 2014) and the confident quantification of changes in allelic frequency (Diehl 
et al. 2008). This can also be exacerbated through improper pre-analytical handling (Ignatiadis 
et al. 2015).  
Analysis of ctDNA is rapidly approaching routine clinical use due to its speed, simplicity and 
relatively low cost. In fact, screening of resistance associated mutations in ctDNA is already 
being applied in non-small cell lung cancer (FDA 2016) and kits for RAS screening in ctDNA 
have recently been CE-marked for utility in CRC (Sysmex-Inostics 2016). Though the 
information provided may be relatively limited, ctDNA is detectable in a relatively high 
proportion of patients and analysis can be screened for mutations of interest. These 
advantages coupled with our current knowledge of CRC genetics and clonal evolution make 
ctDNA a very appealing biomarker. 
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These examples are in the context of targeted therapies with known resistance-associated 
variants or signatures. Chemoradiotherapy in patients with LARC is yet to have an identified 
variant or signature to associate with treatment resistance or sensitivity. Therefore, for 
patients with locally advanced disease ctDNA can hypothetically be used in patient monitoring 
and surveillance to detect disease recurrence. However, ctDNA cannot yet be used to identify 
the progression of chemoradiation resistant disease. Further research is required to identify 
variants or signatures which are indicative of therapeutic resistance to fully exploit ctDNA 
analysis in this capacity. 
1.4.3.4 Circulating MicroRNA 
1.4.3.4.1 MicroRNA Biogenesis 
MicroRNAs are small non-coding RNAs (~18-25 nucleotides long) which have been found to 
regulate targeted mRNA expression in both healthy and cancer tissues. MicroRNA sequences 
are either located in non-coding intergenic regions of DNA or within gene introns (Ameres and 
Zamore 2013). In the nucleus, primary microRNA (pri-microRNA) is synthesised by RNA 
polymerase II enzymes from genetic microRNA sequences in nuclear DNA. These are initially 
synthesised into long (~60nt) stem loop structures. Pri-microRNAs are then cropped into 
shorter intermediates by Drosha (an RNase III enzyme) in combination with Pasha or DCGR8 
(Ameres and Zamore 2013).  
Short pri-microRNAs are then transported into the cytoplasm via the nuclear pore by the 
nuclear transport receptor Exportin 5. In the cytoplasm, the RNase II protein Dicer liberates 
microRNAs into ~22nt microRNA-microRNA* duplexes (Ameres and Zamore 2013). This 
process is referred to as dicing. MicroRNAs then bind to the Argonaute (AGO) protein in the 
cytoplasm. Here the microRNA* strand of the duplex is cleaved and released. The remaining 
microRNA strand and AGO protein recruit other proteins to form the RNA-Induced Silencing 
Complex (RISC). The microRNA then proceeds to guide the RISC complex to complementary 
mRNA sequences in order to regulate expression (Figure 3) (Ameres and Zamore 2013). 
In microRNAs, the major determinant of complementarity is a 5’ 6-8 nucleotide sequence on 
the microRNA which is known as a ‘seed sequence’. This complementary sequence is normally 
found in the 3’ untranslated region (UTR) of the mRNA. Upon binding of the RISC to 
complementary mRNA, the complex represses translation through mRNA degradation (Ameres 
and Zamore 2013). 
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Figure 3: MicroRNA biogenesis from transcription from DNA by RNA polymerase II in the nucleus to mRNA 
degradation in the cytoplasm
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1.4.3.4.2 MicroRNAs in Cancer 
Since microRNAs were originally associated with cancer (Calin et al. 2002), they have been 
linked with numerous roles in tumourigenesis, including migration, invasion and metastasis 
(Ma et al. 2007) and growth, proliferation and inhibition of apoptosis (Cekaite et al. 2015). The 
function of microRNAs can either be tumour suppressing or driving; varying between different 
tissues and cancer types.  
Numerous microRNAs have been investigated for their predictive or prognostic values in 
patients with CRC. Mir-31 was previously demonstrated to be down-regulated in the tumour 
tissue of patients with LARC in comparison to adjacent normal mucosa (Jo et al. 2017). In colon 
cancer cells, Mir-31 was demonstrated to down-regulate the MMR gene MLH1 (Kim et al. 
2014). Mir-31 has also been reported to play a role in cetuximab resistance in KRAS wild-type 
CRC patient tumours (Pugh et al. 2017); though studies still dispute that this may simply be an 
indicator of generally poor prognosis (Carames et al. 2016). 
1.4.3.4.3 Circulating MicroRNAs  
MicroRNAs are relatively stable in circulation due to their protection from RNase activity 
through their association with carrier proteins or inclusion within exosomes (Lindner et al. 
2015). Considerable research has been performed in order to devise cell-free microRNA panels 
for clinical utility; with results varying considerably. Research has been directed at early 
diagnosis, predicting relapse, survival and treatment response and as a general prognostic 
marker (Toiyama et al. 2013; Chang et al. 2016). Various circulating microRNAs have been 
investigated as potential biomarkers, though none have yet been validated. Although several 
studies have been performed, few microRNAs have been consistently identified as diagnostic 
indicators of CRC when compared to healthy control subjects. These few include Mir-21 
(Kanaan et al. 2012; Ogata-Kawata et al. 2014), Mir-29a (Huang et al. 2010) and Mir-19a 
(Zheng et al. 2014; Matsumura et al. 2015). However, these have been in generally small 
cohorts (up to 300 patients) and further investigation will be required to determine clinical 
efficacy as well as why variations exist in the literature. 
Greystoke and colleagues (2015) recently utilised small cell lung cancer (SCLC) circulating 
tumour cell (CTC) Derived Xenograft (CDX) and PDX models to identify a panel of 10-
microRNAs for diagnosis and post-treatment follow-up. The use of these models allowed the 
identification of tumour-specific human miRNAs and limit background interference from non-
tumour DNA in the circulation. The 10-plex miRNA panel could distinguish stage 3 and 4 SCLC 
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patients from healthy volunteers with 82% and 98% sensitivity respectively and both having 
100% specificity. 
This study has established a potential pipeline for developing expression-based 
panels/signatures for clinical use, although the significance of removing the stromal influence 
is not fully understood (Greystoke et al. 2015). 
Although microRNAs do not currently influence subtyping, the CRCSC has reported that CMS2 
tumours up-regulate the MiR-17-92 cluster (including Mirs-17, -19a, -19b-1 and -92a), whilst 
CMS3 and CMS4 down-regulate let-7 and MiR-200 respectively (Guinney et al. 2015). Each of 
these can theoretically be quantified and monitored in plasma or plasma exosomes to predict 
response or stratify patient treatment in the future. The CRIS system has not yet reported 
incorporation of microRNAs.  
As our knowledge of the roles of microRNAs in cancer expands, so will potential applications in 
a clinical setting; though this is still in relatively early stages of research. MicroRNAs may also 
play a role in determining patient treatment, either through targeting miRNAs directly or 
through inferring tumourigenic drivers. We further predict changes in microRNA expression 
may be incorporated into a uniform subtyping infrastructure in the future. 
1.4.3.5 Circulating Exosomes 
1.4.3.5.1 Exosome Biogenesis 
In recent years, there has been increasing interest in the investigation of extracellular vesicles 
as circulating biomarkers in patients with solid tumours (Lotvall et al. 2014). Exosomes are a 
subset of extracellular vesicles which are ~30-120nm in diameter and have various roles; 
including cell-to-cell communication (Valadi et al. 2007).  
Exosomes are formed from early endosomes in the cell cytoplasm. Early endosomes are 
formed through the invagination of the plasma membrane, which swallows extracellular 
ligands and intracellular components. Endocytic vesicles can then share cargo and combine 
forming intraluminal vesicles (ILVs) within early endosomes. Proteins are then sorted in a 
process facilitated by exosome-sorting complex required for transport (ESCRT) proteins or 
other similar pathways (Wan et al. 2018b).  
These mature endosomes are then referred to as multivesicular bodies (MVBs). Some MVBs 
are degraded by the lysosome whilst others proceed to merge with the cell membrane in a 
process facilitated by the SNARE complex. As MVBs merge with the cell membrane, ILVs are 
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released by exocytosis into the extracellular milieu (Figure 4). Once exocytosed, these ILVs 
become exosomes (Wan et al. 2018b). Exosomes have been reported to play key roles in 
several different aspects of molecular biology, including immune cell modulation, apoptosis 
and angiogenesis (Gurunathan et al. 2019). 
Exosomes facilitate intercellular communication by transporting their molecular cargo from 
their parent cell and depositing their cargo into a target cell by fusing with the lipid membrane. 
Exosomal cargo has been reported to include proteins, various RNA species and DNA. It has 
been hypothesized that the contents of circulating tumour exosomes may either give an 
indication as to the genetic profile of parent tumour cells or the interaction of tumour cells 
with surrounding stroma. 
Both the internal (cargo) and external molecular (membrane-bound proteins) features of 
exosomes have been characterised and can be variable between different types of tissues of 
origin. Exosomes may contain various endosome-associated proteins, such as TSG101, which is 
involved in endosome biogenesis (Lotvall et al. 2014). However, as far as we are aware, there 
are some tetraspanins (e.g. CD9 and CD81) which are located and significantly overexpressed 
in the membranes of exosomes from a large variety of tissues in comparison to their cells of 
origin (Escola et al. 1998; Gurunathan et al. 2019). These proteins are often analysed to ensure 
that exosomes have been successfully isolated. There are also proteins which are known not to 
be associated with exosomes , such as AGO (Argonaute/RISC complex) or GM130 (Golgi 
complex) (Lotvall et al. 2014). The presence of such proteins can be analysed to ensure the 
purity of exosomes isolated, rather than exosomes being isolated alongside other 
contaminating extracellular vesicles or microvesicles. 
Exosomes have been demonstrated to be selectively packaged with their molecular cargo by 
their cells of origin to influence local or distant target cells (Ratajczak et al. 2006; Valadi et al. 
2007). The molecular cargo of exosomes has been reported to include proteins and different 
species of RNA (including mRNA and microRNA), however, the presence of exosome-derived 
DNA is still a disputed subject. Previously, Valadi and colleagues (2007) demonstrated that 
both mRNA and microRNA which was packaged into exosomes was found to be transcribed in 
their target cells, highlighting a key function of exosomes and their molecular cargo. This 
transfer of molecular cargo aims to induce a specific cellular function in their target cell. 
Recently, one study reported that mesenchymal stromal cells could secrete exosomes which 
influenced the proliferation and differentiation of Th1 T-cells through TGF-beta signalling 
(Cunha et al. 2020). 
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With the increasing interest in exosomes in recent years, numerous new technologies have 
been developed to facilitate their isolation. Originally, the only accepted way to isolate pure 
exosomes involved differential ultra-centrifugation which was laborious and required access to 
an ultra-centrifuge. However, newly developed methods aim to isolate exosomes is several 
different ways, some by precipitating them out of solution using polymers, others by isolating 
based on the presence of specific receptors (such as CD9 or CD81) or chromatographically, 
based on physical properties such as size and density. However, each of these methods has 
their own respective limitations regarding abundance or purity, which must be overcome as 
circulating exosomes approach clinical utility. 
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Figure 4: Exosome biogenesis and secretion from stimulated endocytosis to the release of exosome into the extracellular milieu by exocytosis 
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1.4.3.5.2 Exosomes in Cancer 
The functions of exosomes have been demonstrated to be co-opted by tumour cells in order to 
promote pro-tumourigenic characteristics, such as proliferation, vasculogenesis and migration 
(Ruiz-Lopez et al. 2018).  
In cancer cell lines, exosomes were demonstrated to transport oncogenic DNA which would 
promote endothelial cell proliferation (Huang and Feng 2017). Another study reported that 
exosomes secreted by colon cancer cell lines containing TGF-B, promoted the differentiation of 
fibroblasts into cancer-associated fibroblast (CAF)-like fibroblasts (Rai et al. 2019). 
Transformed CAFs have also been demonstrated to induce metastasis and chemotherapy 
resistance through the secretion of exosomes (Hu et al. 2019), both of which are hallmarks of 
cancer (Hanahan and Weinberg 2011).  
Studies have also suggested that exosomes transfer oncogenic DNA with similar affects to 
those seen for mRNA and microRNA. Studies have demonstrated the presence of tumour-
specific variants in tumour-derived exosomes from cancer cell lines (Thakur et al. 2014) and 
patients with pancreatic cancer (Kahlert et al. 2014). Exosomes were also demonstrated to 
transfer oncogenic DNA to target cells in vitro (Lee et al. 2014). Cellular uptake of exosomes 
carrying oncogenic DNA resulted in stimulated cellular proliferation in vitro.  
In various cancer types, there is evidence to suggest that oncogenic crosstalk between tumour 
tissue and the surrounding tumour microenvironment is mediated by exosomes. Studies have 
also reported that exosomes can enter the circulation and form pre-metastatic niches in 
distant sites (Costa-Silva et al. 2015). Overall, exosomes appear to be co-opted in cancer and 
play an impactful role in tumour development. 
1.4.3.5.3 Exosomes as a Circulating Biomarker 
Exosomes have been detected in the circulation of healthy individuals (Vlassov et al. 2012) but 
have been reported to be at increased levels in cancer patients and during disease progression 
(Ko et al. 2015). Studies have investigated the molecular cargo of circulating exosomes as 
biomarkers in a variety of cancers, including CRC (Matsumura et al. 2015); with greater 
emphasis on exosomal miRNA.  
One study reported that increased expression of exosome-derived Mir-19a has been suggested 
to be a prognostic biomarker for recurrence in patients with colorectal cancer (Matsumura et 
al. 2015), which is in agreement with other studies quantifying mir-19a in serum, serum 
exosomes and cancer tissue (Zhu et al. 2017).  
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Studies have recently investigated tumour-specific alterations in exosome -derived RNA 
(exoRNA) or DNA (exoDNA) for monitoring patients and stratifying therapy, in a similar vein to 
ctDNA. One such study investigated sequencing concordance, reporting that 14/19 (73.7%) of 
KRAS mutations and 6/8 (75%) of BRAF mutations detected in patient tissue were also 
detected in patient exoRNA (Hao et al. 2017).  
The emergence of cancer-specific exosomal markers may facilitate the detection of subtler 
molecular signatures and limit non-tumour background (Melo et al. 2015). Several studies 
have reported that, using a panel of tumour-exosomal markers, they were able to detect an 
increased frequency of KRAS mutation in exoDNA when compared to generic exosome 
isolation (Melo et al. 2015; Castillo et al. 2017); suggesting that they were able to isolate a 
purer yield of tumour-derived exosomes using a specific panel of surface markers. 
Recently, studies have reported the identification of proteins which are specific to exosomes 
secreted from pancreatic cancer and CRC cells. These tumour-specific exosomal markers may 
facilitate the isolation of an increasingly pure population of tumour exosomes to limit the 
presence of wild-type background of DNA, RNA or proteins and further facilitate analysis. With 
the future emergence of CRC-specific exosomes, it may also be possible to quantify tumour-
exosome levels to hypothesise tumour burden or aggressiveness before in-depth analysis 
begins.  
As suggested previously for CTCs, exosomes may be incorporated into a novel molecular 
subtyping system; as exosomes carry mRNA and microRNA, they may be a possible surrogate 
source for mutation detection or gene expression profiling where tumour tissue is unavailable. 
Concentration of tumour-specific exosomes may also be incorporated into staging, like that 
predicted for CTC numbers. 
Limitations with circulating exosomes do exist and will continue to be encountered as this field 
progresses. For example, as seen with ctDNA and microRNA previously a small concentration 
of exosomes will originate purely from the tumour, and low numbers will likely cause issues 
with molecular analysis, certainly in hypothesis-generating studies. Furthermore, a low 
concentration of exosomes extracted may be from the circulation of locally advanced non-
metastatic patients. Therefore, the presence of non-tumour exosomes and their respective 
molecular cargo may mask subtle signatures and low-level results from tumour-derived 
exosomes. We may yet overcome these issues as the technologies continue to develop, and 
simultaneously, even more limitations will almost certainly arise. 
35 
 
The study of cancer exosomes is a rapidly developing field, with an increasing number of 
publication focussing on exosomes and extracellular vesicles since the early 2000’s (Lotvall et 
al. 2014). As a result, several different technologies have recently emerged which facilitate 
exosome isolation from plasma/serum. Exosomal cargo may then be analysed using several 
methods. 
1.4.3.6 Circulating Tumour Cells 
CTCs are cells detected in the circulation of cancer patients which are CD45-ve whilst expressing 
epithelial markers (Ignatiadis et al. 2015). CTCs are understood to be tumour cells which have 
disseminated into peripheral blood and are precursors and/or direct cause of distant tumour 
metastasis (Janni et al. 2016).  
To date CellSearch is the only Food and Drug Association (FDA) approved method for capturing 
CTCs in a clinical setting (Sastre et al. 2012). This method uses the epithelial markers EpCAM 
and cytokeratins to isolate and enumerate CTCs for further investigation. 
Huang and colleagues (2015) investigated the potential of CellSearch-based CTC detection in 
11 studies and a total of 1847 patients with CRC. This study reported that high CTC counts at 
baseline and throughout treatment were associated with poorer disease control, disease 
relapse/progression PFS and OS. This is in agreement with studies with Bork et al. (2015) and 
Tan et al (2018) who demonstrated this in stage I-III and metastatic CRC patients respectively. 
Further studies have suggested that patients who converted from being CTC-high to CTC-low 
during therapy had better disease control than patients who changed from low to high, or 
remained persistently high (Huang et al. 2014). In patients with rectal cancer, studies have also 
shown that patients with high numbers of CTCs (>5) were more likely to develop distant 
metastases within one year of curative surgery (Tsai et al. 2016). Similarly, another study 
reported that patients with rectal cancer who responded well to neoadjuvant therapy had low 
post-treatment CTCs (Sun et al. 2016). 
Despite initial promise, this biomarker continues to display limitations in the CRC arena. The 
specificity of these techniques has been widely debated; whilst some studies have reported no 
detectable CTCs in benign conditions or healthy individuals (Sun et al. 2013b) others have 
detected CTCs in benign colon disorders (Pantel et al. 2012). Furthermore, detection of one or 
more CTCs per 7.5mL has only been reported in 30-50% of CRC patients (Hardingham et al. 
2015); limiting potential clinical efficacy. There is also the possibility of false negatives due to 
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loss of epithelial markers during epithelial-mesenchymal-transition (EMT); further limiting 
potential utility (Hardingham et al. 2015).  
CTCs have provided greater insight into intra-tumour heterogeneity than biopsies alone. Gasch 
and colleagues (2013) reported that separate CTCs within a single patient had different 
mutational profiles, illustrating that separate regions of the invasive tumour can have 
individual driving mechanisms. Additional studies have also detected relevant mutations in 
CTCs when absent in tumour biopsies, influencing patient-response (Mostert et al. 2013).  
CTCs have been investigated ex vivo in a number of solid tumours; being culminated into cell-
lines (Cayrefourcq et al. 2015) and /or transplanted into immune-deficient mice (Lallo et al. 
2017). Grillet and colleagues (2017) reported that, in CRC, CDX mirrored the response of the 
patient to platinum and etoposide therapy; illustrating the potential to truly personalise 
therapy. Though still in its infancy, this gives an indication into the potential of CTCs as an ex 
vivo microcosm of the tumour itself. 
As CTCs were predictive of the occurrence of distant metastases in patients with rectal cancer 
(Tsai et al. 2016), CTCs may be able to identify patients with micro-metastases after therapy or 
before surgery. Therefore, CTCs may be used for post-therapeutic risk-stratification and 
treatment-decision making with regards to the administration of post-operative adjuvant 
therapy. 
We hypothesise that CTC enumeration could be incorporated into staging or predicting the 
likelihood of metastatic occurrence, further facilitating in treatment decision making. CTCs also 
have the potential to be used as surrogate markers for subtyping where tissue samples are 
unavailable. Reports have stated that CTC-derived microRNA did not correlate with CTC count, 
illustrating that we still have a limited understanding of the roles of both CTCs and microRNA 
in the context of CRC (Tan et al. 2018). Both the CRIS and CMS systems have an EMT-
associated group with enhanced TGF-β signalling (CRIS A/B and CMS4) possibly allowing for 
future incorporation. As CTCs will be free of adjacent stroma, it will allow for a purer cancer 
cell intrinsic signature, potentially corresponding well with CRIS subtyping.  
CTCs and ctDNA have often been compared for their potential clinical impact. Concordance of 
CTCs and ctDNA with mutations detected in primary tumour or metastases has been reported 
at approximately 78% (Kidess-Sigal et al. 2016). In this study, each biomarker was detected in 
one patient where the other was absent; moreover, each biomarker detected a mutation 
previously unseen in the primary tumour or metastasis. This suggests both biomarkers may be 
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equally useful when investigating or considering intra-tumour heterogeneity; although both 
are thus limited and may be best used in tandem. One advantage of ctDNA over CTCs is that 
ctDNA has been reported as detectable in 100% of metastatic CRC, whereas only 35% had 
detectable CTC levels from 10mL whole blood (Germano et al. 2017). However, due to CTCs 
detection not requiring knowledge of existing tumour-specific changes, it can fulfil a role of 
screening and early detection in a superior fashion, having a different niche than that 
predicted for ctDNA.  
Despite recent advances, reported false positives and low CTC numbers are a potential cause 
for concern. New technologies, such as CellCollector, are in development which involve 
inserting probes into directly into patient blood vessels for an extended period of time in order 
to collect larger numbers directly from blood, as opposed to collecting CTCs from a limited 
volume of whole blood (Theil et al. 2016). Other methods, such as the AdnaTest, are relatively 
simple and consistent techniques, having been designed for clinical utility and incorporate 
both isolation and mRNA extraction (Gorges et al. 2016). Future clinical studies can assist in 
creating the basis for clinical utility of CTCs in terms of subtyping, prognostication, 
response/metastasis prediction or treatment stratification. The potential use of CDXs to test 
numerous treatments is also an exciting future direction. 
1.4.3.7 Circulating Metabolites 
Metabolomics is defined as a post genomics research field and the study of metabolic profiles. 
Like miRNA and ctDNA, several groups have used hypothesis-free methods such as mass 
spectrometry (MS) and nuclear magnetic resonance (NMR) imaging to determine metabolic 
signatures in CRC patient subgroups. These signatures were developed for utility in early 
diagnosis (Surinova et al. 2015), monitoring disease progression (Zhu et al. 2015) or 
inflammatory status (Bertini et al. 2012). These signatures include proteins, glycoproteins, 
amino-acids and lipids among other metabolites. 
Zhu and colleagues (2015) used Liquid Chromatography with Mass Spectrometry (LC-MS) to 
analyse sequential patient serum samples from 70 patients with CRC in an attempt to 
distinguish between progressing and stable disease. Using five core-metabolite levels, this 
group demonstrated that they could distinguish patients with progressing and stable disease 
with sensitivity and specificity of 83% and 94% respectively. Furthermore, this study also 
reported that this metabolomic profile was superior to CEA concentrations in predicting 
disease progression (Zhu et al. 2015). 
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Metabolomics has great clinical potential for largely different reasons to the biomarkers 
discussed previously. As previously mentioned, CMS3 and CRIS-A have been defined as 
consisting of metabolic dysregulation (Guinney et al. 2015; Isella et al. 2017). 
The CRCSC has reported a number of metabolic pathways which are deregulated within CMS3; 
some of which agree with a systematic review published by Zhang and colleagues (2017). 
Zhang and colleagues reported deregulated levels of amino acid and carbohydrate metabolism 
in various tissues; organised into pathways by use of the Kyoto Encyclopaedia of Genes and 
Genomes (Goto et al. 1997). The CRCSC reported overall increased expression of these two 
metabolic pathways in CMS3 (Guinney et al. 2015), highlighting the driving mechanism behind 
this subgroup of tumours. This is also in agreement with the CRIS A subtype, which was 
reported to have a sustained glycolytic metabolism (Isella et al. 2017), and which, like CMS3, 
also had a high rate of mutations in KRAS. These factors combined might suggest therapeutic 
targeting of the metabolic deregulation within this subset of CRC tumours. These patients 
might also benefit from staging or monitoring with circulating metabolites rather than other 
biomarkers, as one would be directly utilising the pathway driving tumour development. 
Though these studies may not be directly comparable due to the different questions each 
report poses, the existence of overlap may help patient sub-classification in the future, and 
possibly lead to treatment stratification. Thus, metabolomic analysis of patient tumour and/or 
plasma/urine may become integral for patient subtyping into a future uniform system, with 
the further possibility of treatment stratification. 
In addition to the numerous molecular and circulating biomarkers discussed here, there are 
many others which are in earlier stages or growing in popularity in patients with rectal cancer. 
These include radiomics, the use of radiological imaging to investigate parameters such as 
vascular growth and tumour heterogeneity. In patient circulation, circulating nucleosomes and 
proteomics are also growing fields of interest but we could not discuss all biomarkers of 
interest in such depth here. 
1.5 Technical Evaluation 
Recent technological advances in the field of sequencing have helped to usher in a new era in 
the potential clinical utility of circulating biomarkers. Methods such as NGS and digital 
Polymerase Chain Reaction (PCR) have been an integral part of this evolution.  
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1.5.1 Next Generation Sequencing 
Since 2005, the emergence of commercially available massively-parallel bench top sequencers 
has caused a significant increase in the widespread availability of targeted sequencing and 
analysis, in both a research and clinical setting (Voelkerding et al. 2009). NGS technologies, 
such as the Lifetechnology’s Ion Torrent Proton and the Illumina Miseq, can allow consistent 
and reliable detection of tumour variants in tumour biopsies or ctDNA.  
1.5.1.1 Scientific Basis of Next Generation Sequencing 
NGS technologies involved a large shift from the limited and laborious low-throughput first 
generation sequencing methods which they succeeded. Using NGS, many randomly arrayed 
DNA molecules on a sequencing chip are sequenced and captured in parallel. In most cases, 
thousands of identical DNA strands are bound to a fixed position, sequenced with sequential 
nucleotide washes and scanned in order to detect the addition of new nucleotides. The main 
commercial sequencers apply reversible terminator or semiconductor sequencing for NGS 
analysis.  
Reversible terminator sequencing technology is used in Illumina sequencers such as the Miseq. 
In this process, DNA is amplified, barcoded, washed and bound to a sequencing chip where 
another round of amplification occurs to form amplicon clusters. These clusters are washed 
with nucleotides which contain sequencing terminators, which blocks the addition of >1 
nucleotides and allows the augmentation of a single base at a time. Each added based contains 
a fluorescent tag. Once added, excess nucleotides are washed away, and the added base is 
scanned and recorded. The terminators are then enzymatically cleaved and new nucleotides 
are washed over the sequencing chip and the cycle continues. 
Semiconductor sequencing is applied by LifeTechnologies sequencing such as the Ion Torrent 
Personal Genome Machine (PGM) and the Ion Torrent Proton. This technology also included 
the amplification, barcoding and sequential washing of template DNA. Individual DNA 
molecules are then bound to silicon sphere through their respective barcodes. DNA is then 
amplified so that thousands of copies of each amplicon are then bound to each silicon sphere. 
Spheres are then loaded into a sequencing chip containing tens of millions of wells, each 
designed to contain one sphere. Sequencing chips are then loaded into the sequencer. Each 
chip is then sequentially washed with a single nucleotide at a time. When a nucleotide is added 
to sphere-bound amplicon, a single hydrogen ion is released. The sequencers measure the pH 
after each nucleotide is added, and where pH changes are detected (as a result of the released 
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hydrogen ion) and the sequencers records the addition of said nucleotide. The number of 
nucleotides added is calculated according to the change in pH detected by the sequencer. 
NGS allows massively parallel high-throughput sequencing ranging from small targeted 
sequencing panels to whole exome or genome sequencing and is ideal for hypothesis free 
variant detection.  
1.5.2 Digital PCR 
1.5.2.1 Scientific Basis of Digital PCR 
Digital PCR is the result of advancements in microfluidics and emulsion PCR chemistry to create 
a highly precise, reproducible and sensitive method for rare variant detection. Digital PCR was 
first described by Vogelstein and Kinzler in 1999 in a study which displayed the high sensitivity 
of digital PCR to known RAS variants in patients with CRC (1999). Digital PCR shares similarities 
with real-time quantitative PCR (qPCR) in how the assays use different coloured fluorescent 
probes to signal the detection of variants of interest and wild-type DNA. However, technical 
aspects of digital PCR provide distinct advantages with regards to sensitivity, precision and 
quantification (Cao et al. 2017). 
There are two main types of digital PCR applied, these being chip-based and emulsion-based 
digital PCR. In both cases, digital PCR analysis is based upon three principles, 
compartmentalisation, single-molecule PCR and Poisson statistics (Cao et al. 2017). The only 
difference between chip-based and emulsion-digital PCR is the method by which reactions are 
compartmentalised. Chip-based digital PCR separates a single PCR reaction (containing 
primers, fluorescent probes DNA polymerase enzyme, sample DNA etc.) into a large number of 
wells on a microchip, whereas emulsion digital PCR separates reactions into oil-based droplets. 
Emulsion-digital PCR is also referred to as droplet digital PCR (ddPCR). 
The number of compartmentalised reactions can vary between different technologies but will 
usually be >10,000. Each reaction is designed to contain a single molecule of DNA. Each 
compartmentalised reaction is then amplified under normal qPCR conditions and amplified 
reactions are scanned for fluorescence. As each reaction only theoretically contains up to one 
molecule of DNA, each separate compartment should only have a single detectable 
fluorescence, mutant or wild type. The number of mutant and wild-type compartment can 
then be quantified, allowing reliable VAF calculation and absolute quantification without the 
need of a standard curve. 
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The high sensitivity and precision of this technology makes ddPCR an ideal technique for ctDNA 
analysis. ddPCR is however limited as an individual assay, requiring prior knowledge for variant 
detection. For this reason, among others, ddPCR is often coupled with NGS analysis. NGS 
allows the sensitive analysis of tumour-specific variants across a wider range of genes, from 
smaller targeted sequencing panels to whole exome or genome sequencing. ddPCR can then 
be applied for fast and precise sequential variant detection and quantification. 
1.6 Thesis Overview 
This thesis will focus on the technical aspects of a range of potential prognostic and predictive 
circulating biomarkers in patients with LARC. These circulating biomarkers will specifically 
include ctDNA, cfDNA, circulating exosomes and systemic immunological biomarkers; such as 
NLR, PLR and LMR. This project will involve the design, optimisation and validation of assays 
for the reliable extraction and analysis of ctDNA and circulating exosomes in these patients. 
This study will also involve determining the ability of ctDNA, circulating exosomes and systemic 
immunological biomarkers to predict patient pathological response to pre-operative 
radiotherapy in patients with LARC. The specific aim of this thesis is expressly to determine 
whether these circulating biomarkers can be reliably extracted and analysed in patients with 
LARC. 
1.7 Thesis Aims 
• To choose and validate appropriate methods for the analysis of ctDNA in patients with 
LARC 
• To analyse sequential ctDNA and cfDNA samples in the context of clinical 
characteristics and outcomes in patients with LARC 
• To develop an assay for the extraction and analysis of exoRNA in patients with LARC 
• To analyse sequential exoRNA samples in the context of clinical characteristics and 
outcomes in patients with LARC 
• To analyse standard clinical blood counts and related inflammatory indices in the 
context of clinical outcomes in patients with LARC 
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2  Materials, Methods and Assay Validation 
2.1 Introduction 
In recent years, circulating biomarkers have moved to the forefront of research in patients 
with cancer. This is at least in part, a result of recent technological advances, including the 
emergence of technologies such as NGS and ddPCR. The development of NGS has facilitated 
large scale high-throughput sequencing, whilst ddPCR has allowed highly sensitive and specific 
analysis of low-concentration circulating biomarkers. 
As a circulating biomarker, ctDNA is rapidly approaching common clinical utility for patients 
with cancer. This is DNA which has been shed by tumour tissue into the circulation of patients 
with cancer (Diehl et al. 2005). CtDNA is a subgroup of cfDNA which is shed into the circulation 
by either tumour or non-tumour tissue (Thierry et al. 2010).  CfDNA can contain variably high 
or low levels of tumour-specific variants, depending on a number of factors, such as patient 
stage (Bettegowda et al. 2014). In patients with locally advanced disease, ctDNA levels and 
VAFs can be very low and difficult to reliably detect.  
Circulating exosomes and their molecular cargo is another biomarker which has been growing 
in interest and popularity (Lotvall et al. 2014). The role of circulating exosomes in the clinical 
context is currently not well understood, and thus, is a significant distance away from potential 
clinical utility. Within our study, we investigate the clinical potential of circulating exoRNAs 
alongside cfDNA and ctDNA. 
As part of this study, we intend to design an analytical workflow in order to investigate cfDNA 
and ctDNA using NGS and/or ddPCR across longitudinal plasma samples in patients with LARC. 
In order to achieve this, we needed to decide upon a targeted NGS panel and associated 
sequencing technology and then determine the limit of detection for this assay using reference 
standards. We then proceeded to validate the ability of our targeted NGS panel to identify 
tumour-specific variants in ctDNA. We also determined the limit of detection for ddPCR, which 
would be used in tandem with NGS throughout this thesis. Finally, we designed an analytical 
workflow to be used in this study for variant detection and circulating biomarker analysis in 
patients with LARC.  
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2.2 Materials and Methods 
2.2.1 Patients and Ethics 
Throughout this study, patient samples were acquired from two separate sources. Firstly, we 
consented patients with LARC for our own study through the Wales Cancer Bank (WCB). 
Secondly, additional samples (both tissue and plasma) from patients with LARC were acquired 
from the ARISTOTLE clinical trial. 
2.2.1.1 Wales Cancer Bank 
A research protocol, patient information and subject review was submitted to the WCB to 
recruit patients with LARC undergoing pre-operative radiotherapy. Patients were invited to 
give informed consent to participate in this project, to allow access to previously taken 
formalin fixed and paraffin embedded (FFPE) tumour biopsy tissue, future tumour resection 
tissue, access to clinical case notes and to provide sequential blood samples during the course 
of treatment (See Appendix Section 9.1).  
Ethical approval was acquired from the WCB in January 2016 for consenting and investigating 
up to 40 patients with LARC for the investigation of circulating biomarkers (Project 16/001). All 
patients were seen and consented in Velindre Cancer Centre by the lower gastrointestinal 
team.  
Twenty-one patients were recruited to this study from January 2016 to March 2018. All 
patients were locally advanced at diagnosis and had >1 sequential plasma timepoint available 
for circulating biomarker analysis.  
All patients underwent radiotherapy with the intention of receiving curative surgery following 
recovery. However not all patients were able to undergo surgery after the completion of 
radiotherapy. Patients had either short course (25Gy/5) or long course (45Gy/25) radiotherapy 
over one week or five weeks respectively (Figure 5). 
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Figure 5: Patient treatment regimen of patients with LARC from the WCB undergoing preoperative 
radiotherapy plus surgery. Arrows represent hypothesised blood collection timepoints for circulating 
biomarker analysis 
No patients had primary tumour tissue available for DNA extraction from the WCB from this 
cohort, however, ten patients had excess tumour biopsy DNA available after the completion of 
clinical genetic testing from the All Wales Medical Genetics Service (AWMGS). Therefore, 
excess DNA was available for molecular testing from these 10 patients. 
Patient clinical data was collected by Professor Richard Adams at Velindre Cancer Centre. 
Patient identifiers were anonymised by the WCB and given a unique ID before sample 
extractions and molecular analyses were performed. The full list of clinical factors acquired 
from these patients is in the Appendices Section 9.2. 
2.2.1.2 ARISTOTLE 
Patient samples were also acquired from the ARISTOTLE clinical trial for molecular and ctDNA 
analysis. Each patient was consented for the trial and treated at their respective treatment 
site. Each patient was made aware that DNA and plasma samples may be used for translational 
research. For this study, patients were selected according to the availability of patient biopsy, 
resection and plasma samples.  
A total of 19 patient samples were acquired from the ARISTOTLE trial for sequencing and 
circulating biomarker analysis.  
Patients in the ARISTOTLE clinical trial received five weeks of chemoradiotherapy followed by 
surgery. Surgery was recommended to occur 8-10 weeks after the completion of 
chemoradiotherapy within this clinical trial (Figure 6). All patients received 45Gy of 
radiotherapy in 25 doses over five consecutive days (Monday to Friday) alongside 
capecitabine, which was taken twice daily concurrent with radiotherapy. Patients within a 
single arm of the trial were also treated with irinotectan once per week for the first four weeks 
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of radiotherapy. Details on the method of administration and mechanism by which 
Capetiabine and Irinotecan function were previously described in Chapter 1. 
 
Figure 6: Patient treatment regimen of patients with LARC from the ARISTOTLE clinical trial undergoing 
preoperative radiotherapy plus surgery. Arrows represent specified blood collection timepoints from the 
clinical trial for circulating biomarker analysis 
 
2.2.2 Pre-Analytical Sample Handling 
2.2.2.1 Wales Cancer Bank 
2.2.2.2 FFPE Tissue or Pre-Extracted DNA Collection  
No patients had excess FFPE tissue available for non-clinical analysis, however, excess FFPE 
tumour-derived DNA was available after clinical testing for ten patients. This DNA was 
extracted by the AWMGS using the Promega Maxwell 16 FFPE Plus Low Elution Volume 
Purification Kit (AS1130). 
2.2.2.2.1 Blood and Plasma Collection  
Whole blood (20mL) from WCB patients was collected into EDTA tubes and processed within 
one hour of collection. Whole blood underwent a double spin protocol to minimalize cell lysis 
and resulting cellular DNA contamination into plasma.  
Double spin protocol: Blood samples were initially centrifuged at 2000xg for 10 minutes at 4°C. 
The resulting plasma underwent a second centrifugation step at ~4000xg for 10 minutes at 
room temperature. Plasma was then separated into 1mL aliquots for storage at -80°C. This 
process was carried out by the WCB. 
46 
 
For all patients, up to 2 x 10mL of peripheral blood was collected for circulating biomarker 
analysis at each timepoint. Blood samples were collected before treatment (week 0), during 
radiotherapy and after the completion of therapy during follow up (Figure 5). Collection 
timepoints were variable due to clinical scheduling. 
Plasma samples were transported frozen on wet ice to the Institute of Medical Genetics, 
Cardiff and Vale University Hospital. 
2.2.2.3 The ARISTOTLE Clinical Trial 
2.2.2.3.1 Tumour Tissue Collection 
Patient FFPE tumour tissue was acquired from the ARISTOTLE clinical trial and processed into 
4x5µm thick sections at the Leeds Institute of Cancer and Pathology, St James’ University 
Hospital. A total of four sections on slides from each patient were sent to the AWMGS for NGS 
analysis. 
2.2.2.3.2 Blood and Plasma Collection  
Blood samples were collected from each patient at weeks 0 (pre-treatment), 1 (first week of 
radiotherapy), 5 (last week of radiotherapy) and 10 (during follow-up) as in the timeline 
displayed in Figure 5. Week 0 (pre-treatment) samples were collected up to two weeks before 
the initiation of treatment. At week 0, a second whole blood sample was collected for germ-
line DNA extraction and analysis.  
Samples were collected in either EDTA or Streck tubes (see Table 1 for details). Blood samples 
collected in EDTA tubes were processed into plasma at each respective site before being 
collectively shipped on dry ice to the AWMGS. Blood samples collected in Streck tubes were 
transported at room temperature to the AWMGS and processed into plasma upon receipt. All 
Streck tubes which took more than three days to arrive were discarded. Samples which were 
collected in Streck tubes and processed by the AWMGS used the same protocol as described in 
Section 2.2.2.2.1. The protocol used to process whole blood into plasma from EDTA tubes may 
have varied between laboratories. 
Whether collected in EDTA tubes and shipped as plasma or in Streck tubes and transported at 
room temperature, all samples which took >3 days to arrive at the AWMGS were excluded 
from analysis in this study. This factor was a major requirement for patient selection in this 
study, to try and provide consistent high-quality plasma samples for circulating biomarker 
analysis. 
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No information was provided regarding the time interval between blood collection and 
processing into plasma for samples collected in EDTA at respective treatment sites. Large 
variations in this time interval can affect sample quality during ctDNA analysis. This is less of a 
concern for samples collected in Streck tubes, as these can be processed up to three days after 
collection without significantly impacting sample quality. 
Table 1: List detailing which type of collection tube that sequential plasma samples were collected in for 
each patient from the ARISTOTLE clinical trial 
Patient ID Blood Collection Tube 
ARI-166 EDTA 
ARI-182 EDTA 
ARI-202 EDTA 
ARI-239 EDTA 
ARI-295 EDTA 
ARI-297 EDTA 
ARI-306 EDTA 
ARI-316 EDTA 
ARI-341 EDTA 
ARI-346 EDTA 
ARI-366 Streck 
ARI-373 Streck 
ARI-378 Streck 
ARI-400 Streck 
ARI-403 Streck 
ARI-408 Streck 
ARI-412 Streck 
ARI-413 Streck 
ARI-436 Streck 
 
All plasma samples were separated into 1mL aliquots and stored long-term at -80°C. 
2.2.3 Sample Extraction 
2.2.3.1 FFPE DNA Extraction 
DNA was extracted from FFPE tumour tissue using the Promega Maxwell 16 FFPE Plus Low 
Elution Volume Purification Kit (AS1130) according to the manufacturer’s instructions.  
The tumour tissue was assessed and macro-dissected to ensure tumour content was >20%. 
Tumour assessment was performed by Professor Richard Adams. FFPE tissue was scraped from 
slides using sterile scalpel blades, added to Proteinase K and Promega Incubation Buffer for 
protein degradation and de-paraffinization. Samples were incubated overnight (approximately 
16-18 hours) at 70°C whilst being shaken at 1300rpm in an Eppendorf Mixer C (15158953). 
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After incubation, Lysis Buffer was added to each sample and mixed thoroughly. Samples were 
transferred to Promega Maxwell Cartridges and underwent the automated FFPE/Cells DNA 
protocol on the Maxwell 16 Instrument. The automated process binds DNA to silica clad 
paramagnetic particles which undergo sequential washes in ethanol before being eluted. All 
samples were eluted in nuclease free water and quantified using the Invitrogen High Sensitivity 
Qubit Fluorometer (see Section 2.2.5.1). Extracted DNA was stored at 4°C.  
2.2.3.2 Germline DNA Extraction 
Genomic DNA was extracted from blood samples by the AWMGS. 1mL of ‘buffy coat’ was 
collected from each patient blood sample and stored at -80°C. Genomic DNA was extracted 
using the Maxwell RSC Instrument (Promega). In this instrument, nucleic acids are captured 
using paramagnetic Magnesil® particles, which are washed in a series of ethanol washes 
before being eluted into nuclease free water according to manufacturer’s instructions. 
Resulting DNA was quantified using the Invitrogen Qubit Fluorometer (Section 2.2.5.1) and 
stored long-term at 4°C. 
2.2.3.3 Cell free DNA Extraction 
Plasma was thawed and warmed to room temperature before cfDNA extraction using the 
QiaAmp Circulating Nucleic Acid kit (Qiagen; Cat No. 55114) according to manufacturer’s 
instructions. CfDNA was liberated from protein carriers within plasma by Proteinase K 
treatment. Treated plasma was then mixed with Binding Buffer, containing guanidine 
thycyanate and trometamil, in order to help bind DNA to a QiaAmp MiniElute Silica column. 
The column was washed consecutively with wash buffers and ethanol, dried and eluted into 
elution buffer (an RNase free buffer containing a very low concentration of sodium azide). 
CfDNA was stored long-term at 4°C.  
Isolated cfDNA was quantified using the Thermofisher Scientific Qubit Fluorometer (Section 
2.2.5.1).  
2.2.4 Reference Standards 
Reference standards were purchased from Horizon as pre-extracted DNA from cultured cell 
lines (see Table 2). These were used during experimental validations and limit of detection 
assays for NGS in Section 2.3.1.2. 
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Table 2: Product numbers and expected VAFs for variants contained within reference standard (Horizon 
2019) 
Product 
ID 
Expected VAF for 
Variants in EGFR (%) 
Expected VAF for Variants in 
KRAS, NRAS and PIK3CA (%) 
HD777 5.0 6.3 
HD778 1.0 1.3 
HD779 0.1 0.1 
HD776 0.0 0.0 
 
2.2.5 DNA Quantification 
2.2.5.1 Invitrogen Qubit 3.0 
DNA samples were quantified using the Invitrogen High Sensitivity (HS) double stranded DNA 
(dsDNA) kit (Q32851) and the Invitrogen Qubit 3.0. The HS dsDNA kit utilises a fluorochrome 
which specifically intercalates and binds with dsDNA to quantify DNA concentration. 
Fluorescence levels are then quantified by the qubit 3.0 and normalised to known and supplied 
standards before quantifying sample DNA. The reported detection range for the HS kit is 0.2 – 
100ng/µL.  
All DNA samples were quantified immediately after extraction using the qubit according to the 
manufacturer’s instructions. Qubit dsDNA HS buffer was added to dsDNA HS reagent in the 
ratio 199:1 respectively. The Qubit was always standardised for each batch of extracted 
samples. For standardisation, 10µL of each Standard was added to 190µL of Qubit 
buffer/reagent mix as per manufacturer’s instructions. These standards were provided within 
the Qubit kit.  
For each patient sample, 2µL of DNA was added to 198µL of Qubit buffer/reagent mix. Each 
sample/mixture was mixed thoroughly and incubated for two minutes at room temperature 
before quantification. The sample/mixture was placed into the Qubit 3.0 and the DNA was 
quantified according the level of fluorescence detected by the Qubit and converted into ng/µL.  
2.2.6 Exosome Isolation 
Three methods were directly compared for exosome isolation purity and yield in this study. For 
each method, 1mL of pre-treatment plasma was used for exosome isolation.  
2.2.6.1 Total Exosome Isolation Kit 
The Total Exosome Isolation (TEI) Plasma Kit (Invitrogen; 4484450) was used as per 
manufacturer’s instructions. Plasma was warmed to room temperature and centrifuged at 
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2,000xg for 20 minutes followed by another centrifugation at 10,000xg for a further 20 
minutes. 5µL of Proteinase K was added to the plasma sample and incubated at 37°C for 10 
minutes. The resulting mix was added to 300µL of the Exosome Precipitation Reagent. The 
mixture was mixed thoroughly and incubated on ice for 30 minutes. The sample mix was 
centrifuged at 10,000xg for 5 minutes and the supernatant was discarded. The pellet, 
containing the exosomes, was resuspended in 100µL of PBS and stored at 4°C until processed 
further. 
2.2.6.2 ExoEasy Kit 
Exosomes were isolated using the ExoEasy Maxi kit (Qiagen; 76064) according to the 
manufacturer’s instructions. Briefly, 1ml of plasma was filtered using a 0.22µm filter (Millipore; 
SLGP033RS) and centrifuged at 16,000xg for 10 minutes at 4°C. Resulting plasma was mixed 
with 1mL of binding buffer and warmed to room temperature. The sample mixture was added 
to a membrane affinity column and centrifuged at 500xg for 5 minutes. The column was then 
washed with 3.5mL of wash buffer (XWP) at 3,000xg for 5 minutes. Finally, the exosomes were 
eluted into 400µL of elution buffer (XE) and stored at 4°C until processed further. 
2.2.6.3 ExoSpin Columns 
Exosomes were isolated using ExoSpin columns (CellGS: EX04-20) according to the 
manufacturer’s instructions. ExoSpin columns were warmed to room temperature and washed 
through with 2 x 10mL of PBS. 1mL of plasma was thawed and filtered using a 0.22µm filter. 
Filtered plasma was added to the ExoSpin column and allowed to drain through by gravity. 
3mL of PBS was washed through the column to remove contaminating microparticles. 3.5mL of 
PBS was then added to the ExoSpin column to elute the column-bound exosomes. Resulting 
exosomes were collected and stored at 4°C until processed further. 
Exosomes were processed within 24 hours of isolation following all three methods. 
2.2.7 Exosome Purity Analysis 
Resulting exosomes from each method were analysed for sample yield and purity using a 
particle to protein (P/P) ratio as suggested by Webber and Clayton (2013). In addition to the 
P/P ratio, we also compared vesicle size and protein concentrations to determine the optimal 
method with which to proceed. The exosome size and particle concentrations were quantified 
using Nanosight Tracking Analysis (NTA) from Malvern Panalytical. Protein concentrations 
were quantified using a micro-Bicinchoninic Acid (micro-BCA) assay (Thermofisher; 23235). 
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2.2.7.1 Nanosight Tracking Analysis (NTA) 
All suspended exosomes were diluted 1/1000 in PBS for particle size and concentration 
analyses. 
The NTA is a commonly used method to calculate vesicle size and concentration. Suspended 
particles pass through a chamber in which a laser beam shines through. The particles scatter 
light which is captured by a mounted camera. The particles move under Brownian motion and 
the NTA uses Stokes Einstein equation to calculate particle diameters based on the speed of 
movement. The camera recorded, measured and quantified particles which were passed 
through a flow system at a known speed for a minute in triplicate.  
The particle concentration was calculated in particles (P) per mL (P/mL) and particle size was 
recorded in nm. 
2.2.7.2 BCA Assay 
A micro-BCA assay calculates sample protein concentrations using a working reagent (WR) to 
cause a sample colour change based on the protein concentration when incubated at 37°C. 
The protein concentration of a sample in question is then calculated by comparing levels to a 
standard curve Bovine Serum Albumin (BSA). BSA standards range from 0–2000ng/mL (See 
Appendices Section 9.6). 
The WR was made up by combining BCA reagents A and B in the ratio 50:1. 150µL of WR was 
added to 150µL of each standard and 150µL of isolated exosomes. The samples and standards 
were incubated at 37°C for 30 minutes and read using a spectrophotometer at 562nm within 
10 minutes of incubation. 
Protein concentrations were recorded as µg/mL. 
2.2.7.3 Particle to Protein Ratio 
Particle to protein ratios were calculated using the particle concentrations (P/mL) from the 
NTA and the protein concentration (µg/mL) from the micro-BCA assay. The particle to protein 
ratio was calculated using the following formula; (P/mL)/(µg/mL). Purity levels of resulting 
exosomes were compared to recommended concentrations by Webber and Clayton (2013). 
2.2.8 Exosome-Derived DNA Extraction 
For exoDNA extraction, exosomes were isolated from 1mL of plasma using the ExoSpin Kit as 
described in Section 2.2.6.3. 
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2.2.8.1 Vesicle Treatment 
Exosomes were treated using Proteinase K and DNase I to ensure any extracted nucleic acids 
were intracellular, rather than extracellular.  
Isolated exosomes were incubated at 60°C for 60 minutes in 0.2X Proteinase K (Thermofisher: 
25530049). Proteinase K was heat degraded by incubation at 95°C for 10 minutes before 
cooling down to room temperature. Following this, 0.01X Units of DNase I (Thermofisher; 
ENO521) was added to the sample and incubated at 37°C for 60 minutes. DNase I was 
denatured by heating exosomes at 75°C for 15 minutes before cooling back down to room 
temperature. 
ExoDNA was extracted using the QIAamp Circulating Nucleic Acids Kit as previously described 
in Section 2.2.3.3 and quantified using the Invitrogen dsDNA HS Qubit (see Section 2.2.5.1).  
2.2.9 Exosome-Derived DNA Analysis 
2.2.9.1 Droplet Digital PCR for Variant Detection 
Variant detection was performed using the Bio-Rad ddPCR as described previously in the 
Materials and Methods. 
2.2.9.2 PCR for the Analysis of Variable Lengths of DNA 
ExoDNA length was analysed using primers pairs to generate amplicons of variable lengths in 
the BRCA1 gene by PCR. The primer pairs are described in Table 3. The BRCA1 gene was used 
in this study as it is not relevant in the context of rectal cancer and previously optimised 
primers were available. 
 
Table 3: Primer sequences and amplicon length for the analysis of variable lengths DNA extracted from 
exosomes 
Amplicon Length (bp) Direction Primer Sequence 
224 Forward AGCCTTCATCCGGAGAGTGTAG 
224 Reverse CCAGTCTTGCTCACAGGAGAGA 
500 Forward TGTCTGTTGCATTGCTTGTGTT 
500 Reverse CCGCACATTTCTCATGTTGTAGC 
827 Forward CTACTTTGGATTTCCACCAACACTG 
827 Reverse GGTAAATTCACCCATGTGAGACAAG 
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The reaction was set up using the appropriate primers as described in Table 4 and the 
thermocycler according to the conditions depicted in Table 5. 
Table 4: Reagents and reagent volumes for the amplification of exoDNA and cfDNA 
Reagent Volume (µL) 
10X Anglian Buffer 2.5 
dNTPs (5mM) 1 
Primers 1 
Water 15.4 
Taq 0.1 
DNA (5ng) 5 
Total 25 
 
Table 5: Thermocycler condition for PCR amplification of ExoDNA and cfDNA 
Temperature (°C) Time (Minutes) Cycles 
95 7 1 
95 1  
35 X 1 
72 1 
72 7 1 
4 
 
1 
 
X – Primers which produced 224bp amplicons worked optimally at 62°C, whilst the primers 
producing amplicons of 500bp and 827bp worked optimally at 63°C. 
2.2.9.2.1 Bioanalyzer 2100 
Amplified exoDNA was analysed using the Agilent High Sensitivity (HS) DNA Assay on the 
Agilent Bioanalyzer 2100 according to the manufacturer’s instructions. Briefly, Gel Dye mix was 
created by combining the HS DNA dye concentrate with HS DNA gel matrix. This was mixed 
and centrifuged at 2240xg for 10minutes through a spin filter.  
The loading dye mix was then loaded into an Agilent HS DNA chip followed by the HS DNA 
marker and then ladder/samples in respective wells. The chip was then run on the Agilent 
Bioanalyzer 2100. 
2.2.10 Systematic Reviews 
A systematic review was performed to identify microRNAs of interest in patients with CRC and 
to predict response to radiotherapy. 
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The search engine ‘Pubmed’ was used to look for the terms ‘Circulating microRNA rectal 
cancer’ and ‘Circulating microRNA colorectal cancer’.   
We excluded reviews and meta-analyses from inclusion. We also excluded studies which 
focussed on the application of novel methodologies, were not in English, or looked at non-
colorectal cancers (See results Section 5.2.3.1). 
2.2.11 Exosome-Derived RNA Extraction 
2.2.11.1 Developed ExoRNEasy Protocol 
Extraction of exoRNA was performed using the ExoRNEasy Plasma Kit (Qiagen; 77064) from 
3mL of plasma according to the manufacturer’s instructions. This kit is an extension of the 
Qiagen ExoEasy kit described previously in Section 2.2.6.2 to include exosome lysis and RNA 
extraction. The protocol has been adapted based on suggestions from Enderle and colleagues 
(2015) and in-house changes as described in the Appendices Section 9.7. 
2.2.11.1.1 Exosome Isolation 
Plasma was pre-filtered (0.22µm) and centrifuged at 16,000xg for 10 minutes at 4°C. After 
centrifugation, the plasma was mixed with 3mL of binding buffer (XBP) and warmed to room 
temperature. 
The mixture was warmed to room temperature and added to an ExoEasy Spin column and 
centrifuged at 500xg for 1 minute. The column was then washed by centrifuging 10mL of wash 
buffer XWP through the column at 3,000xg for 5 minutes. Column-bound exosomes were 
treated with RNase buffer which consisted of 6.25µg/mL of RNase A diluted into 400µL of 
wash buffer XWP. The RNase mix was briefly centrifuged through the column before the flow 
through was reapplied and incubated on the column for 30 minutes at room temperature. The 
RNase was washed through the column using 18mL of wash buffer XWP and spun at 3,000Xg 
for 5 minutes. Finally, 400µL of elution buffer (XE) was added to the column and incubated for 
1 minute before being centrifuged at 500xg for 5 minutes. The eluent was re-applied to the 
column incubated for 1 minute at room temperature before being centrifuged for 5 minutes at 
3,000xg. 
2.2.11.1.2 Exosome-Derived RNA Extraction 
Treated exosomes were lysed in 1mL of Qiazol. Qiazol is based on Trizol and is made up of 
phenol and guanidine isothiocynthate (Chomczynski 1993) and is used to lyse cells whilst 
maintaining RNA integrity. 
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The lysed sample was vortexed briefly and incubated at room temperature for 5 minutes and 
180µL of chloroform was added to the lysed sample. The sample was briefly shaken, incubated 
at room temperature for 3 minutes and then centrifuged at 12,000xg for 15 minutes at 4°C. 
The top aqueous phase (approximately 800uL) was aspirated and added to 2X volume of 100% 
ethanol and mixed briefly. The mixture was then spun through a Qiagen RNeasy MiniElute spin 
column to extract RNA. The column was serially washed with wash buffers (1 x RWT, 2 x RPE 
and 1 x 100% ethanol.) 
The RNEasy column was then dried by full-speed centrifugation and eluted into 14µL of RNase 
free water. 
Extracted RNA was stored on ice and reverse transcribed immediately after extraction. 
2.2.12 Reverse Transcription 
2.2.12.1 MicroRNA Reverse Transcription 
2.2.12.1.1 TaqMan MicroRNA RT Kit 
MicroRNA was reverse transcribed using the TaqMan MicroRNA RT Kit according to the 
manufacturer’s instructions. Reagents were added to total RNA as shown in Table 6. 
Table 6: Reagents volumes for microRNA reverse transcription using the TaqMan MicroRNA RT Kit 
Reagent Reagent Volume (µL) 
RT Primer Pool 12 
dNTPs (100mM) 0.6 
Reverse Transcriptase (50U/µL) 6 
10X RT Buffer 3 
RNase Inhibitor (20U/µL) 0.38 
NFW 2.02 
Sample RNA 6 
Total 30 
 
The RT Primer Pool is a combination of all genes of interest making up a total volume of 12µL.  
2.2.13 Next Generation Sequencing 
2.2.13.1 Principles of Next Generation Sequencing with the Ion Torrent Proton 
Whole genome, exome and targeted sequencing methods have become much more common 
and easy to apply, largely due to the emergence of next generation sequencing (NGS) 
technologies. In 2011, several bench-top sequencers became commercially available, including 
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the Ion Torrent PGM and the Illumina Miseq (Liu et al. 2012). The following years saw 
numerous studies comparing the accuracy of single nucleotide polymorphism (SNPS) calling 
between these two methods (Liu et al. 2012; Misyura et al. 2016).  
Ion Torrent Sequencers, including the PGM and the Proton, use semiconductor technology to 
sequencing DNA. In contrast, Illumina sequencers, including the Miseq, use fluorescence-
tagged DNA bases with reversible terminators (Rothberg et al. 2011; Liu et al. 2012). 
Semiconductor sequencers measuring the change in pH, if any, which occurs when a base is 
added to a string of oligonucleotides, releasing hydrogen ions (Liu et al. 2012). This method 
was developed with the intention of overcoming certain limitations of competitor 
technologies; such as the need for imaging technologies to detect fluorescence and specialised 
nucleotides (Bentley et al. 2008).  
However, semiconductor sequencers have their own limitations. Though a change in pH can be 
read simply with the addition of a small number of identical bases (1-4), when larger strings of 
homopolymers are sequenced, there is an increased error-rate in homopolymer length 
quantification. Thus, the false calling of indels may be observed. Furthermore, in comparison 
to competitors, the Ion Torrent methods generally have a higher cost per Gb of data and 
require more hands-on time, increasing the chances of human error (Garrido-Cardenas et al. 
2017). The Ion Torrent has a low machine and operational cost in comparison to other 
technologies with a significantly shorter sequencing time (Garrido-Cardenas et al. 2017).  
In this study, the Ion Torrent Proton platform (LifeTechnologies, Thermofisher Scientific, UK) 
was applied to identify tumour-specific variants in patient tumour tissue and/or matching 
ctDNA. Detected variants could then be used for sequential ctDNA analysis. The process of 
decision-making for sequencing technology and targeted panel are described in Section 2.3.1.1 
in this chapter. NGS analysis using the Proton comprises of three main phases; these are 
library preparation, template preparation, and sequencing and data analysis. Here we describe 
the principles of each phase of NGS analysis, with a more detailed protocol to follow. 
2.2.13.1.1 Library Preparation 
Specific genes and variant hotspots of interest are amplified based on primers and probes 
included in a targeted NGS panel. Samples are initially cleaned and barcoded before being 
bound to magnetic beads. Once bound to these magnetic beads, DNA amplicons are cleaned in 
sequential washes of ethanol. A second-round of DNA amplification also occurs before a 
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second-round of sequential ethanol washes and the final DNA libraries are eluted and 
combined into a single pool for template preparation. 
2.2.13.1.2 Template Preparation 
Pooled DNA libraries are then separated into oil droplets with PCR reagents and ion sphere 
beads (similar to the ddPCR process). Within these droplets, DNA undergoes emulsion PCR and 
is bound to a bead directly by their respective barcodes. Where only a single DNA template is 
present within a droplet, the sphere is deemed monoclonal and appropriate for sequencing. 
Where more than one different template exists within a droplet, the ion sphere is deemed 
polyclonal and no sequencing occurs for these spheres. This highlights the important balance 
of fully loading spheres with DNA without significantly increasing polyclonality. Spheres are 
then loaded onto a sequencing chip which contains 70,000,000 individual wells, one for each 
ion sphere. 
2.2.13.1.3 DNA Sequencing  
Loaded microchips are then inserted into the Ion Torrent Proton for sequencing. The Proton 
washes the chip sequentially with a single base at a time and reads any pH changes, indicating 
the addition of said washed bases. As a nucleotide is incorporated onto a chain, a hydrogen ion 
is released, decreasing the pH, which is detected by the sequencer. The raw sequencing files 
are generated into FASTQ files for each respective barcode for downstream bioinformatic 
analysis.  
2.2.13.2 Next Generation Sequencing Protocol 
2.2.13.2.1 Library Preparation 
Patient DNA samples were amplified using the Ion Ampliseq Cancer Hotspot Panel Version 2 
(CHPv2; Catalogue Number: 4475346). For the first amplification step, 20-30ng of FFPE DNA or 
the maximum volume of 12µL of cfDNA was amplified using the CHPv2 primer pool. This 
difference is specified because cfDNA samples were unlikely to contain such a large amount of 
DNA, whereas this was reliably achievable from FFPE tumour tissue.  
For the first amplification step, two different numbers of cycles were used depending on DNA 
concentration. For FFPE Tumour DNA where 20ng was extracted, 21 amplification cycles were 
used, and for cfDNA samples 25 cycles were used due to low concentrations. The remaining 
library preparation steps were performed using reagents from the Ion Ampliseq Library Kit 2.0 
(Catalogue Number: 4475345) as per manufacturer’s instructions.  
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Amplified DNA was treated for primer digestion with the FuPa reagent before being barcoded 
and bound to magnetic beads for purification in sequential ethanol washes. DNA libraries then 
underwent a second round of DNA amplification before being purified in another round of 
sequential washes in ethanol. The resulting DNA libraries were eluted into Lo-Tris EDTA (Lo-
TE), diluted to 100pM and combined into a single DNA pool as part of template preparation. 
2.2.13.2.2 Template Preparation 
Prepared libraries were quantified using the Qubit 3.0 Fluorometer. 5µL of eluted DNA library 
was added to 195µL of Qubit buffer/reagent mix for quantification. Individual samples were 
diluted down to 100pM (15ng/mL) in Lo-TE and pooled together as per the manufacturer’s 
instructions. The DNA concentration of NTCs were quantified using the Qubit but excluded 
from sequencing as long as they were negative. Once DNA libraries from all samples had been 
pooled together, 10µL of the DNA libraries was added to 190µL of buffer/reagent mix for 
quantification with the Qubit. 
The pooled libraries were diluted further down to 75pM and loaded into the Ion Torrent Chef 
with the Ion Pi Hi-Q Chef Kit for further template preparation as per manufacturer’s 
instructions. Within the Ion Torrent Chef, samples were amplified, purified and bound to ion 
spheres which were loaded into an Ion 318 sequencing chip. 
2.2.13.2.3 Sequencing  
2.2.13.2.3.1 Ion Ampliseq Cancer Hotspot Panel Version 2 Sequencing Optimisation 
A Run Plan was generated for each individual sequencing run. The run plan was set up on the 
Cardiff University Ion Torrent Server (IP Address: 131.251.159.10). The Ion Torrent Proton was 
washed with water and bleach before preparing for sequencing. Wash buffers and sequencing 
reagents were prepared as per manufacturer’s instructions. The Ion Torrent Proton was then 
calibrated to ensure the pH levels were optimal for sequencing. Once the sequencer had been 
calibrated, loaded sequencing chips were taken from the Ion Torrent Chef were inserted into 
the sequencer within four hours of Chef protocol completion. Sequencing occurred over 150 
minutes and resulting data was uploaded to the Ion Torrent Server for variant analysis. 
2.2.14 Next Generation Sequencing Analysis 
2.2.14.1 Ion Torrent Variant Caller 
In this study, sequencing data was processed and converted into a Variant Call Format (VCF) 
file using the Ion Torrent Variant Caller. Ion Torrent Variant Caller is a plugin connected directly 
to the Ion Torrent Server and designed specifically to analyse Ion Torrent Proton NGS data. 
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The Ion Torrent Variant Caller will use bioinformatic tools to align sequencing data to the 
reference genome, calculate the quality of data under specific parameters before identifying 
variants. The tools used to achieve this would include Samtools and bcftools. Variants are then 
filtered by standard and specified features and thresholds using VCFfilter. Such features would 
include VAF and sequencing quality (EdgeBio 2019). 
2.2.14.2 Variant Filtration and Determining Clinical Significance 
2.2.14.2.1 Variant Filtration Principles 
In both a research and clinical setting, generated VCF files are examined to ensure all called 
variants are genuine and clinically relevant in the context of the disease of interest; in this case 
rectal cancer. To determine whether our variants were genuine, as opposed to sequencing 
artefacts, we analysed numerous properties of the VCF file, such as sequencing depth and VAF. 
We also annotated variants before analysing their clinical significance. 
Sequencing artefacts are found where a recorded DNA sequence does not represent the actual 
genotype of the sample due to the accumulation of errors throughout the NGS process. Such 
artefacts can occur through errors in PCR amplification or during sequencing. Studies have 
previously demonstrated that the DNA polymerase enzyme Taq has an approximate total error 
rate of 1 /10,000 bases (Potapov and Ong 2017). Therefore, as our NGS protocol includes a 
pre-amplification step with Taq, some sequencing errors may have occurred at this point. 
Studies have also demonstrated that all NGS methods, including the semi-conductor 
sequencing, have a sequencing error rate; this is the likelihood that a base can be read 
incorrectly (Quail et al. 2012). Although the sequencing quality begins relatively high for the 
first few bases, the quality of each base sequenced will naturally decline as the amplicon 
becomes longer, thus errors can occur after a certain length. For this reason, NGS methods are 
generally paired with shorter PCR amplicons. Sequencing artefacts can also be caused by 
primer dimer or the formation of similar biproducts of PCR and can inappropriately align to the 
reference genome, appearing to be genuine DNA reads. This aspect is less of an issue with 
targeted NGS panels, in comparison to whole exome or genome sequencing. 
A greater concern when analysing FFPE tissue is that sequencing artefacts may also be caused 
by sample fixation. This is more common in FFPE tissue, where cross-links can occur between 
DNA strands as a result of the formalin fixation process. This can cause both DNA 
fragmentation and cytosine deamination, where cytosine bases appear as an uracil base during 
sequencing. Therefore, there is an increase frequency of C>U/T and G>A changes in these 
60 
 
sample types (Ivanov et al. 2017). This should be considered in all future NGS analyses on FFPE 
tissue samples. 
To combat these potential issues, there are bioinformatic filters which can be applied during 
analysis to help avoid mistaking sequencing artefacts for genuine variants. Factors by which 
data is filtered include sequencing quality, the number of total and mutant reads, VAF and 
direction bias. The Ion Torrent Variant Caller will filter out any bases with a quality (Q) score 
below a certain value (Q20 in this pipeline), and trim sequences to remove the low-quality 
bases at the end of long amplicons before generating a VCF file. This pipeline will also compare 
the sequenced DNA to a BED file for specific targeted panel, which shows where DNA should 
be amplified and detected, and will exclude any sequencing not matching these expected 
regions. 
We can also manually filter out variants from the VCF file based on factors such as sequencing 
coverage and VAF. Sequencing depth is the number of times that a base in a specific location in 
the genome is sequenced. Whenever a base is sequenced, this is referred to as a read and is 
denoted by an X (e.g. a genomic location read ten times has 10X coverage). There are 
guidelines as to the number of reads which are recommended for variant detection, for both 
the mutant base and the number of total reads at a single location when using NGS (Jennings 
et al. 2017). These are described further in Section 2.2.14.2.2. 
VAF is the proportion at which a base change occurs in a specific location compared to the 
total number of reads at that location and is often displayed as a percentage. As low numbers 
of sequencing artefacts can filter through to the VCF file, a minimum VAF is often 
recommended to exclude the ‘background noise’ of sequencing artefacts. The minimum VAF 
applied for this analysis was based on the limit of detection performed in Section 2.3.1.2. 
Once sequencing artefacts have been removed and only genuine variants remain, variants are 
then annotated. This process involves aligning a variant’s genomic location to the reference 
genome and identifying whether this gene occurs within a gene, in the coding region of said 
gene, whether this causes a synonymous or non-synonymous change to the coding sequence 
and so on. Many programs will even highlight if a variant has been identified in the germline of 
general populations or alternatively, frequently occurring somatically in certain cancer types 
before. This annotation process can remove variants which are unlikely to influence gene 
function. Variants which pass all filtration processes were investigated for clinical significance 
as described in Section 2.2.14.2.3 of this chapter. 
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2.2.14.2.2 Variant Filtration Protocol 
Variants were initially filtered as described in Figure 7 before being classified as clinically 
significant or benign. Firstly, variants were filtered by VAF according to the sample type. In 
cfDNA variants <1.0% and >90% were removed, due to the likelihood of these being 
sequencing artefacts and homozygous SNPs respectively. Variants at 40-60% were also 
excluded as these were also likely to be heterozygous germline variants. For FFPE tumour 
tissue, variants <10% and >90% were removed for the same reasons. In FFPE tissue, variants at 
40-60% VAF were investigated further and validated as somatic using germline tissue where 
possible. If no germline tissue was available, these variants were included and would be 
analysed further for variant clinical significance. 
Next, variants were filtered by coverage, with ctDNA samples and FFPE tissue requiring ≥1000 
and ≥250 reads to pass respectively. A minimum of ten mutant reads (five in each direction) 
were deemed necessary for further investigation. This initial minimum value is based on 
guidelines from Jennings and colleagues (2017) for somatic variant detection using targeted 
NGS panels. This value would vary based on the total number of sequencing reads acquired 
and limit of detection as described in Section 2.3.1.2 in this chapter. Thus, the minimum of ten 
total reads was applied to facilitate the removal of sequencing artefacts in regions of poor 
coverage. Thereafter, variants with ≥90% direction bias were also removed, due to an 
increased likelihood of these containing artefacts. 
Remaining variants were then annotated using ANNOVAR (Annotate Variation), and non-
coding and non-splice site affecting variants were also removed, as these were less likely to be 
pathogenic and/or clinically actionable. Furthermore, once variants had passed each of these 
filtration steps, each variant was visually inspected in the BAM file using the Integrated 
Genome Viewer (IGV) software to confirm they were not sequencing artefacts. To this end, 
samples and variants were compared to the wild type and positive controls on the same 
sequencing chip to identify the presence of any commonly occurring sequencing artefacts in 
each sequencing run. 
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Figure 7: The Filtration Process for Variants Selected in the Next Generation Sequencing Analysis Pipe-
Line 
After this, variants were classified as clinically significant or benign based on recently published 
clinical guidelines as detailed below. 
2.2.14.2.3 Determining Clinical Significance 
With the rapid development of NGS assays and their implementation in the clinical setting in 
recent years, the decision as to which variants were to be reported also had to adapt and 
develop. For clinical laboratories or assays investigating disease-causing germline variants, 
guidelines have recently been published by the American College of Medical Genetics (ACMG) 
(Richards et al. 2015). These guidelines provided a tiered system by which germline variants 
can be classified as very strongly pathogenic (PVS1) or stand-alone benign (BA1) or a wide 
range in between based on specific evidence. Using these guidelines, variant classification 
requires two pieces of evidence. Firstly, there must be previously demonstrated evidence of 
the gene’s relevance or involvement in the disorder of interest. Secondly, there must be 
evidence demonstrating that the variant in question detrimentally impacts gene function. This 
can either be in the form of predictive in-silico tools or in vitro or in vivo functional assays. 
More recently, a collaboration between the Association for Molecular Pathology (AMP), the 
American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) 
have published similar tiered guidelines for the classification of somatic variants in cancer (Li et 
al 2017). These tiers vary from Tier I (strong clinical significance) to Tier IV (benign/unlikely to 
have clinical significance). Unlike germline variant classification, the somatic variant guidelines 
are based on the clinical ‘actionability’ or relevance of a variant or gene in the context of a 
disease, rather than the pathogenic effect of variants on gene function alone. Similar published 
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institutional practice guidelines from SVC (Sukhai et al 2016) and PHIAL (Van Allen et al 2016) 
have also based their tiered classification systems on clinical actionability rather than variant 
functionality alone. Although there were distinct similarities between the three systems 
mentioned, we evaluated detected variants based upon the guidelines published by Li and 
colleagues (2017). 
In accordance with these guidelines, any of our detected variants which can be used to predict 
response or resistance to any FDA-approved therapies to rectal cancer were classified as Tier I. 
In contrast, Tier II variants (potential clinical significance) had to be indicative of diagnosis or 
prognosis (from ‘convincing’ published data but not necessarily published guidelines) or 
approved as a therapeutic biomarker for a different tumour type (Li et al. 2017a). For our 
variants of interest, this was performed using MyCancerGenome or screening active clinical 
trials using ClinicalTrials.gov. 
For variants to be classified as either tier, they also had to be absent or at very low frequencies 
in population databases, such as Exome Sequencing Project (ESP), the 1000genomes project 
and Exome Aggregation Consortium (ExAC). We also ensured these variants were frequently 
detected in patients with rectal cancer using data from the Catalogue of Somatic Mutations in 
Cancer (COSMIC), cBioportal and The Cancer Genome Atlas (TCGA) Network. We further 
ensured that each variant was predicted to be damaging to protein function using the in-silico 
tools Polyphen2, Combined Annotation-Dependent Depletion (CADD) and MutationTaster. 
Finally, all variants were verified as being related to rectal cancer according to 
MyCancerGenome (Figure 8). 
 
 
Figure 8: Flowchart describing the process of variant classification in accordance with guidelines from Li 
and colleagues (2017) 
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Any variants which did not fit these criteria will either have unknown significance (Tier III) or be 
benign (Tier IV) according to the guidelines from Li and colleagues (2017). Only variants which 
had strong clinical significance (Tier I) or potential clinical significance (Tier II) were used in 
future ctDNA or tumour heterogeneity analysis in subsequent chapters. Due to the lack of 
evidence supporting their role in tumourigenesis, variants classified as Tier III or IV were 
excluded as these are more likely to be ‘passenger’ rather than ‘driver’ variants. This process 
will have also removed germline variants which inappropriately passed the initial variant 
filtration process. 
2.2.14.3 Molecular Analysis 
2.2.14.3.1 Matching Paired Samples 
For all patients with >1 sample being analysed using NGS, the presence of hetero- and 
homozygous germline SNPs were used to ensure paired samples are derived from the same 
patient by ensuring all germline SNPs were detected in both samples at equal VAFs in their 
respective VCF files. 
2.2.14.3.2 Calculating Heterogeneity Scores 
Tumour heterogeneity scores were calculated as previously described by Normanno and 
colleagues (2015) using the following formula. 
𝑇𝑢𝑚𝑜𝑢𝑟 𝐻𝑒𝑡𝑒𝑟𝑜𝑔𝑒𝑛𝑒𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒 = 2 𝑋
100 𝑋 𝑉𝐴𝐹(%)
𝑁𝑒𝑜𝑝𝑙𝑎𝑠𝑡𝑖𝑐 𝐶𝑒𝑙𝑙 𝐶𝑜𝑛𝑡𝑒𝑛𝑡
 
All VAFs were acquired NGS data unless specified otherwise. Neoplastic cell content was 
calculated using a hemotoxin and eosin stain slide by Professor Richard Adams. 
2.2.15 Droplet Digital PCR 
2.2.15.1 Principles of Droplet Digital PCR  
Emulsion-based ddPCR was chosen for this study due to the reportedly greater sensitivity, 
reproducibility and precision offered over similar methods such as qPCR (Huggett and Whale 
2013). This method has built upon the same principles as qPCR, a method which enables real-
time quantification of amplified DNA by using oligonucleotide probes which are tagged with a 
fluorescent reporter and a quencher (Gut et al. 1999). This oligonucleotide probe can be ~20bp 
long and is complementary to a specific DNA sequence of interest.  
Oligonucleotide probes contain fluorophore reporters which naturally emit light at a specific 
wavelength which varies between different fluorophores. The two molecular reporters used in 
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this study were 6-carboxyfluorescein (FAM) and hexachlorofluorescein (HEX) which emit light 
at a wavelength up to 525nm and ~556nm respectively. The different wavelengths at which 
light is emitted and consequently absorbed from each fluorophore can be used to distinguish 
between the two different reporters. Thus, FAM and HEX probes are normally associated with 
separate genes or genotypes in molecular analysis, in this case they were each used to 
represent mutant and wild-type DNA respectively. These molecular reporters are often 
coupled with a quencher on their respective oligonucleotides. 
A black hole quencher is a molecular beacon which efficiently absorbs fluorescence. When 
close to FAM or HEX, the black hole quencher absorbs the emitted fluorescent light, making it 
undetectable to the user. The quenchers are thus generally located on the opposite end of a 
hairpin loop from their respective fluorophores on oligonucleotide probes. However, during 
PCR, when a probe containing both the reporter and quencher binds to complementary DNA, 
reporters and quenchers are separated from each other through the activity of Taq 
polymerase enzyme. This separation of the fluorophore from the quencher allows the reliable 
detection of fluorescence from the reader. Thus, when a mutant (FAM) or wild-type probe 
(HEX) binds to DNA, the probe is broken down by the enzyme and the reporter is separated 
from the quencher, allowing the detection of FAM or HEX, and thus, mutant or wild-type DNA 
(see Figure 9).  
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Figure 9: Illustration of the mechanism of DNA quantification using fluorescent reporter labelled probes 
and black hole quenchers during ddPCR analysis. 
 
As stated previously, digital PCR can provide improved sensitivity, precision and reproducibility 
as a result of the reaction partitioning which defines it. The Bio-Rad ddPCR system partitions a 
single qPCR reaction into ~15,000-20,000 smaller compartments/droplets using emulsion 
chemistry. Alternative forms of digital PCR compartmentalise reactions by using solid 
partitions on chips (Hindson et al. 2011; Kreutz et al. 2011). Furthermore, emulsion-based 
ddPCR can provide a greater number of partitions at a generally lower cost. Overall, ddPCR can 
allow greater sensitivity due to the increased number of partitions and is less prone to being 
affected by PCR inhibitors (Huggett and Whale 2013).  
ddPCR does have inherent limitations, largely involving the concentration of input DNA. A 
lower input DNA concentration can result in a smaller number of DNA-positive reactions and 
decreased confidence in the ability of the user to detect or quantify ctDNA. Overloading a 
ddPCR assay limits the reliability of quantified ctDNA. As each reaction is designed to only 
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contain one single DNA droplet, when the ddPCR is overloaded more than one DNA molecule 
may be contained in each compartment. Therefore, the quantification of ctDNA can become 
less reliable. 
Throughout this project, ddPCR was used to quantify VAF in ctDNA and gene expression levels 
of exosome-derived microRNA exoRNA due to the high sensitivity of the assay and the low 
concentrations of each of these biomarkers. Primers and probes for specific tumour variants 
were designed in-house and ordered from Sigma-Aldrich.  
In ctDNA samples, the Bio-Rad ddPCR system was applied to validate NGS findings in FFPE 
tumour tissue and track variants of interest in sequential plasma samples. Details regarding 
the primers and probes used for ddPCR analysis of exoRNA are described in Chapter 5. 
2.2.15.2 Primer and Probe Design 
Primers and probes were designed using Primer3plus (Untergasser et al. 2007) based on the 
human reference genome (hg19) from Ensembl.org (Hubbard et al. 2002). Genetic sequence 
surrounding the variant in question (>70bp in both directions) was acquired from Ensembl.org 
and pasted into Primer3plus. We then allocated specific conditions for primer design (such as 
optimal annealing temperature and length of amplicon). Pimer3plus then generated numerous 
suggestions for primer and/or probe designs using the information provided. We then 
confirmed the predicted primer pair conditions and specificity using the in-silico browser from 
UCSC.org (Kent et al. 2002). All probes were designed to have a melting temperature >3°C 
greater than associated primers. All oligonucleotides were designed with melting 
temperatures between 50-60°C. Each probe contained a 3’ black hole quencher and a 5’ 
fluorescent probe. All probes detecting variants had 5’ FAM probes whilst wild-type probes 
contained a 5’ HEX probe. For the full list of designed primers, see Table 7. 
2.2.15.3 Primer and Probe Preparation 
For DNA analysis, primers and probes were made up to 100µM in TE according to 
manufacturer’s instructions. Eluted oligonucleotides were then diluted to a concentration of 
10µM and 5µM respectively and combined into a 20X primer/probe mix (Table 7). For exoRNA 
analysis, primers and Probes were purchased from Thermofisher Scientific for four microRNAs 
of interest and a reference gene (RNU6B). See Table 8 for product details. 
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Table 7: Sequences of all primers and probes for sequential ctDNA analysis designed using Primer3plus 
Gene Variant Forward Primer Reverse Primer Mutant (FAM Probe) WT (HEX) Probe 
NRAS p.G13R† GTGTGAAATGACTGAGTAC TCTGGATTAGCTGGATTG TCC[+C]AA[+C]AC[+G]ACC[+T]GCTCC TCC[+C]AA[+C]AC[+C]ACCT[+G]CTCC 
APC p.E1379X CTCAGACACCCAAAAGTC GACAGAAGTACATCTGCTAA CACTATGTTCAGTAGACCCCACTC CACTATGTTCAGGAGACCCCACTC 
KRAS p.G12V† AGGCCTGCTGAAAATGACTG TTGGATCATATTCGTCCACAA TGCCTACGCCAACAGCTCCAACT TGCCTACGCCACCAGCTCCAACT 
KRAS p.G12C AGGCCTGCTGAAAATGACTG TTGGATCATATTCGTCCACAA TGCCTACGCCACAAGCTCCAACT TGCCTACGCCACCAGCTCCAACT 
KRAS p.Q61H† CCTGTCTCTTGGATATTCTC AGTCCTCATGTACTGGTC CTGT[+A]CT[+C]CTC[+A]TGA[+C]CTGCTGT CTGT[+A]CT[+C]CTC[+T]TGA[+C]CTGCTGT 
TP53 p.Q165X CTGTGGGTTGATTCCA CTCACAACCTCCGTC CTGTG[+A]CT[+A]CT[+T]GT[+A]GAT CTGTG[+A]CT[+G]CT[+T]GT[+A]GAT 
TP53 p.R175H CCATCTACAAGCAGTCAC GAGCAATCAGTGAGGAATC TTGTGAGGCACTGCCCCCAC TTGTGAGGCGCTGCCCCCAC 
TP53 p.R213X CTCCTCAGCATCTTATCC TCAGGCGGCTCATAG CACCACACTATGTAGAAAAGTGTTTCT CACCACACTATGTCGAAAAGTGTTTCT 
TP53 p.C242Y GCCTGTGTTATCTCCTAG CAGTGTGATGATGGTGAG CCGCCCATGTAGGAACTGTT CCGCCCATGCAGGAACTGTT 
TP53 p.G245S† CACCATCCACTACAACTAC GAGTCTTCCAGTGTGATG CGGT[+T]CAT[+G]C[+T]GCC[+C]ATGCAG[ CGGT[+T]CAT[+G]C[+C]GCC[+C]ATGCAG 
TP53 p.G266V GACCTGATTTCCTTACTG GGAGATTCTCTTCCTCTG AATCTACTGGTACGGAACAGCTT AATCTACTGGGACGGAACAGCTT 
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Table 8: Product codes for each microRNA analysed, including Gene Name, Assay ID, Product Number 
and Probe Colour for MicroRNAs purchased from ThermoFisher Scientific 
Manufacturer Gene Assay ID Product Number Probe Colour 
Thermofisher Mir-21 Hs04231424_s1 4331182 FAM 
Thermofisher Mir-31 002279 4427975 FAM 
Thermofisher Mir-99a* 002141 4427975 FAM 
Thermofisher Mir-125b 000449 4427975 FAM 
Thermofisher RNU6B Custom Product P/NCCU001S VIC 
 
The RNU6B VIC probe was a custom order which had to be generated specifically for this 
project. It combines the sequence for RNU6B (FAM probe; Assay ID 001093) with a VIC probe. 
2.2.15.4 DdPCR Protocol 
ddPCR reaction mixes were set up to a total volume of 25µL. Forward and reverse primers 
were diluted to 20mM each whilst each set of probes was diluted down to 5mM per individual 
ddPCR reaction. All reagents were warmed to room temperature before use. A total of 20ng of 
DNA from FFPE tissue was analysed using this assay, with the remaining volume made up of 
PCR-grade water. For cfDNA, the maximum volume (10µL) was added to the reaction mix due 
to low sample concentrations(1-2ng). All cfDNA samples were analysed in duplicate and 
pooled for analysis to try and increase the total DNA concentration whilst allowing enough 
remaining sample for repeated analysis.  
For exoRNA analysis, 3µL of cDNA was added to each reaction for analysis due to limited 
sample volume as well as to limit the possibility of contamination-associated PCR inhibition. It 
would also allow for sample re-testing if necessary. ddPCR reactions were set-up as illustrated 
in Table 9 for ctDNA analysis. 
Table 9: Reagent and Sample Volumes and Concentrations for Droplet Digital PCR Analysis of Circulating 
Tumour DNA or Exosome-Derived RNA 
Reagent Volume (µL) Concentration 
Supermix 12.5 2X 
Variant Primers and Probe (FAM) 1.25 20X 
Wild-type Primers and Probe (HEX/VIC) 1.25 20X 
Sample DNA/cDNA χ * 
PCR Grade Water 10- χ n/a 
χ = The volume of DNA required to add 20ng of tumour tissue DNA. For cfDNA and cDNA, 10µL 
and 3µL of sample were added respectively. 
*DNA concentrations for FFPE tissue were approximately 20ng.  
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From this mixture, 24µL of sample mix was added to a Bio-Rad DG8 Cartridge (1864008) with 
70µL of Bio-Rad Droplet Generation Oil for Probes (1863005), covered with a Bio-Rad DG8 
Gasket (1863009) and placed into the QX200 Droplet Generator. This process dispersed the 
reaction mix into approximately 20,000 droplets, each theoretically containing ≤1 copy of DNA 
or complementary DNA (cDNA). The generated droplets (approximately 45µL) were carefully 
transferred to a new plate. The plate was sealed using the Bio-Rad DX1 Plate Sealer, and the 
reaction amplified using the program detailed in Table 10.  
Table 10: Droplet Digital PCR thermocycler conditions of PCR amplification in generated droplets 
*Annealing temperature varied from 50-60°C depending on optimal primer/probe conditions 
 
The reaction was amplified within individual droplets using the Bio-Rad T100 Thermocycler. 
Droplets were read using the Bio-Rad QX200 Droplet Reader and analysed using QuantaSoft.  
In all ctDNA ddPCR runs, positive, wild-type and no template controls (NTC) were used to 
ensure the assay was accurately calling positive and wild-type samples, whilst also being free 
of contamination.  
For exoRNA analysis, an RNA positive control and NTC were used to ensure the assay worked 
and was clean of contamination. 
2.2.15.5 ddPCR Analysis 
2.2.15.5.1 Droplet Digital PCR Analysis using QuantaSoft  
QuantaSoft is software provided by Bio-Rad which can be used to quantify gene expression or 
VAF in template cDNA or DNA respectively. The Bio-Rad droplet reader quantifies the 
fluorescence levels of FAM or HEX/VIC within individual droplets. These fluorescence levels 
were used to determine which droplets contain mutant or wild-type DNA respectively or genes 
of interest and reference genes respectively.  
Time Temperature Ramp Rate Number of Cycles 
10 minutes 95°C ~2°C/second 1 
30 seconds 94°C ~2°C/second 40 
60 seconds * ~2°C/second 
10 minutes 98°C ~2°C/second 1 
∞ 4°C ~1°C/second 1 
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In QuantaSoft, amplified targets within droplets were analysed using 1D and 2D amplitude 
graphs to determine droplet positivity with thresholds acquired using positive control samples 
and definetherain.org. Once the thresholds had been set, the ratio of FAM and HEX positive 
droplets were used to calculate VAF or Gene Expression for ctDNA and exoRNA respectively. 
VAF, gene expression and respective standard deviations were calculated using Poisson 
distribution.  
The number of total droplets generated during ddPCR analysis was also collected to ensure the 
process of droplet generation occurred efficiently and that results were not influenced through 
droplet lysis at any stage. A minimum of 10,000 droplets were required for a ddPCR run to be 
deemed successful. We also required a minimum of four mutant droplets for a variant to be 
confidently detected in ctDNA. The reason for this minimum number of droplets required is 
described in Section 2.3.2.2 in this chapter.  
2.2.16 Clinical Data Analysis 
Clinical data was acquired from 235 patients with LARC who were treated with neoadjuvant 
therapy at Velindre Cancer Centre between 2010-2019. Data collection was performed by Luca 
Galvani using the Cancer Network Information System Cymru (CaNISC) under the supervision 
of Professor Richard Adams. This dataset also includes the initial 16 patients recruited by the 
WCB who also underwent ctDNA, cfDNA and exoRNA.  
All clinical data analysis was completed under the supervision of Professor Richard Adams. 
Statistical analysis was performed using the basic R software. This largely involved two-tailed 
unpaired two-sample T-tests. Resulting p-values were not corrected for according to the 
number of factors investigated. All analysis performed was univariate. 
2.2.17 Statistical Analysis 
During this study, we applied unpaired T-Tests, Chi-Squared and Fisher’s Exact Tests at various 
points during analysis. Statistical analysis was performed using the basic R package with the 
advisement of Dr Matthew Summers, Division of Cancer and Genetics, Cardiff University. 
2.2.17.1 R Packages 
CtDNA VAFs and cfDNA concentration data were plotted using ggplot2 in R. 
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2.3 Assay Validation and Limit of Detection Analysis 
2.3.1 Next Generation Sequencing 
2.3.1.1 Choosing a Target Next Generation Sequencing Panel 
Objective: Which is the most appropriate and efficient targeted NGS panel to detect tumour 
specific variants in patients with LARC? 
In this study, our objective was to use NGS in order to detect tumour-specific variants from the 
tumour tissue of patients with LARC both efficiently and reliably for downstream analysis. 
These variants could then be used to analyse circulating biomarkers, such as ctDNA, in these 
patients. Circulating biomarker analysis has previously been achieved using either NGS or 
ddPCR in patients with LARC (Tie et al. 2018). For variant detection in tumour tissue, whole 
exome or genome sequencing of tumour and germline tissue would have been ideal to ensure 
tumour-specific variants were detected. However, due to limitations in funding, this was not 
feasible and, thus, we chose to proceed with a targeted NGS panel.  
A targeted panel was to be chosen for NGS analysis in order to efficiently detect variants 
within patient tumour tissue. In order to choose the most appropriate targeted panel, we 
considered multiple factors, including the genes and mutational hotspots covered by each 
panel, cost and sequencing platform. 
2.3.1.1.1 Identifying Genes of Interest in Rectal Cancer Patients 
In the first instance, a literature search was performed, using cBioPortal, in order to highlight 
the most frequently mutated genes in patients with rectal cancer.  
2.3.1.1.1.1 cBioPortal 
A review of larger publications via cBioportal (Gao et al. 2013) revealed that >13,000 genes 
were found to be mutated in 140 patients with rectal cancer. These were then filtered to 
remove variants which had been detected in <5% of patients. Of the remaining 473 genes, 61 
were related to cancer, according to OncoKB (See Appendices Section 9.3 for full gene list). 
Four targeted gene panels were initially selected for potential utility within this study. These 
panels included; the Qiagen Colorectal Cancer Panel, the Qiagen Clinically Relevant Panel, the 
LifeTechnologies Ion Ampliseq CHPv2 and the Illumina TruSeq Amplicon Cancer Panel. Full 
gene lists for these panels can be seen in Table 11. 
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Table 11: Genes included within each of the four targeted sequencing panels. The genes in each 
column descend in order of the most frequently mutated in patients with rectal cancer. The % values 
in each cell represent how much of the gene is sequenced by each respective targeted panel.  
Qiagen 
CRC Panel 
Qiagen Clinically 
Relevant Panel 
Ion Ampliseq 
CHPv2 
Truseq Cancer 
Panel 
APC (100%) TP53 (100%) APC (7.7%) APC (18.0%) 
TP53 (100%) KRAS (100%) TP53 (35.0%) TP53 (66.5%) 
KRAS (100%) PIK3CA (100%) KRAS (6.1%) KRAS (10.3%) 
FBXW7 (100%) NRAS (100%) FBXW7 (8.7%) FBXW7 (16.2%) 
PIK3CA (100%) PTEN (100%) PIK3CA (11.9%) PIK3CA (13.6%) 
SMAD4 (100%) CTNNB1 (100%) SMAD4 (12.8%) SMAD4 (16.3%) 
ATM (100%) BRAF (100%) NRAS (5.8%) NRAS (8.5%) 
NRAS (100%) ERBB2 (100%) ATM (11.7%) ATM (22.1%) 
DMD (100%) RET (100%) ERBB4 (7.0%) ERBB4 (11.8%) 
TCF7L2 (100%) KIT (100%) PTEN (9.9%) PTEN (15.0%) 
PIK3R1 (100%) AR (100%) CTNNB1 (3.2%) CTNNB1 (4.7%) 
DCC (100%) ALK (100%) KDR (14.1%) KDR (27.6%) 
CTNNB1 (100%) DDR2 (100%) BRAF (3.8%) BRAF (5.5%) 
SMAD2 (100%) MET (100%) ERBB2 (8.0%) ERBB2 (12.1%) 
BRAF (100%) PDGFRA (100%) RET (10.9%) RET (16.3%) 
ERBB2 (100%) EGFR (100%) GNAS (5.4%) GNAS (4.3%) 
MAP7 (100%) MAP2K1 (100%) KIT (16.5%) KIT (35.3%) 
MSH6 (100%) IDH2 (100%) ALK (3.7%) ALK (5.8%) 
MAP2K4 (100%) FGFR3 (100%) CDH1 (6.8%) CDH1 (10.9%) 
MSH2 (100%) STK11 (100%) JAK2 (11.3%) JAK2 (16.6%) 
PTPN12 (100%) GNA11 (100%) MET (9.3%) MET (13.1%) 
WBSCR17 (100%) GNAQ (100%) MLH1 (4.6%) MLH1 (6.7%) 
CASP8 (100%) IDH1 (100%) PDGFRA (7.2%) PDGFRA (11.4%) 
EP300 (100%) AKT1 (100%) PTPN11 (12.6%) PTPN11 (19.6%) 
MYO1B (100%) 
 
EGFR (9.0%) EGFR (14.6%) 
MLH1 (100%) 
 
RB1 (17.3%) RB1 (29.6%) 
TCERG1 (100%) 
 
HNF1A (5.1%) HNF1A (10.3%) 
FZD3 (100%) 
 
ABL1 (7.3%) ABL1 (16.6%) 
SLC9A9 (100%) 
 
FGFR1 (5.7%) FGFR1 (8.7%) 
ATP6V0D2 (100%) 
 
FGFR2 (10.3%) FGFR2 (21.0%) 
CDC27 (100%) 
 
FGFR3 (12.0%) FGFR3 (21.4%) 
GPC6 (100%) 
 
FLT3 (8.2%) FLT3 (18.5%) 
MIER3 (100%) 
 
IDH2 (4.2%) MPL (9.6%) 
MSH3 (100%) 
 
MPL (6.2%) NOTCH1 (3.8%) 
ACVR1B (100%) 
 
NOTCH1 (2.5%) SMO (23.3%) 
TGFBR2 (100%) 
 
SMO (13.1%) STK11 (41.5%) 
AKT1 (100%) 
 
GNA11 (2.2%) GNA11 (30.6%) 
BAX (100%) 
 
CSF1R (4.5%) CSF1R (9.0%)   
CDKN2A (19.9%) CDKN2A (14.6%)   
EZH2 (3.2%) GNAQ (25.7%)   
GNAQ (1.8%) IDH1 (7.5%)   
IDH1 (4.2%) JAK3 (6.7%) 
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Qiagen 
CRC Panel 
Qiagen Clinically 
Relevant Panel 
Ion Ampliseq 
CHPv2 
Truseq Cancer 
Panel   
JAK3 (5.5%) NPM1 (10.6%)   
NPM1 (6.5%) SMARCB1 (41.5%)   
SMARCB1 (27.7%) VHL (14.9%)   
VHL (8.5%) AKT1 (6.0%)   
AKT1 (7.8%) HRAS (29.6%)   
HRAS (19.3%) SRC (4.1%)   
SRC (2.2%) 
 
 
We initially investigated which genes of interest were covered by each targeted panel (Table 
11). Of all the genes mutated in ≥5% of patients with rectal cancer, the Qiagen Clinically 
Relevant Panel included only six. Furthermore, this panel did not sequence APC, which is the 
most frequently mutated gene in this cohort (78.6%). The Qiagen CRC Panel contained 14 of 
the most frequently mutated genes whilst both the Illumina Truseq Cancer Panel and the 
LifeTechnologies CHPv2 sequenced 12. All of these panels covered hotspots or entire coding 
regions with KRAS, TP53, and PIK3CA, which are three of the four most frequently mutated 
genes in patients with rectal cancer, after APC. At this time, we chose to exclude the Qiagen 
Clinically Relevant Panel due to the reduced number of genes of interest sequenced within this 
gene panel. 
We next chose to investigate the efficiency of sequencing of each of the remaining targeted 
panels. This included costings and number of analysable samples per sequencing cell/chip at 
set theoretical coverages and DNA concentrations required for sequencing (see Table 12). The 
LifeTechnologies Ion Ampliseq CHPv2 and Illumina Truseq Pan-Cancer panels could only be 
sequenced using their respective technologies; whereas the Qiagen CRC panel could be 
applied using either sequencer. For the purposes of this comparison, the efficiency of this 
panel was treated as if sequenced on the Ion Torrent Proton, due to its increased sequencing 
capacity over the Illumina Miseq. This decision was also influenced by the very limited 
availability of Illumina sequencers to our research group, in comparison to the less frequently 
used but well-maintained Ion Torrent Proton. 
Potential sample numbers and coverage were calculated for sequencing cfDNA and FFPE 
tumour DNA. Coverages for cfDNA and tumour tissue DNA were calculated for a minimum of 
5,000 and 1,000 reads respectively. These values are consistent with previous analyses from 
our research group. 
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The number of samples which can be sequenced for each NGS panel using the Proton was 
calculated using the following formula (provided by LifeTechnologies); 
Number of Samples = 
70,000,000
𝑇𝑜𝑡𝑎𝑙 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐴𝑚𝑝𝑙𝑖𝑐𝑜𝑛𝑠 𝑥 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑖𝑛𝑔 𝐷𝑒𝑝𝑡ℎ 𝑝𝑒𝑟 𝐴𝑚𝑝𝑙𝑖𝑐𝑜𝑛
 
Equation 1: Formula provided by ThermoFisher Scientific to calculate number of samples which can be 
sequenced at specific read depths 
The number of samples which can be sequenced for the Illumina Truseq Cancer Panel was 
calculated using the CoverageCalculater from Illumina based on the MiSeq V3 (25,000,000 
read flow-cell). 
Table 12: Required DNA concentration, sample number calculation per chip/flow-cell at specified read 
depths for four targeted sequencing panels 
Sequencing 
Panel 
Sample 
Type 
Minimum DNA 
Input (ng) 
Minimum (Average) 
Coverage (X) 
Samples per 
Chip 
Ion Ampliseq CHPv2 CfDNA 10 5,000 (25,000) 13 
CRC Panel CfDNA 20 5,000 (25,000) 1 
Truseq Cancer Panel CfDNA 250 5,000 (25,000) 3 
Ion Ampliseq CHPv2 FFPE 10 1,000 (5,000) 67 
CRC Panel FFPE 20 1,000 (5,000) 7 
Truseq Cancer Panel FFPE 250 1,000 (5,000) 18 
 
Applying the Qiagen CRC Panel to cfDNA was deemed impractical, as a single cfDNA sample 
and up to five FFPE samples (alongside two control samples) could be sequenced with optimal 
coverage (Table 12). This same deduction was made for the Illumina Truseq Cancer Panel, 
which could sequence three cfDNA (not including controls) per flow cell, although the number 
of FFPE samples was more acceptable. Furthermore, the Illumina Truseq required unrealistic 
DNA concentrations for reliable cfDNA or FFPE DNA analysis in patients with LARC, as we are 
unlikely to have large amounts of tissue or plasma available for analysis. 
Therefore, we decided to proceed with the Ion Ampliseq CHPv2. The Ion Ampliseq CHPv2 
consisted largely of variant hotspots such as KRAS/NRAS codons 12, 13 and 61, and exon 15 
within APC and, alongside the Truseq Cancer Panel, included the highest number of genes of 
interest according to cBioPortal. Furthermore, as this panel largely consists of hotspots, rather 
than entire genes, it contains fewer primer pairs and amplicons, allowing more efficient 
sequencing and analysis.  
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Although we chose to sequence our patient samples using the CHPv2 on the Ion Torrent 
Proton, this panel and sequencing technology are limited by several factors. Although this 
panel provides superior efficiency in terms of coverage and sample numbers, it only targets 
gene hotspots and, therefore, variants outside of common hotspots may be missed. However, 
the identification of novel tumour-specific variants which influence patient response to 
radiotherapy was not the aim of this project. This panel was chosen as it is the most efficient 
panel and sequencing technology which allows reliable detection for tumour-specific variants 
in patients with LARC. 
Like all NGS panels and sequencing technologies, there are limitations to the CHPv2 and Ion 
Torrent Proton which are important to be aware of during sample analysis. Semi-conductor 
sequencing has previously been demonstrated as having limitations when analysing both small 
and large indels (Quail et al. 2012), as we also demonstrate here within EGFR in Section 2.3.1.2 
in this chapter. Therefore, we may find false findings when investigating indels within this 
panel. This technology has also been shown to have difficulties sequencing large strings of 
homopolymers (Quail et al. 2012). As this is targeted at specific regions, and not whole exome 
or genome, this limitation should not impact our ability to confidently identify and call variants 
using this technology. 
Overall, we chose to apply the Ion Ampliseq CHPv2 based upon the list of genes sequenced 
within this targeted gene panel. Furthermore, this panel provides potential benefits regarding 
sequencing efficiency ahead of our other panels of interest. This panel should allow the 
frequent detection of tumour specific variants in patient FFPE tumour DNA and/or ctDNA. 
2.3.1.2 NGS Limit of Detection 
Objective: What is the limit of detection for our chosen NGS panel? 
Once a targeted NGS panel had been chosen, we proceeded to validate the ability of this panel 
to detect known variants in reference standards. 
Reference standards (see Section 2.2.4) were sequenced at variable depths, defined as high, 
medium and low coverage (expected minimum coverages of 5000X, 3000X and 1000X 
respectively). At each of these depths, variants at 6.3%, 3.2%, 1.3% and 0.1% VAFs were 
sequenced alongside wild-type (0%) controls. A total of 10ng of reference standard DNA was 
used for NGS analysis (Table 13).  
The reference standards used here are widely used and commercially available cell-line 
derived DNA, which are well characterised using several methods. This also gives us knowledge 
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as to exactly which variants we should be detecting and at which VAFs. Any anomalies can 
therefore be queried, whereas in uncharacterised patient samples this is not the case as they 
will not be as well characterised.  
We investigated three different sequencing depths in this study for purposes of efficiency. 
Although we expect to see a difference in sensitivity between our three coverages, we aim to 
find out how much sensitivity is lost from one read depth to another. This is because we 
expect to identify ctDNA variants at approximately 1% and wish to identify at which coverages 
we can do so robustly. Decreasing sequencing coverage without harming sensitivity could also 
allow the analysis of a larger number of samples on a sequencing chip and improve the 
efficiency of any NGS-analysis. 
During this analysis, variants were filtered and passed based on our coverage and the number 
of mutant reads as described previously in Section 2.2.14.2.2. Briefly, for a variant to be called, 
≥250 total reads and ten mutant reads (five in each direction) were required.  
Table 13: Results of NGS validation using reference standards with known variants at variable 
sequencing coverages.  
       Observed vs Expected VAF (%) 
Depth Gene Variant Type of 
Variant 
6.30% 3.20% 1.30% 0.10% WT 
(0%) 
5,000X EGFR p.L858R SNV 4.0 1.4 0.5 ND ND 
5,000X EGFR p.T790M SNV 4.4 2.2 1.2 ND 0.1 
5,000X KRAS p.G12D SNV 6.7 3.6 1.3 ND ND 
5,000X NRAS p.Q61K SNV 6.3 2.5 1.1 0.2 ND 
5,000X NRAS p.A59T SNV 6.6 2.8 0.8 0.3 0.1 
5,000X PIK3CA p.E545K SNV 5.3 3.6 1.2 0.3 ND 
5,000X EGFR p.ΔE746 - 
A750 
Indel 10.7 2.7 1.6 ND ND 
5,000X EGFR p.V769 - 
D770insASV 
Indel ND ND ND ND ND 
3,000X EGFR p.L858R SNV 3.2 2.2 0.7 ND ND 
3,000X EGFR p.T790M SNV 4.8 ND ND ND ND 
3,000X KRAS p.G12D SNV 2.5 2.5 ND ND ND 
3,000X NRAS p.Q61K SNV 5.6 2.6 0.8 ND ND 
3,000X NRAS p.A59T SNV 6.4 4.5 0.9 ND 0.2 
3,000X PIK3CA p.E545K SNV 6.5 2.9 1.7 ND ND 
3,000X EGFR p.ΔE746 - 
A750 
Indel 11.6 5.4 2.4 ND ND 
3,000X EGFR p.V769 - 
D770insASV 
Indel ND ND ND ND ND 
1,000X EGFR p.L858R SNV 3.4 1.9 ND ND ND 
1,000X EGFR p.T790M SNV 5.1 ND ND ND ND 
1,000X KRAS p.G12D SNV 5.1 2.5 ND ND ND 
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       Observed vs Expected VAF (%) 
Depth Gene Variant Type of 
Variant 
6.30% 3.20% 1.30% 0.10% WT 
(0%) 
1,000X NRAS p.Q61K SNV 5.8 1.8 2.9 ND ND 
1,000X NRAS p.A59T SNV 6.0 2.7 0.6 ND ND 
1,000X PIK3CA p.E545K SNV 6.3 2.2 1.4 ND ND 
1,000X EGFR p.ΔE746 - 
A750 
Indel 6.4 4.1 ND ND ND 
1,000X EGFR p.V769 - 
D770insASV 
Indel ND ND ND ND ND 
ND- The variant of interest was not detected in this sample. 
Indel – Insertion or deletion 
 
The average coverages for high, medium and low depths were 13,886X (10,443X – 16,475X), 
6,935X (5,573X – 9,334X) and 1,250X (16.17X – 3,492X) respectively.  
At a calculated minimum coverage of 5,000X (high coverage calculated using Equation 1), all 
six Single Nucleotide Variants (SNVs) were confidently detected at 6.3%, 3.2% and 1.3% VAF 
(Table 13). At an expected average depth of 3,000X (medium coverage), only 4/6 SNVs were 
detected at 1.3% VAF. At this coverage, 5/6 and 6/6 SNVs were confidently detected at 3.2% 
and 6.3% VAF respectively. Finally, at a predicted read-depth of 1,000X (low coverage), 3/6 
SNVs were detected at 1.3% and 5/6 SNVs were detected at 3.2% VAF. In contrast, all six SNVs 
were detected at 6.3% VAF at this coverage. 
As predicted, variant detection was less consistent and sensitive for small indels in comparison 
to SNVs. The small insertion in EGFR (p.V769 - D770insASV) was not detected at any VAF or 
read-depth. In contrast, the small deletion in EGFR was confidently detected down to 1.3% VAF 
at both high (5,000X) and medium coverage (3,000X), and 3.1% VAF at low coverage (1,000X; 
Table 13). In this validation only a single deletion was analysed, which can be a major issue, 
especially considering the flaws that this technology has with sequencing indels. However, 
such indels are relatively rare in the context of rectal cancer in comparison to SNVs. Looking 
forward towards future clinical implementation, this technology and targeted panels will 
require more validation regarding the robust detection of small indels. 
Our limit of detection for variants using this NGS panel was dependent on both the type of 
variant analysed and the sequencing coverage. Using 10ng of reference standard DNA the limit 
of detection for SNVs was 1.3% VAF when applying 5,000X coverage. At 3,000X and 1,000X 
coverage, the limit of detection was only 6.3%. It should be noted that only one variant (EGFR 
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p.T790M) was not reliably detected using these two coverages at 3.2% VAF. This was 
unsurprising as this region is known to be difficult region to sequence (Fahoum et al. 2018). 
Few studies have investigated the limit of detection of the Ion Torrent Proton, or other 
semiconductor-based sequencing, to a degree below 5%. Lin and colleagues (2014) reported 
that SNVs in KRAS (p.G13D), BRAF (p.V600E) and EGFR (p.T790M and p.L858R) were 
consistently detected at 1% VAF in cell-line-derived DNA using the PGM. This limit of detection 
is in agreement with previous studies reporting a limit of approximately 1% using custom 
panels (Aloisio et al. 2016) on the Ion Torrent PGM using oligonucleotides. Although results 
generally suggest a 1% limit of detection, some studies have suggested that the Ion Torrent 
Variant Caller may miss variants with a VAF <1% which can be observed using the integrated 
genomics viewer (IGV) software (Mehrotra et al. 2018). This is performed to look for hotspot 
variants in KRAS, for example, but is not a practical solution for all samples moving forward. In 
addition, Tsongalis and colleagues (2014) reported variable limits between single nucleotide 
changes and indels, further reinforcing our findings of unreliable indel detection using this 
targeted panel. 
In agreement with our findings, and in contrast to those mentioned previously, studies have 
reported a limit of detection at ~5% using this technology. Zhang and colleagues (2014) 
demonstrated that variants with VAF <5% were associated with a poor variant accuracy (18%) 
in comparison to variants with >5% VAF (94%). These studies also applied up to 30ng of DNA 
for NGS analysis, rather than the 10ng applied here. Nevertheless, our study was able to 
achieve a similar sensitivity for SNV detection. However, we have only analysed high-quality 
DNA extracted from cell-lines with known variants, rather than investigating FFPE-derived 
tumour DNA with no foreknowledge of exactly which variants will be unearthed. Therefore, we 
may see that background noise levels increase, and our limit of detection decreases with the 
application of FFPE tumour DNA and/or cfDNA. 
Although increase sequencing depth could improve the determined sensitivity of this assay, at 
low VAFs it became increasingly difficult to confidently distinguish tumour-specific variants 
from sequencing artefacts. 
The level of background artefacts was initially examined at each point using WT reference 
standards. At high and medium coverage, artefacts were observed between 0.01-0.13% and 
0.01-0.18% respectively, which overlapped with the 0.1% VAF SNVs in the reference standards. 
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Therefore, we determined that variants at 0.1% VAF could not be confidently called, due to the 
potential for false positive results.  
These background levels are consistent with previous reports. Lin and colleagues (2014) 
reported that the background noise in FFPE tissue was seen up to 1.3% VAF. Similarly, McCall 
and colleagues (2014) also reported the presence of false positives using the CHPv2 on the 
PGM. Both studies saw an increased number of false positive variants within 10-20bp of either 
the 5’ or 3’ end of relatively short amplicons. Lin and colleagues (Lin et al. 2014) also 
demonstrated that these false positives generally had a very large direction bias, whilst McCall 
and colleagues (2014) showed that increased false positive rates were associated with poor 
DNA quality and/or quantity and resulting primer mismatching. Therefore, samples with 
limited DNA concentrations and /or poor sample quality had an increased likelihood of 
producing such false positives. These reports contributed to the variant filtration process 
described previously in Section 2.2.14.2. 
Overall, our limit of detection for NGS using high sequencing coverage was 1% VAF, although 
this was variable depending on sequencing depth. 
2.3.1.3 Targeted Sequencing Panel Validation on Patient cfDNA 
Objective: Can we validate that our NGS panel can be used to sequence cfDNA samples 
extracted from low plasma volumes from patients with LARC? 
In this section, we apply the previously calculated limit of detection from Section 2.3.1.2 and 
aim to analyse patient cfDNA and validate our targeted NGS panel for this purpose.  
When considering ctDNA in patients with LARC, VAFs are likely to be around or below the 1% 
level if detectable at all (Sclafani et al. 2018). We were able to detect variants at this level using 
high sequencing coverage in 10ng of reference standard DNA, but we were unable to achieve 
this sensitivity using a lower read depth. As this does not fully represent the quality of patient 
DNA samples, further validation assays are required to be performed on cfDNA extracted from 
patient plasma to ensure previous validations remained consistent. We also investigated how 
the volume of plasma from which cfDNA is extracted may influence variant detection and the 
quality of resulting NGS analysis. 
Plasma samples from patients with LARC consented by the WCB were used for this pilot run. 
CfDNA was extracted from 2mL of pre-treatment plasma from 14 patients and sequenced with 
a calculated minimum coverage of 5,000X as performed previously in Section 2.3.1.2 of this 
chapter. Samples were sequenced alongside a positive (Horizon HD777; 4,000X), wild-type 
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(Horizon HD776; 4,000X) and a no template control (1,000X). Sequencing was simultaneously 
performed on cfDNA extracted from 1mL of pre-treatment plasma from a separate group of 13 
patients with LARC Table 14. These were sequenced with a minimum calculated coverage of 
5,000X alongside three control samples (1,000X reads each).  
Table 14: NGS analysis of ctDNA in 1mL or 2mL or pre-treatment plasma from patients with LARC 
consented by the WCB 
Patient ID Plasma Volume (mL) Variant Detected VAF (%) 
WCB1203 2 KRAS p.G12D 7.7 
WCB1251 2 WT n/a 
WCB1260 2 WT n/a 
WCB1261 2 KRAS p.Q61H 2.0 
WCB1262 2 WT n/a 
WCB1263 2 WT n/a 
WCB1265 2 WT n/a 
WCB1266 2 TP53 p.G245S 19.5 
WCB1268 2 WT n/a 
WCB1269 2 WT n/a 
WCB1367 2 WT n/a 
WCB1369 2 WT n/a 
WCB1415 2 WT n/a 
WCB1416 2 WT n/a 
WCB1295 1 WT n/a 
WCB1368 1 WT n/a 
WCB1419 1 WT n/a 
WCB1441 1 WT n/a 
WCB1473 1 NRAS p.G13R 1.0 
WCB1476 1 WT n/a 
WCB1477 1 WT n/a 
WCB1478 1 NRAS p.Q61L 1.3 
WCB1479 1 WT n/a 
WCB1493 1 WT n/a 
WCB1602 1 WT n/a 
WCB1603 1 WT n/a 
WCB1604 1 WT n/a 
WT - Wildtype 
 
We detected tumour-specific variants in ctDNA in 2/13 (15.4%) and 3/14 (21.4%) patients with 
LARC from cfDNA extracted from 1mL and 2mL of plasma respectively (Table 14). As these two 
groups are unpaired (i.e. they contain different patients) and our sample numbers are very 
small, we cannot determine whether these values are significantly different or a result of 
sample plasma volume. Although we may have observed a small difference in the frequency at 
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which variants were detected in ctDNA between the two volumes of plasma, we could not 
perform any meaningful statistical analysis at this time. Therefore, we chose to investigate 
technical sequencing metrics from the respective sequencing runs for each plasma volume to 
see if any significant differences were observed here. These metrics include the number of 
total reads, average on-target reads, average read depth and uniformity. These metrics are 
described in Table 15 and illustrated in Figure 10. 
Table 15: Sequencing metrics analysing the difference in read quality and quantity between sequenced 
cfDNA extracted form 1mL or 2mL of plasma from patients with LARC. 
Plasma 
Volume 
Total 
Reads 
Average on Target 
Reads (%) 
Average Read 
Depth (X) 
Uniformity (%) 
1mL 75,617,145 49.90 4,055.00 61.80 
2mL 62,397,999 96.91 13,213.64 61.79 
 
 
Figure 10: Comparison of numerous metrics of Next Generation Sequencing analysis across sequencing 
runs analysing cfDNA extracted from 1mL or 2mL plasma from patients with LARC  
Read-depth refers to the number of times a single base was sequenced for each individual 
sample and on-target reads refers to the proportion of regions/amplicons sequenced which 
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match directly to the human genome reference or, in this case, a BED-file containing our 
regions of interest for the CHPv2.  
Uniformity refers to the distribution of coverage over sequenced regions, with the intent being 
that all sequenced bases within a sample have relatively equal coverage (Quail et al. 2012). 
This, however, means that there can be inter-sample variability which this metric does not 
consider. Uniformity has been reported to vary between sequencing technologies, though the 
Ion Torrent PGM and Illumina Miseq were reported to have similar levels, with Illumina 
platform performing slightly better (Quail et al. 2012). Therefore, the figure we acquired from 
the Ion Torrent Server is a level of relative uniformity. Previous reports have shown that poor 
uniformity can significantly influence sequencing efficiency, more so than other metrics such 
as on-target read rates (Quail et al. 2012). 
Here we saw a significant difference between the number of on target reads and average read 
depth between the two cohorts of samples (p<0.01 in both cases). For average read depth we 
aimed to achieve a minimum of 5,000x, which we achieved in the cfDNA samples extracted 
from 2mL of plasma (~13,000X) but not those extracted from 1mL (~4,000X). Furthermore, this 
run had a higher number of overall reads, suggesting that a significant number of reads were 
lost or were primer-dimer and not genuine patient DNA sequences. This is highlighted further 
by the significant decrease in the frequency of on-target reads from the same patients. 
Previous studies have suggested that 80% of all reads should be on-target during a successful 
sequencing run (de Leng et al. 2016). Although we achieved this in the 2mL plasma samples, 
the sequencing of the 1mL plasma samples fell far short of this target. 
Studies have also recommended that uniformity should be consistently 90% across a 
sequencing run, which we were not able to achieve in either case here (Vanni et al. 2015). 
However, as our sequencing runs contained low concentrations of cfDNA, there may have 
been significant dropout in certain genomic regions by chance. Furthermore, as this metric is 
quantified between samples, the use of reference standards alongside cfDNA may have caused 
a stark contrast and consequential decrease in sequencing uniformity. Uniformity has also 
been reported to be relatively low using semiconductor sequencers (Vanni et al. 2015). Thus, 
our relatively low uniformity may not be purely a consequence of our samples or protocols. 
Studies have also previously suggested that the number of total reads should be >100,000,000 
which is much greater than our current levels (de Leng et al. 2016). In order to improve this 
factor, the protocol may have to be optimised further, particularly regarding the concentration 
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of DNA libraries loaded onto the sequencing chip. This should be performed with caution, as 
overloading the chip may cause a large increase in polyclonality, which can cause an overall 
loss of usable reads. 
Both the frequency of on-target reads and the average sample read depth can be influenced 
by sample quality and quantity, whereas the previous two metrics mentioned are not. A low 
level of on-target reads could suggest that the majority of DNA sequenced for this sample 
consisted of primer-dimer or non-specific off-target primer-binding, both of which can be a 
result of low DNA quality and/or quantity. If coverage is evenly spread and a large amount of 
sequenced data is off-target, this then influences read depth, as usable read-depth is wasted 
on inappropriate DNA amplicons. This is highlighted further by the fact that total sample reads 
were not significantly different between the two volumes. 
Apart from these two significant metrics, the technical sequencing of both runs was consistent, 
according to the total reads and uniformity which did not significantly differ (Figure 10). This 
further suggests that the volume of plasma used for cfDNA extraction may have contributed to 
the differences observed here. However, there are other factors which may have contributed 
to this outcome. 
The two runs were analysed at separate times and separate sequencing runs, so there may be 
some variation in the quality of each of the library preparation and sequencing runs. 
Furthermore, we only analysed a small number of patients over two sequencing. Continuing 
this analysis in the future may help to improve our understanding as to whether plasma 
volume does have a significant impact on sequencing quality and outcomes. Finally, it is vital to 
remember that these are unpaired samples, and this variability in sequencing quality and 
variant detection may be due to biological differences between the two groups of patients. 
Although we have observed significant differences between the two plasma sample volumes, 
these findings are limited and warrant further investigation. 
The difference in sequencing quality between the two plasma volumes (1mL vs 2mL) is likely to 
result from the difference in total cfDNA concentrations. Increased plasma volumes are likely 
to produce higher concentrations, especially as all samples are eluted in the same volume 
using the QiaAmp Circulating Nucleic Acids Kit. Higher DNA concentrations will then lead to an 
increased amount of primers binding to DNA, and, therefore an increase in the proportion of 
on-target reads and sample coverage.  
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Overall, we have demonstrated that this targeted NGS panel can be used to detect variants in 
pre-treatment ctDNA from patients with LARC; although the sensitivity of this panel requires 
further validation. Furthermore, our findings might suggest that the volume of plasma used for 
cfDNA extractions may have an impact regarding downstream sequencing quality and variant 
detection in ctDNA. Although these findings would imply that DNA extraction from 2mL of 
plasma may improve analytical sensitivity, this has improved our understanding that plasma 
volumes may be a limitation in our investigations later on, especially since most of our patients 
only had 1mL of plasma available for sequential analysis. 
2.3.2 Limit of Detection Analysis for Droplet Digital PCR 
Objective: What is the limit of detection for our chosen ddPCR assay? 
2.3.2.1 Optimising Conditions 
All primers and probes were initially optimised and validated on positive control material from 
FFPE patient tumour biopsies with pre-determined variants. 
Primers/probe sets for ddPCR were optimised using a temperature gradient (50-60°C) to 
determine optimal annealing temperatures. Resulting ddPCR data was analysed using 
QuantaSoft as previously described. Primer/probe assays were validated using positive, wild-
type and negative control samples to ensure assay sensitivity and specificity.  
2.3.2.2 Limit of Detection 
Once each assay had been optimised and validated, reference standards (as described 
previously in Table 2) were used to investigate the limit of detection using 1ng, 5ng and 10ng 
of total DNA (Table 16). Variants at 1.3%, 3.2% and 6.3% VAF were analysed at each DNA 
concentration in triplicate. Variant detection, VAFs and error bars were calculated by 
QuantaSoft using Poisson Distribution.  
DNA concentrations were analysed down to 1ng as this is the approximate concentration that 
we expect to acquire during cfDNA extractions. Similarly, VAFs were analysed down to 1.3% as 
we expect to see low ctDNA levels in patients with LARC. We did not merge our triplicate data 
as this combination would not accurately reflect patient ctDNA samples during analysis. 
We initially ensured that DNA concentrations were consistent within all reactions with the 
same input DNA (1-10ng). We saw no significant differences in DNA concentrations between 
paired ddPCR reactions using ANOVA (Analysis of Variance: data not shown), so we proceeded 
to investigate the limit of detection for this assay (Table 16). 
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Using QuantaSoft, at least five FAM (mutant) droplets are required for confident variant 
detection and accurate quantification in accordance with standard operating procedures used 
by the AWMGS (LP-GEN-ddPCR). Fluorescence thresholds in QuantaSoft were manually set 
based on droplet fluorescence from 10ng of positive control DNA.  
Table 16: Limit of Detection analysis of variants at 1%, 3% and 6% using 1ng, 5ng and 10ng of DNA. 
Reactions were performed in triplicate but analysed separately. Five or more mutant droplets were 
required for confident detection of an individual variant. 
Number of Mutant (FAM Positive) Droplets 
DNA Concentration 1.3% Triplicate 3.2% Triplicate 6.3% Triplicate 
1ng 3 0 0 5 4 1 14 13 13 
5ng 1 2 4 7 9 8 61 47 43 
10ng 3 4 6 15 15 7 104 92 n/a 
n/a – Variants at 6% in 10ng of DNA was only analysed in duplicate. 
Values in bold are where error bars did not cross 0, thus this assay confidently detected the 
variant in question 
 
As this analysis was performed using Horizon reference standards (Horizon 2019), the 
reactions where variants were not confidently detected represent the likelihood of 
encountering false negative results. In all accompanying wild type and NTC reactions, no 
mutant droplets were detected, providing this assay a specificity of 100%. 
From these findings, our limit of detection using ddPCR depends on the concentration of input 
DNA and the number of reactions analysed (Table 16). Our limit of detection for a single 
reaction using 1ng of DNA is 6.3% VAF. Therefore, ctDNA is unlikely to be detected at 1-3% VAF 
from 1ng of DNA but variants at 3.2% may be identified using 5-10ng. These concentrations are 
unlikely to be consistently and reliably extracted from 1mL of plasma and, thus, we are likely to 
observe a high rate of false-negatives, and poor sensitivity under these conditions.  
According to the Bio-Rad Best Practice Guidelines for rare mutation detection, Poisson 
distribution only requires the detection of three mutant droplets for the statistical estimation 
of detected VAF. These guidelines also describe a variable limit of detection depending on DNA 
concentration as observed here. The differences in limit of detection between a sample 
containing 300 and 3,000 total DNA molecules is, therefore, ten times lower (1% vs 0.1% 
respectively according to the rule of three detected droplets).  
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As far as we are aware, there are currently no clinical guidelines to standardise ctDNA 
detection across patients with cancer or cancer subtypes. Furthermore, the value used in the 
literature is highly variable; with some studies only requiring two droplets (Hrebien et al. 2016; 
Riva et al. 2017) and others needing five (Huang et al. 2016). We proceeded to analyse our 
data using a minimum of five mutant droplets required for confident ctDNA detection 
assuming all controls were free of contamination. This cut-off was chosen as it is currently 
applied in clinical practice by the AWMGS (ddPCR Standard Operating Procedure; LP-GEN-
ddPCR). Though this may compromise the sensitivity of ctDNA detection, this will provide 
confidence in our findings.  
The difficulty in identifying variants using up to 1ng of DNA at 1-3% highlights some of the 
issues we may encounter during ctDNA analysis. This may impact how frequently we detect 
ctDNA in our patient cohort on top of the biologically relevant factors (such as patients having 
non-metastatic disease).  
This limit of detection for ddPCR is not as sensitive as demonstrated by previous reports, which 
have suggested a limit of detection between 0.0005% - 0.4% under various conditions (Pender 
et al. 2015; Reid et al. 2015; Huang et al. 2016; Yang et al. 2016). Reid and colleagues (2015) 
were able to demonstrate a very low sensitivity of 0.0005% for ddPCR by combining it with 
whole genome amplification in DNA extracted from circulating tumour cells (CTCs). This 
genomic amplification can provide some benefits to analysis by increasing the total yield of 
DNA and improving assay sensitivity. However, this can cause potential issues with absolute 
quantification of VAF by creating amplification bias (Weber et al. 2003).  
The limit of detection reported by Yang and colleagues (2016) was 0.04% from ctDNA in 
patients with stage IV non-small cell lung carcinoma. The limit of 0.01% from Huang and 
colleagues was calculated using 50ng of patient cfDNA (2016) from patients with 
hepatocellular carcinoma. Finally, Pender and colleagues (2015) reported a limit of detection 
down to 0.045% using >500pg of reference standard DNA. These sensitivities are generally 
greater than our findings here, but for several reasons; including use of whole genome 
amplification, analysing ctDNA from patients with advanced diseases producing higher 
quantities of cfDNA and having better quality of DNA using reference standards. In comparison 
we predominantly investigated low quantities (1-10ng) of poor quality FFPE DNA. This may 
explain discrepancies in our limit of detections. We chose to apply such conditions as it would 
better reflect cfDNA samples extracted from patients with LARC.  
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In order to improve assay sensitivity and specificity, in future analyses, all samples will be 
performed in duplicate with a positive, wild-type and NTC for each assay; to ensure assay 
specificity remains high. The presence of ≥1 inappropriate DNA molecule in a control sample 
will void any results acquired from cfDNA during these analyses.  
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2.4 Analytical Workflow 
Objective: What is the optimal process for the detection and tracking of circulating biomarkers 
in patients with LARC in future studies? 
As part of this study, we have chosen a targeted NGS panel which we predicted would allow 
efficient and frequent variant detection in patients with LARC.  We then proceeded to validate 
and demonstrate the limit of detection for our targeted NGS panel and ddPCR assay. We have 
also chosen to use the Invitrogen Qubit to quantify total cfDNA in sequential plasma samples 
from our patient cohort. 
Due to limited financial resources, plasma volumes and sample availability, performing NGS on 
all plasma samples from our patients would not be feasible. Therefore, we designed an 
analytical workflow which will still allow us to analyse circulating biomarkers in these patients 
by analysing tumour-specific variants in ctDNA using ddPCR. 
Initially, we will apply the Ion Ampliseq CHPv2 to detect tumour specific variants in tumour 
tissue from each patient with LARC. Where tumour tissue is unavailable, we will aim to acquire 
excess extracted tumour DNA from the AWMGS or patient RAS status from clinical records. 
Where available, we will also attempt to sequence pre-treatment plasma in patients with LARC 
to examine the ability of this panel to detect ctDNA. 
Once tumour variants are detected, we will proceed to design and optimise tumour-specific 
primers and probes for ddPCR analysis. This will include a mutant (FAM) and wild-type (HEX) 
probe to allow the VAF quantification. Each probe will be optimised on a temperature gradient 
and validated using a positive, wild-type control and NTC. Some primer/probe pairs may also 
be purchased for Bio-Rad in certain circumstances. 
ddPCR primer/probes will then be used to validate the original variant in tumour tissue where 
possible and then detect/quantify ctDNA in sequential plasma samples. Simultaneously, total 
cfDNA concentrations will also be quantified in each plasma sample using the Qubit. These 
findings will then be compared to patient clinical data to identify or discern any clinically 
relevant associations. A flow chart of this workflow can be seen in Figure 11. 
For exoRNA, we did not have access to tumour tissue for hypothesis-free testing of microRNAs 
using either NGS or microarrays. Therefore, a small number of microRNAs were chosen based 
on a review of the literature at the time. These microRNAs were analysed using ddPCR only. 
The analytical workflow for exoRNA analysis is described further in Chapter 5. 
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Figure 11: Flow chart illustrating our optimised workflow for circulating biomarker analysis in patients with LARC
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3 Investigating the Utility and Feasibility of Circulating Tumour DNA in 
Locally Advanced Rectal Cancer 
3.1 Introduction 
CtDNA has emerged as a circulating biomarker of clinical interest in solid tumours, due to its 
ability to facilitate monitoring tumour burden (Reinert et al. 2016) and patient response to 
therapy (Carpinetti et al. 2015; Provencio et al. 2017). This has been investigated frequently in 
patients with metastatic CRC receiving targeted therapies such as cetuximab (Misale et al. 
2012). A comparatively small number of studies have looked at ctDNA in relation to pCRT in 
patients with LARC. 
Due to the increasing clinical interest, numerous technologies have been rapidly developed to 
detect and quantify low levels of ctDNA, including NGS and ddPCR. The ability to detect 
variants at low frequencies is important for patients with non-metastatic disease, where low 
VAFs are commonly reported (Sclafani et al. 2018). Using NGS and ddPCR will allow us to 
identify and monitor tumour-specific variants in longitudinal patient plasma (Tie et al. 2018).  
Reports have also illustrated that longitudinal changes in total cfDNA can be predictive of 
clinical outcomes in patients with solid tumours (Zitt et al. 2008; Schou et al. 2018). The 
quantification of total cfDNA is not reliant on the presence of tumour-specific variants and can 
be analysed quickly. 
We have a limited understanding of the importance of detecting sequential changes in ctDNA 
and cfDNA in patients with LARC undergoing non-targeted therapies. Therefore, we do not 
understand how to predict outcomes and influence patient therapy in the patients.  
3.1.1 Study Objectives 
This study intends to determine the feasibility and limitations of using NGS and ddPCR to 
detect and monitor low-frequency mutations in ctDNA. In this chapter, the aims are: 
• Can ctDNA be detected in the circulation of patients with LARC before the initiation of 
radiotherapy using NGS? 
• Can ctDNA be reliably detected in sequential plasma samples before, during or after 
radiotherapy in patients with LARC using ddPCR? 
o Is ctDNA released into the circulation in relation to radiotherapy in patients 
with LARC? 
o Do longitudinal ctDNA levels correlate with clinical outcomes in patients with 
LARC? 
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• Can we detect and measure quantitative changes in total cfDNA before, during and 
after radiotherapy in patients with LARC? 
o Is cfDNA released into the circulation in relation to radiotherapy in patients 
with LARC? 
o Do longitudinal cfDNA levels correlate with clinical outcomes in patients with 
LARC?  
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3.2 Results 
3.2.1 Next Generation Sequencing Sensitivity in Detecting Circulating Tumour DNA in Pre-
Treatment Plasma Samples 
Objective: Can ctDNA be detected in the circulation of patients with LARC before the initiation 
of radiotherapy using NGS? 
Tumour-specific variants were first identified in tumour biopsies using NGS in order to 
facilitate the detection of ctDNA in pre-treatment plasma from patients with LARC. Variants 
were analysed and filtered as previously described in 2.2.14.2. 
Ten patients with LARC who were consented by the WCB had paired FFPE tumour biopsies and 
pre-treatment blood samples (Table 17). DNA extracted from FFPE tumour biopsies was 
provided by the WCB for sequencing. CfDNA was extracted from 1-2ml of patient plasma and 
patient DNA samples were sequenced using the Cancer Hotspot Panel V2 on the Ion Torrent 
Proton as previously described in the Materials and Methods. 
Table 17: Somatic variant discovery using Next Generation Sequencing in paired patient tumour biopsies 
and cell free DNA. All patients with locally advanced rectal cancer were consented by the Wales Cancer 
Bank 
Patient ID 
Tumour Specific 
Variants 
FFPE Biopsy 
VAF (%) 
CtDNA 
VAF (%) 
Plasma Volume 
(mL) 
WCB1203 
KRAS; p.G12D 4.5 2 
2 NRAS; p.Q61L 9.3 WT 
TP53; p.G245D 1.8 WT 
WCB1251 None Detected WT WT 2 
WCB1260 BRAF; p.V600E 11 WT 2 
WCB1262* 
KRAS; p.G12D 17 WT 
2 
TP53; p.R248Q 16 WT 
WCB1266 TP53; p.G245S 20 3 2 
WCB1269 None Detected WT WT 2 
WCB1441* KRAS p.G12R 8.3 WT 1 
WCB1478* 
NRAS p.Q61L 15 1.3 
1 
APC p.E1379X 33 1.9 
WCB1479* 
KRAS p.G12A 26 WT 
1 
TP53; p.Y220C 52 WT 
WCB1493* 
KRAS p.G13D 10 WT 
1 
TP53; p.Y234H 44 WT 
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*These patients had additional sequential plasma samples available and were used later in 
longitudinal ctDNA analysis. 
VAF – Variant Allele Frequency. 
WT – Wild-Type; variants in question could not be detected in this sample. 
 
Overall, we were able to detect variants in the tumour biopsies from 8/10 patients with LARC 
using our targeted NGS panel. At least one corresponding mutation was successfully detected 
in pre-treatment plasma from 3/8 (37.5%) patients with known tumour-specific variants 
Of the three variants detected in the DNA extracted from the tumour biopsy of patient 
WCB1203, only one was detected in pre-treatment plasma. In all other cases, either all or none 
of the tumour-specific variants were detected in cfDNA. This finding highlights the potential 
benefits of sequencing plasma rather than analysis of a single tumour-specific variant. 
Relatively few studies have investigated the sensitivity of ctDNA analysis in patients with LARC. 
In 35 patients with KRAS mutant tumours, Sclafani and colleagues (2018) reported that 12 
(34.3%) had detectable levels of ctDNA, based on the detection of said KRAS variants. In 
another cohort of 159 patients with LARC with known tumour variants, Tie and colleagues 
(2018) were able to detect pre-treatment ctDNA in 122 patients (76.7%). 
The discrepancy between these two reports is likely to be impacted by analytical differences 
between the studies. Tie and colleagues (2018) applied a small gene panel for variant 
detection in tumour tissue before detecting one of these variants in cfDNA. In contrast, 
Sclafani and colleagues (2018) investigated KRAS variants in ctDNA using ddPCR. Furthermore, 
Tie and colleagues extracted ctDNA from 10mL of plasma, whereas Sclafani and colleagues 
used 2mL. Finally, each study applied a different method for ctDNA analysis, where Tie and 
colleagues applied Safe-SeqS, Sclafani used ddPCR, with each method having respective 
strengths and limitations. A combination of these factors may have contributed to the 
variation in analytical sensitivities observed here. 
Our study found comparable sensitivity to Sclafani and colleagues (2018) (37.5% vs 34.3%). We 
also extracted ctDNA from a similar volume of plasma to this study in comparison to the 10mL 
used by Tie and colleagues. We applied a gene panel to detect ctDNA similar to that of Tie and 
colleagues (2018), although our sensitivity was closer to that of Sclafani (2018). Moreover both 
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our study and that by Sclafani and colleagues (2018) are limited by relatively small sample sizes 
in comparison to 159 patients with LARC (Tie et al. 2018). 
The sensitivity of variant detection in plasma using NGS in our study is also similar to that 
reported by Chang and colleagues (2018), who demonstrated a sensitivity of 42.9% across a 
range of stages in four solid tumour types (including 50% in 4 patients with stage IIIb or IVa 
CRC) using NGS. Similarly, Beije and colleagues (2016) were able to detect 39% of mutations in 
cfDNA using a 21-gene NGS panel in patients with metastatic CRC. However, this group was 
able to improve the sensitivity of ctDNA detection using NGS and ddPCR to 80% and 93% 
respectively in the same cohort. Similarly, Yang and colleagues (2018) were able to improve 
the sensitivity of ctDNA detection in patients with stage IIIb/IV lung cancer from 63.5% to 
83.2% by adding molecular barcodes to their NGS protocols. Rachiglio and colleagues (2016) 
were able to detect KRAS/NRAS mutant ctDNA in 12/19 (63.2%) of patients with metastatic 
CRC. 
Overall, our results are within the expected range based on the literature, though towards the 
lower end of the spectrum. For some of these studies, this may due to differences in patient 
cohorts. The patients in our cohort were predominantly non-metastatic locally advanced, 
whereas some of the previous studies investigated ctDNA in patients with metastatic disease. 
This is based on reports from Bettegowda and colleagues (2014) who showed that ctDNA was 
detected significantly more frequently in patients with metastatic disease than locally 
advanced solid tumour patients across multiple cancers (including CRC). Differences between 
studies in patients with LARC may also be due to plasma volumes and/or analytical methods 
applied in each case. 
3.2.1.1 Concordance between Circulating Tumour DNA in Pre-Treatment Plasma Samples and 
Tumour Biopsies 
From the data illustrated in Table 17, we observed 37.5% (6/16) concordance between ctDNA 
and tissue genotyping in the previous cohort. 
There are a limited number of studies which have examined concordance between pre-
treatment ctDNA and tumour tissue in patients with LARC. Sclafani and colleagues (2018) 
reported a concordance of 68.9% between tumour tissue and ctDNA in patients with LARC. 
Whether this is significantly greater than our observed frequency is difficult to determine with 
only two studies. This difference may also be impacted by our small sample size. 
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As this is one of the only studies to investigate ctDNA concordance in patients with LARC, it is 
difficult to determine whether our results are within the expected range. As previous, we then 
compared our study to those investigating patients with metastatic disease. 
Our concordance rate was lower than those reported between pre-treatment ctDNA and 
tumour tissue from patients with metastatic CRC, which have been reported between 80-90% 
(Rachiglio et al. 2016; Germano et al. 2017; Grasselli et al. 2017; Hsu et al. 2018). Another 
study by Siravegna and colleagues (2015) reported a concordance of 97% in a cohort of 
patients with CRC across a range of tumour stages. This is supported by reports from 
Bettegowda and colleagues (2014), who demonstrated that ctDNA was more frequently 
detected in patients with metastatic disease. Therefore, we expected to see a lower 
concordance between tumour tissue and pre-treatment plasma in patients with LARC. 
We did not detect any tumour-specific variants in pre-treatment plasma which were absent in 
matching patient tumour biopsies at this time. 
3.2.2 Investigating Longitudinal Circulating Tumour DNA using Droplet Digital PCR 
Objective: Can ctDNA be reliably detected in sequential plasma samples before, during or after 
therapy in patients with LARC using ddPCR? 
In Section 3.2.1 we demonstrated that ctDNA could be detected in the circulation of patients 
with LARC before the initiation of therapy. Five of these patients (WCB1262, WCB441, 
WCB1478, WCB1479 and WCB1493) had additional plasma timepoints available for 
longitudinal ctDNA analysis. A further 11 patients with LARC with two or more plasma 
timepoints were also consented for sequential ctDNA and cfDNA analysis.  For these 11 
patients, no FFPE tumour biopsies nor extracted tumour-derived DNA were available for 
research purposes. In this case each patient’s KRAS/NRAS/BRAF status were acquired from the 
WCB. For the original five patients sequenced previously, variants were used from prior NGS 
analysis. Clinical characteristics of this cohort are described in Table 18. 
Table 18: Clinical characteristics of patients with locally advanced rectal cancer consented by the Wales 
Cancer Bank.  
Patient 
ID 
T N M Disease 
Stage 
Radiotherapy 
(Gy in Doses) 
Time Period of 
Radiotherapy 
Tumour-Specific 
Variant for 
ctDNA Analysis 
WCB1262 3 0 0 II 45 in 25 5 Weeks KRAS; p.G12D 
WCB1263 3 1 0 III 45 in 25 5 Weeks KRAS; p.G13D 
WCB1268 3 2 1 IV 45 in 25 5 Weeks KRAS; p.G13R 
WCB1295 3 2 0 III 45 in 25 5 Weeks WT 
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Patient 
ID 
T N M Disease 
Stage 
Radiotherapy 
(Gy in Doses) 
Time Period of 
Radiotherapy 
Tumour-Specific 
Variant for 
ctDNA Analysis 
WCB1368 1 0 0 I 20 in 5 1 Week WT 
WCB1419 3 1 0 III 25 in 5 1 Week WT 
WCB1441 4b 0 0 II 45 in 25 5 Weeks KRAS; p.G12R 
WCB1473 0 0 1 IV 30 in 5 1 Week NRAS; p.G13R 
WCB1476 3 2 0 III 45 in 25 5 Weeks KRAS; p.G13D 
WCB1477 3 0 0 II 45 in 25 5 Weeks KRAS; p.G12D 
WCB1478 4 1 0 III 25 in 5 1 Week NRAS; p.Q61L 
APC; p.E1379X† 
WCB1479 3 2 1 IV 45 in 25 5 Weeks KRAS; p.G12A 
WCB1493 3 0 0 II 45 in 25 5 Weeks KRAS; p.G13D 
WCB1602 3 2 0 III 45 in 25 5 Weeks WT 
WCB1603 4 0 0 II 45 in 25 5 Weeks KRAS; p.G12A 
WCB1604 3 1 0 III 45 in 25 5 Weeks KRAS; p.G12A 
T - Clinical staging of tumour size. 
N – Clinical staging of lymph node invasion. 
M – Clinical staging of metastases. 
Gy in Doses – The amount of radiotherapy received by a patient in Gy and the number of doses 
in which radiotherapy was distributed. 
Disease Stage – Patient staging calculated using TNM stages according to the American Join 
Committee on Cancer (AJCC) as recommended by ESMO guidelines (Glynne-Jones et al. 2017).  
WT – Wild-Type – No tumour specific variants were detected in tumour biopsies from these 
patients. 
 
As tumour-specific variants were identified in 12/16 (75%) patients with LARC, longitudinal 
ctDNA analysis was only possible in these 12 patients. NGS analysis for ctDNA was not possible 
at this time and was, therefore, not available for the four patients with wild-type tumours. 
Sequential analysis was, therefore, performed using ddPCR. ddPCR assays were designed and 
validated for each tumour-specific variant in all 12 patients for sequential ctDNA analysis.  
CtDNA was successfully detected in at least one timepoint from 2/12 (16.7%) patients with 
LARC whilst the remaining ten patients were negative at all times (Table 19). Both patients had 
ctDNA detected in pre-treatment plasma whilst one patient also had ctDNA detected post-
treatment. 
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Table 19: Variant Allelic Frequencies of tumour-specific variants detected in cell free DNA  in longitudinal 
plasma samples collected throughout therapy in patients with Locally Advanced Rectal Cancer. 
Patient ID 
Week of Sample 
Collection 
Treatment Stage at 
Time of Collection 
CtDNA 
VAF (%) 
WCB1262 
0 Pre-Treatment 0 
1 On-Treatment 0 
WCB1263 
1 On-Treatment 0 
3 On-Treatment 0 
9 Post-Treatment 0 
23 Post-Treatment 0 
WCB1268 
0 Pre-Treatment 0 
1 On-Treatment 0 
WCB1441 
-2 Pre-Treatment 0 
-1 Pre-Treatment 0 
1 On-Treatment 0 
WCB1473 
0 Pre-Treatment 1.0 
2 Post-Treatment 2.3 
4 Post-Treatment 0 
13 Post-Treatment 2.8 
WCB1476 
0 Pre-Treatment 0 
12 Post-Treatment 0 
WCB1477 
0 Pre-Treatment 0 
12 Post-Treatment 0 
WCB1478 
0 Pre-Treatment 3.5 
4 Post-Treatment 0 
WCB1479 
0 Pre-Treatment 0 
5 On-Treatment 0 
6 Post-Treatment 0 
8 Post-Treatment 0 
12 Post-Treatment 0 
WCB1493 
0 Pre-Treatment 0 
1 On-Treatment 0 
3 On-Treatment 0 
4 On-Treatment 0 
6 Post-Treatment 0 
WCB1603 
0 Pre-Treatment 0 
1 On-Treatment 0 
5 On-Treatment 0 
14 Post-Treatment 0 
WCB1604 
-8 Pre-Treatment 0 
-3 Pre-Treatment 0 
0 Pre-Treatment 0 
6 Post-Treatment 0 
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Detected ctDNA VAFs varied between 1.0 %– 3.5% in this study, which are above our threshold 
for positive variant detection (1% VAF and five or more mutant droplets; See Section 2.3.2.2). 
Pre-treatment samples were available for 10 patients with known tumour-specific variants, 
within which, ctDNA was detected in two (20%). No patient had ctDNA detected whilst on-
treatment, whilst 1/9 patients with available post-treatment sample (11.1%) had detectable 
levels of ctDNA. Due to the low number of ctDNA positive samples, very few patterns could be 
discerned. Statistical analysis was not possible between patients, stage of treatment or week 
of sample collection. 
Notably, one patient with ctDNA detected in pre-treatment plasma had metastatic disease 
(WCB1473), whilst the other patient (WCB1478) displayed signs of tumour invasion into 
surrounding lymph nodes. However, these numbers are too small to make any meaningful 
deductions from. 
It is currently unclear whether the decline of ctDNA levels in patient WCB1478 between weeks 
0 – 4 is an immediate decline in ctDNA or a gradual decrease. Unfortunately, no patterns after 
this were observed as this patient had no later timepoints available for further analysis.  
Patient WCB1473 had detectable ctDNA at both weeks 0 (pre-treatment) and 2 (post-
treatment). CtDNA was then undetectable at week 4 (post-treatment) before being detected 
again at week 17 (post-treatment). This data may suggest that pCRT was not effective in 
causing significant tumour shrinkage or regression in this patient, as ctDNA can still be 
detected long after the completion of therapy. The undetectable levels of ctDNA at week 4 
may suggest a small initial response to radiotherapy. This may, alternatively, be a result of 
natural biological variation or ctDNA levels being below our technical limit of detection. As this 
finding is only observed in a single patient, no significant conclusions can be drawn without 
expansion with a larger patient cohort. 
We did not detect ctDNA at any time in patient WCB1479 who had metastases detected at 
diagnosis. This might be due to a number of other limitations of the study such as the 
sensitivity of ddPCR or low input plasma volume. 
No ctDNA was detectable in any patient samples whilst on-treatment. Other reports have also 
shown that ctDNA is less frequently detected after pCRT and/or surgery (Tie et al. 2018). 
Provencio and colleagues (2017) showed similar results when they reported that ctDNA 
decreased significantly after the onset of therapy in 7/8 patients with NSCLC. We hypothesised 
that the decrease in ctDNA observed from pre- to on-treatment samples may be indicative of 
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initial patient response as a result of pCRT. However, this is a small number of patients with 
detectable levels of ctDNA, therefore no meaningful analyses can be made with regards to this 
observation. 
Overall, we detected ctDNA in 2/12 (16.7%) patients with LARC using ddPCR. Although this 
may simply be the nature of this cohort, such low ctDNA detection is a potentially large and 
problematic limitation of this study. If this expected frequency is consistent within our patient 
cohort, a larger number of patients will be required for analysis to achieve ctDNA detection in 
enough patients with LARC for statistically meaningful analysis.  
3.2.3 Analysing Sequential Changes in Total Cell Free DNA Throughout Therapy 
3.2.3.1 Cell Free DNA Concentrations 
Objective: Can we detect and measure quantitative changes in total cfDNA before, during and 
after treatment in patients with LARC? 
For all 16 patients with LARC who were previously investigated for sequential ctDNA analysis, 
1mL of plasma was used for total cfDNA extraction and analysis. Total cfDNA concentrations 
were quantified using the Invitrogen Qubit (ng/µL). Plasma samples were separated into pre-, 
on- and post-treatment according to sample collection and treatment dates (See Table 19).  
Total cfDNA was successfully extracted and detected for all patient samples except one 
(patient WCB1479 week 5). No differences were observed between cfDNA samples which had 
detectable ctDNA levels and those which did not. Total cfDNA concentrations varied from 
0.119ng/µL - 0.758 ng/µL (average: 0.29ng/µL), see Appendices Section 9.4 for full dataset. 
We observed a general increase in total cfDNA concentration from pre- to on-treatment 
samples and a decrease from on- to post-treatment samples (Figure 12). Though a trend may 
be seen these differences were not statistically significant when analysed using ANNOVAR 
(pre-treatment vs on-treatment p-value=0.08 and pre-treatment vs post-treatment p-
value=0.19). These findings might be influenced by individual patient responses to therapy. 
Agostini and colleagues (2011) reported that total cfDNA concentrations were significantly 
decreased from pre- to post-CRT plasma samples in patients with LARC who responded well to 
therapy (TRG1-2). Similarly, Park and colleagues (2018) reported that total cfDNA in patients 
with hepatocellular carcinoma did not alter significantly from plasma samples before and after 
the administration of radiotherapy in patients who responded well to therapy. However, 
patients who did not respond or responded poorly displayed a significant increase in total 
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cfDNA concentration after radiotherapy. Therefore, these data may contain two or more 
different signatures based on clinical outcomes that we cannot currently distinguish.  
We did not observe any differences in total cfDNA concentrations according to T/N/M staging 
(Table 18). This agreed with respective ANNOVAR and two-sample t-tests which showed no 
significant differences using any of the stages in univariate analyses. A difference was seen 
using ESMO group staging (Glynne-Jones et al. 2017) in these patients between total cfDNA 
from stage III v IV patients (p-value=0.02; Figure 12). Stage IV patients here displayed 
significantly lower total cfDNA concentrations than stage III patients. However, significance 
was lost when separating cfDNA samples into their respective treatment stage at time of 
collection. This finding is surprising as previous reports have shown the opposite; a positive 
correlation between tumour stage and cfDNA concentration in patients with hepatocellular 
carcinoma (Park et al. 2018). 
The difference observed in cfDNA concentrations between patients with stage III and IV 
disease contradicts previous findings by Boysen and colleagues (2017). This study reported 
that total cfDNA concentrations positively correlated with AJCC grouped stage in patients with 
LARC, whereas we observed a decrease from stage III-IV groups according to ESMO guidelines. 
This same study also reported a significant difference in total cfDNA in patients with LARC who 
had cancer spread to their lymph nodes and those who did not. In contrast, our study showed 
no significant differences. 
Overall, we were able to detect and quantify total cfDNA from all plasma samples except one 
using the Invitrogen Qubit. CfDNA concentrations during therapy were generally but not 
significantly higher than pre- and post-treatment samples using the Qubit. We also observed a 
significant difference between total cfDNA concentrations between patients with stage III and 
IV disease, though significance was lost when samples were grouped into pre-, on- or post-
treatment. Though general patterns of cfDNA change were observed, no meaningful analysis 
can be drawn from these results due to our small sample size and general limitations 
associated with cfDNA analysis.
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Figure 12: Total cell free DNA concentration and distribution across A- When the plasma samples were collected (Pre-, On- or Post-Radiotherapy) and B- Tumour Stage 
According to the European Society of Medical Oncology  
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3.2.4 Patient Clinical Outcomes 
3.2.4.1 General Patient Outcomes 
Clinical outcomes for all 16 patients became available after the completion of circulating 
biomarker analysis described above. This data included patient initial patient response to 
therapy and whether patient experienced distant and/or local relapse within two years of the 
initiation of therapy. Survival was not included due to the limited follow-up time available for 
the majority of patients (median: 25.9 months; range: 5-40 months). Two patients (WCB1368 
and WCB1473) were excluded from clinical outcome analyses due to having received atypical 
treatment. 
Initial patient response to neoadjuvant therapy was recorded as Tumour Regression Grades 
(TRG) as reported on CaNISC. TRG systems were developed to quantitatively analyse tumour 
response according to growth or shrinkage after the administration of neoadjuvant therapy in 
patients with solid tumours, such as oesophageal (Mandard et al. 1994) or rectal cancer 
(Dworak et al. 1997). TRG has traditionally been quantified at the time of surgery (pathological 
TRG; pTRG). pTRG has several limitations (Sclafani et al. 2017). Quantifying a patient’s pTRG 
requires the patient to undergo surgery, which not all patients can, after the administration of 
neoadjuvant therapy. pTRG has also been reported to have a low inter-user variability 
(Lindebjerg et al. 2011). Furthermore, patients may be analysed using different TRG systems 
between different treatment centres, which can create further inconsistencies when deciding 
whether to administer post-operative therapy.  
As a result of advancements in imaging technology, MRI-based Tumour Regression Grading 
(mrTRG) has recently been investigated as a method to predict patient pTRG after completing 
neoadjuvant therapy (Patel et al. 2011). Therefore, where patients cannot or do not want to 
undergo surgery, mrTRG has been suggested to be used in place of pTRG. However, studies 
have demonstrated that the concordance between these two methods is low (Sclafani et al. 
2017), thus mrTRG is not yet reliable enough to be an accurate predictor of pTRG or cCR. As 
imaging methods continue to develop and improve, mrTRG may become a more reliable 
predictor of pTRG and long-term outcomes. At present, these two factors do not concord well 
in patients with LARC.  
In this study, TRG principally refers to pTRG, except where such data was unavailable in which 
case mrTRG was used instead. Although we are aware of the limited correlation between the 
two response values, there was no other available metric which was more comparable to 
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pTRG, thus mrTRG was applied only where necessary. Patients who achieved a complete 
response to therapy (TRG1) may have been gauged either pathologically (pCR) or clinically 
(cCR). Patient clinical characteristics and outcomes are summarised in Table 20 and Table 21. 
Table 20: Treatment outcomes for patients with LARC consented by the Wales Cancer Bank 
Patient 
ID 
Disease 
Stage 
Radiotherapy 
(Gy in Doses) 
TRG 
Patient Experienced Local 
and/or Distant Relapse 
WCB1262 II 45 in 25 1 None 
WCB1263 III 45 in 25 3 None 
WCB1268 IV 45 in 25 3 Distant only 
WCB1295 III 45 in 25 1 None 
WCB1419 III 25 in 5 4 Distant only 
WCB1441 II 45 in 25 4 Distant only 
WCB1476 III 45 in 25 2 None 
WCB1477 II 45 in 25 4 Local only 
WCB1478 III 25 in 5 4 n/a 
WCB1479 IV 45 in 25 3 Distant only 
WCB1493 II 45 in 25 1 Local only 
WCB1602 III 45 in 25 1 None 
WCB1603 II 45 in 25 3 Local and distant 
WCB1604 III 45 in 25 2 Distant only 
n/a 
Table 21: Treatment strategies and outcomes for all patients with locally advanced rectal cancer 
Variables N (%) 
Radiotherapy Regimen 
Short Course (One Week) 2 14.3 
Long Course (Five Weeks) 12 85.7 
Surgery Performed 
Yes 9 64.3 
No 5 35.7 
TRG 
TRG 1 3 21.4 
TRG 2 2 14.3 
TRG 3 5 35.7 
TRG 4 4 28.6 
Disease Recurrence within Two Years† 
Yes 9 69.2 
No 4 30.8 
† - Recurrence data for one patient (WCB1478) at two years was unavailable. 
 
105 
 
Overall, 9/14 patients (64.3%) received surgery after treatment with radiotherapy. Patient 
WCB1419 was not fit enough for surgery whilst three patients (WCB1295, WCB1493 and 
WCB1602) underwent active monitoring as they achieved cCR. In contrast, patient WCB1268 
was found to have distant metastases before surgery could take place. 
Four patients had neoadjuvant chemotherapy in addition to or before the administration of 
radiotherapy (WCB1268, WCB1477, WCB1479 and WCB1603) and two patients had detectable 
metastases at diagnosis (WCB1268 and WCB1479). 
Following the completion of treatment, 9/13 (69.2%) patients experienced disease recurrence 
within two years of follow-up, of which five and six patients experienced local and distant 
recurrence respectively (including two patients who experienced both distant and local disease 
recurrence). Median follow-up for these patients was 64.8 months (range: 11.7-96.9 months).  
From our cohort, three patients (21.4%) achieved a complete response (TRG 1). This in line 
with studies which have reported a complete response in 12.5-20.6% of patients with LARC 
undergoing pre-operative CRT (Maas et al. 2010; Akiyoshi et al. 2012). In total, five patients 
(35.7%) displayed a good response (TRG 1/2) to neoadjuvant therapy, including the three who 
achieved cCR, whilst nine patients (64.3%) displayed a poor response.  
Objective: Do longitudinal ctDNA levels correlate with clinical outcomes in patients with LARC? 
 
Patient response to therapy was separated in a binary fashion (TRG 1/2 and TRG 3/4 for good 
and poor responders respectively). In addition, patients were also separated out into those 
who achieved a complete (TRG 1) vs incomplete response (TRG 2-4) and the recurrence of local 
and/or distant disease within the first two years of follow-up (see Table 22, Table 23 and Table 
24 respectively). We analysed recurrence in patients after two years as studies have reported 
that disease recurrence within this time period was indicative of long-term patient outcomes 
(Sargent et al, 2011). This data was acquired with the ambition of comparing circulating 
biomarker concentrations to each of these clinical responses to identify any clinically 
significant associations.  
Although we had a total of 14 patients with LARC for circulating biomarker analysis, not all 
patients had plasma collected at all timepoints, nor did all patients undergo ctDNA analysis. 
Therefore, some patients are missing from certain sections of the analysis, which is illustrated 
by the variable values in the N column. 
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Table 22: A comparison of longitudinal ctDNA and cfDNA levels across patients with good and poor 
responses to neoadjuvant therapy 
  
Good Response Poor Response 
  
(TRG 1/2) (TRG 3/4) 
Variables N Median (Range) N Median (Range) p-value 
Pre-Treatment Levels 
CtDNA VAF (%) 4 
0 
7 
0 
0.3 
(0.0 – 0.0) (0.0 – 3.5) 
CfDNA Concentration 
(ng/µL) 
6 
0.42 
9 
0.35 
0.79 
(0.22 – 0.45) (0.22 – 0.76) 
On-Treatment Levels 
CtDNA VAF (%) 2 
0 
5 
0 
n/a 
n/a n/a 
CfDNA Concentration 
(ng/µL) 
5 
0.41 
5 
0.19 
0.08 
(0.10 – 0.43) (0.19 – 0.21) 
Post-Treatment Levels 
CtDNA VAF (%) 3 
0 
6 
0 
0.52 
n/a (0.0 – 2.8) 
CfDNA Concentration 
(ng/µL) 
4 
0.36 
8 
0.2 
0.14 
(0.16 – 0.68) (0.12 – 0.47) 
 
Table 23: A comparison of longitudinal ctDNA and cfDNA levels across patients with complete and 
incomplete responses to neoadjuvant therapy 
  Complete Response 
(TRG 1) 
Incomplete Response 
(TRG 2-4) 
  
Variables N Median (Range) N Median (Range) P-Value 
Pre-Treatment Levels 
ctDNA VAF (%) 2 
0 
9 
0 
0.52 
(0.0 – 0.0) (0.0 – 3.5) 
cfDNA Concentration 
(ng/µL) 
4 
0.42 
10 
0.345 
0.78 
(0.34 – 0.43) (0.22 – 0.76) 
On-Treatment Levels 
CtDNA VAF (%) 2 
0 
5 
0 
n/a 
n/a n/a 
CfDNA Concentration 
(ng/µL) 
4 
0.42 
6 
0.19 
<0.01 
(0.34 – 0.43) (0.10 – 0.21) 
Post-Treatment Levels 
CtDNA VAF (%) 3 
0 
6 
0 
n/a 
n/a (0.0 – 2.8) 
CfDNA Concentration 
(ng/µL) 
2 
0.56 
9 
0.2 
<0.01 
(0.44 – 0.68) (0.12 – 0.47) 
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Table 24: A comparison longitudinal ctDNa and cfDNA levels between different patient responses to neoadjuvant therapy. Any recurrence refers to patients who experience 
either local or distant relapse. 
  Local Relapse Distant Relapse Any Relapse 
Variable 
No Relapse; 
Median 
(Range) 
Relapse; 
Median 
(Range) 
p- Value 
No Relapse; 
Median 
(Range) 
Relapse; 
Median 
(Range) 
p- Value 
No Relapse; 
Median 
(Range) 
Relapse; 
Median 
(Range) 
p- Value 
Pre-Treatment Levels 
CtDNA VAF (%) 
0 0 
0.74 
0 0 
0.26 
0 0 
0.50 
(0.0 – 0.6) (0.0 – 3.5) (0.0 – 0.0) (0.0 – 3.5) (0.0 – 0.0) (0.0 – 3.5) 
CfDNA Concentration 
(ng/µL) 
0.36 0.26 
0.36 
0.42 0.35 
0.8 
0.43 0.36 
0.76 
(0.26 – 0.76) (0.22 – 0.41) (0.32 – 0.45) (0.22 – 0.76) (0.34 – 0.45) (0.22 – 0.76) 
On-Treatment Levels 
CfDNA Concentration 
(ng/µL) 
0.21 0.23 
0.85 
0.34 0.19 
0.10 
0.34 0.21 
0.44 
(0.19 – 0.38) (0.19 – 0.41) (0.19 – 0.41) (0.19 – 0.21) (0.19 – 0.38) (0.19 – 0.43) 
Post-Treatment Levels 
CtDNA VAF 
0 0 
0.48 
0 0 
0.36 
0 0 
0.60 
(0.0 – 0.0) (0.0 – 2.8) (0.0 – 0.0) (0 – 2.8) (0.0 – 0.0) (0.0 – 2.8) 
CfDNA Concentration 
(ng/µL) 
0.26 0.21 
0.92 
0.27 0.18 
0.19 
0.26 0.2 
0.76 
(0.16 – 0.47) (0.12 – 0.68) (0.22 – 0.68) (0.16 – 0.47) (0.24 – 0.27) (0.12 – 0.68) 
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Here we observed significantly higher total cfDNA concentrations in patients who achieved a 
complete response to treatment both during and after therapy (Table 23). Although a 
suggestive significance (p=0.08) for patients who had a good response was also seen (Table 
22), this was not reflected in the local and/or distant recurrence analysis (Table 24). This 
remained consistent when patients with pre-treatment metastases were removed from 
analysis. In contrast, Zitt and colleagues (2008) have previously reported that patients with 
LARC who responded well to pCRT saw a decrease in total cfDNA concentrations from pre- to 
post-treatment samples.  
Studies have also reported that high cfDNA concentrations at baseline were indicative of an 
increased risk of recurrence and poor DFS in patients with LARC (Schou et al. 2018). This 
contrasts with our finding that cfDNA concentrations were higher during and after therapy in 
patients who achieved a complete response to treatment. We did not see any correlations 
between tumour stage and pre-treatment cfDNA concentrations, which differs from prior 
reports (Boysen et al. 2017). 
We saw no associations between baseline cfDNA concentrations and initial patient response to 
therapy nor the likelihood a patient would relapse. This also remained consistent when 
patients with pre-treatment metastases were removed from analyses. In contrast, Schou and 
colleagues (2018) reported that high pre-treatment cfDNA was associated with a decreased 
likelihood of achieving pCR and poor DFS in patients with LARC. This is in agreement with a 
study from Vivancos and colleagues (2018) who also demonstrated that high pre-treatment 
cfDNA was associated with an increased risk of recurrence within five years in patients with 
LARC. However, our data does not support this finding. Our findings may contradict the 
literature due to several factors, including the reproducibility or sensitivity of the Qubit, the 
potential impact of pre-analytical handling of samples or the fact that cfDNA is not a tumour 
specific biomarker. 
Whenever ctDNA was detected at baseline, patients would have responded poorly in both 
(100%) cases. Both patients (WCB1295 and WCB1478) had detectable pre-treatment 
metastases and lymph node involvement respectively. Although this might suggest that 
detectable baseline ctDNA is a poor prognostic indicator, this is also likely to be a result of the 
small sample size and number of positive events. Thus, no meaningful findings can be reported 
at this time. No patients had detectable ctDNA either during or after the administration of 
neoadjuvant treatment. This may have been influenced the detectable ctDNA levels. Due to 
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the low numbers of patients with detected ctDNA at any time, comparisons between different 
response rates cannot be performed statistically.  
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3.3 Discussion 
3.3.1 Conclusions 
Objective: Can ctDNA be detected in the circulation of patients with LARC before the initiation 
of therapy using NGS? 
We detected pre-treatment ctDNA in three patients with LARC using NGS (Table 17) achieving 
a sensitivity and concordance of 30% and 37.5% respectively using NGS. Previous studies in 
patients with LARC have shown variable sensitivities when identifying pre-treatment ctDNA 
using NGS (Tie et al. 2018). We postulate that the decreased levels we observed here are the 
result of numerous factors addressed below. 
Lower concordance rates have been reported in locally advanced cancer patients in 
comparison to patients with metastatic CRC (Grasselli et al. 2017; Hsu et al. 2018). This is likely 
a result of the low tumour burden or absence/early stages of metastatic lesions in these 
patients. Carpinetti and colleagues (2015) reported that ctDNA was difficult to detect in 
patients with early stage tumours (T1-T2 stage). Siravegna and colleagues (2015) reported that 
their patients who displayed discordance between tumour tissue and cfDNA all had low 
tumour burden, an important factor to consider within our patient cohort. A similar finding 
was reported by Bettegowda and colleagues (2014), where significant differences were 
observed in the frequency of ctDNA detection between patients with locally advanced and 
metastatic disease across a range of solid tumours (including patients with CRC).  
The sensitivity and concordance of this study are lower than anticipated. Comparisons to other 
studies in the literature are difficult, as we only found two studies directly investigating 
patients with LARC which varied widely in results (Sclafani et al. 2018; Tie et al. 2018). Of 
these, only one used NGS to detect ctDNA (Tie et al. 2018). Although, we intended to compare 
our findings to studies with metastatic patients, the large differences in patient characteristics 
did not allow a fair and direct comparison. 
Our reduced sensitivity and concordance may be due to numerous factors. A low plasma 
volume (1-2mL) providing a low cfDNA concentration, created difficulties in variant detection, 
as the NGS required a larger number of amplification cycles which can cause amplification bias, 
for either wild-type or mutant DNA.  
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Furthermore, the NGS system we applied had a relatively large amount of ‘background noise’ 
making variant detection <1.0% difficult to discern from artefacts. Therefore, true variants in 
this range may have been interpreted incorrectly. 
Our sensitivity and concordance may also be influenced by sample deterioration and improper 
pre-analytical handling. CfDNA is an unstable biomarker which can fragment easily if not 
handled properly or undergoes numerous freeze thaws during storage (El Messaoudi et al. 
2013). Furthermore, as the pre-analytical plasma processing, storage and transportation was 
performed by the WCB, issues may have occurred here which damaged sample quality and 
concentration. This may have further detrimental effects on downstream analysis.  
Another factor which can influence ctDNA detection are the biological characteristics of the 
patients themselves. The findings that ctDNA is less frequently detected and found at lower 
levels in patients with LARC than patients with metastatic disease suggests that tumours shed 
less DNA in these patients. This could be because activity and growth are lower in early-stage 
tumours, or that tumours may not yet be in close proximity to blood vessels. Perhaps the 
tumour has not grown to the size appropriate required for necrosis or other forms of cell 
death to release abundant ctDNA into the circulation for reliable detection. Thus, these 
patients may not benefit from circulating biomarker analysis. 
Overall, we confidently detected ctDNA in pre-treatment samples from patients with LARC 
using NGS. However, our observed sensitivity for detecting ctDNA was below expectations 
based on the literature, which may be due to several technical or biological factors. 
Objective: Can ctDNA be reliably detected in sequential plasma samples before, during or after 
therapy in patients with LARC using ddPCR? 
We observed lower frequencies of ctDNA using ddPCR in comparison to NGS. Our findings 
were also low in comparison to previous studies using ddPCR (Sclafani et al. 2018) or NGS (Tie 
et al. 2018) who reported sensitivities of 34% and 76% respectively for detecting ctDNA in 
patients with LARC. The use of NGS to screen for numerous variants rather than being limited 
to one by ddPCR may therefore provide some inherent advantages to ctDNA detection. Our 
findings may also be influenced by the sensitivity of ddPCR. As ddPCR does not amplify target 
DNA in the same fashion as NGS, analysis is much more limited by sample input. Therefore, 
detecting low VAFs in low DNA concentrations can be difficult, as shown in the Materials and 
Methods Chapter.  
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For a number of these patients, we had no access to tumour tissue for variant detection and 
instead relied upon variants identified during clinical analysis. Furthermore, for the tissue we 
did sequence we did so with a targeted sequencing panel, rather than whole exosome or 
genome sequencing, thus limiting the number of variants we could analyse. This could have 
also assisted the identification of variants in patients where we did not detect any. 
Another important factor which could influence ctDNA detection is cfDNA concentration and 
plasma volumes. Tie and colleagues (2018) applied 10mL of patient plasma for ctDNA analysis, 
whereas our study and that by Sclafani and colleagues (2018) only investigated ctDNA in 1-2mL 
and 2mL of plasma respectively. The use of greater volumes of plasma for cfDNA extraction 
can benefit ctDNA analysis by providing greater concentrations of cfDNA for analysis whilst 
increasing the likelihood of low levels of ctDNA being extracted. The increased concentration 
of cfDNA can improve the confident detection of variants with low VAFs (see Section 2.3.2). 
The large difference in plasma volume applied here may therefore contribute to the difference 
in sensitivities observed between these studies. 
Pre-analytical sample handling is another key factor which may have contributed to our limited 
findings. As samples were collected and processed externally, we cannot be certain whether all 
samples were processed within an appropriate time interval. An increased time period 
between collection and processing can cause the lysis of white blood cells, which consequently 
shed DNA into plasma. This can appear as cfDNA during analysis and may mask the presence of 
ctDNA. 
We were only able to perform ctDNA or cfDNA analysis in a very small number of patients with 
LARC. With small numbers and small positive incidents of ctDNA detection, it is not possible to 
identify changes which are clinically significant. 
The clinical characteristics of our patients are also important to consider when investigating 
ctDNA in cancer patients. Beije and colleagues (2016) have reported ctDNA had a higher 
concordance with metastatic sites (55%) than matching primary tumours (39%) in patients 
with metastatic CRC. This suggests that ctDNA in these patients is largely derived from or 
associated with metastatic lesions. Our study did include three patients with known metastatic 
lesions at diagnosis, of which one (WCB1473) had detectable pre-treatment ctDNA. For patient 
WCB1473 the biopsy was taken from the metastatic lesion, correlating with this finding from 
Beije and colleagues (2016). Our results may agree with these findings as both patients with 
detected ctDNA levels had either metastases (M1) or invasion of local lymph nodes (N1) with a 
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high tumour burden (T4) (Bettegowda et al. 2014). However, this is merely a qualitative 
observation due to our low ctDNA detection rate. Furthermore, we did not detect ctDNA in 
patient WCB1479 who also had metastases detected at diagnosis. This might be because the 
metastatic lesion was not sequenced in this patient, and concordance is higher between 
metastatic lesions and ctDNA. Otherwise, any number of limitations discussed here could be 
the cause of not detecting ctDNA in this patient. 
From the literature we expected to see detectable levels of ctDNA in pre-treatment plasma, 
which would have mostly decreased after the initiation of radiotherapy. We then hoped to see 
changes in ctDNA, after the completion of radiotherapy, which would potentially correlate to 
patient outcomes and response. However, due to our lack of ctDNA positive patients, we were 
unable to see any such association. 
We also anticipated an initial peak in ctDNA release after initiating radiotherapy, which could 
have been indicative of sudden tumour cell death. We did not see any such peak, which may 
be due to this phenomenon not occurring, or issues with plasma timepoints. In order to see 
such an event, plasma samples might have to be collected more frequently or soon after the 
administration of radiotherapy in these patients. We are currently unaware of the optimal 
timings for blood collection to detect the shedding of ctDNA into the circulation and measure 
circulating biomarkers in relation to radiotherapy. Circulating biomarker analysis throughout 
radiotherapy is ideal. However, we need to identify when to collect plasma after the 
administration of radiotherapy to allow optimal circulating biomarker analysis. This requires 
further investigation and standardisation in the future to facilitate predicting patient outcomes 
and response. 
Using ddPCR, we were unable to reliably detect ctDNA in sequential plasma samples from 
patients with LARC which is likely to be a consequence of numerous biological and/or technical 
factors. 
Objective: Can we detect and measure quantitative changes in total cfDNA before, during and 
after treatment in patients with LARC? 
We were able to extract and detect cfDNA within all patient samples except one (patient 
WCB1479 week 5). We were also able to measure quantitative changes in total cfDNA 
throughout pCRT using 1mL of patient plasma. However, the method used to quantify total 
cfDNA in these patients has been shown to possess limitations when compared to qPCR 
(Nakayama et al. 2016). Alternatively, other studies have shown that the Qubit correlated well 
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with qPCR when quantifying with cfDNA (Ponti et al. 2018). Therefore, further studies are 
required to analyse the efficacy of using the Qubit for total cfDNA quantification. As a result, 
we do not yet fully understand whether the small changes in total cfDNA levels are clinically 
significant. 
We observed a general increase in total cfDNA concentration from pre- to on-treatment 
samples followed by a decrease from on- to post-treatment samples. However, these 
differences were not statistically significant. In contrast to our findings, Panditharatna and 
colleagues (2018) reported a decrease in cfDNA concentrations after the initiation of therapy, 
suggesting that this was indicative of tumour down-staging or decreased tumour growth and 
less DNA being shed by the tumour and overall decreased total cfDNA concentrations. The 
increase seen in our study may represent elevated tumour- and surrounding non-tumour cell 
death as a result of treatment. The subsequent decrease may be a result of the cessation of 
therapy and lower rates of cell death. This may also be simply the result of natural biological 
variation in total cfDNA. This hypothesis is based on the total cfDNA levels of patient 
WCB1603, who displayed drastic changes before the initiation of therapy.(Zitt et al. 2008; 
Agostini et al. 2011; Park et al. 2018).  
Differences may also exist between ours and various other studies in the literature due to 
several other factors. Where the studies by Zitt (2008), Agostini (2011) and ourselves focusses 
on changes in patients with LARC, the study by Park and colleagues (2018) investigates 
patients with hepatocellular carcinoma. Albeit that all four studies focus on changes occurring 
as a result of radiotherapy. The pre-treatment total cfDNA we observe here is higher than that 
reported by Zitt and colleagues (0.001-0.017ng/ µL from 125-240µL of plasma) and Agostini 
and colleagues (0.009-0.27ng/µL from 500µL of plasma) in patients with rectal cancer. Even 
when normalised, our findings are generally higher than these two studies. This difference 
might be due to the techniques used to analyse and quantify total cfDNA.  
In each study, a different commercial kit was used to extract total cfDNA, although all were 
based on Qiagen’s QIAamp service. Therefore, some natural variation is likely to occur 
between each of the three methods. Furthermore, where we used the Qubit, the other two 
studies applied qPCR of reference genes to quantify total cfDNA (Zitt et al. 2008; Agostini et al. 
2011). The use of the Qubit is simple but potentially influenced by contamination. The use of 
qPCR or ddPCR for total cfDNA concentration can be more accurate and reliable than 
fluorescent based methods like the Qubit. However, as copy number changes can frequently 
occur in cancer, the number of genes and genes in question for quantification will need 
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standardisation. Once standardised, qPCR and ddPCR provide distinct advantages over the 
Qubit. 
We did observe a significant difference in total cfDNA concentration between patients with 
stage III to IV, where stage IV had significantly lower total cfDNA concentrations. This 
significance was lost when separating cfDNA sample according to treatment stage at time of 
collection (pre-, on- or post-treatment). Otherwise, we did not observe any significant 
differences in total cfDNA concentration based on patient TNM or stage grouping.  
This contradicts findings from Boysen and colleagues (2017) who reported significant 
differences between patients with lymph node positive and negative disease as well as a 
positive correlation between total cfDNA and the stage of patients according the American 
Joint Committee on Cancer (AJCC). Another study by Schou and colleagues (2018) found no 
significant differences according to patient AJCC stage either. In this case, Schou and 
colleagues quantified total cfDNA directly from plasma using a fluorometric method whereas 
Boysen and colleagues quantified reference genes using ddPCR. The different nature of these 
methods, where ddPCR detects specifically amplifiable levels of cfDNA whereas the 
fluorometric assays are less specific could be the cause of differences observed here. 
Fluorometric methods can theoretically quantify cfDNA which is fragmented beyond the point 
where amplification is reliable. However, these methods can be influenced by the presence of 
contaminants. Both studies also investigated larger numbers of patients with LARC (Schou and 
Boysen analysing 123 and 74 patients with LARC respectively). Therefore, the detection of 
significant differences in tumour stage may require a larger cohort to reliably observe. 
Furthermore, total cfDNA levels can be influenced by other physiological factors, because it 
can be derived from both tumour and non-tumour tissue. Such factors can include radiation-
induced toxicities, exercise, severe infection or other causes of inflammation (Vittori et al. 
2019). Significant changes in total cfDNA can also be caused by improper pre-analytical sample 
handling causing white blood cell lysis and DNA to shed into plasma (Pritchard et al. 2012). 
Zwirner and colleagues (2018) also reported that cfDNA concentrations were raised for up to 
three days after radiotherapy. Thus, any concentrations drawn during or shortly after 
radiotherapy must consider this potential confounding factor. Additionally, the presence of 
radiation-induced toxicity or infection can also cause significant increases in concentrations, 
which must be considered for future analyses (Zwirner et al. 2018). 
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As mentioned previously, our study is limited by small sample size. This can create difficulties 
in achieving statistical significance and is likely to contribute to our limited findings. 
Overall, we were able to detect and quantify total cfDNA in most of our patient cohort. The 
significantly higher concentrations observed in total cfDNA samples collected during therapy 
may be indicative of increased tumour and/or non-tumour cell death after the initiation of 
therapy.   
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3.3.2 Clinical Implications 
Objective Do longitudinal ctDNA levels correlate with clinical outcomes in patients with LARC? 
Due to our low frequency of ctDNA detection, comparisons to clinical outcomes to find 
significant associations was not possible. However, we looked at individual patients and their 
clinical outcomes. Patient WCB1478 had detectable pre-treatment ctDNA which subsequently 
depleted before the collection of plasma at week 4 respectively. This patient had a poor 
response to therapy (TRG4) which contradicts the literature. Hsu and colleages (2018) have 
previously reported that a decrease in ctDNA levels from pre- to post-treatment were 
indicative of tumour shrinkage in patients with metastsatic CRC. Similarly, Paditharatna and 
colleagues (2018) reported that a significant decrease in ctDNA after therapy corelated with 
tumour shrinkage in patients with gliomas. . The lack of detectable ctDNA in patient WCB1478, 
may be a consequence of non-biological reasons which are discussed further below or the 
relatively short time period between treatment completion and sample collection (~2 weeks). 
Patient WCB1493 relapsed after the shortest time period of (1.2 months) but had no 
detectable ctDNA at any time using our methods. This was consistent with pre-treatment 
clinical factors, such as no detectable lymph node involvement or metastatic lesions. Although 
we saw no statistical significance, both patients with detectable pre-treatment ctDNA had 
either detectable metastases or lymph node involvement before the initiation of therapy. 
Carpinetti and colleagues (2015) illustrated that ctDNA levels were low at pre-treatment, with 
initial good responders having a further decrease. However, our low overall ctDNA positivity 
makes it difficult to compare our findings at this time. This may be, in part, because we applied 
ddPCR to detect one variant in ctDNA, but changes could be occurring which are missed using 
this method. With the small sample sizes and low number of patients with detectable ctDNA 
levels at this time, comparisons are impossible. 
Other studies have suggested that a post-therapeutic increase in ctDNA levels could be due to 
the presence and/or growth of minimal residual disease and/or micro-metastases (Tie et al. 
2018). Carpinetti and colleagues (2015) reported that post-therapeutic increases in ctDNA 
were associated with disease progression whilst Lecomte and colleagues (2002) established 
that detectable ctDNA at time of surgery predicted poorer overall survival in CRC patients. This 
is in agreement with numerous reports which suggested that post-therapeutic increases in 
ctDNA correlated with decreased overall survival and time to recurrence (Diehl et al. 2005; 
Bettegowda et al. 2014; Provencio et al. 2017). Finally, in renal cell carcinoma, increase in 
118 
 
ctDNA during follow-up correlated with the emergence of brain metastases and was able to 
detect progression earlier than current clinical imaging methods (Yamamoto et al. 2019b). 
These reports suggest that detectable levels of ctDNA after the completion of therapy may 
indicate that treatment did not down-stage tumours to a significant extent. However, due to 
our lack of ctDNA positive samples, especially post treatment samples, we were unable to 
determine whether these findings are consistent in this cohort. 
Studies have suggested that early changes in ctDNA are less significant regarding clinical 
outcomes than post-treatment ctDNA levels (Tie et al. 2018). Long and/or short course 
chemoradiotherapy with total mesorectal excision does provide benefits regarding local 
recurrence through tumour down-staging but not necessarily regarding overall survival in 
patients with LARC (Kapiteijn et al. 2001b). This is also highlighted by the fact that, lymph-node 
down-staging has been reported to be the most significant predictor of patient long-term 
survival (Willis 2007). This is likely to be due to the specific targeting of primary tumour with 
radiotherapy, which does not directly impact pre-existing metastatic lesions. Although pre-
treatment ctDNA has been reported to correlate with stage and the presence of metastases 
(Diehl et al. 2005), detectable levels of ctDNA post-therapy appear to provide greater insight 
into the presence of metastatic lesions. The presence of metastases may also be unknown to 
the clinical team after the completion of treatment and may therefore influence further 
treatment-decision making. 
Detectable ctDNA may simply be indicative of more advanced disease and/or the presence of 
metastatic lesions which may not have been identified previously. This finding is in agreement 
with a previous study which reported that increased baseline ctDNA was predictive of poor 
survival across patients with various cancer types (Bettegowda et al. 2014). As previously 
stated, this finding is merely observational and not statistically significant. 
Patients with no detectable ctDNA may also be false negatives. CtDNA may have been called 
negative falsely, due to other causes such as the incorrect choice of variant for ctDNA analysis, 
pre-analytical handling or limited assay sensitivity as mentioned previously. Alternatively, this 
may be a consequence of the inherent tumour biology of our non-metastatic patients, who 
may shed less ctDNA into the circulation than metastatic counterparts.  
The role of ctDNA in the clinic is rapidly developing, particularly with regards to targeted 
therapies and sensitivity- or resistance-associated tumour variants. With regards to patients 
with LARC undergoing pCRT, the clinical potential of ctDNA is still unravelling. The detection of 
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ctDNA after the completion of pCRT is a potentially useful tool as it may suggest the 
effectiveness of therapy. If so, these patients may have an increased risk of local or distant 
recurrence and therapeutic decisions can be made earlier. 
Objective: Do longitudinal cfDNA levels correlate with clinical outcomes in patients with LARC? 
CfDNA concentrations have reportedly been able to predict the response of patients with LARC 
to pCRT. Here we observed that high sequential (on- and post-treatment) cfDNA 
concentrations were significantly associated with a complete response to therapy. The 
increased concentrations of cfDNA during treatment may be indicative of increased rates of 
tumour cell death and shedding of cfDNA into the circulation (Jahr et al. 2001). This effect may 
still be seen for a short time after the completion of treatment in post-treatment plasma 
samples. We did not identify any association between cfDNA concentration and disease 
recurrence.  
This conflicts with previous reports from Zitt and colleagues (2008), who reported that patients 
who responded well to pCRT saw a decrease in total cfDNA concentration at the end of 
treatment, and those who did not respond well saw an increase. Similarly, .Schou and 
colleagues (2018) found that high cfDNA concentrations at baseline were predictive of poor 
recurrence- and disease-free survival, whilst Boysen and colleagues (2017) showed that high 
pre-surgical cfDNA concentration correlated with risk of recurrence. This is also in agreement 
with reports from Park and colleagues (2018) who demonstrated in hepatocellular carcinoma 
that high pre- and post-CRT cfDNA concentrations were indicative of more advanced disease 
and larger tumours. These reports suggest that high post-treatment cfDNA concentrations 
could suggest that tumour tissue remains in one form or another.  
We observed in our cohort that patient WCB1419 retained consistently high total cfDNA 
concentrations from pre-to post-treatment. According to these reports, this may be indicative 
of poor treatment response and a poor predictive marker of outcomes in this patient. This is in 
agreement with our findings where this patient had a poor response to therapy (TRG4) and 
experienced distant relapse within two years of follow-up. 
We also observed a relatively sharp increase in total cfDNA post therapy in patient WCB1603. 
According to previous reports, this would suggest ineffective treatment and possible tumour 
progression in this patient. These predictions concords with the fact that this patient 
experienced local and disease recurrence within two years. Although promising, these are only 
two examples and significant findings should not be based on these results. 
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For total cfDNA, reports have suggested that levels positively correlate with tumour stage 
(Boysen et al. 2017). Though we did not observe this ourselves, the utility of total cfDNA for 
this purpose at pre-treatment can help more clearly define tumour stage, which is currently 
the only available method which influences treatment decision-making. 
There may be several reasons that our data may conflict with the literature. Firstly, our study 
was comprised of a relatively small number of patients with LARC (n=14) whereas the studies 
by Schou (2018) and Zitt (2008) analysed cfDNA in 123 and 26 patients with LARC respectively . 
Due to our small sample numbers, our significant findings may also be skewed by a small 
number of outliers. Even when using medians instead of means as an average, small sample 
numbers can allow outliers to influence the average cfDNA concentration during statistical 
analysis. CfDNA concentrations may also be detrimentally impacted by pre-analytical sample 
handling or an inefficient cfDNA extraction method. Finally, cfDNA is not specifically tumour-
derived, and thus, may be influenced by the shedding of non-tumour tissue via other 
physiological processes, such as inflammation, infections and radiotherapy (Zwirner et al. 
2018; Vittori et al. 2019).  
This information could theoretically be used to influence treatment-making decisions where 
high-risk patients can undergo post-operative neoadjuvant therapy. Alternatively, low-risk 
patients could avoid unnecessary and toxic procedures with such information.  
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3.3.3 Future Studies 
There are numerous ways with which this study can be altered to improve the reliability and 
consistency of the results. The analysis of more patients would potentially allow us to detect 
more ctDNA positive patients and interrogate resulting patterns. This would also help provide 
greater statistical and clinical significance when comparing ctDNA levels to patient outcomes. 
Having tumour tissue to sequence for patients with longitudinal plasma samples could aid this 
project by allowing the analysis of more variants for ctDNA identification. The availability of 
whole tumours, multiple regions of a single tumour or larger tumour samples for sequencing 
would provide greater confidence in the variants detected and potentially help to resolve 
some issues surrounding intra-tumour heterogeneity. 
The utility of whole exome or genome sequencing for tumour biopsies alongside germline DNA 
would have limited the number of patients without detectable tumour-specific variants. This 
would then increase the number of patients in which ctDNA can be analysed, detected and 
potential patterns observed. 
For longitudinal analysis, the ability to sequence sequential plasma samples could potentially 
help overcome similar obstacles surrounding inter and intra-tumour heterogeneity. This would 
allow the analysis of a multitude of variants which could represent separate tumour clones.  
Finally, the collection and processing of plasma samples in-house could ensure better sample 
quality by limiting sample transport and the risk number of freeze-thaws. 
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4 Analysis and Clinical Utility of Tumour Heterogeneity and Circulating 
Tumour DNA in Patients with Locally Advanced Rectal Cancer 
4.1 Introduction 
 In Chapter 3, we were able to validate our analytical methods for ctDNA analysis as part of a 
pilot study in patients with LARC. In this chapter, we aim to expand upon these findings in a 
larger cohort of patients with LARC undergoing pCRT. In addition, we intend to investigate the 
ability to detect clonal changes in the primary tumour tissue of patients with LARC using a 
targeted NGS panel. As part of this expansion, patient samples were acquired from the 
ARISTOTLE clinical trial.  
4.1.1 Study Objectives 
Using plasma and matching pre- and post- treatment tissue in patients from ARISTOTLE, we 
aim to expand upon our findings in the previous chapter. In this chapter, the objectives are: 
• How effective is our targeted NGS panel at detecting clinically significant variants in 
patients with LARC? 
o Can we identify molecular changes within tumour tissue using our targeted 
sequencing panel in patients with LARC? 
o What molecular changes occur in relation to CRT in patients with LARC? 
• Can ctDNA be reliably detected in sequential plasma samples before, during or after 
neoadjuvant therapy in another cohort of patients with LARC using ddPCR? 
o Is ctDNA released into the circulation in relation to neoadjuvant therapy in 
patients with LARC? 
• Can we detect and measure quantitative changes in total cfDNA before, during and 
after radiotherapy in another cohort of patients with LARC? 
o Is cfDNA released into the circulation in relation to neoadjuvant therapy in 
patients with LARC? 
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4.2 Results 
We initially received permission from Professor Nick West for the acquisition of tumour tissue 
and plasma samples for 24 patients from the ARISTOTLE clinical trial for molecular analysis. 
These 24 patients were chosen because each had all four plasma timepoints, tumour biopsy 
and surgical resection tissue available for molecular analysis. Of these 24 patients, five 
achieved a complete pathological response pCR to neoadjuvant therapy and were excluded 
from molecular analysis due to having limited amounts of tumour tissue available. In total, 
paired tumour tissue and sequential plasma samples were available for molecular analysis in 
19 patients with LARC from the ARISTOTLE clinical trial.  
All 19 patients had five weeks of radiotherapy (45Gy/25 doses) alongside concurrent 
Capecitabine with or without Irinotecan. Plasma samples were collected at weeks 0 (pre-
treatment), week 1 (first week of therapy), week 5 (final week of therapy) and week 10 (post-
treatment). Patients underwent surgery 10 weeks after the completion of pCRT. All tissue 
samples were collected and processed at each patient’s respective trial site before being 
transported to the AWMGS for molecular analysis later.  
Plasma samples were collected and handled differently depending upon when the patient was 
consented during the trial, see Chapter 2 for further details.  
4.2.1 Next Generation Sequencing of tumour tissue from patients with LARC 
Objective: How effective is our targeted NGS panel at detecting clinically significant variants in 
patients with LARC? 
In order to identify tumour-specific variants in 19 patients from the ARISTOTLE clinical trial, we 
sequenced 38 FFPE tumour samples from each patient, including matching tumour biopsies 
and surgical resections. Samples were sequenced using the Ion Torrent CHPv2 as described 
previously in the Materials and Methods Chapter.  
Only the tumour biopsy from patient ARI-166 failed NGS analysis, therefore 37/38 (97.4%) 
tumour tissue samples were successfully sequenced. 
Variants were called, filtered and annotated as previously described in the Materials and 
Methods Chapter. Briefly, variants were filtered according to VAF, coverage and directional 
bias. Our limit of detection for variants in tumour tissue in this study was set at 5% VAF based 
on findings previously described in the Materials and Methods. Thereafter, non-coding 
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variants were removed, and all remaining variants were checked manually in the IGV software 
to ensure they were genuine and not sequencing artefacts.  
Remaining variants were annotated and filtered according to guidelines suggested by the ASCO 
and CAP (Li et al. 2017a). Briefly, variants were filtered according to; the reported minor allele 
frequency in healthy control populations, whether the variant was previously detected in 
patients with rectal cancer, the impact on protein function, and any current clinical association 
with rectal cancer. All variants detected at known clinically relevant hotspots in KRAS (p.G12, 
p.G13 and p.Q61), NRAS (p.G12, p.G13 and p.Q61), BRAF (p.V600E) and PIK3CA (p.E542, 
p.E545 and p.H1047) were automatically included due to their relevance in clinical guidelines 
from the National Institute for Health and Care Excellence (NICE).  
Guidelines from ASCO/CAP suggest categorising variants into separate (Tiers I-IV) to define 
their level of clinical significance (Li et al. 2017a). The categories include variants with strong 
clinical significance (Tier I), potential clinical significance (Tier II), unknown significance (Tier III) 
and benign or likely benign (Tier IV). 
Applying these criteria, we identified 34 strong or likely clinically significant (Tier I/II) variants 
in either pre- or post-treatment tissue from 18 patients with LARC (see Table 25).  
Table 25: Summary of all 34 Tier I/II variants detected in 19 patients wih LARC 
Patient 
ID 
Genomic Location Gene ID 
Protein 
Change 
VAF in 
Biopsy 
(%) 
VAF in 
Resection 
(%) 
Variant 
Tier 
ARI-166 Chr12:25398285C>A KRAS p.G12C 15 16.8 I 
ARI-182 Chr12:25398285C>T KRAS p.G12S 45.1 1.2 I 
ARI-202 Chr12:25398284C>T KRAS p.G12D 28.3 47 I 
ARI-202 Chr17:7578388C>G TP53 p.R181P 35.6 67.6 II 
ARI-239 Chr12:25398285C>A KRAS p.G12C 55.1 37.6 I 
ARI-239 Chr17:7577094G>A TP53 p.R282W 54.7 33.1 II 
ARI-295 Chr17:7578437G>A TP53 p.Q165X 23 31.8 II 
ARI-297 Chr1:115256528T>A NRAS p.Q61H 41.1 20.2 I 
ARI-306 Chr17:7577141C>A TP53 p.G266V 18.9 7.6 II 
ARI-316 Chr5:112175390C>T APC p.Q1367* 27.9 23.3 II 
ARI-316 Chr12:25398285C>T KRAS p.G12S 63 69.4 I 
ARI-316 Chr17:7578455C>G TP53 p.A159P 32.4 31.3 II 
ARI-341 Chr5:112175426G>T APC p.E1379* 25 17.5 II 
ARI-341 Chr12:25398284C>T KRAS p.G12D 23.4 23.2 I 
ARI-341 Chr12:25398284C>A KRAS p.G12V 12 0 I 
ARI-341 Chr17:7578212G>A TP53 p.R213* 30.5 31 II 
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Patient 
ID 
Genomic Location Gene ID 
Protein 
Change 
VAF in 
Biopsy 
(%) 
VAF in 
Resection 
(%) 
Variant 
Tier 
ARI-346 Chr12:25398284C>A KRAS p.G12V 6.5 7.5 I 
ARI-346 Chr3:178936091G>A PIK3CA p.E545K 6.9 8 II 
ARI-366 Chr5:112175216G>T APC p.E1309* 21.6 31 II 
ARI-366 Chr12:25398284C>A KRAS p.G12V 15.1 24.8 I 
ARI-373 Chr5:112175390C>T APC p.Q1367* 32 16 I 
ARI-373 Chr17:7577120C>T TP53 p.R273H 30 23 II 
ARI-378 Chr12:25398284C>A KRAS p.G12V 44 26.5 I 
ARI-378 Chr17:7577556C>T TP53 p.C242Y 47.5 29.9 II 
ARI-400 Chr12:25380275T>A KRAS p.Q61H 22.2 28.8 I 
ARI-403 Chr5:112175328C>A APC p.S1346* 43 58 II 
ARI-403 Chr12:25398284C>A KRAS p.G12V 16.8 24.6 I 
ARI-408 Chr12:25398285C>A KRAS p.G12C 21.8 26.7 I 
ARI-413 Chr12:25398284C>A KRAS p.G12V 29.4 20.5 I 
ARI-413 Chr17:7578263G>A TP53 p.R196* 23.3 20.8 II 
ARI-437 Chr12:25398281C>T KRAS p.G13D 10 27.2 I 
ARI-437 Chr17:7578388C>G TP53 p.R181P 15.3 37 II 
*A nonsense mutation occurred at this location, causing the emergence of a stop codon 
Variant Tier – Variant tier of pathogenicity based on guidelines from ASCO/CAP (Li et al. 2017a) 
 
4.2.1.1 Genomic landscape of LARC 
In either the tumour biopsy or surgical resection, at least one pathogenic variant was detected 
in 18/19 (94.7%) patients with LARC. Variants in KRAS, TP53, and APC were detected in 14 
(73.7%), ten (52.6%) and five (26.3%) patients respectively. A single variant in PIK3CA and 
NRAS were each detected once in two separate patients (5.3%; Table 26). In this study, all 
variants detected in KRAS and NRAS were cross-checked using ddPCR in both pre- and post-
treatment tissue. Variants in TP53, PIK3CA and APC, were cross-checked using ddPCR in 6/14 
(42.8%), 1/2 (50%) and 1/8 (12.5%) variants respectively. Not all variants were cross-checked in 
the same manner due to financial limitations. All variants which were cross-checked were 
found to be positive. 
We were able to detect TP53 variants in ten patients, of which three were nonsense and seven 
were missense variants. These variants were detected within the DNA binding domain of p53 
(Saha et al. 2015). 
126 
 
In KRAS, we were able to detect 15 variants in 14 patients, all of which of were missense and 
located at p.G12, p.G13 (14/15; 93.3%) or p.Q61 (1/15; 6.7%). Two separate KRAS variants 
(p.G12D and p.G12V) were detected in the tumour biopsy of patient ARI-341. However only 
p.G12D was detected in the matching resected tumour tissue from this patient. 
In APC, we were able to detect five pathogenic variants in five patients, all of which were 
nonsense. These variants were in the mutation cluster region (MCR) of APC (Albuquerque et al. 
2002). 
In PIK3CA, we were able to detect one variant in one patient, which was missense (p.E545K). 
We were only able to detect one single missense variant in NRAS (p.Q61H) in tumour tissue 
from one patient.  
The mutational frequencies of these genes are summarised and compared to larger rectal 
cancer studies from cBioPortal and TCGA Network (Network 2012) in Table 26.  
Table 26: Frequency of Variants Detected Within Genes of Interest Within our Cohort in Comparison to 
Other Selected Cohorts 
 
Frequency of Variant Detection (%) 
Gene Our Study cBioportal TCGA Network 
KRAS 73.7 40.5 42.5 
TP53 52.6 68.1 52.4 
APC 26.3 70.4 75.9 
PIK3CA 5.3 19.2 20.3 
NRAS 5.3 4.1 9.0 
TCGA – The Cancer Genome Atlas Network (2012) 
 
A total of 831 patients with rectal cancer were included in the cBioportal-based analysis; 
including 619 from Giannakis and colleagues (2016), 74 from Seshagiri and colleagues (2012) 
and 138 from Brannon and colleagues (2014). 
We observed higher than expected frequencies of variants in KRAS according to cBioportal and 
TCGA Network, whereas variants in APC and PIK3CA occurred less frequently than anticipated. 
This is likely to be because our targeted NGS panel sequences mutation hotspots rather than 
entire genes. Therefore, any variants located outside of such hotspots may be missed during 
sequencing. The frequency of variant detection in TP53 and NRAS were similar to previous 
reports. 
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Variants in KRAS were more frequent than we observed previously in patients with LARC 
consented by the Wales Cancer Bank (WCB) in Chapter 3; which was 52.4% respectively. This 
may have been impacted by the removal of patients who achieved pCR, creating some 
selection bias. 
Overall, we were able to detect pathogenic variants in 18/19 (94.7%) patients with LARC using 
our targeted NGS panel. This includes pathogenic variants in a wide range of genes, including 
KRAS, TP53, APC, PIK3CA and NRAS. These findings suggest that our targeted NGS panel has 
been able to effectively detect pathogenic variants in patients with LARC. 
4.2.1.2 Molecular Changes Occurring as a Result of Therapy 
Objective: Can we identify molecular changes within tumour tissue using our targeted 
sequencing panel in patients with LARC? 
4.2.1.2.1 Calculating Tumour Heterogeneity Scores  
A tumour heterogeneity score is a representation of the proportion of a tumour which 
contains a tumour-specific variant (Normanno et al. 2015). This could provide further 
information regarding individual variants and whether each was located across the entirety of 
a tumour sample or in smaller tumour-subclones. In this study, we applied heterogeneity 
scores to represent individual tumour subclones. Therefore, changes identified over time were 
hypothesised to represent changes in subclonal tumour architecture because of neoadjuvant 
therapy. 
Heterogeneity scores were calculated from VAFs, which were quantified by ddPCR or NGS data 
(see Section 2.2.14.3.2), and then normalised according to tumour cellularity in patient tissue 
as described previously (Normanno et al. 2015). 
The tumour heterogeneity scores of detected variants were compared between paired tumour 
biopsies and resections in our patient cohort (Table 27). Tumour heterogeneity scores can be 
used to predict whether a single variant is present in a sub-clone or a larger proportion of 
tumour tissue. A relatively high heterogeneity score might suggest that a specific variant was 
detected in larger amounts of tumour tissue in comparison to a lower heterogeneity score. 
Heterogeneity scores of ~100 suggest that a variant is harboured across the entire tumour 
biopsy or resection. Scores >100 may suggest the presence of copy number alteration in said 
genes (Li et al. 2017b) and scores <100 may suggest that only a fraction for tumour cells 
harbour said variant. Very low scores, (e.g. <33) might also suggest this variant is present 
within a small tumour sub-clone (Normanno et al. 2015). 
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Table 27: Tumour heterogeneity scores of all detected variants detected in tumour biopsies and 
resections in patients with locally advanced rectal cancer from the Aristotle clinical trial 
 Tumour Biopsy Surgical Resection  
Patient 
ID 
Gene Variant 
VAF 
(%) 
Tumour 
(%) 
HS 
VAF 
(%) 
Tumour 
(%) 
HS 
Difference 
In HS 
ARI-166 KRAS p.G12C† 15 40 75 16.8 50 67.2 -7.8 
ARI-182 KRAS p.G12S† 45.1 60 150.3 1.2 30 8 -142.3 
ARI-202 
KRAS p.G12D† 28.3 
50 
113.2 47 
60 
156.7 43.5 
TP53 p.R181P 35.6 142.4 67.6 225.3 82.9 
ARI-239 
KRAS p.G12C† 55.1 
40 
275.5 37.6 
40 
188 -87.5 
TP53 p.R282W 54.7 273.5 33.1 165.5 -108 
ARI-295 TP53 p.Q165X† 23 50 92 31.8 40 159 67 
ARI-297 NRAS p.Q61H† 41.1 70 117.4 20.2 50 80.8 -36.6 
ARI-306 TP53 p.G266V† 18.9 20 189 7.6 30 50.7 -138.3 
ARI-316 
APC p.Q1367X 27.9 
40 
139.5 23.3 
60 
77.7 -61.8 
KRAS p.G12S† 63 315 69.4 231.3 -83.7 
TP53 p.A159P 32.4 162 31.3 104.3 -57.7 
ARI-341 
APC p.E1379X† 25 
60 
83.3 17.5 
50 
70 -13.3 
TP53 p.R213X 30.5 101.7 31 124 22.3 
KRAS p.G12D† 23.4 78 23.2 92.8 14.8 
KRAS p.G12V 12 40 0 0 -40 
ARI-346 
PIK3CA p.E545K† 6.9 
20 
69 8 
50 
32 -37 
KRAS p.G12V† 6.5 65 7.5 30 -35 
ARI-366 
APC p.E1309X 21.6 
50 
86.4 31 
60 
103.3 16.9 
KRAS p.G12V† 15.1 60.4 24.8 82.7 22.3 
ARI-373 
APC p.Q1367† 32 
30 
213.3 16 
40 
80 -133.3 
FBXW7 p.R465C 47.2 314.7 22 110 -204.7 
TP53 p.C176Y 12.8 85.3 8 40 -45.3 
TP53 p.R273H† 30 200 23 115 -85 
ARI-378 
KRAS p.G12V† 44 
50 
176 26.5 
40 
132.5 -43.5 
TP53 p.C242Y† 47.5 190 29.9 149.5 -40.5 
ARI-400 KRAS p.Q61H† 22.2 30 148 28.8 50 115.2 -32.8 
ARI-403 
APC p.S1346X 43 
30 
286.7 58 
50 
232 -54.7 
KRAS p.G12C† 16.8 112 24.6 98.4 -13.6 
ARI-408 KRAS p.G12C† 21.8 30 145.3 26.7 40 133.5 -11.8 
ARI-413 
KRAS p.G12V† 29.4 
30 
196 20.5 
40 
102.5 -93.5 
TP53 p.R196X 23.3 155.3 20.8 104 -51.3 
ARI-437 
KRAS p.G13D† 10 
30 
66.7 27.2 
40 
136 69.3 
TP53 p.R181P 15.3 102 37 185 +83.0 
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VAF-Variant Allelic Frequency 
HS – Heterogeneity Score 
†Variants were cross-checked and VAFs were quantified using ddPCR 
 
Of our detected variants, 33 (97.1%) were shared between matching patient biopsies and 
resections, whereas only one (2.9%) variant was detected solely in a biopsy and no variants 
were detected in resections alone (Table 28). Thus, there was no evidence of emerging novel 
tumour subclones in these patients that we could detect. This suggests that there were no 
significant changes in the detected variants between pre- and post-treatment tumour tissue. 
 
Table 28: Variant Distribution Between Pre- and Post-Treatment Tumour Tissue 
Variant Location Number of Variants % 
Pre-Treatment Biopsy Only 1 2.9 
Surgical Resection Only 0 0 
Shared 33 97.1 
Total 34 100 
 
In agreement with our findings, Lee and colleagues (2017) reported similar mutations rates 
and composition between tumour tissue before and after tyrosine kinase inhibitor (TKI) 
therapy in patients with lung cancer. This differs from previous reports that 26-65%, 58% and 
67% of variants overlapped between primary tumour tissue and metastatic lesions before and 
after treatment in patients with CRC (Harada et al. 2019), ovarian cancer (Lambrechts et al. 
2015)  and glioblastoma (Kim et al. 2015) respectively. This of course may not be directly 
comparable to our findings as it focusses on changes occurring in metastatic lesions rather 
than within the primary tumour. Furthermore, these studies, including our own, all 
investigated patients with all different tumour types undergoing various modalities of 
treatment.  
Some changes were observed which were of potential interest in the context of clonal changes 
in this patient cohort. In this analysis, we were able to detect evidence of clonal changes 
occurring within patient tumours. Evidence of said clonal changes may be seen in patient ARI-
341 who demonstrated a complete loss of one variant (KRAS p.G12V) from pre- to post- 
treatment tissue. This may represent the complete elimination of a tumour subclone which 
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harboured this variant. However, the remaining three variants detected within this patient’s 
tumour tissue showed relatively little change, suggesting limited clonal changes may have 
occurred as a result of neoadjuvant therapy in these tumour subclone(s) that these variants 
represent. Whether these variants represent the same subclone or individual clones is also 
unknown. 
We also observed what appeared to be a significant decrease in tumour heterogeneity score 
from pre- to post-treatment tissue in the single variant (KRAS p.G12S) detected in patient ARI-
182. Unfortunately, for this patient there were no other pathogenic variants detected to 
monitor clonal changes. Therefore, we cannot determine whether another individual or group 
of subclones developed in place of the loss of the subclone represented by this variant. 
Similarly, ARI-306 displayed a large reduction in the only detectable variant (TP53 p.G266V) 
between the tumour biopsy and surgical resection, with no other variant appearing in its place.  
We proceeded to identify changes in mutated genes and associated heterogeneity scores 
between the tumour biopsies and post-treatment surgical resections in patients with LARC 
using our targeted NGS panel (Table 27). For variants which were cross-checked with ddPCR, 
the VAF quantified by ddPCR was used when calculating respective heterogeneity scores. 
From the variants detected in KRAS, we identified a large range of heterogeneity scores 
ranging from small tumour subclones (44.0) to potential copy number changes (275.5) 
(median: 114, mean: 126) in patient biopsies. The same was also observed in tumour 
resections 6.7-235.6 (median: 90, mean: 97). These differences were not statistically significant 
(p=0.65). In patients with metastatic CRC, Normanno and colleagues (2015) reported that KRAS 
and NRAS variants had average heterogeneity scores of 87.1 and 102.8 respectively, whilst Li 
and colleagues (2017b) found similarly high median heterogeneity scores of 120 and 125 
respectively in pre-treatment tumour tissue . Dienstmann and colleagues (2017a) also 
reported average heterogeneity scores of 112 and 98 for KRAS and NRAS respectively in FFPE 
tumour tissue . Overall, these studies have reported that variants in KRAS and NRAS are 
harboured in a large proportion of tumour cells with similar averages to those observed in our 
study. 
We saw no significant differences between the average heterogeneity scores of variants 
between the biopsy and resection in TP53 (152.8 and 114 respectively) and APC (114.6 and 
117.5 respectively). Similarly, Dienstmann and colleagues (2017a) reported average 
heterogeneity scores of 132 and 100 of variants in TP53 and APC respectively in FFPE tumour 
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tissue. Our findings contradict previous reports from Sakai and colleagues (2014) who reported 
that variants in TP53 saw a significant increase in VAF in patient tumour tissue as a result of 
chemoradiation therapy in patients with LARC. However, this study analysed only the VAF of 
these variants and not the heterogeneity scores, which complicates a direct comparison. 
Furthermore, VAFs and heterogeneity scores of tumour suppressor genes, such as APC and 
TP53 may be more complex to quantify due to the potential presence of loss of heterozygosity 
(LoH) in these genes.  
These results may be influenced by several factors, such as amplification bias from the NGS 
protocol, the subjectivity of estimating neoplastic cell content and the inaccuracy of macro-
dissection which can all impact VAF and heterogeneity score calculations.  
Using our targeted NGS panel, we did not see significant molecular changes between tumour 
biopsies and surgical resections in patients with LARC. We did identify significant molecular 
changes occurring between pre- and post-treatment tissue in a small number of patients. We 
hypothesised that these differences may represent changes in subclonal tumour architecture 
in response to neoadjuvant therapy in this patient cohort.  
4.2.2 Sequential circulating tumour DNA analysis using ddPCR 
Cell free DNA was extracted from 1mL of plasma from patients in this cohort using the QiaAmp 
Circulating Nucleic Acids Kit. CtDNA was then analysed by ddPCR as described in the Materials 
and Methods Chapter. We previously demonstrated that ctDNA analysis using ddPCR had a 
sensitivity of 1%, but this was highly dependent on the input DNA concentration. Therefore, to 
provide consistency across patient samples, a minimum of five mutant droplets were required 
for the confident detection of ctDNA in this study.  
We were unable to analyse >1 tumour specific variant in ctDNA in most patients due to limited 
sample availability. Where possible, variants detected in KRAS/NRAS were analysed, as this 
would also provide consistency and facilitate a potential comparison to previous ctDNA 
analyses in WCB patients from Chapter 3. 
4.2.2.1 Longitudinal Analysis of Circulating Tumour DNA 
Objective: Can ctDNA be reliably detected in sequential plasma samples before, during or after 
neoadjuvant therapy in another cohort of patients with LARC using ddPCR? 
All plasma samples were successfully analysed using ddPCR except for two time-points (ARI-
341 Week 0 and ARI-373 Week 10). CtDNA was successfully detected in three plasma samples 
from 3/18 (16.7%) patients with LARC (See Table 29). This sensitivity (16.7%) for the detection 
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of ctDNA is below our previous findings in patients with LARC consented by the WCB (Chapter 
3), in which 25% of patients had ctDNA detected at any time. 
In this study, detected ctDNA VAFs varied between 1.0 – 2.7%. Unlike our previous cohort in 
Chapter 3, no patients had ctDNA detected after the completion of therapy (week 10). We 
were also able to detect ctDNA in two patients whilst on-treatment (Weeks 1 and 5), whereas 
none were seen in our previous cohort. This may be seen here because we increased our total 
sample size and all 18 patients analysed had an incomplete response to therapy, which may 
have enhanced the likelihood that ctDNA would be observed during therapy.  
Here we were able to monitor ctDNA in patients with KRAS wild-type tumours, which was not 
possible previously. This sensitivity for detecting ctDNA is still very low in comparison to 
previous reports of 76.7% at any time in patients with LARC (Tie et al. 2018). This difference 
may be a result of differences in patient tumour stage, the lower volumes of plasma available 
for our study, differences in technology used, the cut-off applied for ctDNA detection or the 
quality of samples analysed. 
Table 29: Variant allele frequency of ctDNA detected in patients from the ARISTOTLE clinical trial 
  Variant Allelic Frequency (%)  
Patient 
ID 
Variant 
Week 
0 
Week 1 Week 5 Week 10 
ctDNA 
Group 
ARI-373 TP53 p.R273H 1.0 0 0 F A 
ARI-316 KRAS p.G12S 0 1.0 0 0 B 
ARI-408 KRAS p.G12C 0 0 2.7 0 B 
ARI-166 KRAS p.G12C 0 0 0 0 C 
ARI-182 KRAS p.G12S 0 0 0 0 C 
ARI-202 KRAS p.G12D 0 0 0 0 C 
ARI-239 KRAS p.G12C 0 0 0 0 C 
ARI-295 TP53 p.Q165X 0 0 0 0 C 
ARI-297 NRAS p.Q61H 0 0 0 0 C 
ARI-306 TP53 p.G266V 0 0 0 0 C 
ARI-341 KRAS p.G12D F 0 0 0 C 
ARI-346 KRAS p.G12V 0 0 0 0 C 
ARI-366 KRAS p.G12V 0 0 0 0 C 
ARI-378 KRAS p.G12V 0 0 0 0 C 
ARI-400 KRAS p.Q61H 0 0 0 0 C 
ARI-403 KRAS p.G12C 0 0 0 0 C 
ARI-413 KRAS p.G12V 0 0 0 0 C 
ARI-437 KRAS p.G13D 0 0 0 0 C 
F – Sample failed ddPCR analysis 
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Overall, three different patterns of change in ctDNA were observed in sequential plasma 
samples in our patient cohort. We separated these into Groups A, B and C based on each 
associated change based on previous findings from Chapter 3. 
Within Group A, the ctDNA detected in pre-treatment plasma declined to undetectable levels 
by the end of therapy. Patients in Group B began with undetectable pre-treatment ctDNA 
which became detectable during therapy and was then undetectable during follow-up. Finally, 
patients within Group C had no detectable ctDNA at any time.  
The decrease in levels of detectable ctDNA in the circulation of patients with LARC (as seen in 
Group A) has been previously reported as a result of CRT (Carpinetti et al. 2015). This study 
hypothesised that this decrease during therapy may be indicative of a good response to 
therapy.  
At this time, we have not identified any studies which investigate the effects of radiotherapy 
on ctDNA during treatment in patients with LARC (as seen in Group B). In patients with 
nasopharyngeal carcinoma, one study reported an increase in ctDNA during the first week of 
radiotherapy (Lo et al. 2000). However, this increase in ctDNA was never compared to clinical 
outcomes in these patients. This group hypothesised that this change was due to cancer cell 
death after therapy. This study also reported that a single patient presented a second release 
of ctDNA during day 14 of therapy, possibly suggesting further cancer cell death at this time. 
We were unable to identify any studies reporting the release of ctDNA during the last week of 
radiotherapy in any disease. In this case, such a peak may be representative of cancer cell re-
population instead of cell death (Lo et al. 2000). Further studies are required to investigate the 
clinical implications of these changes. 
Most of this patient cohort (15/18) had no ctDNA detected at any time (Group C). This may be 
due to several technical reasons. For example, the low volume of plasma available would result 
in low overall total cfDNA concentrations which would detrimentally influence the sensitivity 
of our ddPCR assay. Furthermore, there may also be issues with sample handling throughout 
the process. This may also be a consequence of the inherent tumour biology of non-metastatic 
patients. 
Overall, our findings suggest that our methods could not reliably detect ctDNA in this extended 
cohort of patients with LARC due to our low number of positive events. Where ctDNA was 
positively detected, we have high confidence in the reliability of these findings. 
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4.2.3 Sequential Cell Free DNA Changes 
4.2.3.1 Variations in Sequential Cell Free DNA Concentrations  
Objective: Can we detect and measure quantitative changes in total cfDNA before, during and 
after radiotherapy in another cohort of patients with LARC? 
As discussed in Chapter 3, studies have previously reported that sequential changes in total 
cfDNA concentrations were associated with patient response to neoadjuvant therapy in 
patients with LARC (Agostini et al. 2011). Although we cannot compare these data to any 
patient clinical information, we proceeded to investigate whether we could identify sequential 
cfDNA changes in these patients; which we intend to compare to our previous findings from 
Chapter 3. 
A total of 74 cfDNA samples were available for molecular analysis in patients with LARC 
collected from the ARISTOTLE clinical trial. CfDNA was extracted from 1mL of plasma using the 
Qiagen QIAamp Circulating Nucleic Acids Kit (55114) and quantified using the Invitrogen Qubit 
High Sensitivity Assay (Q32854) as described in the Materials and Methods Chapter.  
For all patients, except ARI-239, there were no obvious patterns of change observed in 
sequential total cfDNA concentration at this time (Figure 13). For all other patients, total 
cfDNA varied between 0.1-0.7ng/µL, whereas patient ARI-239 displayed a significantly higher 
peak of detectable cfDNA at week 5 (2.0 ng/µL). This resembles the pattern of change for 
cfDNA observed in all samples in Chapter 3, albeit only in this one patient. This may result from 
cellular changes occurring in the patient’s tumour, surrounding non-tumour tissue or 
systemically as a result of neoadjuvant therapy. Alternatively, this may also be due to 
inappropriate pre-analytical handling. As this sample was known to be collected in EDTA, it is 
possible that white blood cell lysis may have occurred before the sample was processed into 
plasma. Therefore, the leakage of white blood cell DNA into the plasma may have been 
misconstrued as cfDNA, causing this significantly high peak over all other samples. 
Apart from patient ARI-239, our results contrast with previous findings in Chapter 3. This 
difference may be a consequence of the exclusion of patients who achieved pCR. Previously , 
Agostini and colleagues (2011) reported that patients with rectal cancer who responded well 
to CRT saw a significant decrease in cfDNA levels after the initiation of treatment. In patients 
with hepatocellular carcinoma, patients who responded poorly to therapy displayed a 
significant increase in total cfDNA concentrations from pre- to post-treatment (Park et al. 
2018). We did not see either trend here. 
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Figure 13: Total  Cell Free DNA Concentrations for all ARISTOTLE Patients at Weeks 0, 1, 5 and 10 
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We proceeded to compare total cfDNA concentrations between whole blood samples which 
were collected in EDTA to those which were collected in Streck Tubes using an un-paired two-
sample T-test (see Appendices Section 9.5). In the first instance, we analysed differences in 
cfDNA concentration across all timepoints (Figure 14).  
 
Figure 14: Total cfDNA concentrations between the two collection tubes across all plasma collection 
timepoints 
Across all plasma samples we observed no significant differences in total cfDNA concentrations 
between the two collection tubes (p=0.12). We proceeded to investigate any differences 
between the two collection tubes at each individual timepoint (Figure 15) 
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Figure 15: Total cfDNA concentrations between the two collection tubes at each plasma collection 
timepoint 
 
We observed no significant differences between collections tubes for plasma samples 
collected at weeks 0, 1 and 5. However, at week 10, we observed that plasma samples 
collected in EDTA tubes had a significantly higher total cfDNA concentration than those 
collected in Streck tubes (0.38 vs 0.25 ng/µL; p<0.01). 
Overall, using the Invitrogen Qubit we did not detect any significant sequential changes in total 
cfDNA concentrations in our patient cohort. We did detect a significant difference in total 
cfDNA at week 10 of collection between plasma samples collected in EDTA and Streck tubes, 
although this may be due to chance rather than a true significant finding.
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4.3 Discussion 
4.3.1 Conclusions 
Objective: How effective is our targeted NGS panel at detecting clinically significant variants in 
patients with LARC? 
Using our targeted NGS panel, we were able to detect pathogenic variants in tumour biopsies 
or resections from all but one patient with LARC from this cohort. When examining the 
frequency at which APC, PIK3CA and KRAS were mutated, we observed differences between 
our findings and expected values based on large-scale studies. 
We detected a number of nonsense variants in the MCR of APC (Albuquerque et al. 2002; 
Christie et al. 2013). Nonsense and frame-shift variants are frequently detected in the MCR of 
APC as an early genomic ‘hit’ during colorectal carcinogenesis. These variants have been 
demonstrated to inhibit the regulatory effect which APC imposes upon β-catenin (Fearon 
2011). This provides some confidence in the positive calling of these detected variants.  
We may have detected variants in APC less frequently than expected for several reasons. 
Firstly, our targeted panel only covered hotspots in the APC gene which revolved around the 
MCR. However, this would only include <10% of the entire gene (Table 11). Thus, any tumour-
specific variants occurring outside of these sequenced regions would have been missed. We 
may also have missed the presence of large deletions or small indels in our patients due to 
limitations of the sequencing chemistry which were discussed in the Materials and Methods 
chapter. Finally, all variants had to be deemed pathogenic to pass through our filtration 
algorithm. This would not have been the case for cBioPortal or TCGA, where they would simply 
be confidently detected, and pathogenicity isn’t a requirement for variant calling.  
In KRAS, the majority of our variants were located at hotspots (p.G12, p.G13 and p.Q61) in 
accordance with previous expectations (Fearon 2011). We saw that KRAS was mutated much 
more frequently than anticipated in our study. This may be a result of patient selection bias. As 
patients who achieved pCR were excluded from these analyses, our patient mutational profiles 
may not cover the full array of patient responses to neoadjuvant therapy. This may then skew 
our findings and may need to be considered during statistical analyses. Additionally, this result 
may also be impacted by our small sample size in comparison to these previous studies.  
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With regards to the difference observed in mutation frequency for PIK3CA, this is likely to be a 
consequence of our small sample size, the hotspot analysis of our NGS panel and the low 
frequency at which this gene is mutated in this population.  
The frequency at which we detected variants in TP53 were found at the approximate expected 
frequency according to cBioPortal  and TCGA (2012). In TP53 we detected numerous missense 
and nonsense variants in the DNA binding domain (amino acid 98-322) (Saha et al. 2015). 
Many of these variants correlated with ‘hotspots’ at p.R175, p.Y220, p.G245, p.R248, p.R249, 
p.R273 and p.R282. Disruptions within the DNA binding domain have been predicted to inhibit 
the ability of p53 to initiate apoptosis, thus providing more support for these variants being 
genuine and pathogenic (Saha et al. 2015).  
There are numerous factors which may have impacted the frequency at which we detected 
clinically significant variants in this study. Our targeted NGS panel was mostly designed to 
identify variants in mutational hotspots, therefore not the entire gene is sequenced in most 
our analysed genes. Consequently, variants outside of hotspot regions may have been missed, 
resulting in our decreased rate of variant detection for some genes, such as APC.  
As with most semiconductor sequencers, the CHPv2 has limitations when detecting large copy 
number variations or small indels. As these types of variants are relatively common in tumour 
suppressor genes, such as APC or TP53, this may contribute to a decreased frequency of 
variant detection. 
Furthermore, our variant filtration algorithm may have been more stringent than those applied 
in the larger studies, as we attempted to replicate clinical analysis in our study. However, 
clinical laboratories will largely concern themselves with analysing targetable variants, 
therefore potentially missing variants which are clinically relevant, if not yet targetable. 
Nonetheless, we are confident that all highlighted variants are clinically significant and not 
random passenger variants. 
Another issue which may have affected our ability to detect variants is sequencing coverage. 
Although sequencing covering was generally good, all detected variants required ≥250 reads, 
thus any regions with less total reads or sequencing dropout may have led to true variants 
being missed. 
Overall, our findings suggest that the CHPv2 was effective at detecting pathogenic variants 
across a range of genes in patients with LARC. This strengthens our initial decision-making 
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process when choosing this targeted NGS panel, as described in the Materials and Methods 
Chapter. 
Objective: Can we identify molecular changes within tumour tissue using our targeted 
sequencing panel in patients with LARC? 
Using our targeted sequencing panel, we were able to observe changes in tumour 
heterogeneity scores, which may represent clonal changes in tumour tissue. We could not 
identify the occurrence of novel variants in tumour resections which might suggest the growth 
of a tumour sub-clone as a result of therapy; as has been seen in patients being treated by 
targeted therapies (Gollins et al. 2017).  
We observed a significant reduction in tumour heterogeneity score (e.g. ARI-182 or ARI-306) or 
complete loss of a variant (e.g. ARI-341) from pre- to post-treatment tissue in a small number 
of patients (Table 27). This may be indicative of clonal shrinkage or loss due to therapy. 
However, we are unable to verify this association without obtaining patient outcomes.  
Previous reports have demonstrated a decrease in the number of detectable variants after 
stereotactic radiotherapy using an in-house 50-gene panel in a patient with lung cancer 
(Nakagomi et al. 2017). Findlay and colleagues (2016) used whole exome sequencing and 
observed that patients with oesophageal cancer who responded well to chemotherapy 
showed more genetic changes after therapy than patients who responded poorly to therapy. 
The greater number of changes observed by these studies may be due to the type of 
sequencing analysis performed in comparison to our study. This may also be a result of the 
different cancer types and treatment modalities (including time-period of treatment) between 
the various studies. 
Conversely, increases in heterogeneity scores may be indicative of clonal growth within a 
patient’s tumour. In the tumour tissue of patients who displayed a mixture of heterogeneity 
score changes, we may be able to observe distinct shifts in clonal dominance in response to 
treatment. Finally, where little or no change is observed, this may suggest genetic stability in 
the patient tumour. 
In selected genes of interest (including APC, KRAS and TP53) one study reported that variants 
in these genes remained relatively constant in metastatic lesions after treatment with FOLFOX 
in patients with CRC (Harada et al. 2019). In contrast, less frequently mutated genes (including 
EP300, MED12 and RUNX1) were seen to develop variants after therapy, the clinical 
significance of which is less understood in the context of CRC (Harada et al. 2019). This finding 
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may also reflect that variants in APC, KRAS and TP53 are early events in tumour development, 
and the later events may be more prone to loss during treatment than early stemming 
variants. Patients with oesophageal cancer also displayed highly variable levels of change in 
clonal composition after chemotherapy (Findlay et al. 2016; Noorani et al. 2017). Although 
these studies analysed patients with different diseases, stages and treatment to our patient 
cohort, this may still contribute to the limited variant and clonal changes we were able to 
observe here. 
In our analysis, surgical resections were collected shortly after therapy, whilst other studies 
analysed tumour tissue upon disease recurrence. This would provide a longer timeframe for 
cellular repopulation and clonal changes to occur as a result of therapy, which may contribute 
to the limited amount of changes we observed.  
Additionally, this analysis is also limited by the sensitivity and limit of detection for this 
targeted panel. Although we have previously demonstrated that variants can be detected at 
~1% VAF, we chose the limit of 5% to ensure selected variants were pathogenic and not 
artefactual. Consequently, genuine pathogenic variants at this VAF may have been missed, as 
displayed in patient ARI-182, where a variant (KRAS p.G12S) was detected at 1.2% and cross-
checked using ddPCR. This was only investigated due to its presence in matching tumour 
biopsy and would have otherwise been missed. Without prior knowledge, identifying variants 
at this VAF could result in the ‘miscalling’ of variants.  
For this study, likely pathogenic (Tier II) or pathogenic variants (Tier I) were chosen based on 
guidelines from ASCO and CAP (Li et al. 2017a). Relevant pathogenic variants may have been 
lost as a result of this stringent filtration process, as they may not directly impact treatment in 
this patient cohort at this time, or their impact on tumour development is not as well 
understood as other variants. 
The calculation of VAFs and tumour heterogeneity may also be influenced of the presence of 
LoH. LoH is commonly observed in tumour suppressor genes, such as APC and TP53. Although 
LoH is common in these genes in the context of CRC, we have not incorporated any potential 
impact that LoH may have on VAF quantification. Alternatively, the calculation of VAF may not 
be entirely accurate due to the potential of PCR amplification bias impacting VAF 
quantification. As the NGS procedure include multiple rounds of amplification, this is a 
potential issue. Furthermore, as we only sequenced a small region of tumour tissue, our 
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calculated VAFs are not necessarily representative of the entire tumour, and we are thus 
limited by intra-tumour heterogeneity (Burrell and Swanton 2014). 
When calculating heterogeneity scores, VAFs were normalised according to neoplastic tumour 
tissue content, as quantified by Professor Richard Adams from a haematoxylin and eosin 
stained tissue slide. Since tumour cellularity is a subjective approximation (Normanno et al. 
2015) and, therefore, these values may be variable, and our heterogeneity scores may also be 
somewhat inaccurate. 
Due to the subjective nature of macrodissections, the tumour cellularity of macrodissected 
tumour tissue may vary to that anticipated, by the accidental inclusion of surrounding non-
tumour tissue. This may impact heterogeneity scores and any downstream analyses. 
Due to the numerous limitations of heterogeneity scores, they may be more appropriately 
applied as rough approximations rather than definitive values when comparing to tumour 
subclones. Although we have attempted to directly analyse clonal architecture by using these 
scores, they were not intended for this purpose. Finally, analysing changes in heterogeneity 
scores can also include a large amount of subjectivity when deciding which changes were large 
and which were small. 
Using our targeted NGS panel, we were able to detect molecular changes occurring between 
pre- and post-treatment tissue in patients with LARC. These changes may be a result of the 
administration of neoadjuvant therapy in these patients. We suspect that said molecular 
changes may represent changes in clonal architecture may be indicative of tumour response. 
However, there are distinct limitations with our methodology which must be considered.  
Objective: Can ctDNA be reliably detected in sequential plasma samples before, during or after 
radiotherapy in another cohort of patients with LARC using ddPCR? 
In this study, we were able to detect ctDNA in 3/18 (16.7%) patients with LARC, but only in 
samples collected before or during the administration of neoadjuvant therapy. This sensitivity 
for ctDNA detection is identical to our previous findings in Chapter 3 (16.7%) but below that of 
other studies in patients with LARC (Bettegowda et al. 2014; Sclafani et al. 2018; Tie et al. 
2018). 
Previously, we saw no patients had detectable ctDNA levels during treatment, but some had 
ctDNA detected after therapy. In contrast here, we observed ctDNA during neoadjuvant 
treatment but none after the completion of treatment.  
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We anticipated that the frequency of patients with detectable ctDNA would increase, due to a 
larger number of variants being available for ctDNA analysis, whereas previously we were 
limited to variants in KRAS/NRAS. This could then have allowed for the inclusion of patients 
with alternative molecular characteristics, which may have impacted on ctDNA detection rates.   
The differences observed in detected ctDNA between the two cohorts may have been caused 
by several factors. Although both sets of patients had LARC, this cohort was treated with 
chemotherapy alongside radiotherapy, whereas the previous cohort were largely treated with 
radiotherapy only. This may impact both the response of patient tumours to treatment and 
sequential ctDNA changes. Furthermore, as patient samples were collected as part of a clinical 
trial, the timing and processing of sample collection may be more standardised in comparison 
to samples collected as part of routine clinics. This may affect sample quality. Finally, the 
timing of plasma collection after the completion of therapy also differs, with longer timepoints 
being available in our previous cohort. This allows a greater time frame for molecular changes 
or tumour recurrence to occur and ctDNA to be detected. 
There may be other factors which contributed to the low frequency of ctDNA detected in this 
study in comparison to findings in the literature. The low volume of plasma (1mL) analysed in 
this study might have limited the concentrations of ctDNA used for ddPCR analysis, limiting the 
sensitivity of ddPCR, as has been demonstrated in the Materials and Methods Chapter. 
Although ddPCR has been reported to be a sensitive assay, the sensitivity of the method is 
entirely limited as it is based on input DNA concentrations. Furthermore, the locally advanced 
non-metastatic nature of our patients may not be entirely appropriate for ctDNA analysis due 
to limited amounts of angiogenesis and consequential DNA shedding into the circulation. 
Another factor that should be considered is the selection bias associated with these patients. 
As patients who achieved pCR were excluded from analysis, this may have led to the loss of 
patients who experienced high amounts of tumour cell death and resulting DNA shedding 
during neoadjuvant therapy.  
There may also be issues with sample collection or the timepoints chosen for analysis, which 
cannot be commented as they were performed and chosen by the Principle Investigators of 
the trial but should still be considered. There may have also been issues with how samples 
were handled during cfDNA extraction and ctDNA analysis which may have limited the efficacy 
of each phase of analysis. Furthermore, analytical sensitivity may have benefited from the 
analysis of each sample being performed in triplicate rather than duplicate. This may have 
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facilitated the confident identification of ctDNA in borderline cases and provided more data for 
analysis. 
An increase in the plasma availability for this patient cohort may help overcome these 
limitations for future analyses, as would more information or direct involvement in pre-
analytical sample handling. As suggested previously in Chapter 3, the processing of samples 
on-site or delivery of samples over days may contribute to our sensitivity issues and may be 
addressed by handling on a single site. Perhaps an additional amplification step, such as co-
amplification at lower denaturation temperature (COLD) PCR, may help improve detection 
rates, although this may introduce issues if attempting to quantify ctDNA. 
As far as we are aware, this is the first time that ctDNA was demonstrably detected whilst 
patients were being administered chemoradiotherapy, as studies primarily investigate pre- and 
post-treatment levels. Therefore, it would be of interest to determine how these patients 
responded to therapy.  
Overall, these findings suggest that these methods are currently unable to reliably detect 
sequential ctDNA in patients with LARC undergoing neoadjuvant therapy. We have discussed 
numerous factors which must be addressed to improve the reliability of ctDNA detection. 
However, these findings may bring into question the clinical efficacy of ctDNA analysis in 
patients with LARC. 
Objective: Can we detect and measure quantitative changes in total cfDNA before, during and 
after CRT in another cohort of patients with LARC? 
We could not decipher any patterns of change in cfDNA concentrations, nor could we identify 
any associations with any patient molecular characteristics in this patient cohort. This 
contrasts findings from Chapter 3 where we saw higher cfDNA concentrations in samples 
collected during therapy.  
As previously described in Chapter 3, total cfDNA concentrations are not tumour-specific 
biomarkers, and can thus be influenced by external factors, such as inflammation, infection, 
radiation-induced toxicity and exercise (Vittori et al. 2019). This might contribute to such a 
difference being seen between our two separate cohorts. However, we do not have this 
information and, therefore, cannot investigate this possibility.  
Any differences may also be a result of patient selection bias. Agostini and colleagues (2011) 
reported that a decrease from pre- to post-treatment cfDNA concentration was observed in 
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patients with rectal cancer who responded well to radiotherapy. Patients who displayed pCR 
were excluded from this study, which may have influenced our findings here. There were no 
methodological changes made from our previous analyses and therefore we are excluding this 
as a possible cause.  
Our findings may also be a consequence of the limitations of the Qubit when quantifying 
cfDNA. The qubit measures DNA using a fluorescence-based assay, in contrast to amplification-
based methods for DNA quantification and analysis, such as the ddPCR. This difference may 
result in variation in findings, for example a fluorescence-based assay may quantify DNA of any 
length, whereas PCR-based quantification may only quantify DNA of a minimum length. 
Fluorescence assays may also be less prone to being influenced by inhibitors of PCR but may 
also be impacted more by contaminants, such as RNA. We also did not investigate the limit of 
detection or the reproducibility for the qubit, and thus the impact this may have on 
quantification is not fully understood and should be investigated in the future. 
It is noteworthy that, in patient ARI-239, we observed a significant increase in cfDNA at week 5 
in comparison to all other patients and timepoints. This peak may be representative of patient 
response to treatment. The presence of this peak may also be indicative of improper pre-
analytical handling, as this may have caused white cell lysis and the shedding of cellular DNA 
into plasma. As this concentration is significantly higher than all others observed, this is likely 
to be the case, although this peak is similar to our findings in Chapter 3. Otherwise, this may be 
a marker of systemic inflammation and/or radiation- or chemotherapy-induced toxicity 
(Zwirner et al. 2018). Alternatively, this may be tumour-derived cfDNA which simply did not 
contain the KRAS variants we specifically investigated. Further investigation by NGS would help 
provide further insight here. 
During our analysis, we identified that plasma samples collected in EDTA tubes had a 
significantly higher total cfDNA concentration at week 10 compared to plasma collected in 
Streck tubes. This significant difference was not seen at other timepoints. This may be a 
consequence of how samples were handled and processed at their respective sites, or how 
samples were shipped to the AWMGs for molecular analysis. If EDTA samples were not 
processed within a specific period of time (within 2-4 hours), white blood cells may lyse and 
shed cellular DNA into the plasma (Pritchard et al. 2012). Furthermore, plasma samples 
shipped on dry ice may have also warmed and/or undergone freeze thaws whilst in transit, 
impacting sample quality. This may be detected and mistaken for cfDNA in this patient cohort, 
possibly explaining this finding.  
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Samples during this analysis were not paired, thus differences may exist in the natural tumour 
biology between the two patient cohorts. Overall, this outlines the need for consistency in 
sample handling during clinical trials, as these factors can cause significant differences during 
molecular analysis.  
This difference observed, though statistically significant, may have been a result of chance as it 
was only observed at week 10 and not at more timepoints. These samples were unpaired, and 
the EDTA samples may have had significantly higher cfDNA concentrations for separate 
biological reasons. This may be impacted by other factors such as small sample size, or how 
patients responded to therapy, a factor we cannot currently account for without clinical 
outcome data for these patients. This analysis could be improved in the future by acquiring 
data from factors (such as outcomes to therapy, time taken to transport samples, time before 
sample processing in EDTA tubes etc.) which may impact cfDNA concentrations and 
incorporate them into multivariate analysis.  
Altogether, we would suggest the ideal method for sample handling in this case, would be 
collection in Streck tubes before transporting samples at room temperature to a single site 
(such as the AWMGS) within three calendar days for processing. This will provide a greater 
consistency in sample extraction, as it would all occur on the same site according to the same 
protocol. However, how the time taken for transportation may affect this process, should also 
be considered as part of future analyses 
Overall, we were able to detect and measure sequential total cfDNA concentrations in our 
patients, but we did not identify any significant quantitative changes occurring throughout 
therapy. We also identified a significantly higher total cfDNA concentrations in plasma samples 
collected in EDTA tubes compared to Streck tubes at week 10. There may be several factors, 
both technical and biological, which may have impacted our findings. We were also unable to 
compare these results to clinical outcomes as this data was unavailable at present. 
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4.3.2 Clinical Implications 
Objective: What molecular changes occur in relation to CRT in patients with LARC? 
Variants in TP53 and/or downstream targets have recently been investigated alongside or in 
place of p53 expression. Wan and colleagues (Wan et al. 2018a) reported that TP53 p.T155I 
was found to be more frequently detected in patients with LARC who responded poorly to 
CRT. Similarly, Sakai and colleagues (2014) reported that 8/9 patients with rectal cancer who 
responded poorly to neoadjuvant therapy had detectable TP53 variants in post-treatment 
tissue samples. This study also reported that TP53 variants VAFs increased from pre- to post-
treatment tissue as a result of pCRT across all patients. A similar finding was reported in 
patients with anal squamous cell carcinoma, where variants in TP53 were only detected in 
recurrent disease after patients underwent pCRT; but was undetected in treatment-naïve 
tumour tissue (Cacheux et al. 2016). 
These findings suggest that variants in TP53 may influence tumour response to neoadjuvant 
therapy in these patients. Furthermore. therapy may cause evolutionary advantage and 
resulting expansion of mutant TP53 in cloned tumour tissue. Such changes would have been 
hypothetically detectable in ctDNA at an earlier stage than in surgically resected tissue. 
Variants in KRAS were previously demonstrated to correlate with decreased pCR rates in 
patients with stage II/III CRC (Chow et al. 2016) and rectal adenocarcinoma (Duldulao et al. 
2013) undergoing CRT. Whether this is a result of KRAS mutant functionality or whether 
mutant KRAS is acting as more of a prognostic marker in these cases, remains unclear. 
Studies have recently suggested that there is predictive value of variants in PIK3CA or the PI3K-
mTOR pathway. In 201 patients with LARC, PI3K pathway mutations were associated with 
reduced rates of pCR after chemoradiotherapy (Abdul-Jalil et al. 2014) With regards to variants 
in NRAS, due to the rarity of NRAS variants in this subgroup of patients, few studies have 
investigated the potential clinical implications in the context of chemoradiotherapy.  
Findlay and colleagues(2016) have previously reported that changes in heterogeneity after 
neoadjuvant therapy may be indicative of treatment response in patients with oesophageal 
cancer. The presence of clonal changes might suggest that tumour drivers may be regressing, 
allowing smaller or more resistant sub-clones to develop.  
Overall, reports suggest that levels of heterogeneity and clonal changes may be associated 
with response to therapy in patients with cancer. Although we cannot compare our findings to 
clinical outcomes, the molecular changes we observed may possibly be used as a predictive 
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tool to detect clonal changes in patients with LARC. However, this research is still in its relative 
infancy, and will require further knowledge on factors or variants predisposing to sensitivity or 
resistance to neoadjuvant therapy in patients with LARC. 
Objective: Is ctDNA released into the circulation in relation to neoadjuvant therapy in patients 
with LARC? 
The potential clinical implications of sequential changes in ctDNA were discussed extensively in 
Chapter 3. Overall, we were unable to detect any post-treatment ctDNA in any patients using 
our current methods which may be indicative of patient outcomes. Previously, studies have 
reported that detectable post-treatment or post-surgical ctDNA was associated with poor 
response to therapy and clinical outcomes (Tie et al. 2018). As we detected no post-treatment 
levels at this time, this would suggest these patients may experience good responses to 
therapy, if not pCR. Otherwise, not detecting post-treatment ctDNA may be due to the 
limitations of the sensitivity of our assay. 
We were able to detect the presence of pre-treatment ctDNA in one patient, which may be 
indicative of advanced stage or the presence of metastatic/pre-metastatic lesions (Bettegowda 
et al. 2014). Such information could provide valuable insight and facilitate treatment decision-
making for some of these patients. Furthermore, in terms of outcome prediction, pre-
treatment samples have been demonstrated to be less useful than post-treatment ctDNA 
detection (Tie et al. 2018). This may bring into question how useful pre-treatment ctDNA levels 
are when predicting patient outcomes. However, we could not examine the significance of this 
as part of this study. 
The detection of ctDNA being released during neoadjuvant therapy (weeks 1 and 5) appears to 
be a novel finding in patients with LARC. These observations match our previous hypothesis 
that ctDNA may be shed early during radiotherapy, potentially indicating tumour cell death. 
Similarly, the detection of ctDNA during week 5 of neoadjuvant therapy may be indicative of a 
delayed response to treatment in these patients, if not tumour-cell repopulation (Lo et al. 
2000). However, without clinical outcome data, it is impossible to decipher the clinical 
implications for ctDNA at present. 
Objective: Is cfDNA released into the circulation in relation to neoadjuvant therapy in patients 
with LARC? 
As previously discussed in Chapter 3, sequential changes in cfDNA concentrations have been 
demonstrated to be associated with patient response to therapy. One study reported that 
149 
 
patients with LARC who demonstrated a decrease in cfDNA concentrations from pre- to post-
treatment plasma samples had an improved response to treatment (Zitt et al. 2008). Similarly, 
high pre-treatment cfDNA levels were also associated with an increased risk of recurrence 
(Boysen et al. 2017) and poor DFS (Schou et al. 2018) in patients with LARC. 
As no distinct patterns were visible, we cannot associate any changes with clinical significance. 
The general stability of total cfDNA concentrations may be indicative of stable disease in our 
patient cohort. These findings may be a result of technical factors which had been discussed 
previously. 
Overall, we were unable to discern any patterns of cfDNA secretion in response to 
neoadjuvant therapy which may be indicative of patient response. Therefore, at present, we 
are unable to determine the power of sequential total cfDNA concentrations in predicting 
patient response to therapy.  
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4.3.3 Future Studies 
At present, it is difficult to gauge the implications of our findings in the context of clinical 
implications, especially without any clinical data or information regarding treatment arms for 
these patients. Therefore, the acquisition of such information, including both short and long-
term outcomes, could allow us to decipher any clinically significant findings. These could then 
be investigated further in a larger cohort of patients with LARC as part of a prospective study.  
In this study, we used the CHPv2 to calculate heterogeneity scores which were analsyed as 
proxy markers for tumour subclones. From this, one can attempt to infer changes in tumour 
heterogeneity, which have been previously demonstrated to associate with tumour 
aggressiveness and response to therapy. Other bioinformatic programs, such as MATH and THI 
would be more appropriate for such analysis, whilst TMB would be a better tool for looking at 
tumour burden. However, we did not sequence enough of the genome to provide sufficient 
power for such analyses. Therefore, we applied tumour heterogeneity scores and quantitative 
changes as a result of therapy as a surrogate marker for clonal changes to infer changes in 
tumour heterogeneity, though this is not ideal nor the designed purpose of tumour 
heterogeneity scores. 
It would also be beneficial to expand our small targeted NGS panel to whole exome/genome 
sequencing or a larger gene panel and to apply this to whole biopsies and/or surgical 
resections. This would allow analysis of tumour heterogeneity across the tumour, rather than 
being limited to investigate a small number of variants to analyse clonal changes. The reports 
that intratumour heterogeneity can be a prognostic indicator could make this an interesting 
area to investigate further. 
Finally, as highlighted by the significant differences between different collection tubes, future 
analyses would benefit from an optimised and standardised protocol for pre-analytical sample 
handling and transportation. Although changes may have been made in the trial to address 
certain issues, this may have impacted circulating biomarker analysis in these patients.
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5 Circulating Exosomes and Exosomal Cargo in Patients with Locally 
Advanced Rectal Cancer 
5.1 Introduction 
Exosomes are a subset of extracellular vesicles which perform an important role in intercellular 
communication by transporting molecular cargo to target cells (Valadi et al. 2007; Huang et al. 
2012). The molecular cargo can then influence the cellular physiology of the recipient cell. In 
cancer, exosomes are reportedly co-opted and selectively packaged in order to promote 
tumour development in nearby and distant cells (Takano et al. 2017). 
Exosomes have been detected in a number of bodily fluids, including plasma, serum and urine 
(Toiyama et al. 2016). The molecular cargo of exosomes has been reported to include proteins 
(Johnstone et al. 1987), mRNA and microRNA (Valadi et al. 2007). However, the presence of 
ExoDNA is still widely debated (Kahlert et al. 2014; Jeppesen et al. 2019). 
MicroRNAs are small (19-26bp) non-coding RNAs which can supress the expression of a 
number of genes (Bartel 2004). MicroRNAs have been shown to be dysregulated in solid 
tumours and are hypothesised to drive tumourigenesis and/or cause treatment resistance 
(Calin and Croce 2006). 
Plasma or serum-derived microRNAs (cell-free or encapsulated into exosomes) have reportedly 
been able to distinguish between healthy controls and patients with rectal cancer (Jo et al. 
2017). Similar studies have also demonstrated the ability of circulating microRNAs to predict 
response to therapy (D'Angelo et al. 2016). MicroRNAs can be released into the circulation 
bound to carriers, such as Argonaute proteins, or encapsulated within exosomes (Chim et al. 
2008) 
The number of published studies investigating exosomes has risen rapidly over recent years 
(Lotvall et al. 2014). This had led to an increase in the development of commercially available 
kits with the purpose of facilitating exosome isolation in order to make it faster, simpler and 
more able to transition into the realm of diagnostics in the future. However, recent studies 
have demonstrated that different commercial kits result in variable exosome yield and purity 
leading to differences in downstream analyses of exoRNA signatures (Van Deun et al. 2014; 
Tang et al. 2017). This highlights the need for methodological standardisation in the analysis of 
exosomes.  
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Here, we intend to determine the optimal method for the isolation of exosomes from the 
plasma of patients with LARC. Isolated exosomes will then be used to validate the presence of 
and subsequently quantify levels of internal molecular cargo. We will then look to analyse 
quantitative changes over time of exosome derived molecular cargo.  
This will be a proof-of-principle study to determine whether detection, quantification and 
analysis of exosome-derived molecular cargo is feasible in the circulation of LARC patients 
before examining these factors in the clinical context. 
5.1.1 Study Objectives 
In this chapter, the objectives are: 
• Which method(s) provide the best yield and purity of exosomes from the plasma of 
patients with LARC? 
• Can we detect, quantify and analyse the molecular cargo of isolated exosomes in 
patients with LARC? 
• Can we detect and measure quantitative changes in the molecular cargo of exosomes 
before, during and after radiotherapy in patients with LARC? 
o How is exosomal molecular cargo released into the circulation in relation to 
radiotherapy? 
o Do longitudinal levels of exosomal molecular cargo correlate with clinical 
outcomes in patients with LARC? 
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5.2 Results 
5.2.1 Exosome Isolation Kit Comparisons 
Objectives: Which method(s) provide the best yield and purity of exosomes from the plasma of 
patients with LARC? 
We explored several commercial kits for exosome isolation before choosing three which we 
then directly compared. The three methods were chosen as each used different technologies 
to isolate exosomes. These include precipitation by volume excluding polymers (TEI kit), 
membrane affinity columns (ExoEasy kit) and size exclusion chromatography (ExoSpin 
columns).  
For each method, 1mL of pre-treatment plasma was used for exosome isolation. The size and 
concentration of isolated vesicles were calculated using the NTA and are illustrated in Figure 
16. Sample purity was assessed using a P/P ratio (Table 30) as suggested by Webber and 
Clayton (2013). 
Sample purity is a critical characteristic to consider in the field of exosome analysis. Current 
methods for examining particle purity involve the investigation of exosome and non-exosome 
specific markers, as well as electron microscopy to ensure vesicular morphology and size. 
Electron microscopy, however, is not widely available in a clinical or research setting, and the 
use of non-exosome markers is neither quantitative nor standardised at this time. Therefore, 
the P/P ratio has been proposed as a simple and quantitative biomarker for exosome purity 
analysis (Webber and Clayton 2013). 
5.2.1.1 Extracellular Vesicle Purity 
Table 30: P/P Ratios and respective exosome purity calculated from protein and particle concentrations 
according to Webber and Clayton (2012) 
Isolation 
Kit 
Particle 
Concentration 
(P/mL) 
Protein 
Concentration 
(µg/mL) 
P/P 
Ratio 
Purity 
TEI 1.70E+12 6817.789987 2.49E+07 Impure 
ExoEasy 5.29E+12 761.8111434 6.94E+09 Low 
ExoSpin 2.29E+13 2854.758585 8.02E+09 Low 
 
Overall, we observed stark differences between these three methods with regards to particle 
size, particle concentration, protein concentration and overall purity.  
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5.2.1.1.1 Total Exosome Isolation Kit 
Eluted microparticles from the TEI kit were deemed to be impure according to the calculated 
P/P ratios (Webber and Clayton 2013). This finding is in agreement with previous studies from 
Van Deun and colleagues (2014) and Tang and Colleagues (2017) who reported that the purity 
of vesicles isolated by the TEI kit were lower in comparison to methods such as sequential 
ultra-centrifugation. These findings contradict Schageman and colleagues (2013), who 
reported that vesicles isolated using the TEI serum or cell culture were as pure as exosomes 
from ultra-centrifugation. 
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Figure 16: Nanosight Tracking Analysis displaying the concentratuion and size of extracellular vesicles 
isolated from 1mL of matching patient plasma samples using; A – the Total Exosome Isolation Kit,  B–the 
ExoEasy Kit and C –ExoSpin columns. 
 
The TEI kit appeared to isolate vesicles between 100-400nm in diameter (Figure 16A) with 
multiple peaks being observed. In contrast, other studies have reported that isolated vesicles 
were generally <300nm (Schageman et al. 2013; Tang et al. 2017). The highest concentration 
peak we observed for this method was 2.1 particles/mL. 
156 
 
Tang and colleagues (2017) also reported a large variation in the modal peak size in different 
serum samples. Schageman and colleagues (2013) reported that the vesicles isolated from the 
TEI kit were more uniform, with only a single modal peak size being observed. Both of these 
studies also showed that the TEI kit isolated a greater concentration of exosomes in 
comparison to sequential ultra-centrifugation (Schageman et al. 2013; Tang et al. 2017) 
whereas this method provided the lowest exosome yield in our study. 
5.2.1.1.2 ExoEasy Kit  
Using the ExoEasy kit, we observed a significant decrease in protein concentration in 
comparison to the TEI kit, however overall purity was still low. This contradicts findings from 
Enderle and colleagues (2015), who reported that exosomes isolated by the ExoEasy kit were 
indeed pure. 
With this method, we isolated vesicles at 50-300nm in diameter (Figure 16B), with most of the 
isolated vesicles being ~200nm. This is concordant with previous studies using this method 
(Enderle et al. 2015; Stranska et al. 2018). These vesicles are slightly larger than expected 
according to recommended guidelines (Witwer et al. 2013). The yield of exosomes was also 
greater than the TEI kit. The highest concentration peak we observed for this method was 1.0 
particles/mL. 
5.2.1.1.3 ExoSpin Columns 
ExoSpin columns provided the greatest level of purity and yield of exosomes. This is in 
agreement with a study from Lobb and colleagues (2015) which demonstrated that ExoSpin 
columns provided greater exosomal purity than precipitation based methods such as ExoQuick.  
Exosomes isolated with ExoSpin columns showed a modal peak at 90-100nm and ranged from 
50-200nm (Figure 16C). The highest concentration peak we observed for this method was 9.0 
particles/mL. These findings are in accordance with suggestions from the International Society 
for Extracellular Vesicle (ISEV) (Witwer et al. 2013; Lotvall et al. 2014). We also observed a rise 
in protein concentration in comparison to the ExoEasy kit, which was also reported in previous 
studies (Welton et al. 2015). 
Overall, our exosome yield and purity data are as expected compared to previous reports. The 
TEI kit provided the lowest sample purity and the ExoSpin columns provided the highest. The 
ExoEasy kit appeared to remove the most plasma-derived proteins whereas the ExoSpin kit 
removed less protein but had vesicles isolated within a narrower and more appropriate size 
range. However, both methods were limited regarding sample purity. 
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Due to the superior purity and yield of isolated exosomes, we chose to proceed with ExoSpin 
columns to analyse the exosomal molecular cargo. In the first instance we chose to investigate 
exoDNA. 
5.2.2 Exosome-Derived DNA Analysis 
Objective: Can we detect, quantify and analyse the molecular cargo of isolated exosomes in 
patients with LARC? 
Here we attempted to validate the presence of DNA in circulating exosomes isolated from pre-
treatment plasma from patients with LARC. ExoDNA was compared to matching cfDNA with 
regards to total DNA concentration, tumour-specific variants and DNA fragment length. 
For this study, two patients with LARC were consented by the WCB (patients WCB1493 and 
WCB1262). Both patients had known tumour-specific variants in primary tumour tissue (KRAS 
p.G13D in patient WCB1493 and KRAS p.G12D in patient WCB1262). 
Exosomes were isolated using ExoSpin columns from 1mL of plasma (Section 2.2.6.3) and DNA 
was extracted as described in Section 2.2.11.  
DNA was quantified using the Qubit and ddPCR system (Table 31). 
Table 31: DNA concentrations of cell free DNA and exosome-derived DNA calculated using the qubit and 
ddPCR 
 
DNA Concentration (Copies/µL) DNA Concentration (ng/µL) 
Patient ID ExoDNA CfDNA ExoDNA CfDNA 
WCB1493 4.77 28.4 0.15 1.1 
WCB1262 5.54 8.16 0.99 1.7 
 
In both patients, exoDNA had a lower concentration than matching cfDNA. This result was 
expected, as exoDNA would theoretically be captured during cfDNA extraction.  
We then attempted to detect and quantify a known-tumour specific variant in each sample 
type. ddPCR was used to compare VAFs between the two sources for each patient. However, 
no tumour-specific variants were detected in either patient from cfDNA or exoDNA.  
Studies have previously reported that tumour specific variants can be more frequently 
detected in exoDNA than in cfDNA in patients with pancreatic cancer (Allenson et al. 2017; 
Bernard et al. 2019). This is in agreement with San Lucas and colleagues’ previous reports that 
a large fraction of exoDNA was tumour-derived (San Lucas et al. 2015) in patients with visceral 
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cancers. Studies have also reported that median VAF was increased and concordance with 
tumour tissue was superior in exoDNA compared to ctDNA in patients with metastatic 
pancreatic cancer (Bernard et al. 2019). 
Though our data does not currently support these findings, our studies have numerous 
differences and limitations which may help explain any discrepancies. 
As no significant differences were observed between exoDNA and cfDNA in terms of VAF, we 
proceeded to compare the length of DNA extracted from each source as described in Section 
2.2.9.2. 
The length of exoDNA was analysed due to previous reports which have demonstrated that 
exoDNA is 2-10kb in length (Kahlert et al. 2014; Thakur et al. 2014). Furthermore, longer DNA 
could allow the analysis of a larger range of variants, expanding from single nucleotide changes 
to larger scale insertions and deletions. The length of extracted exoDNA was measured using 
the Agilent Tapsetation 2200 (see Figure 17). 
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Figure 17: The Gel View of amplified DNA analysed by the BioAnalyser 2100. L – Ladder, samples 1-4 -  
amplified DNA at 200 base pairs for cellular DNA, exoDNA, cfDNA and No Template Control respectively, 
5-8 -  amplified DNA at 500 base pairs for cellular DNA, exoDNA, cfDNA and No Template Control 
respectively, 9-12 -  amplified DNA at 800 base pairs for cellular DNA, exoDNA, cfDNA and No Template 
Control respectively 
These results suggest that exoDNA is not longer than matching cfDNA, with very little being 
observed at ~800bp in comparison to the much stronger band present in cfDNA. This finding 
contradicts other reports, which have shown exoDNA to be >10kb in length (Kahlert et al. 
2014) or up to 2.5kb (Thakur et al. 2014).  
On the contrary, our data indicated exoDNA has similar properties to cfDNA, and appears to 
display none of the theorised benefits of encapsulation in exosomes. We therefore 
hypothesised that the extracted exoDNA may be located on the external surface of exosomes 
rather than encapsulated internally. To test this hypothesis, we performed a Proteinase K and 
DNase I digestion on isolated exosomes before performing DNA extraction. Proteinase K was 
included to ensure the DNA was not bound to contaminating proteins such as Argonautes 
which were isolated alongside exosomes. Paired control samples underwent the same 
temperatures during treatment but were not treated with either enzyme. 
We also ensured that exosomes had been successfully lysed by the DNA extraction process by 
running the lysed sample though the NTA. Here we saw that all exosomes had indeed been 
lysed by the DNA extraction process (data not shown). 
The DNA extracted from paired samples was quantified using the Qubit (Table 32). 
Table 32: Total DNA concentrations of DNA extracted from circulating exosomes and matching 
Proteinase K and DNase I treated circulating exosomes from pre-treatment plasma in patients with LARC 
 
DNA Concentration (ng/µL) 
Patient ID Treated Untreated 
WCB1493 TL 1.3 
WCB1262 TL 1.6 
TL – DNA was too low to be detected using the Invitrogen Qubit 
 
Here we demonstrated that exoDNA from treated exosomes had been completely lost in 
comparison to matching undigested samples. This would suggest that the DNA was in fact 
bound to the external surface of the exosomes. This is in agreement with reports that the 
DNase I treatment of exosomes eliminated all detectable DNA from exosomes isolated from 
cell culture media and human plasma samples (Nemeth et al. 2017; Jeppesen et al. 2019).  
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Furthermore, we saw that the externally bound DNA was largely <1kb in length and shorter 
than matching cfDNA whereas previous reports have suggested that exoDNA was found up to 
2.5kb (Kitai et al. 2017) or >10kb in length (Kahlert et al. 2014) after DNase I digestion. 
Overall, our data suggests that the detected exoDNA was bound to contaminating proteins or 
to the external surface of exosomes, rather than being encapsulated within. 
Confident that we would not detect exoDNA in these patients at this time, we proceeded to 
investigate the potential utility of exoRNA in this cohort. 
5.2.3 Exosome-Derived RNA Extraction and Analysis  
We have previously developed and optimised an assay for the extraction and analysis of 
exoRNA from the circulation of patients with LARC (See Appendices 9.7.1.1). Here we aimed to 
validate the presence of microRNA in circulating exosomes isolated from the plasma of 
patients with LARC.  
Objective: Can we detect, quantify and analyse the molecular cargo of isolated exosomes in 
patients with LARC? 
5.2.3.1 Systematic Review 
We performed a systematic review in order to identify circulating microRNAs of interest with 
respect to patients with CRC or rectal cancer. Pubmed was used to look for the search terms 
‘Circulating microRNA Rectal Cancer’ and ‘Circulating MicroRNA Colorectal Cancer’. These two 
searches provided 12 and 147 hits respectively. Of these studies, six were shared between the 
two searches, therefore a total of 153 reports were examined as part of this systematic review. 
Of the 153 studies, we excluded 37 reviews, 13 studies investigating patients with other cancer 
types, nine methodological development studies, seven-meta-analyses and two which were 
not available in English. Overall, we analysed 85 studies investigating circulating microRNAs in 
patient with colon and/or rectal cancers. 
From these studies we identified 23 different microRNAs which were found to be significant in 
a diagnostic or prognostic manner, each of which was reported in at least three separate 
studies. The total list of identified microRNAs can be found in the Appendices (Section 9.8). 
From this list two microRNAs, Mir-31 and -125b, were chosen for investigation in sequential 
plasma samples throughout radiotherapy in patients with LARC.  
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Aside from this systematic review, we also chose to investigate Mir-99a*, which had previously 
been seen to influence DNA damage repair in response to ionizing radiation in prostate, breast 
and lung cancers (Mueller et al. 2013; Rane et al. 2016; Yin et al. 2018). 
5.2.3.2 Assay Validation 
To validate our developed assay, sequential plasma samples from three patients (WCB1479, 
WCB1493 and WCB1263) were used for sequential exosome-derived microRNA analysis. 
During this validation, microRNAs were analysed without normalisation. 
Table 33: Concetration of microRNAs of interest extracted from circulating exosomes in the plasma of 
patients with LARC at various timepoints around radiotherapy 
Patient 
Sample 
Timepoint 
(Weeks) 
Mir-31 
(copies/µL) 
Mir-99a* 
(copies/µL) 
Mir-125b 
(copies/µL) 
WCB1479 -2 20.8 2.08 225 
WCB1479 6 7.31 0.763 153 
WCB1479 16 10.1 1.65 287 
WCB1493 -2 12.1 0 201 
WCB1493 0 20 3.44 403 
WCB1493 7 2.32 1.51 111 
WCB1263 1 9.74 0.672 88.6 
WCB1263 3 2.69 0.468 62.4 
Week 1 marks the initiation of therapy for all patients 
 
From this validation cohort, we saw variable concentrations of microRNA between timepoints 
and patients (Table 33). Only one timepoint had undetectable microRNA (Mir-99a* in patient 
WCB1493 week -2). Although there was one negative result, we generally saw detectable 
microRNA levels otherwise, and therefore decided to proceed with longitudinal analysis of the 
remaining nine patients. For these patients, microRNAs were normalised using RNU6B.  
5.2.4 Sequential MicroRNA Analysis  
Objective: Can we detect and measure quantitative changes in the molecular cargo of 
exosomes before, during and after radiotherapy in patients with LARC? 
5.2.4.1 Investigating Circulating Exosome-Derived MicroRNA Using ddPCR 
We applied our validated assay to quantify normalised levels of selected microRNAs in the 
circulating exosomes of patients with LARC. This is with the longer-term aim of investigating 
the ability of exosome-derived microRNAs to prognosticate and/or predict outcomes in 
patients with LARC in the future. 
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Nine patients with LARC consented by the WCB were used for longitudinal analysis. Clinical 
details for these patients can be seen in Table 34. 
Table 34: Clinical characteristics of patients with locally advanced rectal cancer consented by the Wales 
Cancer Bank. ESMO stages grouped as suggested by Glynne-Jones et al. 2017 
Patient 
ID 
T N M AJCC Grouped 
Stage 
Radiotherapy 
(Gy in Doses) 
Time Period of 
Radiotherapy 
WCB1295 3 2 0 III 45 in 25 5 Weeks 
WCB1368 1 0 0 I 20 in 5 1 Week 
WCB1441 4b 0 0 II 45 in 25 5 Weeks 
WCB1473 0 0 1 IV 30 in 5 1 Week 
WCB1476 3 2 0 III 45 in 25 5 Weeks 
WCB1477 3 0 0 II 45 in 25 5 Weeks 
WCB1478 4 1 0 III 25 in 5 1 Week 
WCB1603 4 0 0 II 45 in 25 5 Weeks 
WCB1604 3 1 0 III 45 in 25 5 Weeks 
AJCC – Grouped tumour stage in accordance with the American Joint Committee on Cancer  
 
ExoRNA was extracted from sequential plasma samples from each of these patients according 
to the protocol described Section 2.2.11.1. Extracted RNA was reverse transcribed as described 
in Section 2.2.12.1.1 and analysed using ddPCR (Section 2.2.15.5).  
Overall, all three microRNAs were confidently detected in all patients and timepoints at 
variable levels (Table 35). 
Table 35: Normalised expression levels of microRNAs of interest extracted from circulating exosomes in 
the plasma of patients with LARC at various timepoints around radiotherapy. Gene expression was 
normalised using the RNU6B 
ID Week Patient Status Mir-31 Mir-99a* Mir-125b 
WCB1295 -3 Pre-Treatment 0.04 0.01 0.57 
WCB1295 4 On-Treatment 0.02 0.01 0.44 
WCB1368 -2 Pre-Treatment 0.02 0.06 0.24 
WCB1368 1 On-Treatment 0.02 0.09 0.37 
WCB1441 -2 Pre-Treatment 0.12 0.01 0.36 
WCB1441 -1 Pre-Treatment 0.10 0.02 0.54 
WCB1441 1 On-Treatment 0.10 0.01 0.51 
WCB1473 0 Pre-Treatment 0.06 0.01 0.33 
WCB1473 2 On-Treatment 0.02 0.01 0.22 
WCB1473 13 Post-Treatment 0.05 0.01 0.30 
WCB1476 -4 Pre-Treatment 0.03 0.005 0.19 
WCB1476 12 Post-Treatment 0.03 0.02 0.51 
WCB1477 -1 Pre-Treatment 0.04 0.01 0.64 
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ID Week Patient Status Mir-31 Mir-99a* Mir-125b 
WCB1477 12 Post-Treatment 0.04 0.02 0.66 
WCB1478 -4 Pre-Treatment 0.02 0.02 0.41 
WCB1478 4 On-Treatment 0.02 0.008 0.30 
WCB1603 -3 Pre-Treatment 0.05 0.006 0.81 
WCB1603 1 On-Treatment 0.04 0.008 0.32 
WCB1603 5 On-Treatment 0.03 0.003 0.18 
WCB1603 14 Post-Treatment 0.01 0.005 0.23 
WCB1604 -8 Pre-Treatment 0.04 0.02 0.34 
WCB1604 -3 Pre-Treatment 0.05 0.03 0.63 
WCB1604 0 Pre-Treatment 0.04 0.06 0.39 
WCB1604 6 Post-Treatment 0.03 0.06 0.39 
Week 1 marks the initiation of therapy for all patients 
 
5.2.4.1.1 Mir-31 
The reliable detection of Mir-31 across all patients contradicts previous reports which had 
excluded Mir-31 from sequential analysis, due to very low expression levels when analysed 
using qPCR in patients with LARC (Azizian et al. 2015).  
Levels of Mir-31 did not significantly associate with T/N/M or grouped staging according to the 
AJCC in our cohort. This contradicts previous findings where Mir-31 expression correlated with 
tumour stage in the plasma and tissue of patients with CRC (Kanaan et al. 2012; Eslamizadeh et 
al. 2018). 
We could not identify any distinct trends or patterns of change in Mir-31 throughout the 
course of therapy in our patient cohort. In contrast to this, studies have previously reported a 
significant decrease in circulating Mir-31 levels after the completion of therapy in rectal cancer 
(Jo et al. 2017). In agreement with this, Kim and colleagues (2014) reported that Mir-31 levels 
decreased in irradiated colon cancer cells in vitro. Though we may have seen a general 
decrease in circulating mir-31 in some patient samples, no significant differences were 
observed. 
We did notice that patient WCB1441 had higher levels of Mir-31 than the other patients. This 
difference was observed against all patients except WCB1473 (p = 0.06) and WCB1603 (p=0.06) 
at pre-treatment.  
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5.2.4.1.2 Mir-99a* 
We saw no specific trend of change in Mir-99a* levels from pre- to post-treatment samples. 
Previously, Mir-99a* has been reported to increase or decrease after therapy in patients with 
head and neck squamous cell carcinoma (Hou et al. 2015) or ovarian cancer (Yoshimura et al. 
2018) respectively. Therefore, there are no consistent findings with which to compare results 
against on this subject. We also saw no significant associations with clinical pathological 
factors.  
Levels of Mir-99a* were found to be expressed at a greater level in patient WCB1604 in 
comparison to other patients. This difference reached statistical significance in post-treatment 
samples against all available patients (See Appendices Section 9.10 for details). We did not see 
any statistically significant differences between patient WCB1368 and any other patients in 
this analysis, although levels appear to be very high, more so than patient WCB1604 (Figure 
18). 
5.2.4.1.3 Mir-125b 
No patients displayed significantly high or low levels of Mir-125b in circulating exosomes at 
this time. No studies appear to have examined correlations between clinical pathological 
features and Mir-125b expression in patients with LARC or CRC. Previous reports have 
suggested no association exists in patients with chronic lymphocytic leukaemia (Gagez et al. 
2017) and hepatocellular carcinoma (Liu et al. 2016). These contrast with reports that Mir-
125b levels, in both tissue and plasma, were associated with clinical pathological features in 
patients with lung adenocarcinoma (Zhao et al. 2015). Furthermore, levels of Mir-125b have 
also been demonstrated to negatively correlate with tumour size (Sanchez-Sendra et al. 2018) 
and the presence of metastases (Huang et al. 2012) in the primary tumours of patients with 
melanoma, and squamous cell carcinoma respectively. Studies have also shown that low levels 
of circulating mir-125b were associated with more advanced stage in patients with 
osteosarcoma (Luo et al. 2016). 
Raychaudhuri and colleagues (2017) reported that Mir-125b levels significantly increased after 
chemotherapy in the circulation of patients with breast cancer. Here we saw no significant 
changes as a result of radiotherapy in our patients. 
Generally, no patterns of change could be easily discerned from total circulating exoRNA levels 
from these patients. Though concentrations were seen to vary, whether these variations are 
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significant changes which occurred as a result of therapy, or natural biological variation 
remains to be seen.
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Figure 18: Normalised expression levels of microRNAs of interest and across all available timepoints from all patients. Gene expression was normalised using RNU6B. Average 
RNU6B here represents total RNA.
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5.2.5 Patient Clinical Outcomes 
Objective: Do longitudinal levels of exosomal molecular cargo correlate with clinical outcomes 
in patients with LARC? 
Findings from exoRNA analysis were compared to patient clinical outcomes, specifically initial 
response to therapy and disease recurrence within two years as previously performed in 
section 3.2.4. As previously discussed in Chapter 3, two patients (WCB1368 and WCB1473) 
were excluded from clinical outcome analysis due to receiving atypical treatment. The clinical 
outcomes for the remaining seven patients is illustrated below in Table 36. 
Table 36: Treatment outcomes for patients with LARC consented by the Wales Cancer Bank 
Patient 
ID 
Disease 
Stage 
Radiotherapy 
(Gy in Doses) 
TRG 
Patient Experienced Local 
and/or Distant Relapse 
WCB1295 III 45 in 25 1 None 
WCB1441 II 45 in 25 4 Distant only 
WCB1476 III 45 in 25 2 None 
WCB1477 II 45 in 25 4 Local only 
WCB1478 III 25 in 5 4 n/a 
WCB1603 II 45 in 25 3 Local and distant 
WCB1604 III 45 in 25 2 Distant only 
 
As performed previously, clinical outcomes were separated in a binary fashion, including good 
vs poor response (TRG1/2 vs TRG 3/4), complete vs incomplete response (TRG1 vs TRG2-4) and 
whether or not patients experienced local and/or distant relapse in two years of follow-up. 
These are illustrated below in Table 37, Table 38 and Table 39 respectively.  
Analysis of exoRNA levels in relation to patient outcomes was limited, as only seven patients 
who underwent exoRNA analysis had known outcomes. Furthermore, although all eight had 
pre-treatment plasma available, only one patient experienced a complete response to 
neoadjuvant therapy. Therefore, statistical analysis is not possible for the complete vs 
incomplete response (Table 38). 
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Table 37: A comparison of longitudinal circulating exoRNA levels across patients with good and poor 
responses to neoadjuvant therapy 
  
Good Response Poor Response 
  
(TRG 1/2) (TRG 3/4) 
Variables N Median (Range) N Median (Range) p-value 
Pre-Treatment Levels 
Mir-31 Concentration 
(Copies/µL) 
2 
0.04 
5 
0.05 
0.44 
(0.03 – 0.04) (0.01 – 0.1) 
Mir-99a* Concentration 
(Copies/µL) 
2 
0.02 
5 
0.02 
0.40 
(0.01 – 0.02) (0.01 – 0.06) 
Mir-125b Concentration 
(Copies/µL) 
2 
0.38 
5 
0.48 
0.40 
(0.19 – 0.57) (0.36 – 0.81) 
On-Treatment Levels 
Mir-31 (Copies/µL) 1 
0.02 
4 
0.03 
n/a 
n/a (0.02 – 0.10) 
Mir-99a* (Copies/µL) 1 
4 
4 
0.01 
n/a 
n/a (0.003 – 0.02) 
Mir-125b (Copies/µL) 1 
0.44 
4 
0.41 
n/a 
n/a (0.18 – 0.54) 
Post-Treatment Levels 
Mir-31 (Copies/µL) 1 
0.03 
4 
0.04 
n/a 
n/a (0.01 – 0.05) 
Mir-99a* (Copies/µL) 1 
0.02 
4 
0.02 
n/a 
n/a (0.01 – 0.06) 
Mir-125b (Copies/µL) 1 
0.51 
4 
0.45 
n/a 
n/a (0.23 – 0.66) 
 
Table 38: A comparison of longitudinal circulating exoRNA levels across patients with complete and 
incomplete responses to neoadjuvant therapy 
  Complete 
Response (TRG 1) 
Incomplete 
Response (TRG 2-4) 
  
Variables N 
Median 
(Range) 
N 
Median 
(Range) 
P-Value 
Pre-Treatment Levels 
Mir-31 Concentration (Copies/µL) 1 
0.04 
6 
0.04 
n/a 
n/a (0.02 – 0.10) 
Mir-99a* Concentration 
(Copies/µL) 
1 
0.01 
6 
0.01 
n/a 
n/a (0.005 – 0.06) 
Mir-125b Concentration 
(Copies/µL) 
1 
0.57 
6 
0.41 
n/a 
n/a (0.19 – 0.81) 
On-Treatment Levels 
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  Complete 
Response (TRG 1) 
Incomplete 
Response (TRG 2-4) 
  
Mir-31 (Copies/µL) 1 
0.02 
4 
0.03 
n/a 
n/a (0.02 – 0.10) 
Mir-99a* (Copies/µL) 1 
0.01 
4 
0.01 
n/a 
n/a (0.003 – 0.02) 
Mir-125b (Copies/µL) 1 
0.44 
4 
0.41 
n/a 
n/a (0.18 – 0.56) 
Post-Treatment Levels 
Mir-31 (Copies/µL) 0 
n/a 
5 
0.03 
n/a 
n/a (0.01 – 0.05) 
Mir-99a* (Copies/µL) 0 
n/a 
5 
0.02 
n/a 
n/a (0.01 – 0.06) 
Mir-125b (Copies/µL) 0 
n/a 
5 
0.51 
n/a 
n/a (0.23 – 0.66) 
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Table 39: A comparison longitudinal levels of circulating exoRNAs between different patient responses to neoadjuvant therapy. Any recurrence refers to patients who 
experience either local or distant relapse within two years of follow-up. 
  Local Relapse Distant Relapse Any Relapse 
Variable 
No Relapse; 
Median 
(Range) 
Relapse; 
Median 
(Range) 
p- Value 
No Relapse; 
Median 
(Range) 
Relapse; 
Median 
(Range) 
p- Value 
No Relapse; 
Median 
(Range) 
Relapse; 
Median 
(Range) 
p- Value 
Pre-Treatment Levels 
Mir-31 Concentration 
(Copies/µL) 
0.04 0.04 
0.65 
0.04 0.05 
0.16 
0.04 0.05 
0.28 
(0.03 – 0.10) (0.02 – 0.06) (0.03 – 0.04) (0.02 – 0.10) (0.03 – 0.04) (0.02 – 0.10) 
Mir-99a* Concentration 
(Copies/µL) 
0.01 0.01 
0.56 
0.01 0.02 
0.34 
0.01 0.02 
0.45 
(0.01 – 0.02) (0.01 – 0.06) (0.01 – 0.01) (0.01 – 0.06) (0.01 – 0.01) (0.01 – 0.06) 
Mir-125b Concentration 
(Copies/µL) 
0.54 0.41 
0.51 
0.57 0.41 
0.74 
0.38 0.48 
0.37 
(0.19 – 0.57) (0.36 – 0.81) (0.19 – 0.64) (0.36 – 0.81) (0.19 – 0.57) (0.36 – 0.81) 
On-Treatment Levels 
Mir-31 Concentration 
(Copies/µL) 
0.06 0.02 
0.48 
0.02 0.03 
n/a 
0.02 0.03 
n/a 
(0.02 – 0.10) (0.02 – 0.03) (n/a) (0.01 – 0.05) (n/a) (0.02 – 0.10) 
Mir-99a* Concentration 
(Copies/µL) 
0.01 0.01 
0.88 
0.01 0.01 
n/a 
0.01 0.01 
n/a 
(0.01 – 0.01) (0.01 – 0.06) (n/a) (0.003 – 0.02) (n/a) (0.003 – 0.02) 
Mir-125b Concentration 
(Copies/µL) 
0.48 0.3 
0.6 
0.44 0.41 
n/a 
0.44 0.41 
n/a 
(0.44 – 0.51) (0.18 – 0.54) (n/a) (0.18 – 0.54) (n/a) (0.18 – 0.54) 
Post-Treatment Levels 
Mir-31 Concentration 
(Copies/µL) 
0.03 0.04 
n/a 
0.04 0.03 
0.77 
0.03 0.04 
n/a 
(n/a) (0.01 – 0.05) (0.03 – 0.04) (0.01 – 0.05) (n/a) (0.01 – 0.05) 
Mir-99a* Concentration 
(Copies/µL) 
0.02 0.02 
n/a 
0.02 0.01 
0.27 
0.02 0.02 
n/a 
(n/a) (0.01 – 0.06) (0.02 – 0.02) (0.01 – 0.06) (n/a) (0.01 – 0.06) 
0.51 0.45 n/a 0.59 0.39 0.31 0.51 0.45 n/a 
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  Local Relapse Distant Relapse Any Relapse 
Mir-125b Concentration 
(Copies/µL) 
(n/a) (0.23 – 0.66) (0.51 – 0.66) (0.23 – 0.51) (n/a) (0.23 – 0.66) 
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Previous reports have demonstrated that Mir-99a* was up-regulated in the serum of patients 
with ovarian cancer (Yoshimura et al. 2018). Other studies have demonstrated that Mir-99a* 
was significantly down-regulated in the circulation of patients with breast (Yu et al. 2018) and 
bladder cancer (Feng et al. 2014; Du et al. 2015). Furthermore, Mir-31 has been demonstrated 
to be down-regulated in patients with rectal cancer (Jo et al. 2017) and CRC (Wang et al. 2014). 
However, we did not find any studies which have investigated circulating Mir-31 or Mir-99a* 
levels in relation with response to radiotherapy in patients with LARC at this time. 
Increased levels of Mir-125b have been reported in the serum of patients with rectal 
adenocarcinoma which was associated with poor response to neoadjuvant therapy (D'Angelo 
et al. 2016). Similarly, in 56 patients with breast cancer, increased levels of Mir-125b were 
associated with resistance to chemotherapy (Wang et al. 2012). We did not see any such 
correlations in our cohort.  
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5.3 Discussion 
5.3.1 Conclusions 
5.3.1.1 Exosome Isolation Comparison 
Objective: Which method(s) provide the best yield and purity of exosomes from the plasma of 
patients with LARC? 
The purity and yield of isolated exosomes are important characteristics to consider due to the 
implications that these factors can have on down-stream analysis, either in a research or 
clinical setting (Van Deun et al. 2014). Here we observed considerable variation in the yield 
and purity of exosomes isolated by each method. 
5.3.1.1.1 Total Exosome Isolation Kit 
The TEI kit is a precipitation-based method which utilises volumes exclusion polymers, such as 
polyethylene glycol, to isolate extracellular vesicles. This method provided the lowest yield and 
exosome purity of the three tested. This was shown by the large range of the size of vesicles 
isolated and the numerous modal peaks observed. This presence of numerous peaks has been 
previously reported using this kit (Tang et al. 2017), suggesting that larger vesicles were 
isolated alongside exosomes. This contradicts studies which have reported that isolated 
vesicles were uniform when analysed by NTA (Schageman et al. 2013). Differences here may 
exist due to the nature of the isolation reagent. The large and numerous peaks we observed 
may have been the result of vesicle aggregation rather than necessarily representing the 
presence of microparticles of various sizes. 
In this study, we determined vesicle purity using a P/P ratio whereas previous studies 
investigated the presence of exosome-specific markers in accordance with the ISEV (Lotvall et 
al. 2014). Studies have shown that exosomes isolated by the TEI kit lacked exosome-specific 
markers, such as CD63 (Van Deun et al. 2014) and CD9 (Tang et al. 2017). These results suggest 
that other non-exosomal microparticles are co-isolated using this method. In contrast, 
Schageman and colleagues (2013) demonstrated that exosomes isolated by the TEI kit 
expressed both CD63 and CD9. However, this study did not examine these markers using 
fluorescent microscopy as Van Deun and colleagues had, to prove that all isolated vesicles 
contained these markers (Van Deun et al. 2014). 
In agreement with previous studies, our findings have demonstrated that exosomes isolated 
using the TEI kit generally lacked purity.  
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5.3.1.1.2 ExoEasy Kit 
The ExoEasy kit is a membrane-affinity-based isolation method, meaning exosomes are 
captured by being bound to the membrane of a spin column. Exosomes isolated using the 
ExoEasy kit had an improved purity and yield in comparison to those extracted using the TEI 
kit. The size and range of isolated vesicles were similar to that demonstrated in previous 
studies (Enderle et al. 2015). However, this kit isolated microparticles >200nm which are larger 
than typical exosomes and other small extracellular vesicles (Thery et al. 2018).  
Enderle and colleagues (2015) previously demonstrated that exosomes isolated using the 
ExoEasy kit displayed the exosome-specific marker TSG101. However, the ISEV also suggested 
the inclusion of at least two exosome specific markers as well as one non-exosomal marker 
(such as calnexin) for purity analysis (Lotvall et al. 2014). A recent study reported that 
exosomes isolated using this method had very low to undetectable levels of the exosome-
specific markers TSG101 and CD81, suggesting low exosome purity (Stranska et al. 2018). This 
study also reported a high protein concentration with particles >200nm believed to be protein 
aggregates.  
Overall, this approach provided greater yield and purity of exosomes than the TEI kit, but still 
has limitations regarding vesicle purity to a lesser degree. 
5.3.1.1.3 ExoSpin Columns 
ExoSpin is based on size exclusion chromatography and separates vesicles and microparticles 
based on particle size. We demonstrated here that the ExoSpin columns isolated exosomes 
with the greatest purity and yield of our tested methods. This is unsurprising as size exclusion 
chromatography-based methods have been demonstrated to provide superior sample purity 
over precipitation-based methods (Ludwig et al. 2018). Welton and colleagues (2015) 
demonstrated the purity of exosomes isolated with the ExoSpin columns using P/P ratios as 
well as CD9, CD63 and CD81 as exosome-specific markers. However, this report also 
demonstrated that a high level of Apo-B, a lipoprotein marker, was also detected in isolated 
vesicles using this method (Welton et al. 2015). This too brings into question the purity of the 
isolated exosomes in this fraction. Though some plasma albumin was detected, isolating 
exosomes from this fraction was reported to removed >99% of all albumin in patient plasma 
(Welton et al. 2015).  
In this study we used a P/P ratio to examine sample purity. This is not a commonly used 
method for determining vesicle purity in comparison to the detection of exosome and non-
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exosome specific markers, which is currently the gold standard. The detection of such markers, 
by western blots or, ideally, fluorescent microscopy provides greater clarity regarding vesicle 
purity and the presence of contaminating microparticles. The findings displayed in this study, 
though may be a good indicator, will need to be expanded upon, especially with the view to 
moving into the clinical setting in the future. 
Sequential-ultracentrifugation and density gradients were not used or directly compared to 
the methods used in this study. Although sequential ultra-centrifugation was excluded (due to 
the potential difficulties transitioning such a method into the clinical setting in the future) this 
study could have benefitted with its inclusion in a technological comparison. 
Although our purity analysis here was limited, we used our results in conjunction with findings 
from previous studies to select the optimal exosome isolation method in subsequent 
investigations. 
5.3.1.2 Exosome-Derived DNA Analysis 
Objective: Can we detect, quantify and analyse the molecular cargo of isolated exosomes in 
patients with LARC? 
We initially detected exoDNA from the circulation of patients with LARC which was 
subsequently lost after exosomes were treated with Proteinase K and DNase I. This would 
suggest that it was extracellular DNA bound to contaminating proteins or the external surface 
of our isolated vesicles. This is consistent with previous reports (Valadi et al. 2007; Nemeth et 
al. 2017; Jeppesen et al. 2019) but contradicts a number of others (Kahlert et al. 2014; Thakur 
et al. 2014; Jin et al. 2016; Yang et al. 2017; Vagner et al. 2018).  
Upon closer inspection, various reasons were identified for this contrast in findings. Yang and 
colleagues (2017) did not include a DNase digestion step whilst Jin and colleagues (2016) 
detected exoDNA in exosomes isolated using ExoQuick. ExoQuick has previously been shown 
to isolate vesicles of low purity (Van Deun et al. 2014). Therefore, non-exosomal vesicles (such 
as micro-vesicles or apoptotic bodies) may be the source of DNA in this case. In agreement 
with this, when Vagner and colleagues (2018) reported the presence of EV-derived DNA, it was 
encapsulated within larger vesicles (1 - 5.5µm) compared to smaller vesicles (100-400nm).  
Nevertheless, studies have still reported the presence of exoDNA after appropriate exosome 
isolation and DNase treatment. Furthermore, exoDNA has also been reportedly detected 
during viral infections (Ambrosio et al. 2019) or pregnancy (Sheller-Miller et al. 2017). 
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Therefore, it appears DNA can be detected within exosomes under certain conditions, which 
numerous studies have proposed is related to cellular stress.  
Studies have previously demonstrated that DNA and nuclear proteins can re-localise to the 
cytoplasm as a result of oxidative or cellular stress (Montermini et al. 2015; Sheller-Miller et al. 
2017). Once in the cytoplasm, DNA can then be packaged into exosomes. This has also been 
demonstrated to occur to cells undergoing high level of DNA damage (Kitai et al. 2017; 
Takahashi et al. 2017). Whether cellular stress causes an active or passive secretion of genomic 
DNA remains to be determined. These studies may suggest that exoDNA appears or rapidly 
increases as a result of cellular stress and/or DNA damage.  
A number of publications have reported the presence of double-stranded DNA in exosomes 
isolated from the serum of pancreatic cancer patients (Kahlert et al. 2014) and cancer cell lines 
(Thakur et al. 2014). These studies both identified tumour-specific variants from parental cells 
in exoDNA. In agreement with this, Lee and colleagues (Lee et al. 2014) demonstrated that 
exosomes can transfer oncogenic DNA to target cells in vitro. However, none of these studies 
have directly reported the presence of exoDNA in patients with CRC. 
Overall, these studies suggest that DNA may be packaged into exosomes under specific 
conditions. These conditions appear to rely on the presence of cellular stress or DNA damage, 
causing DNA to relocate from the nucleus into the cytoplasm and be packaged into exosomes. 
Cellular stress and DNA damage are both associated with hallmarks of cancer (Hanahan and 
Weinberg 2011), and thus this leak of DNA into the cytoplasm may be a common occurrence in 
patient tumours and cancer cell lines. This may also be further amplified by patient treatment, 
especially radiotherapy, which can cause large amounts of both DNA damage and cellular 
stress in patient tumours.  
We may have been unable to detect exoDNA in our patients for several reasons. Here we only 
analysed DNA from 1mL of plasma, where perhaps more is required to detect exoDNA using 
our methods in these patients. In addition, we only investigated this in two patients, thus 
further investigation of a larger number of patients may have provided more information on 
the subject. Furthermore, these patients were treatment-naïve and exoDNA may have been 
detectable after the initiation of radiotherapy and the associated DNA damage.  
We may have been unable to detect exoDNA due to the sensitivities of the methods applied 
here for DNA quantification. Nor did we examine the sensitivities of our DNA quantification 
assays. Thus, our negative detection of exoDNA is limited according to these unknown 
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sensitivities. Finally, as our patients have locally advanced disease, with a generally low 
systemic tumour burden, their tumours may not yet be secreting exoDNA. These tumours may 
have not grown to the capacity and acquired the levels of cellular stress required for exoDNA 
secretion at this time. Therefore, this may not be the most appropriate patient cohort to 
investigate this feature with. For now, the question of exoDNA remains unanswered. 
5.3.1.3  Circulating Exosome-Derived MicroRNA Analysis in Patients with LARC 
Objective: Can we detect, quantify and analyse the molecular cargo of isolated exosomes in 
patients with LARC? 
We were able to successfully develop a method to extract and analyse microRNA from 
exosomes isolated from the circulation of patients with LARC. From this exoRNA, we were able 
to detect and quantify the presence of three microRNAs of interest using ddPCR.  
Here we showed that Mir-31 levels were reliably detected using the TaqMan MicroRNA RT kit 
and ddPCR. Previously, Azizian and colleagues (2015) reported that Mir-31 levels were too low 
to monitor in the serum of patients with LARC using the MiScript II RT kit and qPCR. However, 
here we showed that our kit allowed the targeted reverse transcription of small genes to 
increase cDNA levels. This can create separate limitations with regards to amplification bias 
which will need to be explored further in the future. Furthermore, ddPCR is a more sensitive 
method for RNA quantification than qPCR (Wang et al. 2019). Therefore, though levels were 
low, we were able to reliably detect and normalise Mir-31. 
We also detected consistently low levels of Mir-99a*. This is not surprising as previous reports 
have suggested that Mir-99a* was down-regulated in the tumour tissue of patients with head 
and neck squamous cell carcinoma (Hou et al. 2015) and bladder cancer (Feng et al. 2014). As 
far as we know, to date, no studies have investigated the role of Mir-99a* in tumour tissue 
from patients with LARC. Mir-99a* displayed little variation, due to the very low levels 
detected and small numbers of patients analysed. Therefore, further work would be required 
to determine whether this microRNA can be used to predict response or clinical outcome in 
patients with LARC.  
Mir-125b levels were relatively high in comparison to Mirs-31 and -99a*. This finding is as 
expected, due to previous reports that Mir-125b is up-regulated in the circulation of patients 
with CRC (Liu, 2018; Yamada, 2015). Furthermore, D’Angelo and colleagues (2016) reported 
that high Mir-125b levels were associated with poor response to pCRT in patients with LARC. 
There was much higher variation in Mir-125b levels between patients and timepoints in this 
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cohort in comparison to Mirs-31 and 99a*. Further investigation is required to determine 
whether these differences are indicative of clinical outcomes or a result of greater natural 
variation. 
Expression levels varied between both microRNAs of interest and between patients. We saw 
that patients WCB1441 and WCB1604 had significantly higher levels of Mir-31 and Mir-99a* 
respectively in comparison to other patients. This might be due to up-regulation of these 
microRNAs within cancer cells or being actively secreted in exosomes. Alternatively, these 
differences may be a result of natural variation between patients. We also saw higher levels of 
Mir-99a* in patient WCB1368 but this was not statistically significant, possibly due to small 
sample numbers.  
Expression levels of each microRNA and total RNA were not associated with T/N/M or AJCC 
staging. Most studies which compare clinical pathological features to microRNA levels 
generally investigate this in tumour tissue. Any correlations therefore do not necessarily 
translate into circulating exoRNA, due to the masking presence of non-tumour derived 
exosomes. This is also emphasised by the low stage and tumour burden associated with our 
patient cohort. Low tumour burden might suggest that a limited number of exosomes are 
being secreted into the circulation by the tumour. Therefore, a smaller number of tumour 
derived exosomes may be detected in the circulation in comparison to more advanced 
patients. As a result, the presence of any signatures may be made more difficult or impossible 
to identify. If these patient tumours are not shedding exosomes at a high rate, then the 
analysis of circulating biomarkers may be meaningless in these patients. 
We must also consider the effects of changing exosome isolation methods for exoRNA analysis. 
The ExoRNEasy kit, an expansion of the ExoEasy kit, was applied for exoRNA extraction due to 
the larger range of plasma input volume, allowing us to reliably detect exoRNA. However, this 
method isolated exosomes of lower purity in comparison to ExoSpin columns. Our quantified 
microRNA expression levels may be influenced by the presence of contaminating vesicles and 
proteins. Furthermore, due to the low expression levels we observe here in Mirs-31 and 99a*, 
differences can be difficult to identify, especially in such a small sample cohort. The reverse 
transcription process used here included targeted amplification of microRNAs of interest, 
which can create amplification bias and the presence of any correlations or association may 
therefore be warped or lost. Finally, these microRNAs were chosen based on a review of the 
literature rather than us performing large scale analyses ourselves in these patients. Therefore, 
we cannot be entirely certain that these microRNAs are appropriate within our patient cohort. 
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Objective: Can we detect and measure quantitative changes in the molecular cargo of 
exosomes before, during and after radiotherapy in patients with LARC? 
We did not identify any significant changes over time for any of our microRNAs nor any 
significant associations to clinical outcomes, which may be due to several reasons. If 
differences did indeed exist, the small number of patients here may not be a large enough 
sample size to identify them with any reliability or confidence.   
One of the most important factors to consider when evaluating such findings are the patient 
characteristics of the cohort in question. As previously stated, these patients’ tumours may not 
be secreting exosomes into the circulation at a particularly high rate. Therefore, the 
microRNAs we have analysed may originate largely from non-tumour tissue, rendering such 
analyses redundant, especially as there is currently no way to investigate tumour-specific 
exosomes or microRNA, in contrast to using tumour-specific variants in ctDNA. Therefore, such 
studies can be limited by the lack of tumour-derived microRNA in such analyses, specifically 
when patients have locally advanced disease with low tumour burden. As a result, the changes 
we observe, whether significant or not, may be the result of natural biological variation over 
time rather than tumour specific differences.  
Another reason that we could not identify sequential changes may be the choice of 
microRNAs. These microRNAs may not be affected by ionizing radiation or be involved in 
cellular response to radiotherapy in patients with LARC. This could be due to reports that 
microRNAs have been demonstrated to be differentially expressed and perform various 
functions between different cancer types. Furthermore, the ExoRNEasy kit may have 
significant effects on gene expression analysis in these patients through the presence of 
contaminating vesicles or proteins and their associated microRNA levels. 
Changes may also be distorted due to the use of targeted amplification during reverse 
transcription. This may, in turn, cause amplification bias and potentially influence microRNA 
levels and level changes between timepoints. However, use of such targeted amplification may 
be necessary to reliably detect some of these microRNA in the circulating exosomes of patients 
with LARC at all. Therefore, more knowledge is required regarding the consistency of 
amplifications in genes of interest using this method. 
Although we analysed exoRNA levels, we did not analyse the concentration of circulating 
exosomes. The inclusion of circulating exosome concentration in tandem with exoRNA data 
could provide more clinically relevant information regarding a patient tumour. Furthermore, as 
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we could not quantify microRNA concentrations before performing reverse transcription, we 
are not aware of how consistent our ddPCR analysis was, due to the potentially variable 
concentrations of input microRNA. 
In this study, RNU6B was used as a reference gene to normalise microRNA expression levels. 
This gene was chosen due to utility in previous studies but may not necessarily be appropriate 
for utility in our cohort. 
At present, we are unaware of the optimal timings for blood collection to measure circulating 
biomarkers in relation to radiotherapy. Circulating biomarker analysis throughout radiotherapy 
is ideal. However, we need to identify when to collect plasma after the administration of 
radiotherapy, whether it is a few hours after therapy or on which days or weeks would allow 
optimal circulating biomarker analysis. This requires further investigation and standardisation 
to facilitate predicting patient outcomes and response. 
181 
 
5.3.2 Clinical Implications 
Objective: Do longitudinal levels of exosomal molecular cargo correlate with clinical outcomes 
in patients with LARC? 
5.3.2.1 Mir-31 
Mir-31 has previously been associated with having important roles in numerous solid tumours. 
In patients with LARC, Mir-31 has been seen to be overexpressed in 17 patient tumours and 
down-regulated in 111 patient plasma in comparison to normal mucosa and healthy control 
patients respectively (Jo et al. 2017). Similarly, other studies have reported that high Mir-31 
levels were associated with decreased response to 5-FU in colon cancer cell lines (Wang et al. 
2010) and tumour tissue in patients with LARC (Carames et al. 2016). Although the study by 
Wang and colleagues (2010) was only performed in vitro, without expansion into patient 
samples, these findings have since been supported in patients by more recent reports 
(Carames et al. 2016). However, only one of these studies investigated circulating Mir-31 (Jo et 
al. 2017). Overall, research in this field is limited with regards to patients with rectal or 
colorectal cancer. Therefore, further investigations are required to ensure these findings are 
consistent in tissue and in circulating exosomes. 
Notably, Mir-31 was chosen for evaluation due to it having been previously reported to be 
associated with ionizing radiation response. In colon cancer cells, Mir-31-5p was shown to 
induce radio-sensitivity in MMR proficient cells by targeting MLH1 (Kim et al. 2014). Similarly, 
Mir-31 levels were positively associated with improved response and cell death in oesophageal 
cancer patients and cell-lines  respectively by targeting DNA repair genes (Lynam-Lennon et al. 
2012). This study also reported that Mir-31 was informatically predicted to target DNA repair 
genes, including PARP and MLH1, and that these genes were down-regulated in radiosensitive 
tumour samples. The targeting of MLH1 and/or other DNA repair genes by Mir-31 may be an 
integral mechanism in cellular response to radiotherapy.  
Furthermore, Mir-31 has been previously linked to p53 status in serous ovarian cancer, which 
is also commonly investigated in the context of response to radiotherapy (Creighton et al. 
2010). Finally, Mir-31 has also previously been linked to the Ras pathway (Sun et al. 2013a) 
which has been implicated in response to radiotherapy (Chow et al. 2016). However, the 
function and expression of levels of Mir-31 has been shown to differ between specific cancer 
types. 
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We did not identify any significant differences or associations regarding Mir-31 levels and 
patient response as part of this analysis. We decided to investigate patient WCB1441 further 
as they displayed significantly higher levels of Mir-31 than other patients. This patient 
responded poorly to therapy (TRG 4) and developed distant metastases in the lung after 20.6 
months. They also had a large tumour volume (T-stage 4b), which may have influenced Mir-31 
levels. However, other patients with lower levels of Mir-31 also experienced a poor treatment 
response with progression.  
Circulating Mir-31 levels may be useful as a prognostic marker in patients with LARC, as studies 
have shown that levels are indicative of patients’ survival to pCRT. However, this will require 
further analysis to verify. 
5.3.2.2 Mir-99a* 
In tumour tissue, Mir-99a* has previously been reported to be down-regulated in patients with 
LARC who respond poorly to pCRT (Svoboda et al. 2012). We therefore hope to examine here 
whether Mir-99a* levels in plasma-derived exosomes can be used in a similar manner.  
Considering diagnostic potential, Yan and colleagues (2018) reported that Mir-99a* was down-
regulated in prostate cancer in comparison to normal prostate tissue. Svoboda and colleagues 
(2012) reported that Mir-99a* was linked to DNA repair by targeting RAD51C and RAD9B, 
genes known to be involved in DNA repair. They therefore hypothesised that Mir-99a* would 
cause a down regulation of DNA repair genes leading to radiosensitivity. This tumour-
suppressive nature of Mir-99a* is in agreement with reports from Molina-Pinelo and 
colleagues (2014) who stated that up-regulated Mir-99a* was associated with improved 
progression-free and overall survival in patients with advanced colorectal cancers. Mir-99a* 
was also shown to inhibit cell proliferation, migration and invasion in prostate cancer cell-lines 
(Arai et al. 2018). 
Studies have generally demonstrated that Mir-99a* provides a tumour suppressive function. 
This is in agreement with reports that Mir-99a* levels are low in the primary tumour in 
patients with more aggressive disease in prostate cancer (Rane et al. 2016). The role of Mir-
99a* and DNA repair in response to radiotherapy makes this an interesting candidate for 
analysis in the cohort. However, studies have primarily focussed on tumour tissue and cancer 
cell-lines, therefore expectations for detection, quantification and clinical relevance of Mir-
99a* in these patients is currently unknown. 
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We did not identify any clinically significant associations between circulating Mir-99a* levels 
and patient clinical outcomes within this study. We hypothesised that patient WCB1604 would 
respond well to treatment, due to their significantly high levels of detect circulating Mir-99a* 
in comparison to other patients. However, this patient experienced a poor response (TRG3) to 
radiotherapy, although had previously received chemotherapy. This patient continued to 
develop metastases in the lungs after 15.8 months. 
5.3.2.3 Mir-125b 
Mir-125b has been demonstrated to influence apoptosis through targeting genes like BAK1, 
Puma, Cyclin C and p53 (Jia et al. 2012; Zhao et al. 2012; Banzhaf-Strathmann and Edbauer 
2014). Hypothetically, Mir-125b levels may be indicative of apoptosis and, therefore, may be 
able to predict or infer response to radiotherapy in patients with LARC. Another study 
demonstrated that circulating levels increased after treatment in patients with breast cancer 
(Raychaudhuri et al. 2017). Mir-125b was reported to be down-regulated before the initiation 
of therapy in the tumour tissue of patients with rectal cancer (D'Angelo et al. 2016) and oral 
squamous cell carcinoma (Shiiba et al. 2013). Mir-125b was also seen to be up-regulated in the 
circulation of patients with breast cancer before therapy began (Wang et al. 2012). 
Consequently, we expected to observe that high Mir-125b was associated with improved 
response to therapy. However, we found that no patients were seen to have significantly high 
or low levels of Mir-125b nor any significant changes throughout radiotherapy. Nor were such 
levels significantly associated with any type of response. This finding is unsurprising due to our 
small sample numbers. 
Although we did not see any initial association with clinical characteristics, these microRNAs 
investigated in this study may still be able to play an important role in predicting outcome and 
response to radiotherapy in patients with LARC. 
Although the three exoRNAs (Mir-31, -99a* and -125b) were chosen based on a review of the 
literature, further investigation will be required to show that these were appropriate choices 
for exoRNA analysis in this cohort of patients. There were also likely to be variable levels of 
amplification bias between microRNAs and patients during this analysis, potentially masking 
any significant association. The presence of these exoRNAs being released by non-tumour 
tissue and physiological processes could also impact our ability to identify any significant data. 
Ideally, further investigation is required to determine whether concentrations of tissue-derived 
microRNA and exoRNA correlate or not. 
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There was also a lack of uniformity for the collection of plasma samples in terms of both stage 
of treatment and the number of samples collected throughout our cohort. This can create 
difficulties when attempting to perform a statistical comparison. Finally, only a small number 
of patients (n=8) underwent exoRNA examination, thus this analysis is underpowered and our 
lack of significant findings is not unexpected. 
The primary objective of this chapter was to develop an assay which would facilitate exoRNA 
analysis from 1mL of plasma in patients in LARC. Therefore, clinical analysis was a secondary 
objective and a way to attempt to apply the data. This assay will require further development 
in the future before attempting further clinical analysis. This will likely include the necessity of 
further optimisation for both exoRNA extraction and/or ddPCR analysis before ensuring the 
assay provides regular reproducible findings from separate aliquots of matching plasma 
samples. Furthermore, the chosen microRNAs will require further investigation to determine 
whether they are suitable for such analysis, and, if not, the identification of suitable 
microRNAs from hypothesis-free studies, such as transcriptomic sequencing or microRNA array 
analysis. Although we achieved our primary objectives, extended investigations will be 
required before repeating such clinical analyses performed here. 
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5.3.3 Future Studies 
Studies have shown that specific protein markers, like Glypican-1 can potentially distinguish 
tumour and non-tumour derived exosomes in patients with pancreatic (Melo et al. 2015) and 
colorectal cancer (Li et al. 2017). Though this field is still in its infancy, utility of such a marker 
in rectal cancer could greatly improve results and clinical applicability of microRNA expression 
in the future. This may discount the role of the tumour-microenvironment, including cancer 
associated fibroblasts, which may be clinically useful. As previously stated, this field is still in an 
early developmental phase and more research is required. 
It would be interesting to investigate whether exoDNA is released and/or detectable after the 
initiation and/or completion of radiotherapy. This is due to the connection that exoDNA 
reportedly has with cellular stress and DNA damage. We would also like to investigate this in 
larger plasma volumes and more advanced patients, in order to identify the extent to which 
these factors can influence exoDNA secretion and detection. 
It would be ideal in the future to perform hypothesis free analytical methods (such as NGS or 
microarrays) to identify a much larger number of microRNAs in patient tissue and/or 
circulating exosomes. From this, a small number can then be analysed further. This would also 
assist in identifying appropriate reference genes for normalisation. This would certainly require 
further assay development for exosome isolation and RNA extraction, as such methods would 
have limited sensitivities in comparison to ddPCR applied here. 
Having tumour tissue available from these patients for microRNA expression analysis could 
assist in identifying microRNAs of interest. The use of tumour tissue before and after 
radiotherapy could also provide valuable insight as to which microRNAs are most heavily 
involved in providing radio-sensitivity or -resistance to cancer cells. Finally, monitoring these 
microRNAs in circulating exosomes and comparing them to changes in tumour tissue, could 
help infer whether microRNAs are released in an active or passive fashion. 
It would also be of interest to compare microRNA profiles of isolated circulating exosomes to 
matching plasma. Findings here could either further enforce the role of circulating exosomes in 
cancer or assist overcoming numerous technical limitations by removing the need to isolate 
exosomes. 
Finally, in future studies we could attempt to analyse the presence of mRNA in depth in place 
of microRNA. This could also potentially allow the detection and quantification of tumour-
specific variants and allow a direct comparison to ctDNA and cfDNA. 
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6 Analysis and Clinical Utility of Circulating Biomarkers in Predicting 
Outcome in Locally Advanced Rectal Cancer Patients 
6.1 Introduction 
Standard therapy for patients with locally advanced rectal cancer (LARC) is neoadjuvant 
therapy and surgery with curative intent. Dependent upon tumour stage, up to 20% of patients 
can achieve pCR (Maas et al. 2010). Patients who achieve pCR or a partial clinical response 
have improved overall survival OS and DFS (Janjan et al. 2001; Maas et al. 2010). However, the 
current methods for predicting patient response to therapy remain limited. 
Pre-operative CEA is currently used to predict response and/or survival to neoadjuvant therapy 
in patients with rectal cancer (Colloca et al. 2017). CEA has recently been reported to predict 
OS and DFS in a systematic review in patients with non-metastatic rectal cancer, suggesting its 
continued clinical importance for patients with LARC (Colloca et al. 2017). 
Several circulating biomarkers may provide benefits over CEA, some of which may have use in 
routine clinical practice. These include; components of the full blood count and related 
systemic inflammatory indices (such as NLR, PLR and LMR).  
Here we analysed full blood count data for 235 patients with LARC who were treated at the 
Velindre Cancer Centre. With this cohort, we aimed to acquire greater statistical power to 
identify significant associations between circulating biomarkers and clinical outcomes in 
patients with LARC. 
We also investigated pre-treatment levels of haemoglobin and CEA to detmerine whether they 
could be predictive of patient outcomes and response to therapy in 14 patients with LARC 
consented by the WCB on which ctDNA, cfDNA and exoRNA analyses were previously 
performed. 
6.1.1 Study Objectives 
This study intends to determine the predictive power of circulating biomarkers in patients with 
LARC undergoing neoadjuvant therapy. In this study, our objectives are: 
• Can clinical full blood counts and derived immune ratios be used to predict clinical 
outcomes in response to neoadjuvant therapy in patients with LARC? 
• Can baseline CEA or haemoglobin levels be used to predict response to neoadjuvant 
therapy in patients with LARC? 
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6.2 Results 
6.2.1 Circulating Biomarker Analysis in Patients with LARC 
Objective: Can clinical full blood counts and derived immune ratios be used to predict clinical 
outcomes in response to neoadjuvant therapy in patients with LARC? 
Clinical data for these patients included the age at which patients were diagnosed, ranging 
from 27-92 (median 62). All patients diagnosed with LARC were treated with curative intent. A 
total of 18 (7.7%) patients received short-course (1 week) therapy and 96 (40.9%) received 
long-course (5 weeks) treatment. No detailed treatment data was available for the remaining 
122 patients (51.5%). Blood was collected at baseline (pre-treatment) and week 5 for each of 
these patients as part of routine clinical care. Week 5 refers to the fifth week after patients 
began therapy, which may be during or after the administration of treatment for patients on 
long- and short-course therapy respectively. From routine blood collections, platelet, 
lymphocyte, neutrophil, and monocyte concentrations were available at both timepoints. 
Median follow-up for the whole cohort was 37 months, and 177 patients had a minimum of 
two years follow-up available for analysis. A summary of available clinical characteristics of this 
cohort are displayed in Table 40. 
Table 40: Clinicopathological characteristics of all 235 patients with locally advanced rectal cancer 
undergoing circulating biomarker analysis  
Clinicopathological Characteristics 
Characteristic N % 
Sex 
Male 160 68.1 
Female 75 31.9 
Clinical T Stage 
T1 1 0.4 
T2 32 13.6 
T3 174 74 
T4 26 10.8 
Unknown 2 0.9 
Clinical N Stage 
N0 62 26.4 
N1 87 37 
N2 72 30.6 
Unknown 14 7.8    
Clinical M Stage 
M0 195 83 
M1 15 6.4 
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Clinicopathological Characteristics 
Characteristic N % 
Unknown 25 10.6 
Recurrence Within 2 years 
Local 45 19.1 
Distant 66 28.1 
Any 72 30.6 
None 115 48.9 
Unknown 48 20.4 
Course of Therapy 
Long Course (5 Weeks) 96 40.9 
Short Course (1 Week) 17 7.2 
Unknown 122 51.9 
Response to Therapy 
Complete Response 9 3.8 
Incomplete Response 175 74.5 
Unknown 56 23.8 
 
We initially investigated whether any components from full blood counts or derived immune 
ratios could predict how patients with LARC responded to neoadjuvant therapy. Response to 
therapy was measured using two separate clinical endpoints. At first, patients were separated 
according to their initial response to therapy (complete vs incomplete). We then compared 
concentrations of each respective circulating biomarker between the two responses to 
therapy. We also investigate whether these biomarkers could predict patients who 
experienced local and/or distant disease recurrence within the first two years of follow-up. We 
analysed recurrence in patients after two years as studies have reported that disease 
recurrence within this time period was indicative of long-term outcomes (Sargent et al. 2011). 
Complete response was defined as ypT0 and ypN0 in this analysis. We applied ypT0 and ypN0 
as definitions of pCR in this part of the study because they refer to the complete absence of 
primary tumour tissue (ypT0) and lymph node involvement (ypN0) after neoadjuvant therapy. 
Local recurrence was defined as intra-pelvic recurrence after primary cancer resection (Cai et 
al. 2014). Therefore, distant disease recurrence arises in lymph nodes or other organs outside 
of the pelvic region.  
The circulating biomarkers analysed within this study included platelet, neutrophil, monocyte 
and lymphocyte concentrations, as well as PLR, NLR and LMR values. An unpaired two-sample 
T-Test was performed to identify any differences between the separate responses to therapy 
in all patients (see Table 41 and Table 42).  
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Table 41: A comparison of pre-treatment blood cell counts between patients who experienced complete 
and incomplete response to neoadjuvant therapy in all 235 patients. Change in variable refers to the 
difference between baseline and week 5 for each respective biomarker. 
  Complete  
Response 
Incomplete  
Response 
 
Variable 
Median 
(Range) 
Median 
(Range) 
P-Value 
 
Pre-Treatment Platelet Count 
211 275 
0.07 
 
(162 – 308) (88.0 – 601.0)  
Week 5 Platelet Count 
183 227 
0.02 
 
(133 – 221) (64.0 – 515.0)  
Change in Platelet Count 
-54 -49 
0.86 
 
(-98 – 10) (-326.0 – 230.0)  
Pre-Treatment Lymphocyte Count 
1.5 1.7 
0.34 
 
(0.8 – 2.9) (0.7 - 3.8)  
Week 5 Lymphocyte Count 
0.7 0.7 
0.93 
 
(0.4 – 1.2) (0.2 - 3.2)  
Change in Lymphocyte Count 
-0.8 -1.1 
0.32 
 
(-1.7 – -0.2) (-2.6 – 0.8)  
Pre-Treatment Neutrophil Count 
3.7 4.6 
0.26 
 
(2.6 – 7.2) (1.9 – 11.0)  
Week 5 Neutrophil Count 
3.2 3.8 
0.20 
 
(1.8 – 4.4) (1.4 – 15.0)  
Change in Neutrophil Count 
-1.6 -1.1 
0.93 
 
(-3.1 – 0.7) (-6.4 – 8.4)  
Pre-Treatment Monocyte Count 
0.5 0.6 
0.54 
 
(0.3 – 1.1) (0.1 – 1.3)  
Week 5 Monocyte Count 
0.4 0.5 
0.43 
 
(0.3 – 0.9) (0.2 – 1.2)  
Change in Monocytes 
0 0 
0.97 
 
(-0.21 – 0.20) (-0.6 – 0.5)  
Pre-Treatment PLR 
139.5 158 
0.56 
 
(92.6 – 340.0) (55.2 – 641.0)  
Week 5 PLR 
242.9 335 
0.12 
 
(141.0 – 470.0) (69.7 – 1477.0)  
Change in PLR 
103.4 172 
0.10 
 
(8.6 – 244.0) (-93.9 – 975.8)  
Pre-Treatment NLR 
2.6 2.6 
0.87 
 
(1.3 – 5.9) (1.0 – 11.1)  
Week 5 NLR 4.6 5.5 0.23  
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  Complete  
Response 
Incomplete  
Response 
 
(1.6 – 8.2) (0.9 – 21.4)  
Change in NLR 
2.1 2.9 
0.23 
 
(-1.0 – 5.1) (-5.3 – 18.3)  
Pre-Treatment LMR 
0.32 0.3 
0.86 
 
(0.2 – 0.6) (0.1 – 1.0)  
Week 5 LMR 
0.6 0.8 
0.25 
 
(0.3 – 1.3) (0.2 – 2.7)  
Change in LMR 
0.37 0.5 
0.19 
 
(0.02 – 0.7) (-0.3 – 2.4)  
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Table 42: A comparison of sequential platelet counts, lymphocyte counts, neutrophil counts, monocyte counts, PLR, NLR and LMR between patients who experienced local 
and/or distant recurrence within two years of follow up in comparison to those who did not. All values were analysed as continuous variables, not as high or low based on a 
designated threshold. Change in variable refers the difference between baseline and week 5 for each respective biomarker. Any recurrence refers to patients who experience 
either local or distant relapse. 
| Local Relapse Distant Relapse Any Relapse 
Variable 
No Relapse; 
Median 
(Range) 
Relapse; 
Median 
(Range) 
p- 
Value 
No Relapse; 
Median (Range) 
Relapse; 
Median 
(Range) 
p- 
Value 
No Relapse; 
Median 
(Range) 
Relapse; 
Median 
(Range) 
p- 
Value 
Pre-Treatment 
Platelet Count 
277.5 182 
0.65 
281 276 
0.57 
280 280 
0.81 
(88.0-494.0) (174.0-540.0) (126.0-601.0) (88.0-562.0) (126.0-601.0) (88.0-652.0) 
Week 5 Platelet 
Count 
224 167.5 
0.11 
231.5 239 
0.37 
232 241 
0.51 
(64.0-465.0) (128.0-515.0) (115.0-465.0) (64.0-515.0) (115.0-465.0) (64.0-515.0) 
Change in Platelet 
Count 
-54 -17 
0.3 
-56 -38 
0.07 
-54 -43 
0.38 
(-326.0-177) (-245-230.0) (-326-166.0) (-326-230.0) (-326-166.0) (-245-230.0) 
Pre-Treatment 
Lymphocyte Count 
1.8 1.4 
0.72 
1.8 1.7 
0.62 
1.8 1.7 
0.42 
(0.6-3.8) (0.9-3.7) (0.6-3.8) (0.9-3.7) (0.6-3.8) (0.9-3.7) 
Week 5 
Lymphocyte Count 
0.6 0.5 
0.12 
0.6 0.7 
0.13 
0.6 0.7 
0.22 
(0.4-2.8) (0.3-3.2) (0.2-2.8) (0.3-3.2) (0.2-2.8) (0.3-3.2) 
Change in 
Lymphocyte Count 
-1.1 -1 
0.24 
-1.1 -1 
0.27 
-1.1 -0.9 
0.22 
(-2.0-1.6) (-2.5-0.8) (-2.9-1.6) (-2.5-0.8) (-2.9-1.6) (-2.5-0.8) 
Pre-Treatment 
Neutrophil Count 
4.6 4.6 
0.46 
4.6 4.6 
0.76 
4.6 4.8 
0.77 
(4.0-11.0) (1.9-8.4) (1.9-11.0) (2.5-9.6) (1.9-11.0) (2.5-9.6) 
Week 5 Neutrophil 
Count 
3.5 2.9 
0.01 
3.5 4 
0.06 
3.5 4 
0.06 
(1.4-9.3) (2.1-15.0) (1.4-9.3) (1.9-15.0) (1.4-9.3) (1.9-15.0) 
Change in 
Neutrophil Count 
-1.2 -0.9 
0.09 
-1.2 -1.1 
0.06 
-1.2 -1.2 
0.22 
(-6.1-4.8) (-4.6-8.4) (-6.1-4.8) (-3.9-8.4) (-6.1-4.8) (-4.6-8.4)4 
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| Local Relapse Distant Relapse Any Relapse 
Pre-Treatment 
Monocyte Count 
0.6 0.5 
0.35 
0.6 0.6 
0.47 
0.5 0.5 
0.5 
(0.2-1.22) (0.1-1.1) (0.1-1.22) (0.1-1.1) (0.3-1.22) (0.1-1.1) 
Week 5 Monocyte 
Count 
0.5 0.5 
0.16 
0.5 0.5 
0.16 
0.5 0.5 
0.2 
(0.2-1.8) (0.3-1.2) (0.2-1.8) (0.3-1.2) (0.2-1.8) (0.3-1.2) 
Change in 
Monocyte Count 
0 -0.2 
0.85 
0 -0.1 
0.79 
0 -0.1 
0.95 
(-0.5-0.6) (-0.7-0.5) (-0.6-0.6) (-0.4-0.5) (-0.6-0.6) (-0.7-0.5) 
Pre-Treatment PLR 
155 124.3 
0.8 
154.6 160.7 
0.74 
153.2 161.3 
0.98 
(102.1-641.4) (205.8-435.5) (50.0-641.4) (55.2-323.3) (50.0-641.4) (55.2-535.5) 
Week 5 PLR 
337.5 342 
0.25 
346 333.9 
0.12 
344.3 330.5 
0.12 
(97.8-1476.7) (70.0-1077.5) (101.4-1476.7) 
(70.0-
1077.5) 
(101.4-
1476.7) 
(70.0-1077.5) 
Change in PLR 
172 204 
0.15 
179.1 133.5 
0.13 
183.7 133.3 
0.08 
?? (20.7-543.3) (-139.4-975.8) (-93.9-865.8) (-139.4-975.8) (-93.9-865.8) 
Pre-Treatment NLR 
2.5 2.6 
0.47 
2.6 2.7 
0.93 
2.5 2.8 
0.69 
(1.0-11.1) (1.3-6.3) (1.0-11.1) (1.9-5.5) (1.0-11.1) (1.3-6.3) 
Week 5 NLR 
5.4 5 
0.82 
5.5 5.8 
0.62 
5.4 5.7 
0.62 
(1.0-20.0) (0.9-21.4) (1.0-20.0) (0.9-21.4) (1.0-20.0) (0.9-21.4) 
Change in NLR 
3 2.3 
0.99 
3 2.8 
0.72 
3 2.6 
0.52 
(-5.3-18.3) (-0.9-17.6) (-5.3-18.3) (-2.9-17.6) (-5.3-18.3) (-2.9-17.6) 
Pre-Treatment LMR 
3.3 3.3 
0.17 
3.4 3 
0.25 
3.5 3 
0.24 
(1.0-12.5) (1.3-16.7) (1.0-14.3) (1.3-16.7) (1.0-12.5) (1.3-16.7) 
Week 5 LMR 
1.3 1.1 
0.48 
1.25 1.3 
0.35 
1.25 1.3 
0.34 
(0.4-9.1) (0.6-6.25) (0.6-6.25) (0.5-6.25) (0.6-6.25) (0.5-6.25) 
Change in LMR 2 1.8 0.23 2 2.1 2.1 2 2.1 0.14 
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| Local Relapse Distant Relapse Any Relapse 
(-0.4-3.0) (-0.8-5.6) (-0.4-5.0) (-0.6-3.0) (-0.4-5.0) (-0.6-3.0) 
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Where data was available, we also separated patients according to the treatment regimen 
received (short or long-course). This data can be found in the Appendices (Section 9.11). 
From Table 41, we observed that patients who had an incomplete response to therapy had 
significantly higher platelet count at week 5 (p=0.01). Similarly, patients who had an 
incomplete response also had higher baseline platelet counts, although this difference was not 
significant (p=0.07). In agreement with these findings, in patients receiving short-course 
therapy an increase in platelet count from baseline to week 5 was suggestive of distant disease 
recurrence (p=0.05) and any disease recurrence (p=0.05) within two years of follow-up. This 
did not correlate with any significant differences with regards to PLR at any time point or 
change between timepoints. 
This finding has similarities with prior reports that high pre-treatment platelet counts were 
associated with a decreased rate of pCR, DFS and OS in patients with LARC (Belluco et al. 
2018). This study also reported that local recurrence and distant metastases both occurred at 
increase rates in patients with elevated platelet counts using a cut-off of 300x109/L (Belluco et 
al. 2018). Although, we saw no association with disease recurrence (Table 42), another study 
reported that a high pre-treatment platelet count was associated with decreased DFS in 
patients with rectal cancer (Toiyama et al. 2015). Such studies have primarily investigated pre-
treatment platelet levels, thus comparing our findings at week 5 to the literature is difficult.  
Although platelet counts were significantly associated with tumour response, we found no 
significant association between PLR and tumour response or disease recurrence. The literature 
on the predictive value of PLR in patients with rectal cancer is inconsistent. Li and colleagues 
(2016) have reported that high pre-operative PLR (>144) was associated with decreased OS 
and DFS, in patients with non-metastatic rectal cancer, but only in univariate analysis. In 
contrast, Jung and colleagues (2017) reported that high PLR (>92.88) was associated with 
improved RFS in both univariate and multivariate analysis. Dudani and colleagues (2019) 
reported that PLR had no significant association with OS, DFS or pCR in patients with LARC. 
Therefore, our lack of significant findings when predicting pCR and disease recurrence using 
this inflammatory ratio was not unexpected. 
Here we observed that significantly higher neutrophil count at week 5 was associated with an 
increased risk of local recurrence (Table 42). As with previous findings, this should be treated 
with caution, considering the number of factors analysed in this study and the probability of 
seeing a significant result by chance alone. As far as we are aware, no studies have reported 
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that neutrophil count alone was associated with response to neoadjuvant therapy or disease 
recurrence. However, numerous studies have investigated the potential utility of NLRs in 
patients with LARC. 
Although we saw no associations, we would have expected to see that increased NLR was 
associated with an incomplete response to therapy or an increased likelihood of disease 
recurrence. Studies have shown that high pre-treatment NLR was associated with poor OS 
(Ward et al. 2018) and DFS (Braun et al. 2019) in patients with rectal cancer. Similarly, patients 
with rectal cancer who had higher pre-treatment NLR were significantly less likely to achieve 
pCR (Jeon et al. 2019) and more likely to experience local relapse (Vallard et al. 2018). In 
patients with NSCLC treated with an anti-PD-1 antibody, high post-treatment NLR (week 6) was 
predictive of decreased DFS and OS (Cao et al. 2018). These studies show the potential utility 
of post-treatment NLR as a predictor of survival in patients with different solid tumours.  
Although we saw no direct significance when analysing NLR, there is some agreement between 
the literature and our association of high neutrophil counts with increased rates of local 
relapse. However, this assumes that neutrophil count and NLR have similar clinical implications 
in the context of patients with LARC undergoing neoadjuvant therapy. This may also be 
underestimating the importance of the lymphocyte count in the clinical utility of NLR. 
We found no associations between initial patient response or disease recurrence and LMR in 
our patient cohort. However, in patients who received long-course therapy, low baseline LMR 
was suggestive of an increased risk of local disease recurrence (p=0.05). Similarly, in patients 
receiving short-course therapy, high monocyte concentrations at week 5 were also suggestive 
of an increased risk of local recurrence (p=0.05). Previously, Jung and colleagues (2017) 
reported that high pre-treatment LMR (>6.8) was associated with improved RFS under 
univariate but not multivariate analysis in patients with rectal cancer. Similarly, Xiao and 
colleagues (2015) reported that high (>3.78) LMR was associated with improved DFS in 
patients with rectal cancer. Other studies have also reported that high LMR was associated 
with improved OS (Zhao et al. 2017; Ward et al. 2018). However, we did not investigate OS in 
our patient cohort, and thus our findings are not directly comparable. Overall, we saw some 
potential for LMR as a predictive biomarker in our patients. 
Using this clinical dataset, we were able to analyse patient response and disease recurrence in 
a larger cohort than possible in previous chapters. This analysis has demonstrated that high 
platelet and neutrophil concentrations at week 5 were associated with significantly improved 
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response and an increased likelihood of local recurrence. However, other white blood cells and 
inflammatory indices displayed limited power when predicting these clinical endpoints in 
patients with LARC. 
6.2.2 Pre-Treatment Clinical Characteristics of Patients with LARC 
Objective: Can baseline CEA or haemoglobin levels be used to predict response to neoadjuvant 
therapy in patients with LARC? 
6.2.2.1 Baseline Clinicopathological Features 
Previously, in Chapters 3 and 5, we analysed concentrations of ctDNA, cfDNA and exoRNA and 
compared these to patient clinical outcomes, in a small cohort of up to 14 patients with LARC. 
In this chapter, we have expanded on the previous circulating biomarkers by also investigating 
the possible predictive power of pre-treatment haemoglobin and CEA levels in the same 14 
patients. A reminder of the baseline clinical characteristics and clinical outcomes for these 
patients and a summary of the pretreatment haemoglobin and CEA levels are described below 
in Table 43 and Table 44 respectively. 
Table 43: Clinicopathological characteristics of patients with locally advanced rectal cancer undergoing 
circulating biomarker analysis to predict response to radiotherapy plus surgery 
Patient 
ID 
Disease 
Stage 
Radiotherapy 
(Gy in Doses) 
Baseline 
CEA 
(ng/mL) 
Baseline 
Haemoglobin 
(g/dl) 
TRG 
Patient Experienced 
Local and/or Distant 
Relapse 
WCB1262 II 45 in 25 2 105 1 None 
WCB1263 III 45 in 25 4 119 3 None 
WCB1268 IV 45 in 25 220 136 3 Distant only 
WCB1295 III 45 in 25 2 137 1 None 
WCB1419 III 25 in 5 2 142 4 Distant only 
WCB1441 II 45 in 25 1 131 4 Distant only 
WCB1476 III 45 in 25 0.5 153 2 None 
WCB1477 II 45 in 25 1 90 4 Local only 
WCB1478 III 25 in 5 41 127 4 n/a 
WCB1479 IV 45 in 25 10 139 3 Distant only 
WCB1493 II 45 in 25 2 131 1 Local only 
WCB1602 III 45 in 25 5 160 1 None 
WCB1603 II 45 in 25 12 109 3 Local and distant 
WCB1604 III 45 in 25 6 117 2 Distant only 
AJCC– Tumour staging according to the American Joint Committee on Cancer (Glynne-Jones et 
al. 2017) 
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Table 44: Pre-treatment blood cell counts of all patients with locally advanced rectal cancer undergoing 
pre-operative radiotherapy 
Variable N Median Range 
Haemoglobin (10ˆ9/L) 14 131 90-160 
CEA (10ˆ9/L) 14 3 0.5-220 
 
As in previous chapters, patient outcomes were separated in a binary fashion into good vs 
poor response (TRG1/2 vs TRG3/4), complete vs incomplete response (TRG1 vs TRG2-4) and 
whether patients experienced local and/or distant relapse within two years of follow-up). A 
statistical comparison of CEA levels to each of these outcomes is performed and described 
below in Table 45, Table 46 and Table 47. 
6.2.3 Circulating Biomarkers for Predicting Response to Therapy in Patients with LARC 
Table 45: A comparison of pre-treatment haemoglobin and CEA levels across patients with good and 
poor responses to neoadjuvant therapy 
  
Good Response Poor Response 
  
(TRG 1/2) (TRG 3/4) 
Variables N 
Median 
(Range) 
N 
Median 
(Range) 
p-value 
Pre-Treatment Levels       
Haemoglobin 
(10ˆ9/L) 
5 
138 
9 
127 
0.12 
(105 – 160) (90 – 142) 
CEA (10ˆ9/L) 5 
2.0 
9 
4.0 
0.35 
(0.5 – 10.0) (1.0 – 220.0) 
n/a – ranges or p-values could not be calculated due to limited number of samples 
Table 46: A comparison on pre-treatment haemoglobin and CEA levels across patients with complete and 
incomplete responses to therapy 
  Complete 
Response (TRG 1) 
Incomplete 
Response (TRG 2-4) 
  
Variables N Median N Median P-Value 
Pre-Treatment Levels 
Haemoglobin 
(10ˆ9/L) 
4 
134 
10 
130 
0.55 
105-160 90-142 
CEA (10ˆ9/L) 4 
2 
10 
4 
0.47 
2.0-5.0 0.5-220 
n/a – ranges or p-values could not be calculated due to limited number of samples 
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Table 47: A comparison circulating pre-treatment haemoglobin and CEA levels between different patient responses to neoadjuvant therapy. Any recurrence refers to patients 
who experience either local or distant relapse. 
  Local Relapse Distant Relapse Any Relapse 
Variable 
No Relapse; 
Median 
(Range) 
Relapse; 
Median 
(Range) 
p- 
Value 
No Relapse; 
Median 
(Range) 
Relapse; 
Median (Range) 
p- 
Value 
No Relapse; 
Median 
(Range) 
Relapse; 
Median 
(Range) 
p- Value 
Pre-Treatment Levels 
Haemoglobin 
(10ˆ9/L) 
136.5 123.5 
0.35 
131 131 
0.9 
128 131 
1.0 
(105 – 153) (90 – 160) (90 – 160) (109 – 142) (105 – 153) (90 – 160) 
CEA (10ˆ9/L) 
3.0 2.0 
0.63 
2.0 10.0 
0.17 
2.0 6.0 
0.39 
(0.5 – 220.0) (1.0 – 12.0) (0.5 – 5.0) (1.0-220.0) (0.5-5.0) (1.0-220.0) 
n/a – ranges or p-values could not be calculated due to limited number of samples 
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This analysis demonstrated that pre-treatment levels of CEA were not significantly associated 
with response to radiotherapy in our cohort of patients with LARC. This is in agreement with a 
systematic review which reported that CEA levels had a low sensitivity and positive predictive 
value when detecting recurrences in patients with CRC (Sorensen et al. 2016). However, 
reports have also demonstrated that pre-treatment CEA levels were significantly higher in 
patients with LARC who did not experience a complete response to neoadjuvant therapy (Yang 
et al. 2019).  
We observed no significant associations between haemoglobin levels at any time and patient 
response to therapy. In contrast, studies have recently demonstrated that high pre-treatment 
levels of haemoglobin were associated with an improved response rate to neoadjuvant 
therapy (Formica et al. 2018) and OS (Franco et al. 2018) in patients with LARC and anal cancer 
respectively. Similarly, Khan and colleagues (2013) reported that low haemoglobin levels were 
associated with an increased risk of local recurrence in a study of 463 patients with LARC. 
However, Clarke and colleagues (2017) found only a suggestive association between pre-
treatment haemoglobin levels and response to therapy in patients with LARC. 
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6.3 Discussion 
6.3.1 Conclusion 
In this study, we looked at how numerous circulating biomarkers could predict patients who 
achieved a complete response to therapy or patients who experienced disease recurrence 
within two years of follow-up. 
Objective: Can clinical full blood counts and derived immune ratios be used to predict clinical 
outcomes in response to neoadjuvant therapy in patients with LARC? 
We found that increased platelet and neutrophil counts at week 5 were associated with 
incomplete response and an increased likelihood of local relapse after neoadjuvant therapy 
(Table 41). This finding remained consistent when patients were separated according to the 
course of therapy administered.  
Our findings agree with prior reports that high platelet counts are indicative of poor prognosis 
in patients with rectal cancer. However, these studies generally analysed pre-treatment 
concentrations, whereas we observed a significant association at week 5 and not pre-
treatment. This significance was not reflected in PLR values at any time. 
High platelet counts have previously been suggested to drive cancer progression through 
inducing metastatic dissemination through angiogenesis (Wojtukiewicz et al. 2017), and by 
protecting tumour cells from immune elimination (Gay and Felding-Habermann 2011). 
Elevated platelet counts have also been identified in patients with rectal cancer, which was 
found to be associated with poor prognosis and tumour aggression in these patients (Belluco 
et al. 2018).  
High pre-treatment neutrophil counts were found to be a significant predictor for local 
recurrence within two years of follow-up in our patient cohort (Table 42). However, the 
literature is limited at this time regarding neutrophil counts only, and largely refers to pre-
treatment NLRs. Nevertheless, this finding is still in relative agreement with studies which have 
shown that high baseline NLR was predictive of poor DFS in patients with rectal cancer (Braun 
et al. 2019). 
Although neutrophil concentration was predictive of disease recurrence, NLR was not found to 
be significantly associated with any clinical outcome measured in this study. NLRs, among 
other systemic inflammatory indices, have recently emerged as a circulating biomarker of 
interest due to our increasing knowledge of the role of the immune system in cancer 
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development. Neutrophils have recently been recognised as having a pro-tumour influence via 
their capacity to induce inflammatory and angiogenic pathways, including IL-6, IL-8 and 
Vascular Endothelial Growth Factor (Terzic et al. 2010). In contrast, lymphocytes are 
hypothesised to have an anti-tumour effect, due to the beneficial presence that TILs have (Pine 
et al. 2015). 
However, as previously stated, we saw no significant associations between NLR and any of our 
clinical endpoints. This finding may differ from the literature for several reasons. The cut-offs 
of high and low NLR varied from 1.7-5.0 in the literature, which can cause inconsistencies 
when comparing studies and attempting to draw conclusions. Furthermore, NLR values may 
have been influenced by the administration of neoadjuvant therapy. Kitayama and colleagues 
(2010) reported that lymphocyte numbers decreased during radiotherapy administration, 
whereas the levels of neutrophils specifically, were relatively unaffected (Kitayama et al. 
2010). Although we would assume that this would impact all week 5 NLR values, the variability 
of this effect between patients and therapies has not yet been determined. Therefore, the 
inflammatory ratios measured at week 5 may have been influenced by neoadjuvant therapy 
and a longer follow-up may be beneficial before NLRs are examined again to allow 
normalisation of lymphocyte counts. This may also suggest why we observed a significant 
difference using the neutrophil count alone. 
Any association that neutrophil counts have with clinical outcomes may be due to the role that 
neutrophils may perform in facilitating distant metastasis in patients with cancer (Wculek and 
Malanchi 2015). Potentially, neutrophil counts could be used to identify high-risk patients who 
may require additional post-surgical adjuvant therapy, closer follow-up or even avoiding the 
unnecessary toxicity of surgery if a complete response can be predicted and then confirmed 
pre-surgery. This data would require validation in a much larger cohort and might then impact 
how patients are treated or managed during follow-up. Neutrophil counts may also be 
impacted by external, non-tumour factors, such as bacterial infection (Kitayama et al. 2010). 
We did not identify any significant associations between pre-treatment inflammatory ratios 
and patient outcomes to neoadjuvant therapy in our main patient cohort. When patients were 
divided according to treatment received, patients on long-course chemoradiotherapy, low 
baseline LMR was suggestive of an increased risk of local disease recurrence. Similarly, high 
monocytes at week 5 were also suggestive of an increased likelihood of local disease 
recurrence. As previously mentioned, there are some conflicting results in the literature and 
no significance was seen in our main cohort. Thus, this finding should not necessarily be taken 
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at face value and further analysis will be necessary to confirm the predictive power of LMR in 
this cohort. 
In recent years, PLRs and LMRs have been investigated either alongside or in place of other 
inflammatory markers (such as NLR) for clinical utility in patients with rectal cancer. This has 
been coupled with an increased understanding of the role of platelets and monocytes in 
cancer progression.  
As previously stated, the literature regarding PLR in patients with rectal cancers are 
inconsistent. This has created difficulties when assessing whether our findings agree with 
previous studies. This might be the result of numerous factors. Before inflammatory ratios 
could be applied in the clinical setting, more uniformity and standardisation will be necessary. 
For example, although considerable research has been performed regarding NLR, there is 
currently no standard cut-off value to distinguish between high and low values in patients with 
LARC. Previous studies have reported a wide range of cut-offs ranging from 1.8-5. Most of 
these studies chose their respective cut-off values based upon Receiver Operating 
Characteristic (ROC) Curve and/or Area Under Curve (AUC) analysis. With such a wide range 
being applied for inflammatory marker analyses, proper standardisation is required before 
clinical utility or testing can be considered. This factor remains consistent in both PLR and LMR 
studies.  
Other non-cancer factors may also affect immune-derived ratios, such as the impact of 
neoadjuvant therapy or infection. The consistency and reproducibility of PLR, NLR or LMR 
values over hours or days is also unknown and may require further investigation. 
As the full blood count data was obtained as part of routine clinical management, we can have 
reasonable confidence in the accuracy and reproducibility of each circulating biomarker. 
Furthermore, the size and breadth of data available within the large dataset allows us to 
perform more powerful statistical analysis than we could in previous chapters. Nevertheless, 
this analysis will still have inherent limitations which must be considered. No multivariate 
analysis or statistical corrections were performed. Therefore, this analysis did not incorporate 
additional relevant factors, such as whether patients received concurrent chemotherapy, types 
of surgery or any post-surgical interventions or the number of factors analysed in total.  
Finally, this dataset would have benefited from the inclusion of other circulating biomarkers of 
interest which are included in standard clinical analysis, such as baseline and sequential 
haemoglobin and/or CEA.  
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Our lack of significant findings in immune-derived ratios suggest that these inflammatory 
indices may not be entirely appropriate for patients with LARC. This has been noted previously, 
where studies have demonstrated that ctDNA is more readily detectable in patients with 
metastatic disease, rather than locally advanced cancer. As mentioned previously, monocytes, 
platelets and neutrophils can all play a key role in facilitating the development of tumour 
metastases. Therefore, these circulating biomarkers may be more clinically significant in 
patients with metastatic tumours, than those analysed as part of this study. 
This may be a consequence of the tumour biology and relatively early stage of these patients 
as neutrophils, platelets and monocytes have all been implicated in facilitating tumour 
metastasis. Therefore, the non-metastatic nature of this patient cohort may limit the 
effectiveness of these circulating biomarkers. However, there may be important scope for 
detecting patients which are more likely to develop or have already developed undetected 
micro-metastatic lesions. As we did not investigate this clinical outcome, we cannot comment 
on this.  
Furthermore, using systemic inflammatory indices relies on the assumption that lymphocytes 
only fulfil an anti-tumour function. However, studies have illuminated the role of CD4+ 
regulatory T-cells which dampen the immune function of CD8+ cytotoxic T-lymphocytes 
(Ramsay 2013). Therefore, such ratios might be limited by the inclusion of CD4+ and CD8+ T-
cells in the lymphocyte count. 
As this study progresses, we begin to suspect that this subgroup of patients, may not shed 
tumour-derived biomarkers into the circulation at a readily detectable rate. This could 
contribute to our lack of significant findings in this study. However, we have evidence to 
suggest that high platelet and neutrophil counts at week 5 may be predictors of incomplete 
response to therapy and local disease recurrence respectively in patients with LARC. 
Objective: Can baseline CEA or haemoglobin levels be used to predict response to neoadjuvant 
therapy in patients with LARC? 
We expected to see that high baseline CEA concentrations were associated with poorer 
response to neoadjuvant therapy, as this has been previously reported in patients with rectal 
cancer. Huh and colleagues (2018) reported that post-treatment CEA levels could be 
significantly elevated in patients with rectal cancer who had a poor response to CRT. This study 
also demonstrated that elevated post-treatment CEA levels were indicative of decreased 5-
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year OS. Similarly, Jeong and colleagues (2016) reported that high post-operative CEA was 
predictive of distant recurrence and was significantly associated with shortened RFS.  
We observed no such association at this time. This may be because this patient cohort is only 
locally advanced and, therefore, may secrete less CEA. Alternatively, this may suggest that CEA 
may have limitations as a circulating biomarker for this cohort. Finally, our lack of significant 
findings may be a result of low sample numbers limiting statistical analysis. 
Overall, we were unable to identify any statistically significant associations between pre-
treatment haemoglobin levels and patient response to neoadjuvant therapy. However, there 
were different findings reported on the potential predictive value of baseline haemoglobin in 
patients with rectal cancer (Khan et al. 2013; Clarke et al. 2017). This may have been a 
consequence of variable cut-offs defining high and low levels (12-14 g/dL). Furthermore, 
clinical endpoints, though similar, were not identical between studies, and patient treatment 
will have some variation between different treatment centres (including our own). Overall, 
these confounding factors may have contributed to our lack of significant associations 
between haemoglobin levels and patient response to therapy. 
Both CEA and haemoglobin analyses were limited as they only included pre-treatment samples 
from a small number of patients. This study would benefit from increasing this to include 
sequential analysis in a larger cohort, such as that investigated in Section 6.2.1. However, 
these two circulating biomarkers will be relatively reliable as they would have been collected 
to high standards as part of routine clinical management. Therefore, there are limited 
concerns regarding pre-analytical handling or sample quality. 
As the remaining circulating biomarkers provided limited predictive value for patient response 
to therapy, we again question whether our chosen circulating biomarkers are appropriate for 
clinical analysis in patients with LARC. Alternatively, these findings may be attributed to 
limitations with the assays applied, such as choice of methods, statistical analysis or 
technological sensitivity. 
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6.3.2 Future Studies 
This study would benefit from the inclusion of pre-treatment and post-treatment CEA and 
haemoglobin concentrations in the large dataset analysed in Section 6.2.1. This would allow 
further exploration into these routine clinical biomarkers in line with that previously 
performed for NLR etc. 
This study would also benefit from longer follow-up (>3 years) to analyse longer-term 
outcomes, such as PFS and OS. The circulating biomarkers may have greater predictive power 
for longer-term outcomes than initial response. 
As stated in previous chapters, greater volumes of plasma for cfDNA, ctDNA and exoRNA 
analysis could help improve the sensitivity of circulating biomarker analyses. A larger number 
of patients would also help to identify any statistically significant associations with patient 
outcomes. Expanding the number of microRNAs in exoRNA analysis alongside numerous 
reference genes may also help overcome some of the limitations highlighted previously for this 
biomarker.
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7 General Discussion and Future Research 
7.1 Summary of Key Findings 
Recent advancements in surgical techniques and the administration of pre-operative 
radiotherapy have improved local control in patients with locally advanced rectal cancer 
(LARC) (Peeters et al. 2007). Despite this improvement, many patients will still experience 
distant disease recurrence and disease-related mortality (Maas et al. 2010). 
At this time, the only clinical factors which can predict long-term clinical outcomes are 
achieving tumour-downstaging or pCR to therapy (Maas et al. 2010). There are no clinical or 
molecular markers that can predict how patients will respond to pre-operative 
chemoradiotherapy pCRT. 
As part of this thesis, our investigation has focussed on the potential utility of circulating 
biomarkers in predicting and/or monitoring response to neoadjuvant therapy in patients with 
LARC. Research into circulating biomarkers has often focussed upon patients with metastatic 
disease, because these patients have more advanced disease or metastases and because 
outcomes for these patients are generally very poor. This increases the likelihood of systemic 
and circulating biomarkers being detected and clinically relevant. These patients also have 
targeted treatments available for them, such as cetuximab, and thus have known resistance 
associated variants to detect and monitor in ctDNA (Reinert et al. 2015).  
In the first instance, our aim was to select a clinically relevant and economically efficient NGS 
panel for the detection of tumour-specific variants in both tumour tissue and ctDNA. Our 
choice of panel appeared to be appropriate, given the high rate of detection for clinically 
significant variants in tumour tissue from patients with LARC. However, this did not translate 
into ctDNA due to several limitations. We also determined a limit of detection threshold for 
both NGS and ddPCR to be ~1%, although ddPCR was demonstrated to be dependent on input 
DNA concentration. 
We proceeded to determine whether ctDNA and cfDNA could be reliably detected in patients 
with LARC. Overall, we were able to detect ctDNA at any time using ddPCR in 2/12 (16.7%) and 
3/18 (16.7%) patients in two separate cohort from Chapters 3 and 4 respectively. In Chapter 3, 
our cohort consisted of 16 patients with LARC who were consented at the Velindre Cancer 
Centre by the WCB. Of these 16 patients, 12 had KRAS variants previously detected which 
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could be used for ctDNA analysis in longitudinal plasma samples. This sensitivity for detecting 
ctDNA was lower than expected according to previous reports.  
We also observed higher total cfDNA concentrations from plasma samples collected during 
compared to those collected before or after. We hypothesised that this was a result of 
elevated tumour and non-tumour cell death, causing increased levels of cfDNA release into the 
circulation. However, this finding was not consistent when analysed in a similar patient cohort 
in Chapter 4. 
In chapter 4, we expanded our ctDNA analysis further using samples from a cohort of patients 
with LARC acquired from the ARISTOTLE clinical trial. We also aimed to investigate the ability 
of our targeted NGS panel to detect variants and analyse clonal changes in tumour tissue 
occurring as a result of neoadjuvant therapy. We successfully detected tumour-specific 
variants in rectal tumour tissue from 18/19 (94.7%) patients with LARC.  
Using this NGS data, we calculated heterogeneity scores based upon tumour cellularity and 
calculated VAFs as previously described by Normanno and colleagues (2015). We used these 
variant heterogeneity scores as a proxy marker for individual tumour clones and were also able 
to observe some clonal changes between pre- and post-treatment tumour tissue. We 
speculated that observed clonal changes in tumours after neoadjuvant therapy may be 
indicative of patient response.  
Continuing from chapters 3 and 4, we continued our investigation to include exoRNA as a 
potential circulating biomarker which, unlike ctDNA, is still in its relative translational infancy. 
Therefore, in chapter 5, we needed to develop a technique for the extraction and analysis of 
exoRNA in patients with LARC. For this chapter, we used plasma samples from the same 
patients used previously in chapter 3, who were consented by the WCB. We successfully 
developed and optimised an analytical process for the extraction and analysis of exoRNA from 
this patient cohort. This included choosing the optimal technology for exosome isolation, a key 
component to determine as this can impact sample purity during downstream analysis. This 
also required the optimisation of exoRNA extraction and appropriate reverse transcription, to 
ensure resulting microRNAs were reliably detected during ddPCR analysis.  
Three microRNAs of interest (Mir-31, -99a* and -125b) and a reference gene (RNU6B) were 
chosen for sequential analysis based on a review of the literature. We were able to confidently 
detect each of these microRNAs and the reference gene at variable levels in sequential plasma 
samples from our patients using ddPCR. We also investigated the more controversial subject of 
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exosome-derived DNA (exoDNA). Although we did not detect any exoDNA in our patients, 
there are further avenues to explore and the presence of exoDNA may not be as straight-
forward as exoRNA. 
As part of Chapter 6, we investigated the utility of components of clinical full blood counts and 
related inflammatory ratios to predict patient clinical outcomes in 235 patients with LARC. 
These included neutrophil, lymphocyte, platelet, and monocyte counts, as well as NLR, PLR and 
LMR. We demonstrated that patients who achieved a complete response to therapy had 
significantly lower platelet counts at week 5 of treatment, particularly in patients who received 
long-course neoadjuvant therapy. Furthermore, a high neutrophil count at week 5 was also 
significantly associated with disease recurrence in these patients. 
In addition, we also compared CEA and haemoglobin concentrations alongside previously 
quantified circulating biomarkers from chapters 3 (ctDNA and cfDNA) and 5 (exoRNA) to 
patient clinical outcomes in our prior 14 patient cohort. We observed that patients who had a 
complete response to treatment had significantly higher cfDNA concentrations both during 
and after therapy. We did not identify any other significant associations between circulating 
biomarkers and patient outcomes. 
7.1.1 Limitations of our Findings 
Although we were able to make some significant achievements throughout this thesis, our 
findings have inherent limitations. With regards to our ctDNA analysis in Chapter 3 (using 
patients from the WCB), our detection rate was low compared to expectations based on the 
literature (Tie et al. 2018). We have speculated that this may be a result of low plasma 
volumes leading to low cfDNA concentrations. This can then detrimentally impact the 
sensitivity of ddPCR and NGS analysis as demonstrated in the Materials and Methods, 
suggesting a cause for our low ctDNA detection rate. 
When comparing these findings to patient clinical outcomes, we have no significant 
associations between ctDNA levels and patient response to therapy. This was unsurprising due 
to the low number of ctDNA positive timepoints identified in this analysis. However, = we did 
observe that patients who achieved a complete response to therapy had significantly higher 
total cfDNA concentrations. This may have been due to increased DNA shedding as a result of 
greater levels of tumour cell death after therapy. 
Our detection rate for ctDNA in Chapter 4 was also still below expectations. Furthermore, 
although we identified some interesting findings in variant heterogeneity scores, we did not 
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have access to any clinical information from the ARISTOTLE trial with which we could compare 
our findings, these results will become available in late 2020. Therefore, at this time, we 
cannot discern any clinically significant results until such data becomes available. 
In Chapter 5, although we were able to confidently detect our genes of interest in exoRNA, we 
did not observe any significant associations between sequential exoRNA levels or sequential 
changes therein to any clinical characteristics in these patients. This may be a consequence of 
our choice of microRNAs and reference gene, the non-metastatic status of our patients or the 
relatively small size of our cohort. When comparing longitudinal exoRNA levels to clinical 
ooutcomes, we found no significant associations in this cohort of patients. 
In Chapter 6, we identified platelet and neutrophil counts as significant predictors of response 
to therapy and disease recurrence within two years of follow-up in 235 patients with LARC. 
There was a possibility that this significance was seen by chance due to the large number of 
factors analysed. Furthermore, each factor was analysed in univariate, therefore significance 
may have been lost during multivariate analysis. Each value here was analysed as a continuous 
variable and not as high or low based on a designated threshold. This was because we did not 
identify a common threshold from the literature, nor from AUC/ROC analysis. Furthermore, we 
only investigated these factors in relation to the recurrence of the disease and not directly 
against PFS or OS.  
7.2 Application of our Findings for Future Clinical Implementation 
7.2.1 Molecular Characterisation of Tumour Tissue in Patients with Locally Advanced Rectal 
Cancer  
The detection of tumour-specific variants is critically important across various solid tumour 
types. In patients with metastatic CRC, the detection of variants in RAS are associated with 
resistance to anti-EGFR monoclonal antibodies, such as cetuximab or panitumumab (Misale et 
al. 2012). There are currently no molecular biomarkers which can predict patient response to 
chemo- or radiotherapy, which is the current standard treatment for patients with LARC 
(Glynne-Jones et al. 2017). 
In our cohort, variants were frequently detected in both KRAS and TP53, both of which have 
been previously hypothesised to impact patient response to neoadjuvant therapy in patients 
with LARC. However, we could not compare these molecular findings to clinical outcomes in 
this cohort as no clinical data were available (see chapter 4). 
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Once molecular markers which can predict response to neoadjuvant therapy have been 
identified, it will be vital to ensure that current methods (NGS and ddPCR) can be applied as 
part of a reliable and robust clinical assay. 
We have demonstrated that the 50-gene CHPv2 can reliably detect variants in a wide range of 
genes (including TP53) and hotspot mutations in genes such as KRAS. Whether these variants 
are relevant in the context of neoadjuvant therapy remains to be confirmed. Furthermore, this 
panel focusses on mutational hotspots in genes of interest in CRC, capturing most clinically 
relevant variants. However, important variants outside of these hotspots or within other genes 
not included in this panel may be missed during sequencing. These may include genes involved 
in p53- or non-p53-mediated apoptosis. Such variants could influence response to neoadjuvant 
therapy in this patient cohort.  
Predicting response to neoadjuvant therapy may not be possible using tumour-specific 
variants alone. The CRC Subtyping Committee (CRCSC) have recently developed a novel 
subtyping system referred to as the Consensus Molecular Subtypes (CMS) which are separated 
into groups 1-4 (Guinney et al. 2015). These subtypes are based on the gene expression 
profiling of >4000 patients with CRC. Similarly, Bertotti  and colleagues (2016) have also 
developed a novel subtyping system referred to as ColoRectal cancer Intrinsic Subtypes (CRIS), 
which is also based upon gene expression profiling in patients with CRC. The recent emergence 
of these novel subtyping systems has increased our understanding in how variable expression 
profiles can be between different CRC subgroups and, in some cases, which genes or pathways 
are frequently altered. Therefore, using these subtyping systems, or similar gene expression 
profiling methods, we may be able to identify expression alterations in genes or pathways 
which can predict response to neoadjuvant therapy. Thus, the presence of specific variants 
alone may not be significant enough to achieve this. 
Although these studies can provide valuable information regarding patients with colon cancer, 
their potential value for patients with rectal cancer specifically may be more limited. For the 
~2,500 patients with known primary tumours sites, only ~15% were located in the rectum in 
the cohort analysed by the CRCSC (Guinney et al. 2015). As part of this analysis, the CRCSC 
initially compared RNA sequencing data between colon and rectal tumours which was 
previously published by TCGA Network. This study reported no significant differences in the 
RNA sequencing data between the two primary sites, suggesting that these subtypes may be 
applied to patients with rectal cancer. Further testing in a larger number of patients with rectal 
cancer, is required to verify this. 
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In contrast, the proportion of patients who had primary rectal tumours in the study from 
Bertotti and colleagues (Bertotti et al. 2016) was not disclosed. Therefore, the clinical value of 
this subtyping system in patients with rectal cancer will require further validation in the future.  
Although our findings in relation to the literature may provide some interesting avenues for 
future investigations, the analytical context of our study must be considered. In this thesis, we 
had access to both pre-treatment tumour biopsies and post-treatment surgical resections for 
molecular analysis. Whether this is feasible in the clinical setting will remain to be seen. The 
utility of both forms of tissue (pre- and post-treatment) may reveal more information 
regarding the molecular changes occurring in the tumour as a result of therapy. This combined 
information may prove to be more valuable than the molecular data gathered from either pre- 
or post-treatment tissue in isolation. 
A major concern for the molecular characterisation of LARC tumour is that each tissue sample 
will only represent a snapshot of the tumour as a whole and is not necessarily representative 
of the entire tumour. Nor is this information representative of distant metastases which can 
arise despite the implementation of neoadjuvant therapy. Therefore, in the clinical setting, the 
detrimental impact of both inter- and intra-tumour heterogeneity should be considered in 
tandem with genetic testing as part of treatment-decision making.  
7.2.2 Sequential Analysis of Circulating Biomarkers in Patients with LARC 
Of the circulating biomarkers investigated within this thesis, ctDNA is the only biomarker 
currently being used in clinical practise to monitor patient response to therapy. In comparison, 
the clinical potential of exosomes is still in its relative infancy but with growing interest. 
Although studies have shown that exosomes are generally increased in patients with cancer, 
there is considerable inconsistency regarding the molecular cargo of circulating exosomes 
between studies, particularly regarding microRNA (Silva et al. 2012). This inconsistency also 
exists in studies investigating circulating microRNAs in patients with cancer and is not specific 
to exosome-derived microRNAs alone. With studies having demonstrated that most circulating 
microRNAs are exosome-derived, these two issues are certainly linked. 
The inconsistency of microRNAs of interest reported between studies is a cause for concern 
regarding future clinical implementation. Although we chose three microRNAs of interest 
which were previously reported in patients with LARC, there was a wide array from which to 
choose in the literature and studies frequently contradicted one another. These 
inconsistencies may exist for several clinical or technical reasons. The clinical variability may 
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arise from many factors, including the different clinical endpoints used during analysis, variable 
treatment being applied and inconsistent plasma sampling timepoints between studies. With 
regards to technical variables, these include methods for exosome isolation, RNA extraction 
and microRNA analysis and expression normalisation. The combinations of these factors were 
certain to create inconsistencies in the literature. Furthermore, the analysis of circulating 
biomarkers such as ctDNA and circulating exosomes can also be influenced by the individual 
patient’s tumour, specifically how active the tumour is and how much material the tumour 
sheds into each patients’ circulation. This is another major factor which can detriment 
circulating biomarker analysis in non-metastatic disease. 
Although white cell counts are currently used in clinical practise, their combination as systemic 
inflammatory indices is not yet regularly applied. Studies tend to agree that systemic 
inflammatory indices (such as NLR, PLR and LMR) are useful prognostic indicators but cut-offs 
remain highly variable in the literature and require standardisation. As white cell counts are 
widely used, such markers will be relatively easy to integrate into routine clinical practice. 
Furthermore, as the methods for white cell counting have been used for an extensive period, 
both the technical and analytical validity of these assays has already been assessed. 
CtDNA is currently being used to experimentally to detect emerging treatment resistance in 
patients with metastatic CRC undergoing anti-EGFR monoclonal antibody therapy. The 
presence or quantity of ctDNA (regarding KRAS or related variants) has been used to identify 
tumour resistance earlier than current methods allow. However, ctDNA is yet to be applied in 
the context of neoadjuvant therapy, likely because there are no resistance-associated variants 
to specifically analyse. The presence of detectable ctDNA in post-surgical plasma samples in 
patients undergoing neoadjuvant therapy with surgery was demonstrated to be a poor 
prognostic marker for disease-free and overall survival (Tie et al. 2018). This is consistent with 
our findings in Chapter 6, where patients with detectable ctDNA after chemoradiotherapy 
experienced a faster time to recurrence. 
7.2.3 Technical Evaluation 
NGS platforms have the potential to screen large regions of the genome in order to identify 
variants or expression profiles of interest. However, prior results have demonstrated that this 
technology can be prone to generating sequencing artefacts. Furthermore, the bioinformatic 
analysis of NGS data can be highly variable between different studies and research groups, 
both for variant calling and the removal of such artefacts. The calling of variant pathogenicity is 
also variable between studies. Although freely available online predictive tools are often used 
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for this aspect, different tools can provide variable results. Guidelines to standardise variant 
pathogenicity calling have been suggested by the ACMG-AMP which combat this issue. This 
lack of consensus in the literature regarding both sequencing technologies and bioinformatic 
analyses are hurdles which must be overcome as this becomes more common practise in the 
clinical setting. 
ddPCR has been frequently applied for the detection of low-level variants in both ctDNA and 
tumour tissue. Here we demonstrated that the sensitivity of variant detection by ddPCR 
appeared to be dependent on input DNA concentrations, with more DNA allowing improved 
sensitivity for mutant detection. In the materials and methods chapter of this thesis (Chapter 
2), we reported that variants at 1% VAF could be detected using 10ng of DNA, but this 
sensitivity was reduced when using 1ng of DNA. This is critical for the analysis of ctDNA from 
patients with low volume disease such as LARC. In this thesis, cfDNA concentrations from 
patients with LARC were very low, which caused numerous sensitivity and detection issues 
during ddPCR analysis. Here we applied a cut-off of five molecules and 1% VAF for confident 
variant detection in ctDNA. This cut-off value was variable in the literature and, therefore, 
requires standardisation, both in the literature and in the clinical setting. As ddPCR sensitivity 
is highly variable and dependant on input DNA, variable cut-offs for confident detection may 
be necessary between different input DNA concentrations or total DNA molecules detected 
during analysis. As this field continues to grow rapidly, such factors will have to be addressed. 
For exosome isolation and exoRNA extraction and analysis, a much greater range of 
commercial off-the-shelf kits used in the literature. This creates difficulties with the analysis or 
review of other studies, the selection of methods for research and the standardisation of the 
process with clinical implementation in mind. Exosome isolation kits have been shown, both in 
this thesis and in the wider literature, to isolate extracellular vesicles of variable size and purity 
(Van Deun et al. 2014; Tang et al. 2017). This brings into question whether these studies are 
truly analysing the same microparticles. Although we did not investigate this as part of this 
thesis, studies have also demonstrated that RNA extraction methods can extract different RNA 
species preferentially, which influences down-stream molecular analysis (Tang et al. 2017). The 
same possibly applies to different off-the-shelf reverse transcription kits. These factors could 
have compromised the microRNA concentrations and gene expression levels detected by 
ddPCR in this thesis.  
Overall, different commercial kits are available for each step between exosome isolation and 
microRNA reverse transcription, each of which can cause variability and impact analytical 
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findings. Much further work will be required to identify why differences exist between certain 
methods and which methods would be most appropriate for future clinical implementation. 
This will require large retrospective patient studies once the process has been standardised. 
7.3 Guidelines for the Clinical Implementation of Genetic Testing 
The transfer of genetic tests from research to clinical practise is defined as stage three 
translational research (Unim et al. 2019). In this context, translational research is defined as 
research which ‘attempts to move evidence-based guidelines into health practice’ (Unim et al. 
2019). This can be influenced by factors inherent to the research, the delivery of healthcare 
and external commercial factors. Consequently, models or frameworks have recently been 
introduced with the purpose of facilitating the translation of genetic tests from research into 
the clinic.  
Most of these models were designed for genetic tests which identify germ-line variants which 
can predict or predispose a patient to a congenital disorder. In contrast with the research 
performed in this thesis, either specific models must be generated (of which we could find 
none at this time) or the current available models must be adapted for purpose. This is 
because these models include the concept of germ-line variant screening in a population, 
which is not directly applicable to variants for predicting response to neoadjuvant therapy in 
patients with LARC. 
The most frequently referenced model is the Analytic validity, Clinical validity, Clinical utility 
and ethical, legal and social implications (referred to as the Rapid-ACCE model) (Gudgeon et al. 
2007). Other frameworks have also included these factors in their respective frameworks 
(Pitini et al. 2018).  
The Rapid-ACCE model is a list of 44 questions aimed at creating a comprehensive review of 
genetic testing (Gudgeon et al. 2007). These questions aim to address analytical and clinical 
validity of a genetic test, as well as the clinical utility and ethical, legal and social implications 
of the test.  
Analytical validity is defined as the ability of a test to accurately and reliably measure the 
genotype in question (Pitini et al. 2018). This would also include the sensitivity and specificity 
of an assay, i.e. how often is a test positive when the variant is present, and negative when 
absent. The Rapid-ACCE also questions the quality control and precision of said assay as well as 
robustness across multiple laboratories (Gudgeon et al. 2007). In the context of patients with 
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cancer, proving an assay is precise, accurate, robust and reliable will be the first essential 
condition for analytical validity. 
Clinical validity is defined as the ability of a test or assay to accurately and reliably detect or 
predict a clinical condition (Pitini et al. 2018). Clinical validity also refers to the sensitivity and 
specificity of an assay. In this case, how often does a positive variant represent the presence of 
a disorder, and how often is a negative result representative of disease absence. The Rapid-
ACCE also questions the positive (PPV) and negative predictive values (NPV) of the assay in this 
setting. In the context of patients with LARC, we are attempting to identify patients who are 
more or less likely to respond to neoadjuvant therapy (Gudgeon et al. 2007). Therefore, clinical 
validity require verification as to what proportion of patients who test positive respond or are 
resistant to neoadjuvant therapy. 
Clinical utility compares the risks and benefits of testing and provides clinical usefulness for the 
integration of the test/assay (Pitini et al. 2018). This factor relates to the clinical implications of 
a positive or negative result on patient care and the availability of treatment in either case. 
This is also an economic evaluation, comparing the cost and consequences of various tests. 
The Rapid-ACCE also questions what other tests are available for this condition, whether 
quality assurance measures are in place for patients who receive a positive result, availability 
of methods for long-term monitoring and the economic benefits resulting from the result 
patient testing (Gudgeon et al. 2007). In the context of patients with LARC, the benefits of 
identifying patients who would not respond to therapy could improve quality of life by 
avoiding unnecessary exposure to cytotoxic agents. Alternatively, it may suggest that a more 
aggressive approach to treatment would be more appropriate. In either case it would suggest 
a change in treatment strategy, although which alternative strategies would provide better 
outcomes remains to be seen.  
Ethical, legal and social implications are less appropriate in the context of non-hereditary 
genetic tests as this refers to the presence of any impediments (such as stigmatisms or 
discrimination) resulting from a positive diagnosis (Pitini et al. 2018). The Rapid-ACCE also 
questions whether effective safeguards are properly in-place to avoid such impediments 
causing issues with patients in the future (Gudgeon et al. 2007).  
Although there are models and frameworks in place to appropriately facilitate the clinical 
implementation of genetic tests, our findings are far from this phase of research. A larger 
number of studies, with larger patient cohorts collecting ‘big data’ will be required to 
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thoroughly investigate the molecular characteristics of LARC tumours and how these influence 
patient response to therapy and/or long-term clinical outcomes such as survival. Any findings 
will then have to be validated in larger patient cohorts as, possibly as part of a retrospective 
study.  
With regards to exoRNA analysis, our study thus far has largely been proof-of-principle to 
verify that such biomarkers can be analysed in these patients. These findings will require 
further investigation to identify clinically significant signatures or sequential changes in 
patients with LARC before the test can be validated using a larger cohort. 
7.4 Concluding Remarks and Future Directions 
At present, there are no biomarkers available to predict response to neoadjuvant therapy in 
patients with LARC, and the only current marker for survival in these patients is response to 
therapy. The ability to predict which patients will respond to treatment before the initiation of 
therapy will help limit patients who undergo the unnecessary toxicity of chemoradiotherapy 
and potentially optimise the selection of patients for non-surgical approaches.  
There is evidence to suggest that variants in TP53, KRAS and/or PIK3CA may impact response 
to neoadjuvant therapy in patients with LARC (Duldulao et al. 2013; Sakai et al. 2014; Chow et 
al. 2016). However, these could simply be general prognostic factors. With the collection of 
pre- and post-treatment tissue in large scale retrospective studies, such as ARISTOTLE, we can 
begin to perform deeper molecular analysis to identify any variants or signatures of interest in 
this context.  
More research needs to be targeted towards this group of patients who have been 
underrepresented in the literature. Once a variant or molecular signature has been 
determined which can predict response to radiation-based therapy, huge strides can be made 
in treatment-stratification for these patients, rather than the one-size-fits-all method currently 
applied. 
Once a tissue-based marker has been identified, resistance-associated variants or signatures 
can be analysed in circulating biomarkers, either via ctDNA or exoRNA respectively. Studies 
have previously demonstrated that ctDNA can identify the presence of minimal residual 
disease and/or new tumour growth more swiftly than current methods allow. Even without 
the knowledge of resistance associated signatures, known tumour-specific variants can still 
allow the monitoring of tumour activity/growth after therapy. Greater knowledge about 
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tumour resistance signatures can allow an expanded repertoire for variants to monitor in 
ctDNA after surgery. 
A greater understanding of exosome isolation and exoRNA extraction methods and their 
respective strengths and weaknesses will be required before strides can be taken towards 
clinical implementation. Although we have shown, in this thesis, that exoRNA can be analysed 
under clinical conditions, much more basic research is required to standardise, optimise and 
further validate the most appropriate methods for such analysis. Once this has been 
accomplished, translational work can then proceed to identify exoRNA or exoDNA signatures 
which can be used to predict outcomes or response to neoadjuvant therapy in patients with 
LARC. 
Each of these assays will require both technical and clinical validation in the future, to ensure 
the analytical results are accurate, robust and sensitive enough to be applied for clinical utility 
in non-metastatic patients. The sensitivity, specificity, positive- and negative predictive values 
of each assay would then be ascertained to ensure findings were clinically relevant and 
economically viable. Large scale retrospective studies will be required to achieve this.  
Our findings have suggested that patients with LARC might receive a limited benefit from the 
clinical implementation of circulating biomarkers, due to the non-metastatic nature of their 
disease. CtDNA was only detected in patients who had distant metastases before the initiation 
of treatment, which is consistent with previous reports. If most of these patients 
demonstrated limited shedding of molecular components into the circulation, this would 
contribute to the small number of significant findings achieved in this thesis. This would also 
detrimentally affect the clinical relevance of circulating biomarkers in this population. 
However, circulating biomarkers may provide valuable information on the presence of 
undetected micro-metastases or lymph-node invasion which can then benefit treatment 
decision-making. For the remaining patients, there is a possibility that tumours do not shed 
enough material to be detected with our current methods and at present, may not benefit 
from the clinical implementation of circulating biomarker analysis. 
Although our findings here are mainly proof-of-concept, we have demonstrated that, in a 
subgroup of patients with LARC, ctDNA can be detected and monitored in sequential plasma 
samples. We have demonstrated that we can isolate circulating exosomes and extract and 
analyse exoRNA under restrictive conditions in these same patients. More work is still required 
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before considering clinical implementation, from technical standardisation to retrospective 
translational patient studies.
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9 Appendices 
9.1 Application for Access to Samples to the Wales Cancer Bank 
 
APPLICATION FOR ACCESS TO SAMPLES (v2.8 June 2015) 
 
I. This application (v2.8) is intended for the use and processing of samples utilised by the 
laboratory and/or personnel that fall under the supervision of the Principal Investigator listed 
in the application.  Any transfer of samples or aliquots to personnel or laboratories that are not 
under the supervision of the indicated PI requires the following: 
An explanation of the need to transfer the materials and benefit to the investigator's research 
A copy of the enclosed Wales Cancer Bank agreement page signed by the collaborator 
 
The WCB does not supply samples to banks solely for distribution to third party researchers; 
those researchers should be encouraged to apply to the WCB directly. 
 
The information requested in these forms is necessary in order to document correctly your 
request for tissue and other services and to ensure that the WCB operates within the 
guidelines of the Human Tissue Authority.  When submitting a written request for supply of 
material: 
 
Please print neatly or type. 
 
Patient identity is confidential.   Samples will be coded and supplied with a minimum data set. 
The cost recovery and/or processing fee per sample will vary according to the type of sample 
requested. 
 
The Wales Cancer Bank is authorised by the REC for Wales to release samples to researchers.  
Researchers receiving samples from WCB are NOT required to have approval from NRES for 
the use of these samples as samples will be provided anonymously with only the minimum 
data set.  However, researchers must be able to satisfy the External Review Panel of the 
WCB that the project they submit is both ethically and scientifically valid.  IF researchers are 
already in possession of NRES approval for their projects, a copy of the NRES letter should be 
supplied with the application.  Researchers are advised that it is their responsibility to 
ensure that they comply with the Human Tissue Act or other appropriate laws that cover the 
use of human material in research.  An HTA licence is NOT needed to store tissue sourced 
from WCB for an approved project that is subject to a signed Material Transfer Agreement. 
 
If the research has been peer reviewed by a recognised funding body as part of a grant 
application, please include the grant application and approval letter.  If the sample collection 
and use of samples is clearly detailed (to the satisfaction of WCB) in the approved 
application, WCB will not send it for further external review. 
 
Transfer of samples from WCB to researchers will be by Courier.  Researchers are required to 
cover the cost of transport of their samples and supply appropriate customs declarations if 
appropriate. 
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Please email the completed application form to wcbresearchapplications@cf.ac.uk and send 
hard copy of the signed Material Transfer Agreement (final page) to: 
 Wales Cancer Bank 
 Cardiff University 
 2nd Floor, Room 2LB4 64 
 A Block 
 
 Main Building, University Hospital of Wales 
 Heath Park 
 Cardiff 
 CF14 4XN 
 
For additional information please contact the Wales Cancer Bank Secretariat on +44 (0)2920 
743243 
II. INVESTIGATOR DATA 
 
A. Principal Investigator Adams                                                                                  
      
     Last Name                First Name Middle Initial
  Degree                    
Investigator's Title                                                                                                                                                          
Address  
                             
 
 
 
 
 
 
 
Post code 
 
 
Phone / Fax 
 
Email 
   
 
Contact Person (if different from above) 
Name 
 
Contact number 
 
Email                                                              
  
 
 
B. Shipping Address (if different from above):  
 
 
Adams  Richard A MD 
Dr  
Institute of Cancer & Genetics  
Cardiff University School of Medicine 
Velindre Hospital 
Cardiff  
 
 
 
CF14 2TL 
 
 
 
 
 
 
 
 
029 2031 6206 
Richard.Adams@wales.nhs.uk 
Panayiotis Georgiades  
07792838208  
georgiadespa@cardiff.ac.uk 
Institute of Medical Genetics Building 
Cardiff University 
Heath Park Campus 
CARDIFF  
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Post code 
 
 
 
 
C. Invoice information.  Is a purchase order required for shipment of specimens to your 
institution? 
 
 Yes              No                If yes, please supply purchase order when project has been approved. 
 
Invoices will be sent to the shipping address listed in section B.  If you would like the original 
invoice to be provided by post to another location (eg. your finance department), please 
enter that address below.  A shipping list will be included with the samples, please complete 
and fax back to WCB to acknowledge receipt. 
 
 
 
Person to whom invoice should be addressed (if different from above):  
 
 
 
Invoice Address (if different from above): 
 
 
 
 
 
 
Post code 
 
 
 
 
 
Courier services are provided by either DHL (Europe and Japan) or Federal Express (USA).  
Please state if you require another Courier and provide the appropriate customer number 
below. 
 
 Preferred Courier  _______________________________Customer Number 
_______________________               
 
 
 
III.   RESEARCH  INFORMATION 
 
Specimens will be provided to all investigators, based either in Academia or Industry 
 X
  
Rachel Butler 
 
Institute of Medical Genetics, UHW. CF14 4XW 
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  A. Please indicate the source of funds for your proposed project.  If this is Institutional 
Funding, please enclose a letter from your Head of Department indicating that funds and 
premises are available to complete your project. 
 
               Funding Source                                                                      Period of Support                
 
         
 
 
 
 
 
B. Please provide a short lay summary (max 200 words) of the intended research.  Please 
note, this information will be used in WCB reports to funders, NRES, in the public Annual 
Report and on the WCB website so only include information that is not commercially sensitive. 
This summary will be reviewed by a lay representative. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. Please provide the title and a short research summary (2-4 pages of A4) of the 
proposed research on the samples you are requesting from the WCB (use additional pages 
where necessary).    Sufficient information should be provided to enable the External Review 
Panel to determine the scientific validity of your study.  Please fully justify the number and 
type of samples requested and address ALL the headings below.   
 
If your project has already been successfully peer reviewed as part of a grant application, 
you may supply a copy of the scientific part of that grant application and confirmation of the 
grant award. If details of the sample collection and usage are clearly shown in the 
application (to the satisfaction of WCB), no further information is required in this form.  
Please go to the Material Transfer Agreement.   
Richard Adams PhD research account  January 2016 to January 
2018 
Over the past decade, the advancement of sequencing technologies has greatly improved our 
understanding of the mutational spectrum of colorectal cancer (CRC). We now have greater 
knowledge of the location of ‘hotspots’ where mutations are likely to occur, which can affect 
treatment and prognostis. We can apply this knowledge by interrogating circulating biomarkers such 
as circulating tumour DNA (ctDNA), exosomal nucleic acids and tumour educated platelets (TEPs) and 
proteins in patient blood. Exosomes are cell-derived vesicles that are present in many biological fluids. 
TEPs are platelets, which have been shown to sequester cell-free nucleic acids. 
ctDNA levels within plasma have been investigated as a sensitive method of monitoring patients and 
predict relapse and response to treatment in certain cancer types. Circulating exosomes originate 
from tumour and/or wild type cells, providing nucleic acids with more structural stability and 
preventing degradation. We plan to use exosome, platelet and protein isolation techniques with 
sequencing to interrogate and compare all biomarkers in CRCs at diagnosis and throughout therapy. 
These studies may provide clinicians with a non-invasive method with which to assess patient 
response and monitor progress. This has potential implications in choice of treatment and enables 
clinicians to halt toxic treatments that appear ineffective. 
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Title: 
 
Temporal changes in circulating biomarkers in patients undergoing chemo or radiotherapy in 
colorectal cancers 
 
 
ii. Introduction (including an overview of the state of the art in your proposed project 
area): 
 
  
Problems regularly arising in molecular diagnostics by sequencing tumour biopsies include; 
 
Inadequate tissue being available from the diagnostic specimen  
No evidence of invasive cancer in diagnostic specimen 
No tumour sample being available for analysis due to the location of tumour blocks 
being unknown 
For patients whose CRC was first diagnosed before progression to metastatic disease, 
the use of archival pre-metastatic tumour sample for RAS testing instead of a recent 
sample, to avoid re-biopsy. 
Heterogeneity of tumours such that a single biopsy is not indicative of the overall 
tumour load 
The time taken to locate and retrieve tumour samples, which can cause delays in RAS 
testing turnaround times that prohibit timely treatment of eligible patients with anti-
EGFR therapy 
The cost of retrieval and transport of tumour samples, which places a burden on the 
pathology laboratories 
 
Research in recent years has had particular emphasis on the use of liquid biopsies to aid both 
in monitoring disease and in determining treatment options. It has recently become routine 
clinical practice, to sequence for mutations in the tumour biopsy, in genes such as KRAS and 
NRAS in CRCs (Misale et al. 2014). Data from such analyses, however, can be limited as they 
provide a single snapshot in time of a particular region of the tumour. Deep sequencing of 
different circulating biomarkers, such as ctDNA and exosomal nucleic acids, has been 
hypothesised to provide an unbiased overview of the genetic landscape of the tumour, and 
any metastases, at the time of the biopsy being taken (Diaz et al. 2012). It should also be noted 
that other circulating biomarkers, such as circulating tumour cells and cell free microRNA have 
also been analysed as circulating biomarkers.  
 
Cell-Free Tumour DNA (ctDNA) 
 
Recent studies suggest that a complex array of genetic alterations exist in all human cancers.  
Genetic alterations, which include gene deletions, gene amplifications, point mutations, and 
chromosomal rearrangements, play a major role in the development and progression of 
cancers and can be utilised as unique identifiers that distinguish tumour cells from their wild 
type counterparts. The exclusive nature of tumour-defining genetic alterations makes them 
attractive systemic biomarkers with a theoretical specificity of 100%, when detectable. 
 
As cells turn over, nucleic acids are released into the systemic circulation. In patients with a 
malignancy, a fraction of the circulating nucleic acids (CNAs) are tumour-derived (Diehl et al. 
2005). Distinguishing the fraction of tumour-derived nucleic acids in plasma from normal 
nucleic acids has been accomplished by screening for genetic alterations. The most amenable 
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and best studied genetic alterations for analysis from the CNA pool are point mutations.  
Unlike deletions and amplifications, point mutations can easily be differentiated from the 
complementary normal nucleic acids in plasma. In addition, point mutations are often found in 
clusters and in a large percentage of patients with a given tumour type.  
 
Deep sequencing studies into both hereditary and somatic CRCs have provided a large amount 
of information about the molecular alterations critical for the development of CRC. This 
knowledge allows us to perform targeted sequencing on a panel of ‘hotspot’ genes where 
mutations are likely to occur, as well as give a potential prognostic indicator in the case of 
KRAS mutations (Diaz et al. 2012). These mutations are detected in the blood and can be used 
to monitor levels of disease and detect the emergence of resistant clones. 
 
Exosomal Nucleic Acids 
 
In recent years, there has been an increasing interest in investigating circulating exosomes as 
biomarkers in a large number of cancers. Exosomes are small microvesicles (30-120nm in 
diameter), which have a role in cell-cell communication (Raposo and Stoorvogel 2013). They 
perform these roles by budding off from their parent cell to later fuse with a target cell and 
deposit its cargo, which includes, DNA proteins, mRNA and microRNAs. It has thus been 
hypothesized that the contents of tumour exosomes can give an indication as to the genetic 
profile of their parent tumour cells by sequencing the nucleic acids stored. Nucleic acids stored 
in exosomes have also found to be more stable (Kahlert et al. 2014) allowing larger fragments 
to be interrogated for larger-scale genetic changes, chromosomal aberrations or expression 
levels. 
 
Exosomes are present in the circulation of both healthy and cancer patients (Vlassov et al. 
2012) but have been reported to be at increased levels in cancer patients and during cancer 
progression (Ko et al. 2015). Studies have since looked into using the genetic contents of 
circulating exosomes as biomarkers in a variety of cancers including ovarian (Taylor and Gercel-
Taylor 2008), lung (Rabinowits et al. 2009), prostate (Hessvik et al. 2012) and, more recently, 
colorectal (Matsumura et al. 2015), with a large emphasis looking at exosomal microRNA 
(miRNA). These works have generally been looking to define miRNA profiles for early 
detection, monitoring and prediction of prognosis and recurrence in these cancers, though 
much work still needs to be done validate these studies for clinical utility.  
 
Tumour Educated Platelets 
 
Platelets have very recently emerged in the literature as a potential biomarker and source of 
tumour RNA (Nilsson et al. 2015). Studies have shown that platelets can carry tumour nucleic 
acids in circulation, the methods of which are not entirely understood. It has been 
demonstrated that platelets can accumulate tumour derived nucleic acids through 
microvesicle-dependent mechanisms, e.g. exosomes in circulation (Nilsson et al. 2015). These 
have been referred to as tumour educated platelets (TEPs). TEPs have been hypothesized to 
act through microvesicle-independent mechanisms, such as by sequester circulating free or 
protein bound nucleic acids in circulation (Best et al. 2015; Nilsson et al. 2011). Though this 
was shown to be the case some time ago (Nilsson et al. 2011), it has only very recently been 
attempted as a biomarker in certain cancer types. 
 
Proteins: as an additional component of this pilot we will aim to see if proteins are effectively 
stabilised in Streck tubes, as this will inform future optimisation of collections. 
 
252 
 
Here we propose a translational research study to define the utility of exosomes and TEPs to 
improve our understanding of cancer progression and prognosis and to offer insights in to the 
evolution and heterogeneity of colorectal cancer. 
 
ii. Aim(s) (please clearly state the aim(s) of your project): 
 
Primary project objective 
 
To evaluate, in patients with newly diagnosed and/or advanced CRC, the feasibility of 
extracting exosomes from plasma, the best anticoagulants in which to store patient samples 
and whether sequencing results from exosomes correlate with that of ctDNA and the primary 
tumour in FFPE. These samples will also be used to determine and optimize the best method 
with which to isolate exosomes from patient plasma and the best technique with which to 
validate the presence and concentration of exosomes. The same investigations will then be 
performed looking at optimizing isolation and nucleic acid extraction of tumour derived nucleic 
acids in TEPs. These will then be compared to circulating exosomes, cell free nucleic acids and 
the FFPE tumour biopsy. 
 
Secondary project objectives 
 
To assess the concentration and fragment size of nucleic acids extracted from circulating 
exosomes and tumour derived nucleic acids from platelets. Samples may also be used to 
determine whether mutations or genetic variants detected in exosomes and platelets correlate 
with those found in the original tumour biopsy and compared wild-type tissue located in the 
FFPE block and/or buffy coat. 
 
We shall also aim to assess the impact of timing of treatment and of diurnal variation on 
exosome and/or platelet secretion to the circulation. 
 
Other objectives 
 
Samples may also be used for quality control and other assay development purposes.  
 
 
iv. Experience of group and/or company carrying out analysis (please provide information 
to indicate that your research group has experience in the techniques you intend to use, either 
by use of preliminary data from other work carried out in your group or by providing 
references to publications from your group/company that are relevant to this application): 
 
 
Recent work has been performed in this group using the Proton Torrent (Life Technologies) 
and droplet digital PCR (Bio-Rad) in order to look at levels of ctDNA in three different lung 
cancer subtypes in 30 patients sequentially throughout chemo/radiotherapeutic treatment. 
This work was performed by Dr D. Nelmes and supported by WCB. The samples for this project 
will thus be expanding on this study in lung cancers and focussing on CRCs. Collaborations with 
Dr A. Clayton’s group, who have experience in extracting and quantitating exosomes in both 
plasma (Welton et al., 2015) and analysing exosomes functionally in cell-lines (Chowdhury et 
al., 2015), will allow us to optimize our techniques and compare and contrast ctDNA with 
exosomal nucleic acids as potential biomarkers of CRC. Though no work has been performed 
using platelets by our group, platelet extraction and storage are routinely used in diagnostics, 
and nucleic acid extraction and analysis from these samples will be similar to that of exosomes. 
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v. If hypothesis generation is the specific purpose of your application, what do you 
envisage its application in the  clinical setting will be? 
 
 Please give as much detail as possible on target identification, validation etc 
 
 
We hypothesise that one may be able to track minimal residual disease, detect mutations of 
interest and potentially subgroup CRC patients based on DNA sequencing and mRNA 
expression data from exosomes and/or TEPs.   
 
 
 
vi. Methods (please detail the methods you intend to use, indicating controls and the 
experimental design you will use where relevant include statistical information): 
 
 
Sample storage 
 
Samples collected will be spun down stored as plasma at -80°C until exosomes can be isolated 
and quantified and nucleic acids can be extracted. We shall explore collection both in Streck 
tubes and in EDTA tubes following standardized local protocols. All samples will be stored with 
their unique anonymised WCB identifier and no other details. In the case of TEP studies, 
platelets may be isolated and lysed within 24 hours and stored at -80°C in lysis buffer until RNA 
extraction is performed. 
 
Exosomal isolation 
 
Several different methods of exosomal isolation will be assessed during this pilot, including 
ultracentrifugation, ultracentrifugation with a sucrose gradient and kits manufactured for the 
purpose such as Exoquick (Systembio), PureExo (101bio), Exo-Spin (CellGS) or ExoEasy 
Maxi/Midi kit (Qiagen). 
 
Exosomal Validation 
 
In order to determine the presence of exosomes and their concentration from the sample 
taken, several methods may be applied. Use of electron microscopy can be applied to visualise 
the microvesicles and determine their size and shape. Use of Nanosight has a similar function 
in a real-time scenario. Exosomes can be further validated by their surface markers (CD63, CD9 
and/or CD81) through flow cytometry or western blotting. 
 
Assessment of Nucleic Acid Content and Concentration 
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The concentration of nucleic acids extracted from exosomes can be assessed by using the 
Bioanalyzer 2100 to determine both concentration and fragment length of the nucleic acids. 
This can then be validated using the Bio-Rad droplet digital PCR.  
 
Panel Sequencing 
 
Exosomal nucleic acids will likely be sequenced and compared to results from FFPE tumour 
tissue using next generation sequencing based techniques. This will involve the application of a 
50 gene cancer ‘hotspot’ panel and the Proton Torrent  both supplied by Life Technologies or 
whole exome/transcriptome sequencing on the HiSeq Supplied by Illumina. Mutations 
detected in the FFPE will be interrogated in exosomal nucleic acids to ensure all results match 
and/or correlate.  
 
Data collection and management 
 
Patients identified and recruited to this research, will be consented by WCB. On consent, they 
are assigned a unique, anonymised WCB research identifier. Clinical/research samples 
collected from each patient will be labelled with their unique WCB identifier. For each patient, 
paired clinical data, e.g. scan results will also be labelled with the unique WCB identifier and 
anonymised. 
 
Data storage, relating to clinical information or results from lab work on clinical research 
samples, will be done using the anonymised WCB numbers, on secured Cardiff University 
computer and server. 
 
Data analysis 
 
Samples will be processed using only the anonymised WCB identifier, and results generated to 
be analysed will be done using the same. 
 
vii. How many samples do you need to do your study and explain why you need these 
numbers? This is a finite resource so therefore it is important for us to understand the number 
and type of samples required.  NB. Larger sample requests will require a more detailed 
explanation. 
 
We would initially like to intake 20 patient samples, being baseline plasma and matching FFPE 
tumour biopsy. This will be in order to optimize certain aspects of the project, such as the 
anticoagulant for the blood samples the exosome and platelet isolation techniques and the 
nucleic acid extraction techniques. 
 
Once protocols have been optimized, we would like to request samples from approximately 40 
patients (20 undergoing chemotherapy and 20 undergoing radiotherapy), with one baseline 
and three sequential blood samples from easch patient. These patients can be a mixture of 
early and advanced/metastatic CRC, with preferably more emphasis on advanced (15:5 in 
each). This would allow us to directly assess the ability extract appropriate samples in a quality 
controlled fashion and also to compare the effects of timing of samples in the therapeutic 
strategy and their relation to outcome.  
 
 
IV. SPECIMENS REQUESTED (Please refer to the biosample search facility on 
www.walescancerbank.com  to ascertain the type of tissue or tissue products available  The 
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WCB will undertake bespoke collection of material if required.  If you require a bespoke 
collection please supply details of your request on a separate sheet.) 
 
Please specify exactly what you require e.g. 20 samples of RNA extracted from ER positive 
invasive ductal carcinoma of the breast RIN>7 
 
Please list sample requirements and format (RNA, serum etc).  Ensure any age, pathological 
sub-types are clearly indicated 
 
Sample Information Required: (Anatomic site of tissue, pathological diagnosis, patient age, sex 
will be provided for all samples.) Additional patient information may be available, but you 
must request it in this application and justify its necessity for your research.  It may be 
possible to provide some samples with details of treatment and outcome – although this 
may not be possible for all samples.                                                                                                                                                                          
 
For single sample patients; two plasma samples collected in both Streck DNA (10ml) and 
EDTA tubes (10ml), the latter spun and frozen within 1 hour. 
For multi-sample patients; three sequential plasma samples of patients undergoing chemo and/or 
radiotherapy for colorectal cancer collected in Streck tubes (10-20ml) and/or EDTA tubes (10-
20ml); additional to a baseline sample at diagnosis 
Corresponding FFPE tissue (4-5 slides) from tumour samples at diagnosis for each patient 
where KRAS/NRAS or general mutational status is unavailable. Where possible, these slides 
would preferably contain both tumour and normal adjacent tissue. 
The patients can either be consented by Dr Adams or WCB. 
This is a prospective study and all samples must be taken fresh and not be historical 
 
AGREEMENT FOR USE OF TISSUE 
 
The recipient/investigator agrees that the tissues provided by the Wales Cancer Bank (WCB) 
will be used only for the purposes specified in this application.  The recipient agrees not to 
attempt to obtain information identifying the individuals providing tissues to the WCB.  The 
recipient agrees that it shall not sell any portion of the tissues provided by the WCB, or 
products directly extracted from these tissues (e.g. protein, mRNA or DNA).  The recipient also 
agrees that they shall not transfer tissue (or any portion thereof) supplied by the WCB to third 
parties without the prior written permission of the WCB.  Any subsequent transfer that may be 
made to other parties, with prior agreement from WCB, will require signature of this 
agreement between the final recipients of the material and the WCB. 
 
The recipient understands that while the WCB attempts to avoid providing tissues that are 
contaminated with highly infectious agents such as hepatitis and HIV, all tissues should be 
handled as if potentially infectious.  The individuals who have supplied tissue to the WCB have 
not agreed to have clinical tests performed on this tissue (e.g. for the presence of infective 
agents such as hepatitis), therefore, the recipient agrees not to perform such tests on the 
tissues supplied by the WCB.  The recipient acknowledges that the institution where the tissue 
will be used follows Human Tissue Authority or appropriate local regulations if outside 
England, Wales and Northern Ireland, for handling human specimens and will instruct their 
staff to abide by those rules.  The recipient further agrees to assume all responsibility for 
informing and training personnel in the dangers and procedures for safe handling of human 
tissues. 
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Tissues are provided as a service to the research community without warranty of 
merchantability or fitness for a particular purpose or any other warranty, express or implied.  
The WCB accepts no responsibility for any injury (including death) damages or loss that may 
arise either directly or indirectly from their use. 
 
The recipient agrees to acknowledge the contributions of the Wales Cancer Bank in all 
publications resulting from the use of these tissues.  Recommended wording to the methods 
or acknowledgement section is as follows:  “Tissue samples were obtained from the Wales 
Cancer Bank which is funded by the Welsh Government and Cancer Research Wales.  Other 
investigators may have received specimens from the same subjects.” 
 
The institution agrees to assume all risks and responsibility in connection with the receipt, 
handling, storage and use of tissues from the Wales Cancer Bank.  It further agrees to 
indemnify and hold harmless the Wales Cancer bank and the Welsh Government from any 
claims costs, damages or expenses resulting from the use of the tissues provided by the WCB.  
The undersigned warrant that they have authority to execute this agreement on behalf of the 
recipient institution. 
BY MY SIGNATURE I AGREE TO THE TERMS SET FORTH IN THE ABOVE AGREEMENT 
 
Richard Adams        Institute of Cancer & Genetics Velindre Cancer Centre 
_______________________________      _______________________________     
___________________________ 
Typed Name of Principal Investigator                        Institution                                  Division or Department 
 
 
        02/02/2016 
_______________________________ _______________________________           ________________________ 
Signature of Principal Investigator                             Date   Institutional signatory (if 
applicable) 
UPON RECEIPT OF THESE SIGNED UNDERSTANDINGS AND THE INFORMATION REQUESTED ABOVE, THE 
WALES CANCER BANK WILL CONSIDER THIS REQUEST.  Specific questions about your application should be directed 
to Dr Alison Parry-Jones, Project Manager, Wales Cancer Bank, Cardiff University, A2 corridor, 2 Floor, Main Building, University 
Hospital of Wales, Heath Park, Cardiff CF14 4XN.  Tel: +44 (0)2920 743243, Fax: +44 (0)2920 744309, Email:  parry-
jonesa@cardiff.ac.uk  
Further Amendments 
Query plasma preparation methodology and whether appropriate for cfDNA, exosomes and 
platelet DNA – standard methods for cfDNA isolation recommend that include 2 
centrifugation steps. 
 
Two centrifugation steps will be performed for any sample tubes which will be analysed for 
ctDNA only (shown in modified section below).  For platelets and (potentially) exosomes, these 
will also undergo two-step centrifugation of different speeds to those for ctDNA. We will first 
produce platelet-rich plasma with a slow spin followed by a faster spin to pellet platelets and 
leave platelet-poor-plasma.  Isolation of exosomes from platelet-poor-plasma will be tested for 
efficacy. 
 
Plasma Isolation 
 
For cell-free nucleic acid and exosome isolation, samples will be spun twice, at 1000rpm for 
10min, 2ml plasma aliquots made and spun again at 4000rpm for 10 min to isolate plasma. For 
platelet isolation, blood will be spun down at 150rcf for 10min to produce platelet-rich plasma, 
aliquots of which will be spun again at 1000rpm to pellet the platelets and produce platelet-
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poor plasma. This platelet poor plasma will also be examined for potential exosome isolation 
and cell-free nucleic acid utility. 
 
Applicant is requesting plasma to be frozen at -80oC within 1 hour of blood sample collection 
– is this suitable for the subsequent preparations of exosomes and platelet DNA. 
 
We will perform studies to determine whether freezing has any effect on the RNA content of 
exosomes or platelets. Platelets will, in fact, by lysed in a lysis buffer before being frozen, as 
suggested by other researchers in the field (see modified section below). If we find that 
freezing of lysed cells or plasma affects RNA quality at any point, we will alter protocols to 
process samples fully through to RNA extraction before freezing. 
 
Sample storage 
 
Streck tube samples will be processed into plasma within 72 hours of collection, being left at 
room temperature in-between. EDTA samples will be processed and platelets and platelet-
poor-plasma isolated within 24 hours of collection, being left at room temperature until 
processing.  Variation in times and temperatures before processing will be analysed for future 
clinical utility. Plasma will be stored at -20°C to -80°C before exosome and/or ctDNA isolation, 
depending on manufacturer’s instructions and time-frame before extraction. If isolation or 
extraction immediately follows plasma centrifugation, samples will be kept on ice. This is a 
preliminary plan and may be altered if found certain conditions affect exosome quality or 
quantity.  
 
All samples will be stored with their unique anonymised WCB identifier and no other details. In 
the case of TEP studies, platelets will be isolated and lysed within 24 hours and stored at -80°C 
in lysis buffer until RNA extraction is performed 
 
Mention in hypothesis that will include mRNA expression data from exosomes and platelet 
nucleic acids – this is not evident in any other part of the proposal. Are they going to 
measure mRNA expression? 
 
Yes we will be sequencing and quantifying mRNA expression data from exosomes and 
platelets.  
 
Amended Lay Summary 
 
Recent improvements of DNA sequencing technology have improved our knowledge colorectal cancer 
(CRC) genetics. CRC is a very complex disease, associated with several genetic changes and pathways. 
We will use biological markers to detect important genetic changes in the blood and personalise patient 
therapy. These biomarkers include ctDNA, exosomes and platelets. 
 
Each of these is a different molecule which can be found in the blood. We can examine each of them by 
analysing their protein, DNA or RNA sequence and quantities. RNA is an intermediate molecule between 
DNA and protein, and is often measured to calculate DNA expression levels.  
 
We will isolate proteins and sequence DNA or RNA from each of these sources. We will investigate and 
compare ctDNA, platelets and exosomes as biomarkers in CRC. Samples will be taken at diagnosis and 
throughout therapy, to see which is most effective at disease monitoring and sub-grouping.  
 
These studies may provide clinicians with a non-invasive method to assess patient response and monitor 
progress. The use of blood-based testing to monitor patients can potentially allow regular testing. This 
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testing can also include monitoring disease burden and choosing therapies which would benefit patients 
most. This can also enable clinicians to halt ineffective toxic treatments. 
9.2 Clinical Factors Acquire for Patients from the Wales Cancer Bank 
Table 48: Patient clinical factors for the small group of 16 patients consented by the WCB 
Patient Clinical Factors 
cT Stage 
cN Stage 
cM Stage 
CEMVI+/- 
ypT 
ypN 
EMVI 
R0/R1/R2 
CEA concentration 
Tumour location: High/Mid/low 
Baseline Neutrophil Count 
Baseline Lymphocyte Count 
Baseline Monocyte Count 
Baseline Platelet Count 
Baseline Haemoglobin Concentration 
White Cell Count 
Lymphocyte Count at Week 5 
Neutrophil Count at Week 5 
KRAS Status 
NRAS Status 
BRAF Status 
Surgery 
Follow-Up 
Radiotherapy (Gy) 
mrTRG 
ypTRG 
Censored Alive 
Censored Disease Free 
Additional Notes 
 
9.3 Cancer Genes using cBioPortal 
Table 49: List of cancer relevant genes frequently mutated in patients with rectal cancer from cBioportal 
Gene Frequency 
Mutated (%) 
Gene Frequency 
Mutated (%) 
APC 78.6 LRRK2 6.4 
TP53 71.4 CREBBP 5.7 
KRAS 37.1 EPHA5 5.7 
FAT4 18.6 EPHB1 5.7 
FBXW7 17.9 FAT1 5.7 
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LRP1B 16.4 PRKDC 5.7 
PIK3CA 15.0 PTEN 5.7 
SMAD4 14.3 PTPN13 5.7 
ATM 10.0 ROS1 5.7 
NRAS 10.0 ARID1A 5.7 
TCF7L2 9.3 TRRAP 5.7 
ERBB4 8.6 PCLO 5.7 
AMER1 8.6 TET1 5.7 
RELN 7.9 BCL9L 5.7 
PDE4DIP 7.9 BCL9 5.0 
RNF213 7.9 CBLB 5.0 
CARD11 7.9 CTNNB1 5.0 
BRCA2 7.1 DNMT3B 5.0 
RUNX1T1 7.1 KDR 5.0 
ROBO1 7.1 SMAD2 5.0 
PTPRT 7.1 NF1 5.0 
GRIN2A 6.4 PIK3CG 5.0 
MKI67 6.4 RANBP2 5.0 
PCBP1 6.4 TRIP11 5.0 
PIK3R1 6.4 KMT2B 5.0 
PTPRC 6.4 MED12 5.0 
SMARCA1 6.4 MGA 5.0 
SOX9 6.4 SETD2 5.0 
ZNF521 6.4 PREX2 5.0 
EP400 6.4 
  
 
9.4 cfDNA concentrations for patients from the WCB  
Table 50: Total cfDNA concentrations and collection tube used for each patient and plasma timepoint 
Sample 
ID 
Week cfDNA Concentration 
(ng/uL) 
WCB1203 0 0.741 
WCB1251 0 0.432 
WCB1260 0 0.324 
WCB1262 0 0.342 
WCB1262 1 0.282 
WCB1263 1 0.439 
WCB1263 3 0.194 
WCB1263 9 0.238 
WCB1263 23 0.308 
WCB1266 0 0.301 
WCB1268 0 0.36 
WCB1268 2 0.185 
WCB1269 0 0.482 
WCB1295 0 0.433 
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WCB1295 4 0.344 
WCB1367 0 0.939 
WCB1419 0 0.758 
WCB1419 11 0.472 
WCB1441 0 0.378 
WCB1441 0 0.259 
WCB1441 1 0.212 
WCB1473 0 0.328 
WCB1473 2 0.183 
WCB1473 4 0.175 
WCB1473 13 0.218 
WCB1476 0 0.451 
WCB1476 12 0.271 
WCB1477 0 0.315 
WCB1477 12 0.215 
WCB1478 0 0.283 
WCB1478 4 0.195 
WCB1479 0 0.378 
WCB1479 5 TL 
WCB1479 6 0.128 
WCB1479 8 0.162 
WCB1479 10 0.175 
WCB1493 0 0.416 
WCB1493 1 0.144 
WCB1493 3 0.257 
WCB1493 4 0.408 
WCB1493 6 0.444 
WCB1602 0 0.406 
WCB1602 1 0.238 
WCB1602 2 0.488 
WCB1602 5 0.229 
WCB1602 10 0.676 
WCB1603 0 0.377 
WCB1603 1 0.122 
WCB1603 5 0.189 
WCB1603 14 0.119 
WCB1604 0 0.443 
WCB1604 0 0.197 
WCB1604 0 0.223 
WCB1604 6 0.134 
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9.5 Blood collection tubes and cfDNA concentrations for patients from 
ARISTOTLE 
Table 51: Total cfDNA concentrations and collection tube used for each patient and plasma timepoint 
Patient ID. Week of Sample Collection CfDNA Concentration Collection Tube 
ARI-166 Week 0 0.22 EDTA 
ARI-166 Week 1 0.31 EDTA 
ARI-166 Week 10 0.20 EDTA 
ARI-166 Week 5 0.28 EDTA 
ARI-182 Week 0 0.22 EDTA 
ARI-182 Week 1 0.49 EDTA 
ARI-182 Week 10 0.49 EDTA 
ARI-182 Week 5 0.32 EDTA 
ARI-202 Week 0 0.3 EDTA 
ARI-202 Week 1 0.37 EDTA 
ARI-202 Week 10 0.26 EDTA 
ARI-202 Week 5 0.22 EDTA 
ARI-239 Week 0 0.10 EDTA 
ARI-239 Week 1 0.14 EDTA 
ARI-239 Week 10 0.43 EDTA 
ARI-239 Week 5 2.03 EDTA 
ARI-295 Week 0 0.26 EDTA 
ARI-295 Week 1 0.22 EDTA 
ARI-295 Week 10 0.33 EDTA 
ARI-295 Week 5 0.37 EDTA 
ARI-297(a) Week 0 0.26 EDTA 
ARI-297(a) Week 1 0.18 EDTA 
ARI-297(a) Week 10 0.35 EDTA 
ARI-297(a) Week 5 0.13 EDTA 
ARI-297(b) Week 0 0.23 EDTA 
ARI-297(b) Week 1 0.14 EDTA 
ARI-297(b) Week 10 0.34 EDTA 
ARI-297(b) Week 5 0.16 EDTA 
ARI-306 Week 0 0.30 EDTA 
ARI-306 Week 1 0.40 EDTA 
ARI-306 Week 10 0.38 EDTA 
ARI-306 Week 5 0.34 EDTA 
ARI-316 Week 0 0.69 EDTA 
ARI-316 Week 1 0.40 EDTA 
ARI-316 Week 10 0.57 EDTA 
ARI-316 Week 5 0.28 EDTA 
ARI-341 Week 0 0.53 EDTA 
ARI-341 Week 1 0.19 EDTA 
ARI-341 Week 10 0.38 EDTA 
ARI-341 Week 5 0.26 EDTA 
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ARI-346 Week 0 0.29 EDTA 
ARI-346 Week 1 0.20 EDTA 
ARI-346 Week 10 0.44 EDTA 
ARI-346 Week 5 0.19 EDTA 
ARI-366 Week 0 0.23 Streck 
ARI-366 Week 1 0.22 Streck 
ARI-366 Week 10 0.32 Streck 
ARI-366 Week 5 0.38 Streck 
ARI-373 Week 0 0.31 Streck 
ARI-373 Week 1 0.42 Streck 
ARI-373 Week 5 0.34 Streck 
ARI-378(a) Week 0 0.22 Streck 
ARI-378(a) Week 1 0.13 Streck 
ARI-378(a) Week 10 0.15 Streck 
ARI-378(a) Week 5 0.53 Streck 
ARI-378(b) Week 0 0.30 Streck 
ARI-378(b) Week 1 0.32 Streck 
ARI-378(b) Week 10 0.31 Streck 
ARI-378(b) Week 5 0.34 Streck 
ARI-400 Week 0 0.28 Streck 
ARI-400 Week 1 0.30 Streck 
ARI-400 Week 10 0.33 Streck 
ARI-400 Week 5 0.32 Streck 
ARI-403 Week 0 0.33 Streck 
ARI-403 Week 1 0.23 Streck 
ARI-403 Week 10 0.12 Streck 
ARI-403 Week 5 0.23 Streck 
ARI-408 Week 0 0.21 Streck 
ARI-408 Week 1 0.20 Streck 
ARI-408 Week 10 0.19 Streck 
ARI-408 Week 5 0.24 Streck 
ARI-412 Week 1 0.43 Streck 
ARI-412 Week 10 0.28 Streck 
ARI-412 Week 5 0.31 Streck 
ARI-413 Week 0 0.21 Streck 
ARI-413 Week 10 0.20 Streck 
ARI-413 Week 5 0.13 Streck 
ARI-437 Week 0 0.23 Streck 
ARI-437 Week 1 0.31 Streck 
ARI-437 Week 10 0.27 Streck 
ARI-437 Week 5 0.34 Streck 
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9.6  BCA Assay Set Up 
Table 52: Concentrations for the BCA assay standard curve 
BSA Concentration 
(ng/ml) 
0 
1.953125 
3.90625 
7.8125 
15.625 
31.25 
62.5 
125 
250 
500 
1000 
2000 
BSA – Bovine Serum Albumin 
 
9.7 ExoRNEasy Protocol Changes 
9.7.1.1 Assay Development and Optimisation 
Due to the consistency of its reported overexpression in CRCs, we used Mir-21 during the 
development of exosome-derived microRNA extraction and analysis. Simultaneously, we 
looked to detect levels of mRNA using an mRNA specific KRAS primer/probe set. The KRAS 
gene was chosen for validation as the majority of these WCB patients had KRAS mutant 
tumours. Levels of mutant KRAS could later be compared between ctDNA and exoRNA in the 
circulation of these patients. 
The Mir-21 probe coupled with the Qiagen MiScript RT Kit II could not distinguish between 
DNA and microRNA. Therefore, exosomes had to be treated with Proteinase K, DNase I and 
Rnase A during assay development. Throughout methodological optimisation, contaminating 
DNA levels were examined in parallel as described in Section 2.2.15.  
Exosomes were isolated from 1mL of plasma from patients with LARC using ExoSpin columns. 
These exosomes were treated and then applied directly to ExoRNEasy kit in place of patient 
plasma. Exosomes were bound to a membrane affinity column where they were lysed for RNA 
extraction using Qiazol.  
We also spiked non-human RNA (C. Elegans) into the assay to verify RNA extraction efficiency 
without interfering with results. 
Using 1mL of plasma collected from patient with LARC, no microRNA or mRNA was observed 
whilst the spike-in control C. elegans mir-39 (cel-mir-39) was detected by qPCR. The protocol 
was adapted to elute exosomes into an elution buffer (400µL of buffer XE; See Section 2.2.6.2) 
before lysis, which improved spike-in detectable yield but had no bearing on exoRNA. 
We hypothesised that 1mL of plasma was not enough for reliable exoRNA detection in these 
patients at this time. We chose to revert to adding pre-filtered (0.22µm) patient plasma 
directly into the Qiagen ExoRNEasy Maxi Kit (an extension of the ExoEasy kits). This allowed 
the application of 1-4mL of patient plasma.  
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The purity and yield of exosomes would be directly comparable to that expected of the 
ExoEasy kit, so we did not repeat the comparisons of exosome quality. We compared input 
volumes of 2mL and 3mL of patient plasma to determine how much sample is required for 
confident and reliable RNA detection. 
 
Figure 19: Levels of Mir-21 Detected in 2mL and 3mL of Patient Plasma using Droplet Digital PCR. 
Exosome Derived RNA was Extracted the Optimised ExoRNEasy Kit. A & B – 2mL Patient Plasma was used 
for ExoRNA Extraction, C&D 3mL of Patient Plasma was used for ExoRNA Extractions. 
Mir-21 was successfully detected in 2mL and 3mL of plasma. The use of 3mL increased the 
confidence and reliability of sample detection. As the use of >1mL plasma was not compatible 
with the ExoSpin kit, pre-filtered plasma was added directly to ExoRNEasy Maxi kit during 
further microRNA analyses. We could not detect mRNA in any of these sample volumes and 
therefore chose to proceed with microRNA analysis alone. 
We expected to see ~50 copies of Mir-21 in exoRNA from 1mL of plasma, however we were 
unable to see any (data not shown). This may be because of the small volume and reverse 
transcription process. There may have been no Mir-21 extracted from 1mL of plasma, or at 
least not enough to allow reliable reverse transcription. The levels we observe in 2mL and 3mL 
may also be deceiving, as they underwent two hours of reverse transcription, possible 
increasing the detected levels cDNA further. We, therefore, hypothesised that Mir-21 was 
simply undetectable or too low for reliable detection from 1mL of plasma in patients with 
LARC at this time. 
To avoid the potential of DNA contamination influencing results, a new reverse transcription 
kit (TaqMan MicroRNA RT Kit) was tested.  As a result, Mir-21 analysis was discontinued, due 
to incompatibility of our Mir-21 probe with the Taqman MicroRNA RT Kit. 
A total of 10ng of genomic DNA underwent reverse transcription to examine the impact DNA 
contamination would have on reverse transcription and ddPCR. No cDNA was detected after 
reverse transcription and ddPCR analysis of genomic DNA (data not shown). This change of 
reverse transcription chemistry removed any issues regarding DNA contamination influencing 
microRNA quantification. 
With a developed assay ready, we proceeded to investigate our microRNAs of interest in 
circulating exosomes from patients with LARC.  
9.8 MicroRNA Literature Review 
Table 53: A representation of the which circulating microRNAs have been investigated in patients with 
colon and/or rectal cancer and the number of times analysed. Review was performed in January 2018 
MicroRNA N 
Let-7a 3 
Let-7e 1 
let-7g 2 
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Mir-1 1 
Mir-10 2 
Mir-100 1 
Mir-103 1 
Mir-106a 4 
Mir-106b 1 
Mir-10a 1 
Mir-10b 1 
Mir-122 1 
Mir-1229 1 
Mir-1246 3 
Mir-1254 1 
Mir-125a 3 
Mir-125b 4 
Mir-126 1 
Mir-129 1 
Mir-1290 1 
Mir-130 1 
Mir-130b 1 
Mir-133a 2 
Mir-134 1 
Mir-135b 4 
Mir-139-3p 1 
Mir-141 5 
Mir-142 2 
Mir-143 3 
Mir-145 4 
Mir-146 1 
Mir-148a 1 
Mir-149 1 
Mir-150 4 
Mir-152 1 
Mir-155 1 
Mir-15b 2 
Mir-16 3 
Mir-16-2 1 
Mir-16-5p 1 
Mir-17 7 
Mir-18 1 
Mir-181 1 
Mir-181b 2 
Mir-181d 1 
Mir-182 1 
Mir-1826 1 
Mir-187 1 
Mir-188 1 
Mir-18a 5 
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Mir-18b 2 
Mir-191 1 
Mir-192 1 
Mir-193 2 
Mir-193a 2 
Mir-194 1 
Mir-195 1 
Mir-196 1 
Mir-196a 1 
Mir-198a 1 
Mir-199a 1 
Mir-19a 4 
Mir-19b 2 
Mir-200 2 
Mir-200b 1 
Mir-200c 1 
Mir-203 5 
Mir-20a 10 
Mir-21 21 
Mir-210 2 
Mir-2110 1 
Mir-21-5p 1 
Mir-216a 1 
Mir-22* 1 
Mir-221 3 
Mir-222 4 
Mir-223 5 
Mir-224 2 
Mir-23a 4 
Mir-23b 3 
Mir-24 3 
Mir-241 1 
Mir-26a 1 
Mir-27 1 
Mir-27a 2 
Mir-27b 3 
Mir-29 1 
Mir-29a 10 
Mir-29b 2 
Mir-29c 2 
Mir-30a 1 
Mir-30b 2 
Mir-30c 2 
Mir-31 7 
Mir-3156 1 
Mir-320a 4 
Mir-326 1 
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Mir-328 1 
Mir-331 1 
Mir-335 1 
Mir-338 1 
Mir-342 1 
Mir-345 1 
Mir-34a 3 
Mir-372 2 
Mir-376a 1 
Mir-376c 1 
Mir-378 1 
Mir-38a 1 
Mir-423 1 
Mir-425 2 
Mir-4669 1 
Mir-483 1 
Mir-484 1 
Mir-486 1 
Mir-495 1 
Mir-532 1 
Mir-572 1 
Mir-576 1 
Mir-579 1 
Mir-601 1 
Mir-652 1 
Mir-720 2 
Mir-760 1 
Mir-777 1 
Mir-92 5 
Mir-92a 12 
Mir-95 1 
Mir-96 1 
Mir-96-5p 1 
RNU6B 1 
U2 1 
N – Number of articles which each analysed  
9.9 Circulating Mir-31 Analysis 
Table 54: ANNOVAR for Mir-31 concentrations across each patient in this study. Significant findings are 
highlighted in bold, and suggestive significance in italics 
Patient Comparison Difference Lower Limit Upper Limit Adjusted p-Value 
WCB1441-WCB1368 0.09 0.05 0.13 <0.01 
WCB1603-WCB1441 -0.07 -0.11 -0.04 <0.01 
WCB1478-WCB1441 -0.09 -0.12 -0.05 <0.01 
WCB1604-WCB1441 -0.07 -0.10 -0.04 <0.01 
WCB1441-WCB1295 0.08 0.04 0.12 <0.01 
268 
 
WCB1476-WCB1441 -0.08 -0.12 -0.04 <0.01 
WCB1473-WCB1441 -0.07 -0.10 -0.03 <0.01 
WCB1477-WCB1441 -0.07 -0.11 -0.03 <0.01 
WCB1473-WCB1368 0.02 -0.01 0.06 0.44 
WCB1604-WCB1368 0.02 -0.02 0.06 0.55 
WCB1477-WCB1368 0.02 -0.02 0.06 0.61 
WCB1478-WCB1473 -0.02 -0.06 0.02 0.65 
WCB1603-WCB1368 0.02 -0.02 0.05 0.73 
WCB1604-WCB1478 0.02 -0.02 0.05 0.77 
WCB1478-WCB1477 -0.02 -0.06 0.02 0.80 
WCB1603-WCB1478 0.01 -0.02 0.05 0.91 
WCB1476-WCB1368 0.01 -0.03 0.05 0.96 
WCB1368-WCB1295 -0.01 -0.05 0.03 0.97 
WCB1473-WCB1295 0.01 -0.03 0.05 0.97 
WCB1476-WCB1473 -0.01 -0.05 0.03 0.98 
WCB1477-WCB1295 0.01 -0.03 0.05 0.99 
WCB1477-WCB1476 0.01 -0.03 0.05 0.99 
WCB1604-WCB1295 0.01 -0.03 0.04 1.00 
WCB1478-WCB1476 -0.01 -0.05 0.03 1.00 
WCB1604-WCB1476 0.01 -0.03 0.04 1.00 
WCB1478-WCB1295 -0.01 -0.05 0.03 1.00 
WCB1603-WCB1473 -0.01 -0.04 0.03 1.00 
WCB1603-WCB1477 -0.01 -0.04 0.03 1.00 
WCB1603-WCB1295 0.00 -0.03 0.04 1.00 
WCB1603-WCB1476 0.00 -0.03 0.04 1.00 
WCB1604-WCB1603 0.00 -0.03 0.03 1.00 
WCB1604-WCB1473 0.00 -0.04 0.03 1.00 
WCB1478-WCB1368 0.00 -0.04 0.05 1.00 
WCB1604-WCB1477 0.00 -0.04 0.03 1.00 
WCB1476-WCB1295 0.00 -0.04 0.04 1.00 
WCB1477-WCB1473 0.00 -0.04 0.04 1.00 
WCB1441-All other patients 0.07 -0.09 -0.06 <0.01 
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Figure 20: Boxplot representation of Mir-31 concentrations across all nine patients analysed
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9.10 Circulating Mir-99a* Analysis 
Table 55: ANNOVAR for Mir-99a* concentrations across each patient in this study. Significant findings 
are highlighted in bold, and suggestive significance in italics 
Patient Comparison Difference Lower Limit Upper Limit Adjusted p-Value 
WCB1603-WCB1368 -0.07 -0.11 -0.03 <0.01 
WCB1473-WCB1368 -0.07 -0.10 -0.03 <0.01 
WCB1441-WCB1368 -0.06 -0.10 -0.02 <0.01 
WCB1368-WCB1295 0.06 0.02 0.11 <0.01 
WCB1478-WCB1368 -0.06 -0.10 -0.02 <0.01 
WCB1476-WCB1368 -0.06 -0.10 -0.02 <0.01 
WCB1477-WCB1368 -0.06 -0.10 -0.02 <0.01 
WCB1604-WCB1603 0.04 0.01 0.07 <0.01 
WCB1604-WCB1473 0.04 0.00 0.07 0.03 
WCB1604-WCB1441 0.03 0.00 0.06 0.06 
WCB1604-WCB1295 0.03 0.00 0.07 0.07 
WCB1604-WCB1478 0.03 0.00 0.07 0.11 
WCB1604-WCB1368 -0.03 -0.07 0.01 0.15 
WCB1604-WCB1476 0.03 -0.01 0.07 0.19 
WCB1604-WCB1477 0.03 -0.01 0.06 0.23 
WCB1603-WCB1477 -0.01 -0.05 0.03 0.98 
WCB1603-WCB1476 -0.01 -0.05 0.03 0.99 
WCB1603-WCB1441 -0.01 -0.04 0.03 1.00 
WCB1477-WCB1473 0.01 -0.03 0.05 1.00 
WCB1603-WCB1478 -0.01 -0.04 0.03 1.00 
WCB1476-WCB1473 0.01 -0.03 0.05 1.00 
WCB1477-WCB1295 0.01 -0.04 0.05 1.00 
WCB1476-WCB1295 0.01 -0.04 0.05 1.00 
WCB1473-WCB1441 0.00 -0.04 0.03 1.00 
WCB1603-WCB1295 0.00 -0.04 0.03 1.00 
WCB1478-WCB1477 0.00 -0.05 0.04 1.00 
WCB1603-WCB1473 0.00 -0.04 0.03 1.00 
WCB1441-WCB1295 0.00 -0.04 0.04 1.00 
WCB1477-WCB1441 0.00 -0.04 0.04 1.00 
WCB1478-WCB1473 0.00 -0.04 0.04 1.00 
WCB1478-WCB1476 0.00 -0.05 0.04 1.00 
WCB1478-WCB1295 0.00 -0.04 0.05 1.00 
WCB1476-WCB1441 0.00 -0.04 0.04 1.00 
WCB1473-WCB1295 0.00 -0.04 0.04 1.00 
WCB1478-WCB1441 0.00 -0.04 0.04 1.00 
WCB1477-WCB1476 0.00 -0.04 0.04 1.00 
WCB1368-All other patients 0.06 -0.19 0.08 0.13 
WCB1604-All other patients 0.03 -0.06 0 0.08 
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Figure 21: Boxplot representation of Mir-99a* concentrations across all nine patients analysed. 
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9.11 Local and/or Distant Relapse rates Within an Extended WCB Cohort 
Table 56: A comparison of sequential platelet counts, lymphocyte counts, neutrophil counts, monocyte counts, PLR, NLR and LMR between patients undergoing short-course 
therapy who experienced local and/or distant recurrence within two years of follow up in comparison to those who did not. All values were analysed as continuous variables, 
not as high or low based on a designated threshold. Change in variable refers the difference between baseline and week 5 for each respective biomarker. Any recurrence refers 
to patients who experience either local or distant relapse 
  Local Relapse Distant Relapse Any Relapse 
Variable 
No Relapse; 
Median 
(Range) 
Relapse; 
Median 
(Range) 
p- 
Value 
No Relapse; 
Median 
(Range) 
Relapse; 
Median 
(Range) 
p- 
Value 
No Relapse; 
Median 
(Range) 
Relapse; 
Median 
(Range) 
p- 
Value 
Baseline Platelet 
Count 
282 217 
0.62 
275 253 
0.68 
305 217 
0.38 
(143.0 - 465.0) (188.0 - 386.0) (143.0 - 465.0) (188.0 - 386.0) (143.0 - 465.0) (188.0 - 386.0) 
Week 5 Platelet 
Count 
221 377 
0.37 
221 295 
0.19 
221 295 
0.19 
(141.0 - 424.0) (223.0 - 459.0) (141.0 - 344.0) (209.0 - 459.0) (141.0 - 344.0) (209.0 - 459.0) 
Change in Platelet 
Count 
-22 6 
0.47 
-41 21 
0.05 
-41 21 
0.05 
(-245 - 135) -11 - 73) (-245 - -2) (-11 - 135) (-245 - -2) (-11 - 135) 
Baseline 
Lymphocyte Count 
1.9 2.3 
0.62 
1.8 2.2 
0.52 
1.8 2.3 
0.43 
(1.4 - 3.4) (1.0 - 3.7) (1.4 - 3.4) (1.0 - 3.7) (1.4 - 3.4) (1.0 - 3.7) 
Week 5 Lymphocyte 
Count 
1.1 2.8 
0.07 
1.1 1.3 
2.7 
1.1 1.3 
0.28 
(0.8 - 1.8) (0.7 - 3.2) (0.8 - 1.8) (0.7 - 3.2) (0.8 - 1.8) (0.7 - 3.2) 
Change in 
Lymphocyte Count 
-0.7 -0.8 
0.36 
-0.4 -0.8 
0.91 
-0.4 -0.8 
0.91 
(-1.5 - -0.2) (-1.0 - 0.8) (-1.3 - -0.2) (-1.5 - 0.8) (-1.3 - -0.2) (-1.5 - 0.8) 
Baseline Neutrophil 
Count 
5.5 5.9 
0.86 
5.9 4.7 
0.46 
5.9 4.8 
0.6 
(2.5 - 7.2) (4.3 - 6.6) (2.5 - 7.2) (4.2 - 6.6) (2.5 - 7.2) (4.2 - 6.6) 
Week 5 Neutrophil 
Count 
3.7 3.7 
0.19 
3.7 3.8 
0.59 
3.7 3.8 
0.59 
(2.5 - 8.0) (2.5 - 8.0) (2.6 - 8.0) (2.5 - 15.0) (2.5 - 8.0) (2.5 - 15.0) 
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Change in 
Neutrophil Count 
-1.6 -1.3 
0.17 
-1.6 -1.3 
0.39 
-1.6 -1.3 
0.39 
(-3.0 - 1.6) (-1.3 - 8.4) (-3.0 - 1.6) (-1.7 - 8.4) (-3.0 - 1.6) (-1.7 - 8.4) 
Baseline Monocyte 
Count 
0.7 0.7 
0.98 
0.7 0.7 
0.84 
0.6 0.7 
0.80 
(0.4 - 1.2) (0.4 - 0.9) (0.4 - 1.2) (0.5 - 0.9) (0.4 - 1.2) (0.4 - 0.9) 
Week 5 Monocyte 
Count 
0.5 0.9 
0.07 
0.4 0.5 
0.18 
0.4 0.5 
0.18 
(0.3 - 0.6) (0.6 - 1.2) (0.3 - 0.6) (0.5 - 1.2) (0.3 - 0.6) (0.5 - 1.2) 
Change in Monocyte 
Count 
-0.2 -0.1 
0.23 
-0.2 -0.1 
0.66 
-0.2 -0.1 
0.66 
(-0.4 - 0.1) (-0.2 - 0.3) (-0.4 - 0.1) (-0.3 - 0.3) (-0.4 - 0.1) (-0.3 - 0.3) 
Baseline PLR 
145.7 104 
0.62 
156.3 104.8 
0.51 
156.9 104 
0.18 
(95.3 - 191.6) (81.7 - 198.0) (81.7 - 191.6) (90.4 - 198.0) (95.3 - 191.6) (81.7 - 198.0) 
Week 5 PLR 
196.6 173 
0.92 
196.6 190 
0.48 
196.6 190 
0.48 
(121.1 - 333.9) (69.7 - 421.4) (128.2 - 210.5) (69.7 - 421.4) (128.2 - 210.5) (69.7 - 421.4) 
Change in PLR 
32.8 51.6 
0.68 
23.9 91.1 
0.10 
23.9 91.1 
0.10 
(-2.9 - 228.4) (-20.7 - 241.1) (-2.9 - 54.2) (-20.7 - 241.4) (-2.9 - 54.2) (-20.7 - 241.4) 
Baseline NLR 
2.6 2.6 
0.89 
2.7 2.2 
0.60 
2.8 2.5 
0.51 
(1.5 - 4.3) (1.7 - 3.9) (1.8 - 4.3) (1.5 - 4.5) (1.8 - 4.3) (1.5 - 4.5) 
Week 5 NLR 
3.3 1.8 
0.31 
3.3 1.9 
0.62 
3.3 1.9 
0.62 
(1.9 - 7.3) (0.9 - 21.4) (2.1 - 7.3) (0.9 - 21.4) (2.1 - 7.3) (0.9 - 21.4) 
Change in NLR 
0.5 0 
0.21 
0.5 0.4 
0.42 
0.5 0.4 
0.42 
(-1.0 - 3.0) (-0.9 - 17.5) (-1.0 - 3.0) (-0.9 - 17.5) (-1.0 - 3.0) (-0.9 - 17.5) 
Baseline LMR 
3.3 3.3 
0.96 
3 3.2 
0.95 
2.9 3.2 
0.79 
(2.5 - 5.0) (2.0 - 5.0) (2.5 - 5.0) (2.0 - 5.0) (2.5 - 5.0) (2.0 - 5.0) 
Week 5 LMR 
2.5 3.3 
0.37 
2.7 2.4 
0.50 
2.7 2.4 
0.50 
(1.7 - 5.0) (0.6 - 5.0) (1.7 - 5.0) (0.6 - 5.0) (1.7 - 5.0) (0.6 - 5.0) 
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Change in LMR 
0 0 
0.28 
0 0 
0.40 
0 0 
0.40 
(0.0 - 5.0) (-0.8 - 10.0) (0.0 - 5.0) (-0.8 - 10.0) (0.0 - 5.0) (-0.8 - 10.0) 
 
Table 57; A comparison of sequential platelet counts, lymphocyte counts, neutrophil counts, monocyte counts, PLR, NLR and LMR between patients undergoing long-course 
therapy who experienced local and/or distant recurrence within two years of follow up in comparison to those who did not. All values were analysed as continuous variables, 
not as high or low based on a designated threshold. Change in variable refers the difference between baseline and week 5 for each respective biomarker. Any recurrence refers 
to patients who experience either local or distant relapse 
| Local Relapse Distant Relapse Any Relapse 
Variable 
No Relapse; 
Median 
(Range) 
Relapse; 
Median 
(Range) 
p- 
Value 
No Relapse; 
Median 
(Range) 
Relapse; 
Median 
(Range) 
p- 
Value 
No Relapse; 
Median 
(Range) 
Relapse; 
Median 
(Range) 
p- 
Value 
Baseline Platelet 
Count 
287 300 
0.31 
287 320 
0.27 
282 307 
0.21 
(126.0 - 601.0) (192.0 - 540.0) (126.0 - 601.0) (182.0 - 426.0) (126.0 - 601.0) (182.0 - 562.0) 
Week 5 Platelet 
Count 
233 244 
0.25 
233 244 
0.11 
233 244 
0.16 
(126.0 - 452.0) (168.0 - 294.0) (126.0 - 452.0) (163.0 - 426.0) (126.0 - 452.0) (163.0 - 426.0) 
Change in Platelet 
Count 
-57 -72 
0.85 
-58 -56 
0.92 
-56.6 -72 
0.49 
(-245.0 - 102.0) (-245.0 - 6.0) (-326.0 - 82.0) (-236.0 - 8.0) (-326.0 - 82.0) 
(-245.0 - 
102.0) 
Baseline 
Lymphocyte Count 
1.8 1.8 
0.54 
1.8 1.9 
0.79 
1.7 1.9 
0.86 
(0.6 - 3.8) (0.9 - 3.5) (0.6 - 3.8) (0.9 - 3.5) (0.6 - 3.8) (0.9 - 3.5) 
Week 5 
Lymphocyte Count 
0.6 0.7 
0.27 
0.6 0.7 
0.11 
0.6 0.7 
0.1 
(0.3 - 2.6) (0.4 - 0.9) (0.3 - 1.2) (0.4 -1.5) (0.3 - 1.2) (0.4 - 1.5) 
Change in 
Lymphocyte Count 
-1.1 -0.9 
0.21 
-1.1 -1.1 
0.61 
-1.1 -1.1 
0.53 
(-2.9 - -0.2) (-2.5 - -0.3) (-2.9 - -0.2) (-2.5 - -0.3) (-2.9 - -0.2) (-2.5 - -0.3) 
4.6 51 0.78 4.7 4.8 0.86 4.6 5.1 0.37 
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Baseline 
Neutrophil Count 
(2.5 - 10.3) (4.0 - 5.8) (2.5 - 10.3) (2.6 - 5.9) (2.5 - 10.3) (2.6 - 9.6) 
Week 5 Neutrophil 
Count 
3.4 3.7 
0.45 
3.4 3.8 
0.25 
3.4 3.8 
0.25 
(1.4 - 9.3) (2.8 - 4.4) (1.4 - 9.3) (1.9 - 4.9) (1.4 - 9.3) (1.9 - 7.4) 
Change in 
Neutrophil Count 
-1.1 -1.2 
0.71 
-1.1 -1.2 
0.44 
-1.1 -1.3 
0.95 
(-6.1 - 2.8) (-4.5 - 1.7) (-6.2 - 2.8) (-3.9 - 1.7) (-6.1 - 2.8) (-4.6 - 1.7) 
Baseline Monocyte 
Count 
0.5 0.6 
0.14 
0.5 0.6 
0.2 
0.5 0.6 
0.05 
(0.3 - 1.0) (0.3 - 1.1) (0.3 - 1.0) (0.1 - 1.1) (0.3 - 1.0) (0.1 - 1.1) 
Week 5 Monocyte 
Count 
0.5 0.5 
0.24 
0.5 0.5 
0.2 
0.4 0.5 
0.11 
(0.3 - 1.2) (0.2 - 0.7) (0.3 - 0.9) (0.3 – 0.8) (0.3 - 1.2) (0.3 - 0.9) 
Change in 
Monocyte Count 
0 -0.1 
0.61 
0 -0.1 
0.88 
0 -0.1 
0.54 
(-0.3 - 0.4) (-0.5 - 0.1) (-0.5 - 0.4) (-0.4 - 0.2) (-0.3 - 0.4) (-0.4 - 0.5) 
Baseline PLR 
154.6 161.3 
0.41 
154.6 161.3 
0.84 
154.3 161.3 
0.53 
(50.0 - 471.7) (102.1 - 435.5) (50.0 - 471.7) (78.3 - 25-.6) (50.0 - 471.7) (78.3 - 435.5) 
Week 5 PLR 
396.7 338 
0.32 
396.7 352.5 
0.33 
398.3 338 
0.27 
(140.9 - 1180.0) (251.3 - 473.3) (140.9 - 1180) (163.6 - 497.5) (140.9 - 1180) (163.6 - 497.5) 
Change in PLR 
220.4 159.6 
0.12 
209.3 178.1 
0.21 
217.6 159.6 
0.11 
(8.6 - 801.4) (-44.5 - 287.5) (8.6 - 801.4) (-44.5 - 295.5) (8.6 - 801.4) (-44.5 - 295.5) 
Baseline NLR 
2.4 3 
0.66 
2.6 2.7 
0.65 
2.4 2.8 
0.91 
(1.1 - 8.1) (2.1 - 3.9) (1.1 - 8.1) (1.3 - 3.9) (1.1 - 8.1) (1.3 - 3.9) 
Week 5 NLR 
5.3 5.8 
0.41 
5.4 5.3 
0.35 
5.4 5.3 
0.32 
(1.6 - 16.0) (3.8 - 7.5) (1.6 - 16.0) (2.8 - 7.5) (1.6 - 16.0) (2.8 - 7.5) 
Change in NLR 
3 2.2 
0.28 
3 2.5 
0.44 
3.1 2.2 
0.27 
(-5.3 - 12.8) (01.3 - 4.5) (-5.3 - 12.8) (-1.3 - 5.9) (-5.3 - 12.8) (-1.3 - 5.9) 
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Baseline LMR 
3.3 2.5 
0.06 
3.3 3.3 
0.36 
3.3 2.9 
0.14 
(1.4 - 10.0) (1.0 - 5.0) (1.4 - 10.0) (2.0 - 10.0) (1.4 - 10.0) (1.25 - 10.0) 
Week 5 LMR 
0.8 0.8 
0.63 
0.8 0.8 
0.42 
0.8 0.83 
0.48 
(0.4 - 3.3) (1.4 - 2.0) (0.4 - 3.3) (0.8 - 3.3) (0.4 - 3.3) (0.8 - 3.3) 
Change in LMR 
0.5 0.475 
0.18 
0.5 0.5 
0.19 
0.5 0.5 
0.15 
(-0.6 - 10) (0 - 1.4) (-0.6 - 10.0) (0 - 1.4) (-0.6 - 10.0) (0 - 1.4) 
 
 
